
<html lang="en"     class="pb-page"  data-request-id="5103e99a-78f0-47b3-91a7-89213b4f2446"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b01492;issue:issue:10.1021/jmcmar.2019.62.issue-10;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective" /></meta><meta name="dc.Creator" content="Aimie&#xA;E.  Garces" /></meta><meta name="dc.Creator" content="Michael J.  Stocks" /></meta><meta name="dc.Description" content="Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many..." /></meta><meta name="Description" content="Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 24, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01492" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01492" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01492" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01492" /></link>
        
    
    

<title>Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01492" /></meta><meta property="og:title" content="Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0029.jpeg" /></meta><meta property="og:description" content="Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases. The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chemistry with over 600 medicinal chemistry-based publications and patents appearing to date, leading to 38 clinical candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017. This Perspective will discuss medicinal chemistry design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compounds that have progressed into clinical development or that have revealed new structural motifs in this highly competitive area of research." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01492"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01492">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01492&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01492&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01492&amp;href=/doi/10.1021/acs.jmedchem.8b01492" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4815-4850</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01298" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b00843" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Aimie E. Garces</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aimie E. Garces</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Biomolecular Sciences, University Park Nottingham, Nottingham NG7 2RD, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aimie%0AE.++Garces">Aimie E. Garces</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Michael J. Stocks</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Stocks</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Biomolecular Sciences, University Park Nottingham, Nottingham NG7 2RD, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#d3bebab0bbb2b6bffda0a7bcb0b8a093bdbca7a7babdb4bbb2befdb2b0fda6b8"><span class="__cf_email__" data-cfemail="04696d676c6561682a77706b676f77446a6b70706d6a636c65692a65672a716f">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Stocks">Michael J. Stocks</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3046-137X" title="Orcid link">http://orcid.org/0000-0003-3046-137X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01492&amp;href=/doi/10.1021%2Facs.jmedchem.8b01492" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4815–4850</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 24, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 September 2018</li><li><span class="item_label"><b>Published</b> online</span>24 December 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4815%26pageCount%3D36%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAimie%250AE.%2BGarces%252C%2BMichael%2BJ.%2BStocks%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D10%26contentID%3Dacs.jmedchem.8b01492%26title%3DClass%2B1%2BPI3K%2BClinical%2BCandidates%2Band%2BRecent%2BInhibitor%2BDesign%2BStrategies%253A%2BA%2BMedicinal%2BChemistry%2BPerspective%26numPages%3D36%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4850%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01492"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5279</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">51</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01492" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Aimie\nE.&quot;,&quot;last_name&quot;:&quot;Garces&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Stocks&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4815-4850&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01492&quot;},&quot;abstract&quot;:&quot;Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases. The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chemistry with over 600 medicinal chemistry-based publications and patents appearing to date, leading to 38 clinical candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017. This Perspective will discuss medicinal chemistry design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compounds that have progressed into clinical development or that have revealed new structural motifs in this highly competitive area of research.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01492&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01492" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01492&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01492" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01492&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01492" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01492&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01492&amp;href=/doi/10.1021/acs.jmedchem.8b01492" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01492" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01492" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DGarces%26date%3D2019%26atitle%3DClass%2B1%2BPI3K%2BClinical%2BCandidates%2Band%2BRecent%2BInhibitor%2BDesign%2BStrategies%253A%2BA%2BMedicinal%2BChemistry%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/jmcmar.2019.62.issue-10/20190523/jmcmar.2019.62.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate the 3-OH of the inositol ring of phosphoinositides, and deregulation of this pathway has implications in many diseases. The search for novel PI3K inhibitors has been at the forefront of academic and industrial medicinal chemistry with over 600 medicinal chemistry-based publications and patents appearing to date, leading to 38 clinical candidates and the launch of two drugs, idelalisib in 2014 and copanlisib in 2017. This Perspective will discuss medicinal chemistry design approaches to novel isoform-selective inhibitors through consideration of brief case histories of compounds that have progressed into clinical development or that have revealed new structural motifs in this highly competitive area of research.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphatidylinositol 3-kinases (PI3Ks) are a family of intracellular signal transducer enzymes possessing regulatory roles in critical cellular processes including cell growth, proliferation, differentiation, motility, and intracellular trafficking. Specifically, these lipid kinases phosphorylate the 3-position hydroxyl group of the inositol ring of phosphatidylinositol.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Deregulation of the phosphoinositide 3-kinase (PI3K) pathway has been implicated in numerous pathologies such as cancer, diabetes, thrombosis, rheumatoid arthritis, activated PI3Kδ syndrome (APDS), and asthma. The eight known family members are subdivided into three classes, I, II, and III where class I PI3Ks have been the most extensively studied; class I is further subdivided into IA (PI3Kα, β, and δ) and IB (PI3Kγ), based upon the types of regulatory subunits with which the catalytic domains combine in the active heterodimeric forms. Class 1A PI3Ks mediate the signal transduction from receptor tyrosine kinases (RTKs), while PI3Kγ is principally activated by G-protein-coupled receptors (GPCRs). PI3Kα and β are ubiquitously expressed, whereas PI3Kδ and γ are present in the hematopoietic system, epithelial cells, and the central nervous system (CNS). Genetic deregulation of PI3K activity (such as overexpression) has been implicated in cancer for all the class I PI3K isoforms.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2−7)</a> In addition, mounting evidence supports a role for inhibition of PI3Kα in diabetes,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> PI3Kβ in thrombosis therapy,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> PI3Kδ and PI3Kγ in both rheumatoid arthritis and asthma therapy,<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> and PI3Kδ for APDS.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19">(15−19)</a> Further, increased PI3Kγ expression in fibroblasts and basal cells has been implicated in idiopathic pulmonary fibrosis.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> It should be noted though that apart from cancer therapy, none of the other indications have been clinically validated to date.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">Consequently, the selective inhibition of individual PI3K isoforms using small molecule ATP-competitive inhibitors has been well documented as a promising therapeutic strategy to treat these conditions. This increasing validation of the role of PI3K in several diseases has seen an expansion of research outputs from pharmaceutical companies and academic groups alike. This perspective examines the published recent chemical literature, concentrating on case histories for the design of PI3K inhibitors that have entered into clinical development, as well as selected examples of structurally diverse compounds. However, we should comment on the huge amount of medicinal-chemistry-based patent disclosures within this time frame, with a total of 418 chemical patents being published since 2012 alone. This clearly demonstrates the large medicinal chemistry effort being employed to discover new inhibitors of PI3Ks. The number of patent publications has been mirrored to a good degree by the number of medicinal chemistry publications (<i>n</i> = 192) that have been published within this corresponding time frame (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PI3K medicinal-chemistry-based publications and PI3K chemical patents from 2012 to 2018 (source SciFinder).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to understand mechanisms underlying the isoform selectivity of these inhibitors, ligand-bound X-ray structures on isoform- and pan-selective class I PI3K inhibitors have been extensively studied. These results have revealed that selectivity, mainly toward PI3Kδ, can be achieved by exploiting the conformational flexibility and sequence diversity of active site residues that do not contact ATP.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In their pioneering work, Berndt et al.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> suggested that inhibitors can be organized into three general classes through a consideration of their binding to the ATP active site, namely, the following:<table class="listgroup" border="0" width="95%" id="list1" list-type="label"><tr class="li1"><td valign="top">(a)</td><td colspan="5" valign="top" class="paragraph"><p class="last">inhibitors that adopt a “propeller-shaped” conformation when bound to the enzyme leading to the stabilization of a conformation that opens a hydrophobic “specificity” pocket in the active site that is not present in the apo-structure of the enzyme (these are mostly PI3Kδ selective inhibitors);</p></td></tr><tr class="li1"><td valign="top">(b)</td><td colspan="5" valign="top" class="paragraph"><p class="last">inhibitors that are essentially “flat” which are mostly pan-selective class I PI3K inhibitors that do not provoke such a conformational rearrangement;</p></td></tr><tr class="li1"><td valign="top">(c)</td><td colspan="5" valign="top" class="paragraph"><p class="last">inhibitors that have a “distorted propeller-shape” when bound to the enzyme but do not open the “specificity” pocket (again, these are these are mostly PI3Kδ selective inhibitors).</p></td></tr></table></div><div class="NLM_p">The ATP-binding pockets of the compounds discussed by Berndt et al. were shown to contact a core set of six residues in the ATP-binding pocket and, apart from the hinge residue Val827 in PI3Kδ, were invariant in all of the class I PI3K isoforms. Four regions within the ATP-binding pocket were shown to be important for inhibitor binding including an “adenine” pocket (hinge), a “specificity” pocket, an “affinity” pocket, and the hydrophobic region II located at the mouth of the active site (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ligand bound X-ray crystal structure of IC87114 in PI3Kδ showing the essential hinge binding interaction of Val828 and the specificity and affinity pockets as well as the hydrophobic region II (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X38">2X38</a>) visualized in PyMOL.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As well as searching for isoform-specific PI3K inhibitors, many groups have investigated dual inhibition design, and these approaches will be discussed in this Perspective.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">The major dual inhibitor approach is the search for compounds that inhibit both PI3Kα and the mammalian target of rapamycin (mTOR). The kinase mTOR is a member of the PIKK (phosphatidylinositol-like kinase) family and is activated downstream of AKT leading to increased protein synthesis and growth. Analogs of rapamycin, which inhibit mTOR when complexed in part to rapamycin-insensitive companion of mammalian target of rapamycin (rictor, mTORC1 complex), have been approved for the treatment of advanced renal cell carcinoma, thus validating this target in humans.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, a potential limitation of exclusive mTORC1 inhibition by such analogs is that the mTOR kinase can also participate in the mTORC2 protein complex, leading to activation of the oncogene AKT, and in doing so promote cell survival through other signaling mechanisms.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, to avoid this undesired feedback mechanism leading to potential resistance, ATP competitive mTOR kinase inhibitors that can inhibit both mTORC1 and mTORC2 have been pursued as alternatives to the rapamycin analogs.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Given the quantity of evidence implicating both PI3K and mTOR in cancer, various groups have developed compounds that inhibit both kinases.</div><div class="NLM_p">This Perspective will investigate the medicinal chemistry evolution of these inhibitor classes leading to clinical candidates (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), as well as discuss new series of compounds grouped by chemical structure, highlighting those that have progressed to deliver structurally diverse clinical candidates.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. PI3K Inhibitors Progressed to Clinical Evaluation and Development Status as of July 2018</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">other names</th><th class="colsep0 rowsep0" align="center">primary indication</th><th class="colsep0 rowsep0" align="center">biological target</th><th class="colsep0 rowsep0" align="center">trial phase<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">company</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alpelisib</td><td class="colsep0 rowsep0" align="left">BYL719</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kα</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMG319</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kδ</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Amgen</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apitolisib</td><td class="colsep0 rowsep0" align="left">GDC-0980</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Genentech</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD8186</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kβ</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BGT226</td><td class="colsep0 rowsep0" align="left">NVP-BGT226</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bimiralisib</td><td class="colsep0 rowsep0" align="left">PQR309</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">I/II</td><td class="colsep0 rowsep0" align="left">PIQUR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">buparlisib</td><td class="colsep0 rowsep0" align="left">BKM120</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CH5132799</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kα</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Chugai</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">copanlisib</td><td class="colsep0 rowsep0" align="left">BAY 80-6946</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="left">Bayer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CUDC-907</td><td class="colsep0 rowsep0" align="left">fimepinostat</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kα,β,δ/HDAC</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Curacite</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dactolisisb</td><td class="colsep0 rowsep0" align="left">BEZ235</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">duvelisib</td><td class="colsep0 rowsep0" align="left">IPI-145</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kδ,γ</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Verastem</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GDC-0084</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Genentech</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gedatolisib</td><td class="colsep0 rowsep0" align="left">PF-05212384; PKI-587</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Pfizer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK2292767</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">COPD/asthma</td><td class="colsep0 rowsep0" align="left">PI3Kδ</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK2636771</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kβ</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">idelalisib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kδ</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="left">Gilead</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IPI-549</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kγ</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Infinity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leniolisib</td><td class="colsep0 rowsep0" align="left">CDZ173</td><td class="colsep0 rowsep0" align="left">primary immunodeficiency disease</td><td class="colsep0 rowsep0" align="left">PI3Kδ</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LY3023414</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Lilly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nemiralisib</td><td class="colsep0 rowsep0" align="left">GSK2269557</td><td class="colsep0 rowsep0" align="left">COPD/asthma</td><td class="colsep0 rowsep0" align="left">PI3Kδ</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">omipalisib</td><td class="colsep0 rowsep0" align="left">GSK2126458</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">I/II</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PF-04691502</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Pfizer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pictilisib</td><td class="colsep0 rowsep0" align="left">GDC-0941</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Genentech</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pilaralisib</td><td class="colsep0 rowsep0" align="left">SAR245408; XL147</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Sanofi/Exelixis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RV-1729</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">COPD/asthma</td><td class="colsep0 rowsep0" align="left">PI3Kδ/γ</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">RespiVert</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sapanisertib</td><td class="colsep0 rowsep0" align="left">MLN0128; TAK-228; INK128</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Millenium</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAR260301</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kβ</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Sanofi</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serabelisib</td><td class="colsep0 rowsep0" align="left">MLN1117; INK1117; TAK-117</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kα</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Takeda</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SF1126</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K (prodrug)</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">SignalRx</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sonolisib</td><td class="colsep0 rowsep0" align="left">PX-866</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kα,γ,δ</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Oncothyreon</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">taselisib</td><td class="colsep0 rowsep0" align="left">GDC-0032</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kα/PI3Kβ-sparing</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Genentech</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tenalisib</td><td class="colsep0 rowsep0" align="left">RP6530</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kδ/γ</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Rhizen-Pharmaceuticals</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">umbralisib</td><td class="colsep0 rowsep0" align="left">TGR-1202</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3Kδ</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">TG Therapeutics</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">voxtalisib</td><td class="colsep0 rowsep0" align="left">SAR245409; XL-765</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Exelixis/Sanofi</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VS-5584</td><td class="colsep0 rowsep0" align="left">SB2343</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Verastem</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WX-037</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">WILEX AG</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZSTK474</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">pan-PI3K</td><td class="colsep0 rowsep0" align="left">not progressing</td><td class="colsep0 rowsep0" align="left">Zenyaku</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">For chemical structures, see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01492/suppl_file/jm8b01492_si_001.pdf" class="ext-link">Supporting Information (Table ST1)</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Source: Fruman et al.,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> PubChem.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Propeller-Shaped PI3Kδ-Selective Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2006, a series of compounds were disclosed<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> describing a new class of PI3K compounds that existed in a “propeller-shaped” configuration. The class of compounds exemplified by <b>1</b> (PIK-39) was more potent (>50-fold) toward the PI3Kδ isoform relative to the other class 1 PI3Ks. This selectivity was attributed to the unusual overall shape of the molecules, as typical “flat kinase inhibitors” bound in the ATP-binding pocket with no significant difference in activity between the PI3K isoforms. It was considered and demonstrated through X-ray crystallography<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> that the quinazolinone forces a key methionine (Met752 PI3Kδ numbering) that is conserved in all isoforms to move to accommodate the large quinazolinone group. This ligand-induced fit confers a conformational shift in the peptide backbone leading to a conformational change in the ATP-binding region, enhancing isoform selectivity in favor of the PI3Kδ isoform (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This unique binding mode has been the source of inspiration for many groups involved in the search for selective PI3Kδ inhibitors, and a summary of key findings will be discussed here.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of <b>1</b> (PIK-39) in PI3Kδ demonstrating the propeller-shape conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF">2WXF</a>), visualized in PyMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Idelalisib (<b>2</b>) was the first-in-class selective inhibitor of PI3Kδ, which was approved by the FDA in 2014 for use with patients with chronic lymphocytic leukemia (CLL), focular lymphoma (FL), and small lymphocytic lymphoma (SLL). Idelalisib was initially discovered by Calistoga and was later advanced by Gilead and represented an important advance in the search for highly selective PI3Kδ inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The European Medicines Agency (EMA), at the request of the European Commission, is currently reviewing idelalisib following concerns over serious adverse events in ongoing trials, mostly due to infections. TGR-1202 (<b>3</b>), a selective PI3Kδ inhibitor, is currently undergoing phase 2 studies to assess the safety and efficacy in patients with CLL who are intolerant to prior Bruton tyrosine kinase (BTK) or PI3Kδ inhibitor therapy. Duvelisib (<b>4</b>), a dual inhibitor of phosphoinositide 3-kinase PI3Kδ and PI3Kγ, was shown to be clinically active in advanced hematologic malignancies, and U.S. FDA approval is currently being sought in both FL and CLL. In addition, a structural analog tenalisib (<b>5</b>), a dual inhibitor of phosphoinositide 3-kinase PI3Kδ and PI3Kγ, recently obtained U.S. FDA fast track designations for treatment of relapsed/refractory peripheral T-cell lymphoma and relapsed refractory cutaneous T-cell lymphoma in addition to orphan-drug designations for treatment of peripheral and cutaneous T-cell lymphoma.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0030.gif" alt="" id="dgr1" /></img></div><div class="NLM_p">Unfortunately, to date, there has been no journal publication detailing the discovery of idelalisib. However, the ligand-bound X-ray crystal structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) revealed the rationale for the observed high PI3Kδ selectivity. Idelalisib binds in a similar conformation to <b>1</b> in the ATP binding site of the P110 catalytic subunit of PI3Kδ, with the purine forming two hydrogen bonds with key hinge residues (Val828 and Glu826).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of idelalisib bound to the ATP site of the P110 catalytic subunit of PI3Kδ showing the “propeller shape” adopted and the key hinge interactions with Val828 and Glu826 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XEO">4XEO</a>), visualized in PyMOL.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fluorine containing quinazolinone ring assumes a perpendicular conformation to the hinge binder and is embedded in a specificity pocket between Trp760 and Met752 that is closed in the apo structure of the enzyme. The phenyl ring adopts a binding conformation perpendicular to the quinazolinone ring and protrudes into a hydrophobic region out of the ATP-binding pocket. The improved PI3Kδ selectivity of these “propeller shaped” compounds is proposed to be a consequence of the lower energy requirement for the creation of the specificity pocket in PI3Kδ relative to the other class 1 PI3K isoforms. The remainder of this section will concentrate on new medicinal chemistry disclosures based around the core structures of compounds <b>2</b>–<b>5</b> disclosed since 2012, highlighting key areas of SAR and learning from the original papers.</div><div class="NLM_p">Scientists at Gilead Sciences investigated the replacement of the hinge binding purine ring present in idelalisb, which was a known primary site of metabolism.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The starting compound for their studies was <b>6</b>, as this had a combination of good activity (PI3Kδ IC<sub>50</sub> = 1 nM) and good overall isoform selectivity (1200 α/δ; 290 β/δ; 55 γ/δ).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">In their initial design, the purine was replaced with a series of substituted heterocyclic rings, maintaining the N-3 pyrimidine nitrogen and the 4-amino moiety which were believed to be essential for activity (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Unfortunately, the structural modification led to a 100-fold drop in potency of <b>7</b> (PI3Kδ IC<sub>50</sub> = 99 nM, selectivity of >100 α/δ, β/δ, γ/δ). It was suggested that the loss in potency was due to the removal of the N-7 nitrogen of the purine ring which participates in a water-mediated hydrogen bonding interaction. In addition, removal of the 4-amino group resulted in a large drop in potency <b>8</b> (PI3Kδ IC<sub>50</sub> = 1700 nM). The potency and isoform selectivity were recovered through the introduction of a 5-cyano group <b>9</b> (PI3Kδ IC<sub>50</sub> = 8 nM), <b>10</b> (PI3Kδ IC<sub>50</sub> = 0.4 nM, selectivity 4600 α/δ; 200 β/δ; 680 γ/δ); however, conversion to the pyridine analogue led to a drop-off in activity <b>11</b> (PI3Kδ IC<sub>50</sub> = 30 nM). Compound <b>10</b> was progressed to an in vivo metabolism study; however, its clearance (1.1 L h<sup>–1</sup> kg<sup>–1</sup>) was 5-fold higher from its predicted clearance derived from in vitro microsomes, signifying the possibility of extra hepatic aldehyde oxidase (AO) metabolism. This was confirmed by the addition of the known AO inhibitor raloxifene in metabolism studies. In the presence of raloxifene there was very little turnover in human hepatocytes, which was similar to that observed in human liver microsomes. In addition, metabolite identification demonstrated a major metabolite <b>12</b> (PI3Kδ IC<sub>50</sub> = 1500 nM). Extensive structure–activity relationship studies were initiated exploring modification of the pyrimidine ring to generate <b>13</b> (PI3Kδ IC<sub>50</sub> = 0.1 nM, selectivity 2200 α/δ; 80 β/δ; 60 γ/δ, hHeps 0.21, 0.10 (+raloxifene)). This was followed by derivatization of the phenyl ring and replacement of the 2-chloro substituent with a fluorine atom to give <b>14</b> (PI3Kδ IC<sub>50</sub> = 2.2 nM, selectivity 1900 α/δ; 650 β/δ; 180 γ/δ, <i>h</i>Heps 0.34 L h<sup>–1</sup> kg<sup>–1</sup>).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0031.gif" alt="" id="dgr2" /></img></div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Exploration of the Hinge Binding Groups Present in <b>2</b> (Idelalisib)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>14</b> offered a favorable combination of biochemical potency, isoform selectivity, and metabolic stability. Additionally, when tested in a whole blood basophil cellular assay, <b>14</b> inhibited PI3Kδ with an EC<sub>50</sub> of 1 nM. In a KinomeScan screen against 395 nonmutant kinases <b>14</b> displayed a high degree of kinase selectivity. When administered in vivo, <b>14</b> demonstrated low to intermediate total clearance in both rat (0.74 L h<sup>–1</sup> kg<sup>–1</sup>) and dog (0.58 L h<sup>–1</sup> kg<sup>–1</sup>), high volumes of distribution, and high oral bioavailability (rat <i>F</i> = 106 ± 24%) and (dog <i>F</i> = 100 ± 40%), suggesting a good profile for target coverage at predicted trough concentrations after twice-daily dosing. Additionally, in a rat whole blood assay, <b>14</b> inhibited ex vivo anti-IgD stimulation of B cells with EC<sub>50</sub> and EC<sub>90</sub> values of 11 and 100 nM, respectively. Therefore, <b>14</b> was progressed to a rat collagen-induced arthritis (CIA) model. In this model, dosing of <b>14</b> to rats with established CIA showed a significant and dose-dependent reduction in ankle swelling. In addition, a pharmacokinetic/pharmacodynamic (PK/PD) correlation between plasma concentration and efficacy was established. Although <b>14</b> proved to be a good compound for in vivo concept testing, it was still predicted to require twice-daily dosing, and so Gilead scientists explored further refinement to reduce clearance and improve half-life.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> A correlation had been shown between a reduction of calculated lipophilicity (cLogP) and predicted clearance in <i>h</i>Heps.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Replacement of the phenyl group present in <b>14</b> (cLogP = 3.0) with a pyridine ring gave <b>15</b> (cLogP = 1.6, PI3Kδ IC<sub>50</sub> = 0.6 nM), a compound with lower predicted clearance and excellent isoform selectivity (selectivity 1720 α/δ; 167 β/δ; 120 γ/δ, <i>h</i>Heps = 0.34 L h<sup>–1</sup> kg<sup>–1</sup>). When dosed in rats, <b>15</b> had a good overall PK profile (CL = 1.5 ± 0.13 L h<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> = 1.9 ± 0.3 L/kg; <i>t</i><sub>1/2</sub> = 2.5 ± 1.4 h; <i>F</i> = 42%). However, it was demonstrated that the pyridine-containing compounds degraded rapidly at low pH due to ring opening of the quinazolinone ring, mediated through protonation of the pyridine nitrogen. A strategy to reduce the basicity of the N-1 quinazolinone nitrogen by substitution with small electron withdrawing groups in the 5- and 8-positions on the quinazolinone ring resulted in <b>16</b> (PI3Kδ IC<sub>50</sub> = 0.4 nM, cpK<sub>a</sub> = 0.28), a compound with a reduced N-1 basicity compared to <b>15</b> (cpK<sub>a</sub> = 1.97). This change resulted in a 7-fold increase in chemical stability (<i>T</i><sub>1/2</sub> = 19 h) when measured at 40 °C, pH 2. Further SAR through changing the methyl substituent to a cyclopropyl group afforded <b>17</b>, which was selected as the preclinical development candidate as GS-9901 (PI3Kδ IC<sub>50</sub> = 1 nM, selectivity 750 α/δ; 100 β/δ; 190 γ/δ, stability at 40 °C, pH 2, <i>T</i><sub>1/2</sub> = 20 h, rat PK CL = 0.43 L h<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> = 0.83 L/kg; <i>F</i> = 57%).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0032.gif" alt="" id="dgr3" /></img></div><div class="NLM_p">Further exploration to build PI3Kβ potency into the PI3Kδ-selective template was achieved through targeting of the nonconserved PI3Kβ Asp856 in the hydrophobic region of class 1 PI3Ks. This was achieved through incorporation of an H-bond donor moiety on the phenyl ring (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Building on PI3Kδ inhibitor idealisib to generate the PI3Kα/β inhibitor <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In their initial work they replaced the phenyl ring in idelalisib (<b>2</b>) with a 4-phenol group to give <b>18</b> (PI3Kδ IC<sub>50</sub> = 14 nM; PI3Kβ IC<sub>50</sub> = 2.7 nM; PI3Kα IC<sub>50</sub> = 1600 nM; PI3Kγ IC<sub>50</sub> = 4300 nM). This change led to a large increase in PI3Kβ activity compared to <b>2</b> (PI3Kδ IC<sub>50</sub> = 18 nM; PI3Kβ IC<sub>50</sub> = 3700 nM; PI3Kα IC<sub>50</sub> = 7500 nM; PI3Kγ IC<sub>50</sub> = 2100 nM), demonstrating that the concept of targeting the nonconserved Asp856 present in PI3Kβ was correct, to increase PI3Kβ activity. Further SAR studies demonstrated that the phenol could be replaced with a pyrazol-3-yl group <b>19</b> (PI3Kδ IC<sub>50</sub> = 0.6 nM; PI3Kβ IC<sub>50</sub> = 2.5 nM; PI3Kα IC<sub>50</sub> = 82 nM; PI3Kγ IC<sub>50</sub>= 990 nM) with slightly improved physicochemical properties, although selectivity over PI3Kα was compromised. Unfortunately, the addition of the further H-bond donor groups dramatically decreased permeability <b>20</b> as well as decreased metabolic stability. Further structural modifications afforded <b>21</b> (PI3Kδ IC<sub>50</sub> = 5.3 nM; PI3Kβ IC<sub>50</sub> = 7.8 nM; PI3Kα IC<sub>50</sub> = 850 nM; PI3Kγ IC<sub>50</sub> > 10000 nM; Caco-2 (AB/BA) 5.7/21.7 × 10<sup>6</sup> cms<sup>–1</sup>; rat PK CL = 0.26 L h<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> = 0.52 L/kg; <i>F</i> = 66 ± 17%) as a potent and selective PI3Kβ/δ inhibitor with good pharmacokinetic properties that demonstrated efficacy in a PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.</div><div class="NLM_p">Scientists at Amgen were also inspired by the rationalization of the PI3Kδ/β isoform selectivity imposed by the induced fit of the propeller-shaped compounds. In 2012 they reported the discovery and in vivo evaluation of a series of dual PI3Kδ/β inhibitors for the treatment of inflammatory diseases. A series of constrained and highly substituted 4-aminoquinolines (e.g., <b>22</b>–<b>25</b>) were prepared. After several rounds of SAR, <b>22</b> (PI3Kδ IC<sub>50</sub> = 30 nM; PI3Kβ IC<sub>50</sub> = 58 nM; PI3Kα IC<sub>50</sub> = 3960 nM; PI3Kγ IC<sub>50</sub> = 2010 nM) became a promising lead. The addition of a pyridine ring led to a slight increase in activity and selectivity (PI3Kδ IC<sub>50</sub> = 7 nM; PI3Kβ IC<sub>50</sub> = 30 nM; PI3Kα IC<sub>50</sub> = 1720 nM; PI3Kγ IC<sub>50</sub> = 92 nM). Replacement of the hinge binding morpholine with other heterocycles could be achieved, although PI3Kδ/β isoform selectivity was reduced, e.g., <b>24</b> (PI3Kδ IC<sub>50</sub> = 3 nM; PI3Kβ IC<sub>50</sub> = 18 nM; PI3Kα IC<sub>50</sub> = 510 nM; PI3Kγ IC<sub>50</sub> = 28 nM). The addition of a tetrahydropyran ring afforded a compound with enhanced water solubility, improved selectivity and good in vivo pharmacokinetics <b>25</b> (PI3Kδ IC<sub>50</sub> = 11 nM; PI3Kβ IC<sub>50</sub> = 44 nM; PI3Kα IC<sub>50</sub> = 3250 nM; PI3Kγ IC<sub>50</sub> = 509 nM, sol. (PBS) 146 mg/μL, rat PK CL 0.8 L h<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> 3.3 L/kg; <i>F</i> = 65%). Compound <b>25</b> was found to be efficacious in several inflammation models including a keyhole limpet hemocyanin study and a collagen-induced arthritis model.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0033.gif" alt="" id="dgr4" /></img></div><div class="NLM_p">Further investigation of this class of compound initially explored the linker group between the quinoline bicycle and the purine hinge binder (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Discovery of the selective PI3Kδ inhibitor <b>33</b> (AMG319).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although <b>26</b> (PI3Kδ IC<sub>50</sub> = 0.24 μM) was a reasonable starting point, the thioether was highlighted as a potential metabolic liability and SAR exploration revealed that the ether linkage <b>27</b> (PI3Kδ IC<sub>50</sub> = 0.017 μM) had higher enzymatic activity, whereas the methylene linker <b>29</b> was much less active (PI3Kδ IC<sub>50</sub> = 3.6 μM). In addition, because of specific ligand–protein interactions, there was a demonstrable difference between the enantiomers <b>30</b> ((<i>S</i>)-enantiomer PI3Kδ IC<sub>50</sub> = 7.1 nM) and <b>31</b> (PI3Kδ IC<sub>50</sub> = 2.6 μM) due to a steric clash between the (<i>R</i>)-methyl and the protein. Importantly, the amino linker <b>28</b> (PI3Kδ IC<sub>50</sub> = 0.041 μM) had a similar level of activity to <b>27</b> which was mirrored in the preference for the (<i>S</i>)<b>-</b>enantiomer <b>32</b> (PI3Kδ IC<sub>50</sub> = 8 nM). Unsurprisingly, the compounds proved poorly soluble and had high microsomal instability displaying poor rat pharmacokinetics. Extensive SAR to optimize biological activity, isoform selectivity and CYP2D6 inhibition was achieved. Removal of the 8-methyl group and subsequent fluorination of the quinoline ring in addition to substitution of the 2-aryl group with a 2-pyridyl group led to an increase in solubility and improvement in rat pharmacokinetics. The detailed SAR study eventually resulted in the identification of <b>33</b> (PI3Kδ IC<sub>50</sub> = 18 nM; PI3Kβ IC<sub>50</sub> = 2.7 μM; PI3Kα IC<sub>50</sub> = 33 μM; PI3Kγ IC<sub>50</sub> = 0.85 μM, sol. (PBS) 146 mg/μL, rat PK CL = 0.34 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 54%). Compound <b>33</b> had excellent activity in a whole blood assay (IC<sub>50</sub> = 16 nM) and selectivity over a large panel of kinases. In addition, <b>33</b> displayed a high level of in vivo efficacy as measured in two rodent disease models of inflammation and is currently being evaluated in phase 2 clinical trials for the treatment of human papillomavirus (HPV) and negative head and neck squamous cell carcinoma (HNSSCC).</div><div class="NLM_p">In a series of papers and patent disclosures, Amgen scientists demonstrated that the core quinoline scaffold present in <b>22</b>–<b>33</b> could be exchanged for a wide range of heterocycles<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> in combination with exchanging the purine ring for other hinge binding motifs. The regioisomeric quinoline underwent extensive SAR studies exploring substitution at the quinoline 4-position, as typified by compound <b>34 (</b>PI3Kδ IC<sub>50</sub> = 2.4 nM, rat PK CL = 0.057 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 51%).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In an additional publication,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> exploration of the quinoline with a novel 4-carboxamide group generated compounds as typified by <b>35 (</b>PI3Kδ IC<sub>50</sub> = 2.9 nM; rat PK CL = 0.51 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 70%) and <b>36 (</b>PI3Kδ IC<sub>50</sub> = 4.6 nM; rat PK CL = 0.42 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 29%), with very high selectivity over the class 1 PI3K isoforms <b>35</b> (6068 α/δ; 979 β/δ; 1217 γ/δ), <b>36</b> (3082 α/δ; 478 β/δ; 700 γ/δ). <b>36</b> had selectivity against a panel of 442 protein kinases as well as excellent cellular potency in mouse B cells (pAKT IC<sub>50</sub> = 0.7 nM and 0.8 nM, respectively). Efficacy experiments in a key rat limpet hemocyanin model demonstrated that administration of <b>35</b> or <b>36</b> resulted in a strong dose-dependent reduction in IgG and IgM antibodies, making the compounds suitable for preclinical development.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0034.gif" alt="" id="dgr5" /></img></div><div class="NLM_p">In a final publication<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> the quinoline core was exchanged for a substituted benzimidazole, resulting in the disclosure of two further preclinical candidates with good pharmacokinetic properties: <b>37</b> (PI3Kδ IC<sub>50</sub> = 16 nM; PI3Kβ IC<sub>50</sub> = 1.78 μM; PI3Kα IC<sub>50</sub> = 58.2 μM; PI3Kγ IC<sub>50</sub> = 5.8 μM; mouse B cell (pAKT) IC<sub>50</sub> = 4.6 nM; rat PK CL = 0.93 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 45%); <b>38</b> (PI3Kδ IC<sub>50</sub> = 19 nM; PI3Kβ IC<sub>50</sub> = 2.33 μM; PI3Kα IC<sub>50</sub> = 27.2 μM; PI3Kγ IC<sub>50</sub> = 5.9 μM; mouse B cell (pAKT) IC<sub>50</sub> = 4.2 nM; rat PK CL = 0.99 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 41%). The compounds inhibited B cell receptor (BCR)-mediated AKT phosphorylation (pAKT) in PI3Kδ-dependent in vitro cell based assays and were effective when administered in vivo at unbound concentrations consistent with their in vitro cell potency as a consequence of improved unbound drug concentration (0.36, 0.32 respectively fraction unbound (rat)) with lower unbound clearance. In addition, the compounds demonstrated efficacy in a rat keyhole limpet hemocyanin, where the blockade of PI3Kδ activity led to effective inhibition of antigen-specific IgG and IgM formation after immunization with KLH.</div><div class="NLM_p">Erra et al. reported on a series of selective PI3Kδ inhibitors based on a pyrrolotriazine scaffold (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Moving the methyl group from the phenyl ring in <b>39 (</b>PI3Kδ IC<sub>50</sub> = 130 nM) to the linker in <b>40 (</b>PI3Kδ IC<sub>50</sub> = 75 nM) not only resulted in a slight increase in activity but also removed the potential for atropisomerism. Extensive SAR studies exploring the hinge binder, linker, and substitution on the pyrrolotriazine resulted in <b>41</b> (PI3Kδ IC<sub>50</sub> = 2.6 nM; PI3Kβ IC<sub>50</sub> = 94 μM; PI3Kα IC<sub>50</sub> = 8.2 μM; PI3Kγ IC<sub>50</sub> = 72 μM; M-CSF-induced AKT in THP-1 cells IC<sub>50</sub> = 7.8 nM; rat PK CL = 1.4 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub><i>z</i></sub> = 1.2 L/kg ; <i>F</i> = 98%) and entered clinical development as LAS191954 for the treatment of pemphigus.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Discovery of <b>41</b> (LAS191954) through an Extensive SAR Exploration</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Wei et al. reported on the synthesis and evaluation of 5-alkynyl substituted quinazolin-4(3<i>H</i>)-ones as selective PI3Kδ inhibitors.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Interestingly, they also reported on a series of analogs where the hinge binder is linked to the quinazolin-4(3<i>H</i>)-one via a four- or five-membered ring. The optimal compounds had good potency, e.g., <b>42</b> (PI3Kδ IC<sub>50</sub> = 6.7 nM), <b>43</b> (PI3Kδ IC<sub>50</sub> = 7.1 nM), demonstrating that the incorporation of the ring linking group was not detrimental to biological activity. In addition, the compounds had good selectivity over PI3Kα (133-fold) and good cellular activity of IC<sub>50</sub> = 37.2 nM and 58.9 nM in a SU-DHL-6 cell line challenge.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0035.gif" alt="" id="dgr6" /></img></div><div class="NLM_p">Evans et al. from Infinity Pharmaceuticals described the discovery of a series of selective PI3Kγ inhibitors for the treatment of immuno-oncology diseases.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Once again starting from the 8-Cl isoquinolone core, a series of hinge binding groups were explored resulting in the discovery of a substituted pyrazolo[1,5-<i>a</i>]pyrimidine as a new hinge binding motif. Interestingly, this change resulted in a PI3Kγ-selective inhibitor, e.g., <b>44</b> (PI3Kδ IC<sub>50</sub> = 400 nM; PI3Kγ IC<sub>50</sub> = 40 nM). Further SAR of the C-8 alkynyl substitution in <b>45</b> (PI3Kδ IC<sub>50</sub> = 700 nM; PI3Kγ IC<sub>50</sub> = 14 nM) resulted in the discovery of <b>46</b> (PI3Kδ IC<sub>50</sub> > 8400 nM; PI3Kγ IC<sub>50</sub> = 16 nM), a compound with very good mouse hepatocyte stability (<i>T</i><sub>1/2</sub> = 6 h) and selectivity over other lipid kinases. In addition, <b>46</b> demonstrated favorable pharmacokinetic properties (mouse PK CL = 3.6 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> = 10.8 L/kg; <i>F</i> = 88%) and showed robust inhibition of PI3Kγ mediated neutrophil migration in vivo and is currently in phase 1 clinical trials in patients with advanced solid tumors as IPI-549 for a monotherapy or in combination with pembrolizumab (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Exploration of the Hinge Binding Regions and Introduction of a C-8 Alkynyl Substituent</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the search for further new hinge binding motifs Srinivas et al. used the Huisgen cycloaddition reaction to synthesize a range of 1,4-substituted 1<i>H</i>-12,3-triazoloquinazolin-4(3<i>H</i>)-ones (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The chemistry resulted in the identification of a series of weak PI3Kδ inhibitors, e.g., <b>47</b> (PI3Kδ IC<sub>50</sub> = 5 μM; PI3Kβ IC<sub>50</sub> = 430 μM; PI3Kα IC<sub>50</sub> = 250 μM; PI3Kγ IC<sub>50</sub> = 1 μM).</div><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Huisgen Cycloaddition To Generate a Range of Analogs Such as <b>47</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Perry et al. disclosed the synthesis of soluble and cell-permeable PI3Kδ inhibitors for long-acting inhaled administration for the treatment of asthma (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Incorporation of dibasic groups to improve lung tissue retention after delivery through inhalation</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The novel thiazolidinpyridone core was substituted to give <b>48</b>, a potent and selective PI3Kδ inhibitor (PI3Kδ pIC<sub>50</sub> = 9.4; PI3Kβ pIC<sub>50</sub> = 7.3; PI3Kα pIC<sub>50</sub> = 6.2 μM; PI3Kγ pIC<sub>50</sub> = 7.9). Unfortunately, the compound had modest solubility and had no detectable level in lung tissue when dosed through inhalation (i.t.). An X-ray crystal structure of <b>48</b> in PI3Kδ revealed that substitution of the aryl group in the <i>meta-</i>position (group R) was favorable to position a potential solubilizing group into the exposed solvent. In light of this, a strategy was evolved to attach a (di)basic group to improve both the solubility and lung tissue retention.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> This resulted in <b>49</b> (PI3Kδ pIC<sub>50</sub> = 9.3); however this compound was not retained in lung tissue for sufficient time to have a pharmacodynamic effect. The addition of a dibasic group, e.g., <b>50</b> (PI3Kδ pIC<sub>50</sub> = 9.3) and <b>51</b> (PI3Kδ pIC<sub>50</sub> = 9.2) gave compounds with excellent solubility and lung pharmacokinetic half-lives of 23.2 and 9.9 h, respectively. However, dibasic compounds generally exhibit poor cell permeability resulting in a decrease in activity from the isolated enzyme activity. Perry et al. describe the basicity and lipophilicity requirements to balance lung tissue retention and cell permeability and suggested the overall driver of cell permeability was lipophilicity and concluded if log <i>D</i> is greater than ∼1.6, then a compound with a good enzyme activity will most probably have good cell potency, and this was reflected in the cell-based potency of pIC<sub>50</sub> of 8.0 and 8.9, respectively.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Flat PI3K Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0036.gif" alt="" id="dgr7" /></img>In 2008, Folkes et al. from Genentech disclosed the synthesis and biological evaluation of a series of thieno[3,2-<i>d</i>]pyrimidines that demonstrate potent inhibition of PI3Kα culminating in the discovery of the pan PI3K inhibitor pictilisib <b>52</b> (GDC-0941).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A crystal structure of <b>52</b> bound to PI3Kγ was obtained demonstrating a binding mode that many compounds in this Perspective section share: the morpholine oxygen forms a pivotal hydrogen bond to the hinge region of the kinase via the amide of Val882, and the indazole moiety points toward the affinity pocket where the indazole nitrogen atoms make key interactions with the carboxyl group of Asp841 and the phenol oxygen of Tyr867.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, the 4-methanesulfonylpiperazin-1-ylmethyl group extends out to solvent where the piperazine ring packs against the side chain of Met804, and the sulfonyl group oxygen atoms are within hydrogen bond distance of the side chain of Lys802 and the amide nitrogen of Ala805 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. X-ray crystal structure of <b>52</b> (GDC-0941) in PI3Kγ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS">3DBS</a>) visualized in PyMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In their discovery, Genentech scientists utilized the thienopyrimidine <b>53</b> previously identified by Hayakawa et al.,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> which was shown to be potent against PI3Kα and showed significant antiproliferative activity in vitro. However, the PK profile of <b>53</b> was poor with a half-life of less than 10 min after interperitoneal administration in mice, and at the onset of the project, Genentech’s scientists aim was to improve upon physicochemical properties, metabolic stability, and potency of <b>53</b>.</div><div class="NLM_p">Initially, the importance of the morpholine ring for P13K activity was shown when its substitution resulted in large reductions in potency; thus the morpholine group on all further derivatives was maintained.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Methyl substitutions at the 6- and 7-position on the thienopyrimidine ring was investigated showing that 6-Me substitution <b>54</b> (PI3Kα IC<sub>50</sub> = 6 nM) was well tolerated but 7-Me substitution showed a decrease in activity <b>55</b> (PI3Kα IC<sub>50</sub> = 21 nM). Effort was focused on the 6-position to block metabolism at this position. From the large range of active substituents, the addition of tertiary amines offering the potential for salt formation to aid kinetic solubility dissolution rates as well as in vivo absorption and tumor exposure proved promising. Of these, the piperazine analogs, such as <b>56</b> (PI3Kα IC<sub>50</sub> = 10 nM), displayed enhanced metabolic stability in human and mouse microsomes (85–90%). However, they exhibited low bioavailability in mouse and rat (<i>F</i> = 0–11%) mainly due to glucuronidation of the phenol. This metabolic liability led to the exploration of bioisostere replacements using hydrogen bond donating heterocyclic groups. Ultimately, these changes led to the discovery of <b>52</b> (IC<sub>50</sub> PI3Kα = 0.003 μM, PI3Kβ = 0.033 μM, PI3Kδ = 0.003 μM, PI3Kγ = 0.075 μM, mTOR = 0.58 μM). Acceptable oral bioavailability was achieved in all species tested including mouse (77%), rat (30%), dog (71%), and monkey (20%).</div><div class="NLM_p">Good levels of selectivity were observed for <b>52</b> when tested against members of PI3K classes II, III, and IV, including C2β (0.670 μM), Vps34 (>10 μM), DNA-PK (1.23 μM), and mTOR (0.58 μM). Additionally, <b>52</b> displayed outstanding selectivity for the PIK family kinases over a panel of 228 kinases in the kinase profiler panel from Millipore (formerly Upstate Biotechnologies). Only two kinases displayed greater than 50% inhibition at 1 μM. Flt3 displayed 59% inhibition, and TrkA displayed 61% inhibition by <b>52</b> μM, (IC<sub>50</sub> = 2.85 μM). <b>52</b> showed minimal inhibition of six of the principal cytochrome P450 isoforms, and at a concentration of 25 μM there was negligible induction of CYP1A and CYP3A4. There was also no significant blockade of the <i>h</i>ERG channel (IC<sub>50</sub> = 64 μM) in the patch clamp assay. <b>52</b> was progressed to in vivo studies, and it was found that <b>52</b> exhibited a strong inhibitory effect on the growth of human U87MG glioblastoma xenografts in athymic mice (tumor growth inhibition of 83%). <b>52</b> progressed to phase I and II clinical trials, but further studies have been not progressed at this time.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0037.gif" alt="" id="dgr8" /></img></div><div class="NLM_p">In 2009, with increasing evidence of clinical need for a dual mTOR/PI3K inhibitor, Genentech scientists set out to build mTOR activity into <b>52</b>. They used Piramed’s PI-103 (<b>57</b>) as a tool compound as it contained the morpholinopyrimidine core and was known to inhibit mTOR and the PI3Ks. They aimed to improve clearance of the compounds while maintaining or improving on potency and solubility. Additionally, analogs containing a methyl group on the thienopyrimidine core (<b>54</b>, <b>55</b>) showed that it was possible to inhibit both mTOR and class 1 PI3Ks simultaneously.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a></div><div class="NLM_p">When the indazole group in <b>52</b> was replaced with 2-aminopyrimidine <b>58</b>, a 20-fold increase in mTOR activity was observed (from 570 nM to 29 nM). However, this change did not dramatically change the proliferation potency. The microsomal stability data correlated well with in vivo data except in dog pharmacokinetic studies, where a methyl substitution on the core was required to improve dog clearance <b>59</b> (GNE-477, PI3Kα IC<sub>50</sub> = 4 nM, mTOR IC<sub>50</sub> = 21 nM).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">However, these structural changes led to solubility issues and the design focus moved to improving compound solubility while maintaining the good biological and pharmacokinetic properties. This was achieved by considering changes to the solvent exposed sulfonamide. A series of piperazine amides were prepared to maintain the neutral charge of the distal amine using both amino and hydroxy acids with and without substitution at the 7-position to modulate metabolic stability (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Chemical Exploration of the Piperizine Group through Amidation To Deliver (<i>S</i>)-<b>61</b> (Apitoloisib)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Amine-based analogs all had good potency <b>60</b> (PI3K<sub>α</sub> IC<sub>50</sub> = 1.0 nM, mTOR IC<sub>50</sub> = 14 nM) and showed good improvement in solubility (1.0 mg/mL, pH 6.5). However, bioavailability was poor (<i>F</i> = 6%). The alcohol-based amides, such as (<i>S</i>)-<b>61</b> and (<i>R</i>)-<b>61</b>, showed much better PK properties giving reasonable solubility (0.084 mg/mL, pH 6.5), low to moderate predicted human clearance (3.1–6.5 mg min<sup>–1</sup> kg<sup>–1</sup>), and good oral bioavailability (<i>F</i> = 77–100%). The enantiomer (<i>R</i>)-<b>61</b> demonstrated reduced biochemical activity and increased microsomal stability compared with (<i>S</i>)-<b>61</b> and was chosen for further study due to its low predicted clearance in human (3.1 mL min<sup>–1</sup> kg<sup>–1</sup>), its low in vivo clearance in rat (15 mL min<sup>–1</sup> kg<sup>–1</sup>), and its high oral bioavailability (<i>F</i> = 100%).</div><div class="NLM_p">The in vivo profile of (<i>S</i>)-<b>61</b> was characterized through PK studies conducted in several different species. Clearance was low (predicted Cl<sub>h</sub> = 33 mL min<sup>–1</sup> kg<sup>–1</sup>, Cl<sub>p</sub> = 9.2 mL min<sup>–1</sup> kg<sup>–1</sup>), PPB was low (71%), solubility was good (0.084 mg/mL, pH 6.5), and the volume of distribution was 1.7 L/kg. The maximum tolerated dose of (<i>S</i>)-<b>61</b> was found to be 7.5 mg/kg, and at this dose tumor stasis or regression was observed in PC-3 and MCF-7 neo/HER2 mouse xenograft models. This is likely due to the high cellular potency, low plasma clearance, and relatively high free-fraction of the drug in vivo. (<i>S</i>)-<b>61</b> was found to show a high degree of selectivity over off-target kinases even while maintaining dual inhibition of mTOR and the PI3K isoforms. This was confirmed by Invitrogen’s SelectScreen panel. Of the 240 kinases in the panel, only 5 other kinases consistently showed greater than 60% inhibition when treated with 1 μM (Fgr 697 nM, Mlk1 232 nM, PAK4, Syk 134 nM, and Yes1). (<i>S</i>)-<b>61</b> was highly selective over closely related PIKK family kinases: C2α (1300 nM), C2β 794 nM, VPS34 2000 nM, and DNA-PK 623 nM. (<i>S</i>)-<b>61</b> (GDC-0980, Apitolisib) was advanced into development and is currently in phase I and II clinical trials.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0038.gif" alt="" id="dgr9" /></img></div><div class="NLM_p">Having disclosed a pan-PI3K and a pan PI3K/mTOR inhibitor, Genentech scientists disclosed the development of a series of PI3Kδ-selective compounds<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> including <b>62</b> (PI3Kδ = 1.8 nM, δ/α = 129, δ/β = 104, δ/γ = 1444) which used a 4-substituted indole as the phenol bioisostere replacement. They hypothesized that although the residues in the affinity pocket are highly conserved between the PI3K isoforms, disruption of the strong hydrogen bond between the indazole nitrogen atom and Tyr867 could radiate and extend past the conserved affinity pocket resulting in undesirable conformational changes for the antitargets (α, β, γ), thereby providing PI3Kδ specificity when the indazole is replaced with an indole. Although this bioisosteric replacement led to improvements in selectivity, they also observed dramatic differences in time-dependent CYP3A4 inhibition, which could lead to autoinhibition and poor drug–drug interactions. They employed several strategies to reduce this time-dependent inhibition to develop <b>63</b> (PI3Kδ = 12.3 nM, δ/α = 50, δ/β = 815, δ/γ = 112). Unfortunately, they were unsuccessful in identifying an indole containing compound with the combination of reduced time-dependent inhibition, acceptable potency, selectivity, and drug-like properties.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0039.gif" alt="" id="dgr10" /></img></div><div class="NLM_p">After their previous programs that led to the discovery of <b>52</b> and (<i>S</i>)-<b>61</b>, Heffron et al. extended the study toward brain penetrant inhibitors.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Compound <b>52</b> ([brain]<sub>u</sub>/[plasma]<sub>u</sub> ≤ 0.05) and (<i>S</i>)-<b>61</b> ([brain]<sub>u</sub>/[plasma]<sub>u</sub> ≤ 0.05) were found to poorly penetrate the blood–brain barrier (BBB), which was attributed to efflux by the two most prevalent transporters in the BBB, P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1). The properties of these compounds are markedly different from marketed drugs that target the CNS, where the median values are MW = 305, HBD = 1, TPSA = 45, and cLogP = 2.8. In order to bring these properties in line with the median, they initially truncated the solvent exposed regions of the compounds, showing that the compounds retained biological activity. Additionally, using a central nervous system multiparameter optimization (CNS MPO) scoring system (a score of 0–6) which was shown to display a correlation between higher CNS MPO score and low Pgp efflux, they prioritized the synthesis of compounds that have a CNS MPO score of ≥4.5 for their study. Of the molecules they made prior to implementing an in silico evaluation, 53% had high efflux mediated by P-gp and 66% by Bcrp1. After employment of the CNS MPO score of ≥4.5 as a filter, new compounds were more than twice as likely as those made before to have low efflux as a result of either P-gp or Bcrp1 transporters. This design strategy led to the discovery of <b>64</b> ([brain]<sub>u</sub>/[plasma]<sub>u</sub> = 0.5, PI3Kα = 1 nM, mTOR = 10 nM) and <b>65</b> ([brain]<sub>u</sub>/[plasma]<sub>u</sub> = 0.4, PI3Kα = 2 nM, mTOR = 9 nM). Both compounds were highly potent brain penetrant PI3K/mTOR inhibitors. Furthermore, compounds <b>64</b> and <b>65</b> were evaluated in a panel of 59 kinases provided by Invitrogen’s SelectScreen service. Only <b>65</b> inhibited any kinase in the panel by >75% at 1 μM concentration of the test compound (PI3KC2β, 77%).</div><div class="NLM_p">By utilizing the highly selective substituted indole group as a bioisostere for the phenol group, Sutherlin et al. reported a highly selective PI3Kδ compound, <b>66</b> (PI3Kδ = 3.8 nM, δ/α = 340, δ/β = 200, δ/γ = 410).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Additionally, they reported that the methyl groups of the tertiary alcohol of <b>66</b> could form hydrophobic contacts with the face of Trp760. This interaction would allow them to specifically target the space created by the Thr750 side chain in PI3Kδ, which is electronically and structurally distinct from the residues found in PI3Kα, β, and γ (Arg770, Lys771, and Lys802, respectively). This hydrophobic region present in PI3Kδ is often referred to as the “tryptophan shelf”. Compound <b>66</b> was progressed to in vivo studies in mouse and rat and showed moderate hepatic clearance (53 mL min<sup>–1</sup> kg<sup>–1</sup> and 59 mL min<sup>–1</sup> kg<sup>–1</sup>, respectively). Reasonable half-lives were observed upon oral dosing (2.6–5 h and 2.6–4 h, respectively) as well as good oral bioavailability (80% and 90%, respectively).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0040.gif" alt="" id="dgr11" /></img></div><div class="NLM_p">Murray et al. identified benzimidazole-based inhibitors of PI3Kδ with improved selectivity against other PI3K isoforms as well as improved in vitro and in vivo pharmacokinetic properties.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> They initially looked at modification of the central heterocycle, which they hypothesized would allow them to tune the interaction of the solvent region of the inhibitors with the “tryptophan shelf”. They explored a range of heterocyclic replacements and found that purines were interesting replacements for the thienopyrimidine, as these inhibitors were inactive against PI3Kγ and only weak inhibitors of PI3Kβ. The calculated ground state conformation of the purines indicated that a low-energy conformation is adopted in which the purine and benzimidazole rings are coplanar. Further optimization of PI3Kδ selectivity was achieved by increasing interactions with Trp760 through substitution of the solvent exposed group with alternative sterically demanding amines, compounds containing a hydrophobic groups attached to the piperazine ring, bulky amine groups, and azetidines. Although substitution with the 4-methanesulfonylpiperazine of <b>52</b> resulted in a significant increase in activity versus PI3Kα and PI3Kγ, <b>67</b> (PI3Kδ = 2 nM, δ/α = 100, δ/γ = 260) is a representative example of the series; it is soluble in aqueous solution (sol. at pH 6.5 = 338 μg/mL) and has good permeability in a standard MDCK assay (<i>P</i><sub>app</sub> = 16 × 10<sup>–6</sup> cm/s). Rat (90%) and human (91%) plasma protein binding were moderate/good. There was no reversible or time-dependent CYP inhibition associated with <b>67</b> in testing against five CYP isoforms. Additionally, very weak inhibition (less than 25% inhibition at 1 μM) was observed against a panel of 55 diverse kinases. Pharmacokinetic profiling of <b>67</b> indicated that it had moderate to low clearance, CL(rat) = 34 mL min<sup>–1</sup> kg<sup>–1</sup> and a <i>V</i><sub>ss</sub> of 6.5 L/kg and <i>T</i><sub>1/2</sub> = 2.6 h.</div><div class="NLM_p">Safina et al. reported<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> that inhibitors such as <b>67</b> were found to induce micronuclei formation in both the micronucleus test (MNT) and human chromosome aberration (HCA) assays in the absence of compound metabolism using the liver S9 fraction (-S9). However, it was determined to be nongenotoxic in the Ames test, suggesting that neither the MNT nor HCA result was directly linked to DNA mutation. They reported that genotoxicity SAR suggested that it was the combination of the purine core with the benzimidazole moiety that was responsible for the observed genotoxicity. Initially compounds that tested negative in the MNT assay were successfully identified through modifications of the molecular volume of the 2-benzimidazole. However, while they were exploring the conformational preferences required for selectivity toward PI3Kδ, they simultaneously explored the effects of substitution and conformational restriction on genotoxicity. They designed analogs that altered the dihedral angle between the amine group and the purine N-7, mainly by substitution of the methylene carbon with heteroatoms. Through crystallographic and docking studies, the preferred dihedral angle was determined to be 10–30°. This led to the discovery of <b>68</b>, where an isopropyl group increases the molecular volume of the 2-benzimidazole and an oxygen linker favors a torsional angle of <30°. <b>68</b> tested negative in the HCA assay and exhibited excellent PI3K isoform selectivity (PI3K δ = 0.47 nM, δ/α = 256, δ/β = 420, δ/γ = 219) and broad kinase selectivity through Invitrogen’s 239 kinase panel at 1 μM; only B-Raf was inhibited at 61% and PI4Kβ at 71%. Additionally, <b>68</b> possessed favorable pharmacokinetic properties with low predicted hepatic clearance in human (1.7 mL min<sup>–1</sup> kg<sup>–1</sup>) and moderate permeability (MDCK <i>P</i><sub>app</sub>(A to B) = 8.23 × 10<sup>–6</sup>) which led to high oral absorption across species (<i>F</i> = 82–100%) and acceptable half-lives (<i>T</i><sub>1/2</sub> = 2.59–11.6 h).</div><div class="NLM_p">Unfortunately, the series of thienopyrimidine containing brain penetrant PI3K inhibitors were deemed not suitable for clinical development due to projected poor metabolic human stability. With the knowledge that desirable metabolic stability was attainable with a purine scaffold they evaluated purine-based analogs of their previous thienopyrimidine series, ultimately resulting in <b>69</b> (GDC-0084 PI3Kα = 2 nM, mTOR = 0.07 μM). <b>69</b> exhibited excellent human metabolic stability in microsomal and hepatocyte incubations (CL(mouse) = 19 mL min<sup>–1</sup> kg<sup>–1</sup>) and had good oral bioavailability in mouse (<i>F</i> = 75%). <b>69</b> was shown to penetrate the BBB through determination of the brain-to-plasma ratio in mouse, where [brain]<sub>u</sub>/[plasma]<sub>u</sub> = 0.4. Additionally, <b>69</b> was studied in a subcutaneous U87 tumor xenograft model of glioblastoma in mice, showing a dose-dependent tumor growth inhibition. As a consequence, <b>69</b> was progressed to clinical development.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0041.gif" alt="" id="dgr12" /></img></div><div class="NLM_p">ZSTK474 (<b>70</b>) was discovered as a library hit by the Japanese Foundation for Cancer Research and showed strong antiproliferative activity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> However, its molecular target and therefore its potential as a novel anticancer drug were unknown at that time. They initially observed that the cellular potencies of <b>70</b> against a panel of cell lines closely correlated with the cellular potencies of LY294002 (<b>71</b>), so they examined the ability of <b>70</b> to inhibit PI3K, observing that <b>70</b> was 20-fold more active (PI3Kα = 8.9 nM, PI3Kβ = 17 nM, PI3Kγ = 53 nM, PI3Kδ = 16 nM) than LYS294002 (<b>71</b>) against PI3K and did not substantially inhibit the activity of 139 other protein kinases.</div><div class="NLM_p">In 2011, Burger et al. reported the identification of <b>72</b> (buparlisib, NVP-BKM120), (PI3Kα = 52 nM, PI3Kβ = 166 nM, PI3Kγ = 262 nM, PI3Kδ = 116 nM). Their original hit came from a high throughput screen on a series of 2-morpholino-6-(3-hydroxyphenyl)pyrimidines identified from a solid phase combinatorial library of 2,4,6-trisubstituted pyrimidines in the same chemical class as <b>70</b>.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> After further modification the compounds per se had good oral bioavailability, low or subnanomolar biochemical potency, and submicromolar cellular potency against PI3Kα but had high clearance in rat. Their goal was to decrease clearance while maintaining and optimizing potency, solubility, permeability, and safety. Initially improved clearance was achieved through substituting with an aminoquinoline in the solvent exposed region. In addition to increased potency they made substitutions in the activity pocket. In changing the pyrimidyl group to a pyridyl group, they found that the biochemical potency increased upon the addition of an electron withdrawing group in the C-4 position of the pyridine, forcing the group out of plane to slightly improving aqueous solubility. This did not compromise the PK properties however; the compounds still exhibited low aqueous solubility and low Caco-2 permeability. From previous work it was known that substitution of the C-4 position on the pyrimidine core could tolerate a wide range of moieties. Additionally, it was known that a morpholine group at the C-4 position of the core maintained reasonable potency while improving solubility relative to the aminoquinoline, and thus the aminoquinoline was substituted for a morpholine to give <b>72</b>. The additional morpholine at the C-4 position did not compromise the rat PK parameters, and solubility was improved.</div><div class="NLM_p">The biochemical activity of <b>72</b> was assessed across related lipid kinases and against more than 200 protein kinases (VPS34 (2.4 μM), mTOR (4.6 μM), DNAPK (>5 μM), PIK4β (>25 μM)). No significant activity was observed against the protein kinases tested. The in vivo profile of <b>72</b> was characterized through PK studies conducted in several different species including mouse, rat, dog, and monkey. With the favorable cellular potency, kinase selectivity, preclinical pharmacology and rodent, dog, and monkey pharmacokinetics, physical properties, and preclinical safety profile, <b>72</b> was advanced into clinical trials in 2008. It was later reported that <b>72</b> exhibited an off-target activity at high concentrations that is not related to PI3K inhibition. This off-target activity was found to be linked to mitosis and ultimately found to be due to inhibition of tubulin polymerization.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">In order to overcome tubulin binding of <b>72</b>, Bohnacker et al. from the University of Basel described the discovery of <b>73</b> (bimiralisib, PQR309).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> They reported the crystal structure of <b>72</b> bound to tubulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E">5M7E</a>) and showed that high affinity binding of <b>72</b> to tubulin occurs via the pyrimidine core C–H group which is oriented toward βMet259 of tubulin. <b>73</b> was found to not bind to tubulin, which can be explained by the core C–H being replaced with a nitrogen atom. <b>73</b> was found to be highly potent (PI3Kα = 15 nM, PI3Kβ = 11 nM, PI3Kγ = 25 nM, PI3Kδ = 25 nM) and showed a satisfactory PK profile in vitro, showing low clearance in rat, dog, and human liver microsomes. <b>73</b> was progressed to in vivo studies in rodents and dogs, where it was found to be orally bioavailable and brain penetrable. The in vivo profile and a PC3 xenograft model in nude rats validated <b>73</b> as a clinical candidate, and thus <b>73</b> was advanced through phase I clinical trials and is currently in phase II studies in relapsed and refractory lymphoma and advanced solid tumors.</div><div class="NLM_p">Zhang et al.<i>,</i> contrary to SAR studies conducted by Novartis and The University of Basel on the 4- and 6- positions, designed derivatives by replacing the C-2 morpholine with various aliphatic or long-chain substituted aromatic amines. Their work led to the discovery of <b>74</b> as a potent PI3K inhibitor (PI3Kα = 18 nM, PI3Kβ = 2014 nM, PI3Kδ = 13 nM, PI3Kγ = 80 nM) that showed comparable bioactivity with <b>70</b>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0042.gif" alt="" id="dgr13" /></img></div><div class="NLM_p">The discovery of <b>79</b> (Gedatolisib, PKI-587 or PF05212384)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> by Wyeth (later Pfizer) followed on from the discovery of <b>75</b> (PKI-402).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The initial lead compound was a triazolopyrimidine <b>76</b> that exhibited good potency against PI3Kα (IC<sub>50</sub> = 83 nM), PI3Kγ (IC<sub>50</sub> = 435 nM), and mTOR (IC<sub>50</sub> = 50 nM). However, activity, particularly against mTOR, and microsomal stability, was improved by replacement of a benzylic alcohol with a substituted urea. The urea containing compound <b>77</b> was highly potent against PI3Kα (IC<sub>50</sub> = 3.5 nM), PI3Kγ (IC<sub>50</sub> = 24.8 nM), and mTOR (IC<sub>50</sub> = 0.32 nM); however the compound exhibited very poor solubility. In order to increase solubility, basic amines were introduced onto the urea, giving compounds such as <b>75</b>. However, solubility issues still persisted and advanced studies were halted until modifications to <b>75</b> were implemented to decrease the overall lipophilicity of the series. In addition, another morpholine group was included to address a reported morpholine metabolic liability via oxidation α to the morpholine ring oxygen causing loss of potency. This morpholine change to the bismorpholino-1,3,5-triazine scaffold, such as <b>78</b>, led to potent PI3Kα, PI3Kγ, and mTOR inhibitory activity but only moderate potency in cell proliferation assays, attributed to poor solubility and permeability. Due to the retention of biochemical potency, they probed the SAR to improve cellular potency. They observed a drop in PI3K activity when substituting the phenyl moiety of the urea with an alkyl group. However, the compounds maintained mTOR potency, and incorporating basic amines onto the phenyl ring, as in the case of <b>79</b>, led to excellent biochemical and cell potencies. These analogs had good microsomal stability across species and exhibited good to moderate solubility. On the basis of enhanced potency (PI3Kα = 0.4 nM, PI3Kβ = 6.0 nM, PI3Kγ = 8 nM, PI3Kδ = 6 nM, mTOR = 1.6 nM), solubility (14 μg/mL, pH 7.4), microsomal stability, and a lack of Cyp inhibition, <b>79</b> was chosen for further in vivo evaluations, showing low plasma clearance (7 mL min<sup>–1</sup> kg<sup>–1</sup>), high volume of distribution (7.2 L/kg), and long half-life (<i>T</i><sub>1/2</sub> = 14.4 h). <b>79</b> was also evaluated against a panel of 236 human protein kinases at 10 μM, where it was found to be highly selective for PI3K and mTOR. <b>79</b> progressed to phase I and phase II clinical trials.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0043.gif" alt="" id="dgr14" /></img></div><div class="NLM_p">Miller et al. reported a series of inhibitors in the same structural class as <b>63</b>, although they were consistently less potent.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Compound <b>80</b> (PI3Kα IC<sub>50</sub> = 375 nM, PI3Kβ IC<sub>50</sub> = 214 nM, PI3Kγ IC<sub>50</sub> ≥ 10 μM, PI3Kδ IC<sub>50</sub> = 110 nM) is representative of that series. Overall, they found that substitution in the 5-position was consistently ∼10-fold more potent than substitution at the 6-position. In a subsequent paper the morpholine in the solvent exposed region was replaced with piperazine amides derived from amino acids, <b>81</b> is representative of the series.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> They sought to form interactions with Asn836 of PI3Kδ to gain selectivity toward PI3Kδ but found that <b>81</b> was a β/δ inhibitor (PI3Kα IC<sub>50</sub> = 2611 nM, PI3Kβ IC<sub>50</sub> = 36 nM, PI3Kγ IC<sub>50</sub> = 5859 nM, PI3Kδ IC<sub>50</sub> = 12 nM). In a subsequent publication, Pinson et al. highlighted <b>82</b> as a compound with high PI3Kβ isoform selectivity (PI3Kα IC<sub>50</sub> = 4700 nM, PI3Kβ IC<sub>50</sub> = 63 nM, PI3Kγ IC<sub>50</sub> ≥ 100 μM, PI3Kδ IC<sub>50</sub> = 2200 nM) through targeting of the nonconserved Asp862 on PI3Kβ. Compound <b>82</b> showed strong inhibition of cellular Akt phosphorylation and growth of PTEN-deficient MD-MBA-468 cells.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Also, in the same structural class are a series of inhibitors reported by Dugar et al. from Sphaera Pharma.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Compound <b>83</b> was identified as their candidate compound for further development exhibiting good potency toward PI3Kα (IC<sub>50</sub> = 60 nM) and good cellular potency (IC<sub>50</sub> = 500 nM). <b>83</b> also showed a high level of microsomal stability, excellent oral bioavailability (AUC = 5.2 μM/h), no <i>h</i>ERG liability, and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 μM concentrations. Gamage et al. produced extensive SAR on analogs of <b>70</b>; replacing one of the morpholine groups with a sulfonamide containing substituents led to a series of PI3K inhibitors.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Most compounds synthesized suffered solubility issues; however <b>84</b> (PI3Kα IC<sub>50</sub> = 22 nM, PI3Kβ IC<sub>50</sub> = 116 nM, PI3Kδ IC<sub>50</sub> = 13 nM), as the methanesulfonate salt, showed suitable solubility (3.82 μg/mL) to be progressed in vivo. Compound <b>84</b> was evaluated in a mouse study using U87MG human glioblastoma tumor xenografts in Rag1<sup>–/–</sup> mice at a dose of 60 mg/kg QD × 10 by i.p. injection, which effectively slowed tumor growth over the 10 day dosing period.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0044.gif" alt="" id="dgr15" /></img></div><div class="NLM_p">Ohwada et al. from Chugai Pharmaceutical Co. superimposed compounds <b>57</b> and <b>71</b>. The structure based design led to a phenol and morpholine containing lead <b>85</b>, which showed excellent activity (PI3Kα IC<sub>50</sub> = 8.6 nM) but exhibited poor metabolic stability in human microsomes and poor oral bioavailability in mouse mainly due to rapid glucuronidation of the phenol.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> They sought to address the metabolic instability through bioisosteric replacement of the phenol with an aminopyrimidine moiety, which showed a slight reduction in PI3Kα activity but exhibited good antitumor activity in vivo in a human prostate cancer PC3 xenograft model, as a result of improved metabolic stability and oral bioavailability. With room for improvement in terms of its physicochemical and ADME profile, they embarked upon modification of the solvent exposed region to ultimately lead to the discovery of <b>86</b> (CH5132799), a clinical candidate that showed good activity against PI3Kα (IC<sub>50</sub> = 14 nM), good oral bioavailability in mouse (<i>F</i> = 101%), good human liver microsomal stability, and in vivo antitumor activity in the PC3 xenograft model (TGI: 101% at 25 mg/kg, 11 days). <b>86</b> selectively inhibits class I PI3Ks and showed less inhibition of class II PI3Ks (C2α ≥ 10 μM, C2β = 5.3 μM), class III PI3K (Vps34 ≥ 10 μM), and mTOR (IC<sub>50</sub> = 1.6 μM). Additionally, <b>86</b> showed no inhibitory activity (IC<sub>50</sub> > 10 μM) against 26 other protein kinases.</div><div class="NLM_p">After the development of <b>86</b>, Kawada et al. made changes to further improve the PK profile. The chemistry focused on introducing a solubilizing group in the solvent exposed region to give compound <b>87</b>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Additionally, <b>87</b> incorporates an <i>ortho-</i>substituent which disrupts the molecular planarity and improves water solubility. The pharmacokinetic profile of <b>87</b> in mouse showed a good clearance (CL = 11.1 mL min<sup>–1</sup> kg<sup>–1</sup>) and oral bioavailability (<i>F</i> = 86%), without significant loss of inhibitory activity (PI3Kα = 42 nM).</div><div class="NLM_p">In a follow-up paper, Kawada et al. from Chugai Pharmaceutical Co reported that the introduction of an urea functionality, as in the case of <b>88</b>, enhanced PI3Kα activity (22 nM).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> They proposed that this observation was due to the urea acting as a spacer, placing the aromatic ring close enough to the Trp760 to make a favorable interaction, thus enhancing the inhibitory activity. This change however introduced a solubility issue, due to intermolecular hydrogen bonding between the urea and the pyrimidine core, resulting in a flat conformation that increases the crystallization propensity. They attempted to disrupt the planarity by introducing a methyl group to the <i>ortho-</i>position on the amino-pyrimidine; however, this led to an 8-fold reduction of potency as disrupting the planarity in this region of the inhibitor was not acceptable for keeping key interactions in the affinity pocket. They then shifted attention back to the urea region introducing <i>ortho-</i>substituents to the phenyl ring and including solubilizing amines such as ethylpiperazine. However,this was not enough to improve the solubility to a satisfactory level. Incorporating an <i>ortho-</i>fluorine on the phenyl ring in which electrostatic repulsion between the fluorine atom and the urea carbonyl can be expected, resulting in a flat conformation and thus poor solubility. However, evaluation of the difluoro compound showed a modest increase to the solubility as this compound prefers a twisted conformation that avoids the electrostatic repulsion of the second fluorine atom with the urea carbonyl group. Liver microsomal stability of <b>88</b> was good in both mouse (7.6 μL min<sup>–1</sup> mg<sup>–1</sup>) and human (2.2 μL min<sup>–1</sup> mg<sup>–1</sup>), and permeability was also acceptable (1.1 × 10<sup>–6</sup> cm/s in PAMPA).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0045.gif" alt="" id="dgr16" /></img></div><div class="NLM_p">Wang et al. from the Chinese Academy of Sciences utilized the structural information of <b>57</b> to design a series of 4-(2-arylpyrido[30,20:3,4]pyrrolo[1,2-<i>f</i>][1,2,4]triazin-4-yl)morpholine derivatives containing phenolic esters.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The compounds had comparable PI3Kα activity to <b>57</b>. All of the compounds showed selectivity over 15 protein kinases and antiproliferative activity at micromolar concentration against several cancer cell lines. An example of the series is compound <b>89</b> (PI3Kα IC<sub>50</sub> = 33.6 nM).</div><div class="NLM_p">González et al. from the Spanish National Cancer Research Centre developed <b>90</b> (ETP-46321), employing a similar strategy as the Genentech team in the development of <b>52</b>. Through a rational design exercise, they replaced the C–C unit between the pyrimidine ring and the thiophene with a C–N unit.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In an effort to optimize potency and in vivo properties, they explored a variety of heteroaromatic groups at the imidazo[1,2-<i>a</i>]pyrazine C-6 position, leading to the discovery of <b>90</b> (PI3Kα IC<sub>50</sub> = 2.3 nM, PI3Kβ IC<sub>50</sub> = 170 nM, PI3Kγ IC<sub>50</sub> = 179 nM, PI3Kδ IC<sub>50</sub> = 14.2 nM). Compound <b>90</b> was shown to be a potent PI3Kα/δ inhibitor that was highly selective over mTOR (IC<sub>50</sub> = 4.88 μM) and 288 representative kinases and demonstrated a good pharmacokinetic profile in mice (CL = 0.6 L h<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 90%). Compound <b>90</b> was selected for preliminary in vivo evaluation in a lung tumor mouse model driven by a K-RasG12V oncogenic mutation and showed significant tumor growth inhibition (∼51%). In a later publication<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> they applied a conformational restriction strategy to enable the exploration of the solvent-exposed region. <b>96</b> (PI3Kα IC<sub>50</sub> = 0.5 nM) is an example of the series and was progressed to a preliminary in vivo PK study and showed similar results to <b>90</b>. Additionally González et al. reported a scaffold hopping strategy to replace the core moiety of <b>90</b> to produce compounds such as <b>97 (</b>PI3Kα IC<sub>50</sub> = 1.52 nM, PI3Kβ IC<sub>50</sub> = 155 nM).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">With the goal of developing a dual mTOR/pan PI3K inhibitor, structure and ligand-based design was used to develop the lead structure <b>98</b> from <b>91</b> (VS-5584; SB2343). Using the SAR of compounds <b>57</b>, <b>71</b>, and <b>70</b> in combination with core modification, they developed a lead structure <b>98</b>, possessing a purine core substituted with a morpholine ring, a phenol head group, and a hydrophobic substituent.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Compound <b>98</b> showed good potency against PI3Kα (IC<sub>50</sub> = 89 nM) and mTOR (IC<sub>50</sub> = 400 nM); however the phenol group posed a metabolic liability through glucoronidation. In order to overcome the metabolic liability, bioisoteric replacement of the phenol was employed resulting in substitution of the phenol for an aminopyrimidine head group. The aminopyrimidine head group was found to be equipotent with the phenol in inhibiting mTOR (300 nM) but introduced an imbalance in the inhibitory activity between mTOR and PI3Kα, being 10-fold more potent toward PI3Kα (IC<sub>50</sub> = 34 nM). Optimization of the 8- and 9-position side chains led to the discovery of <b>91</b>, a compound with improved mTOR potency (IC<sub>50</sub> = 37 nM) and PI3K activity (PI3Kα IC<sub>50</sub> = 16 nM, PI3Kβ IC<sub>50</sub> = 68 nM, PI3Kδ IC<sub>50</sub> = 42 nM, and PI3Kγ IC<sub>50</sub> = 25 nM). <b>91</b> was selected for further profiling and found to have excellent PK and ADME properties, as well as being active in animal models. <b>91</b> progressed to phase I trials in patients with advanced nonhematologic malignancies or lymphoma.</div><div class="NLM_p">Nacht et al. from Celgene Avilomics Research described <b>92</b> (CNX-1351), the first example of a targeted covalent inhibitor of the lipid kinase family that is an isoform-selective inhibitor of PI3Kα.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> After examining the ATP binding site and nearby residues of PI3Kα to identify opportunities for selective covalent modification, they identified Cys862, which is unique to PI3Kα, as a promising amino acid to target for covalent inhibition. Using the core of <b>52</b> in combination with a series of design cycles exploring both linker spacing and electrophilic functional groups, they identified <b>92</b>, and although it is useful as a tool compound, the pharmacokinetic properties were suboptimal; thus they are currently focusing their efforts on improving the oral bioavailability.</div><div class="NLM_p">Saurat et al. described a series of dual mTOR/PI3K inhibitors based on a pyridopyrimidine scaffold that have nanomolar enzymatic and cellular activities with an acceptable kinase selectivity profile. <b>93</b> (PI3Kα IC<sub>50</sub> = 58 nM, mTOR IC<sub>50</sub> = 5 nM) is a representative example of the series.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">Starting from a morpholinopyrrolotriazine heterocyclic lead, Dugar et al. from Sphaera Pharma Pte. Ltd. developed their preclinical compound <b>94</b>.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a><b>94</b> (PI3Kα IC<sub>50</sub> = 20 nM) was found to be inactive in a panel of close homology kinases except for other isoforms of PI3K (PI3Kβ 54% inhibition at 1 μM, PI3Kδ 67% inhibition at 1 μM) and mTOR (85% inhibition at 1 μM).</div><div class="NLM_p">Wang et al. described a series of compounds based on a quinazoline scaffold. <b>95</b> (PI3Kα IC<sub>50</sub> = 96 nM, PI3Kβ IC<sub>50</sub> = 128 nM, PI3Kδ IC<sub>50</sub> = 330 nM, and PI3Kγ IC<sub>50</sub> = 465 nM) is representative of the series. <b>95</b> showed antiproliferative effects in vitro and was found to induce apoptosis. Western blots suggested that <b>95</b> can block the PI3K/AKT/mTOR pathway. Additionally, <b>95</b> inhibited tumor growth on a mouse S180 homograft model.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0046.gif" alt="" id="dgr17" /></img></div><div class="NLM_p">Wang et al. synthesized a series of inhibitors based on a thiopyranopyrimidine core such as compound <b>99</b> (PI3Kα IC<sub>50</sub> = 8.38 μM). These compounds showed cytotoxicity against four cancer cell lines (IC<sub>50</sub> = 6.02–10.27 μM).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In a later publication they incorporated the core from <b>97</b> to produce a series of compounds, where <b>101</b> (PI3Kα IC<sub>50</sub> = 1.25 μM) is representative of the series.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">Considering <b>52</b> as the chemical starting point, Schwehm et al. investigated the incorporation of a tricyclic molecular scaffold leading to the discovery of a series of potent and highly selective PI3Kδ inhibitors.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Compound <b>100</b> includes a 4-substituted indole group in the activity pocket, which was reported to give rise to good PI3Kδ selectivity.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Additionally, they reported that an overlay of the available crystal structures of the class I PI3K isoforms reveals a potential key π–cation interaction present in the structures of the PI3Kα (Arg770), PI3Kβ (Lys771), and PI3Kγ (Lys802) isoforms with Trp760 (δ-numbering) that is not present in PI3Kδ (Thr750). They reported that this may suggest that their inhibitors might be able to form an extra van der Waals π–π face to face interaction with Trp760, an interaction that is obstructed in the case of the other isoforms. These effects coupled together produced a synergistic group effect to introduce high δ-selectivity. The physicochemical properties of compound <b>100</b> were calculated (PI3Kδ (pIC<sub>50</sub> = 9.1), MW = 540.7, cLogP = 3.9, clogD = 2.5, TPSA = 88 Å<sup>2</sup>, solubility at pH 7.4 in water of 0.02 mg/mL, solubility category “low”, LIPE = 5.2), and they report that the properties may not be ideal for oral druglikeness; however the compounds may fulfill inhalation delivery criteria.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p last">The remainder of the Perspective will examine the medicinal chemistry design and evaluation based on a core chemical structure categorized by scaffold class.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Pyrrolo[2,1-<i>f</i>][1,2,4]triazin-4-amines</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0047.gif" alt="" id="dgr18" /></img>A novel series of pyrrolo[2,1-<i>f</i>][1,2,4]triazin-4-amines have been reported by researchers from Bristol-Myers Squibb, resulting in the identification of selective PI3Kδ inhibitors. Bhide et al. reported on the identification of <b>102</b> (PI3Kδ IC<sub>50</sub> = 22 nM) from a kinase-directed screen.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> However, <b>102</b> was shown to be nonselective against other PI3K isoforms (fold selectivity PI3Kα/β/γ = 4/120/0.4) and a potent CYP inhibitor which was attributed to the 4-pyridyl moiety as well as poor microsomal stability due, in part, to the lipophilic cyclohexyl ring. Extensive SAR aimed at changing the cyclohexyl group and the pyridine ring resulted in the identification of <b>103</b> (PI3Kδ IC<sub>50</sub> = 2 nM, fold selectivity PI3Kα/β/γ = 665/800/130), a compound with improved metabolic stability (58% remaining at 0.5 μM, 10 min incubation) and good pharmacokinetics (mouse PK CL = 82.1 mL/kg/kg; <i>V</i><sub>ss</sub> = 6.2 L/kg, <i>F</i> = 46%) that subsequently demonstrated in vivo efficacy in a mouse keyhole limpet hemocyanin (KLH) and collagen-induced arthritis (CIA) model, when dosed at 100 mg/kg. The efficacy was reported to be better than that of methotrexate at 1 mg/kg. Qin et al. reported on the optimization of the ADMET properties of the compounds leading to the identification of <b>104</b> (PI3Kδ IC<sub>50</sub> = 1.3 nM, fold selectivity PI3Kα/β/γ = 611/1443/44), a compound with reduced <i>h</i>ERG activity (18% at 10 μM, patch clamp) and metabolic stability. <b>104</b> progressed to a 4-day exploratory toxicity study in mice dosed up to 300 mg kg<sup>–1</sup> day<sup>–1</sup> (QD) and was found to be well tolerated at all doses. In addition, <b>2</b> showed efficacy in the KLH model when dosed at 3 mg/kg, reflecting the improvement in whole cell potency and pharmacokinetic properties, compared to <b>103</b>.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Running in parallel, Marcoux et al. reported further SAR studies to improve the physical and pharmacokinetic properties of <b>104</b>. Further exploration of the substituted piperazine and the replacement of the substituted pyrazole with smaller moieties resulted in the identification of the highly isoform-selective PI3Kδ inhibitor <b>105</b> (PI3Kδ PIC<sub>50</sub> ≤ 0.2 nM, fold selectivity PI3Kα/β/γ of ≥1000) that was highly potent in a human B cell proliferation assay (IC<sub>50</sub> = 1 nM). In addition, <b>105</b> was shown not to inhibit any CYPS or ion channels. It possessed very good permeability but unfortunately exhibited poor stability toward liver microsomes where it was determined that the morpholine ring was extensively metabolized and was not progressed further.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Liu et al. finally reported on the identification of a preclinical candidate <b>108</b> identified after further extensive SAR studies to improve on the pharmacokinetic properties within the evolving series. Guided by X-ray crystallography of <b>106</b> (PI3Kδ IC<sub>50</sub> = 2.4 ± 0.8 nM, fold selectivity PI3K γ = 270), in PI3Kδ (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), the polar pyrazole group was replaced with either a simple chlorine atom or a trifluoromethyl group, which led to <b>107</b> (PI3Kδ IC<sub>50</sub> = 3 ± 1 nM, fold selectivity PI3Kα/γ = 110/37), a compound with improved Caco-2 permeability, reduced <i>h</i>ERG activity (12% at 3 μM, patch clamp), and increased selectivity profile, while maintaining potency in the CD69 <i>h</i>WB assay.</div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. X-ray cocrystal structure of <b>106</b> bound into PI3Kδ. Key interactions between <b>106</b> and the hinge included Val828 and Glu826 and a close interaction between the carbonyl of the acetamide group and Thr750. The pyrazole group of <b>106</b> filled a hydrophobic pocket formed by Ile825 (not shown) and participated in an edge-to-face interaction with Tyr813 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VLR">5VLR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Final optimization of the aryl substitution identified <b>108</b> (PI3Kδ IC<sub>50</sub> = 1.9 ± 0.9 nM, fold selectivity PI3Kα/β/γ = 700/1443/>5000), where it was shown that the 4-CN group led to an improved human/rodent scaling in microsomal metabolic stability and excellent cross species pharmacokinetics (e.g., rat PK CL = 2.3 ± 0.3 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>ss</sub> = 0.5 ± 0.1 L/kg; <i>F</i> = 71%). <b>108</b> proved highly efficacious in a mouse collagen-induced arthritis model for 42 days. Although lower than expected exposures were observed for <b>108</b>, a dose-dependent reduction of the clinical score was observed where doses of 2 and 5 mg/kg showed greater than 50% suppression of paw swelling. Taking the exposure into consideration, an EC<sub>50</sub> of 10 nM at 24 h (ED<sub>50</sub> of ∼1.25 mg/kg) was derived.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Amino Triazine-Based Hinge Binders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In a series of publications scientists from Amgen reported on the optimization of a novel series of substituted aminotriazines culminating in the identification of <b>113</b> (AMG 511, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). In their first paper, Smith et al. discussed the optimization of a benzimidazole triazine <b>109</b> obtained from a HTS screen.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a><b>109</b> had favorable properties (PI3Kα IC<sub>50</sub> = 0.32 μM; PI3Kβ IC<sub>50</sub> = 0.38 μM; PI3Kδ IC<sub>50</sub> = 0.24 μM; PI3Kγ IC<sub>50</sub> = 0.1 μM, mTOR IC<sub>50</sub> = 0.097 μM) and a cocrystal structure was determined in PI3Kγ, demonstrating that <b>109</b> bound in the ATP binding site. Optimization of <b>109</b> led to <b>110</b> (PI3Kα IC<sub>50</sub> = 9 nM; PI3Kβ IC<sub>50</sub> = 5 nM; PI3Kδ IC<sub>50</sub> = 2 nM; PI3Kγ IC<sub>50</sub> = 4 nM, mTOR IC<sub>50</sub> = 4.8 μM), where the substituted piperazine was making interactions with the ribose pocket and the metabolically labile 3-phenol was replaced with a substituted pyridine. <b>110</b> had good oral exposure in mice (<i>F</i> = 95%, 25 mg/kg po) and inhibited HGF-stimulated PI3K signaling in a mouse liver PD assay where a 75 mg/kg dose was able to maintain sufficient plasma concentrations for 24 h to provide at least 64% target coverage over a 24 h period (plasma free fraction concentration of 68 nM at 24 h). Subsequently, <b>110</b> caused a dose-dependent inhibition of tumor growth with an ED<sub>50</sub> of 6.0 mg/kg (AUC<sub>0–24 h</sub> = 7.6 μM/h) in CD1 nude mice and tumor stasis was achieved at 25 mg/kg QD. However, it was concluded that continuous robust inhibition of PI3K over 14 days may be poorly tolerated.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Wurz et al. reported on the hybridization of compounds; combining the aminotriazines, such as <b>110</b> with a series of substituted aminobenzthiazoles <b>111</b> (PI3Kα IC<sub>50</sub> = 1.2 nM; mTOR IC<sub>50</sub> = 2.1 nM)<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> to generate <b>112</b> (PI3Kα IC<sub>50</sub> = 7.7 nM; PI3Kβ IC<sub>50</sub> = 0.4 nM; PI3Kδ IC<sub>50</sub> = 2 nM; PI3Kγ IC<sub>50</sub> = 1 nM, mTOR IC<sub>50</sub> = 163 μM), which exhibited good oral bioavailability in rats (<i>F</i> = 63%) and showed a dose dependent reduction in the phosphorylation of Akt in a U87 tumor pharmacodynamic model with a plasma EC<sub>50</sub> = 193 nM.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Norman et al. reported on further optimization of <b>110</b> to identify <b>113</b>, a potent pan inhibitor of class I PI3Ks with a superior pharmacokinetic profile (PI3Kα <i>K</i><sub>i</sub> = 4 nM; PI3Kβ <i>K</i><sub>i</sub> = 6 nM; PI3Kδ <i>K</i><sub>i</sub> = 2 nM; PI3Kγ <i>K</i><sub>i</sub> = 1 nM).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a><b>113</b> was shown to potently block the targeted PI3K pathway in a mouse liver pharmacodynamic model as indicated by a dose-dependent decrease in phosphorylated AKT (p-AKT) at Ser473, and a nonlinear regression analysis revealed a plasma EC<sub>50</sub> of 228 ng/mL. It was shown that inhibition of AKT phosphorylation directly correlated with plasma concentrations. <b>113</b> inhibits tumor growth in a U87 malignant glioma glioblastoma xenograft model where treatment at 1 mg/kg QD resulted in significant inhibition of tumor growth of approximately 70% compared to the vehicle control group. Tumor stasis was observed in the cohort treated with 3 mg/kg, and tumor regression was observed in the 10 mg/kg cohort. The ED<sub>50</sub> of compound <b>113</b> was 0.6 mg/kg, with an AUC at EC<sub>50</sub> of 3.6 μg·h/mL. On the basis of its excellent in vivo efficacy and pharmacokinetic profile, compound <b>113</b> was selected for further evaluation as a clinical candidate. However, to date, no further information has been reported.</div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Aminotriazine-based hinge binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In a subsequent paper, Lanman et al. reported on studies to replace the piperazine sulfonamide portion of <b>113</b> with an array of primary alcohols to reduce molecular weight and improve interaction within the ribose binding pocket, leading to the identification of <b>114</b> (PI3Kα <i>K</i><sub>i</sub> = 23 nM), a compound with much reduced MW compared to <b>113</b> (327 Da for <b>114</b> vs 518 Da for <b>113</b>). <b>114</b> demonstrated a similar pharmacokinetic profile as that of <b>113</b> with oral bioavailability slightly reduced (37% vs 57%) and clearance elevated (1.1 vs 0.45 L h<sup>–1</sup> kg<sup>–1</sup>). <b>114</b> was further evaluated in a mouse liver pharmacodynamic model that measured the inhibition of hepatocyte growth factor (HGF)-induced Akt phosphorylation at Ser473 in female CD1 nude mice, and it significantly suppressed PI3K signaling at 10 and 30 mg/kg, bringing about a dose-dependent decrease in p(S473)Akt. A nonlinear regression analysis established an EC<sub>50</sub> of 239 ng/mL, comparable to that obtained from compound <b>113</b> (EC<sub>50</sub> = 240 ng/mL). The biological activity of the significantly truncated analog <b>114</b> relative to <b>113</b> highlights the efficiency of the 2-hydroxypropyl group as a ribose pocket binding group; however, compounds from this class were unable to replicate the enzymatic potency of the piperazine sulfonamide series.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Stec et al. investigated the use of the imidazo[1,2-<i>a</i>]pyridine ring system as a scaffold and identified <b>115</b> as a potent dual phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor (PI3Kα <i>K</i><sub>i</sub> = 11 nM; PI3Kβ <i>K</i><sub>i</sub> = 17 nM; PI3Kδ <i>K</i><sub>i</sub> = 0.6 nM; PI3Kγ <i>K</i><sub>i</sub> = 5.3 nM) mTOR IC<sub>50</sub> = 206 nM). When dosed orally in rats (2 mg/kg), <b>115</b> showed good oral bioavailability (51%) and moderate plasma exposure (AUC = 640 ng·h/mL). The in vivo activity of compound <b>115</b> was evaluated in the mouse liver pharmacodynamic assay and showed significant inhibition of AKT phosphorylation at all three doses with a maximum inhibition of 56% at the 30 mg/kg dose. The calculated ED<sub>50</sub> relative to vehicle was 11 mg/kg.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">2,3-Dihydroimidazo[1,2-<i>c</i>]quinazolin-5-yl)pyrimidine-Based Inhibitors (Copanlisib)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Scott et al. recently reported on the identification of <b>119</b> (copanlisib), a selective PI3Kα/β inhibitor that has been granted an accelerated approval as a treatment for patients with relapsed follicular lymphoma who have received at least two prior systemic therapies (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> HTS on a series of PI3Kγ-active leads led to the discovery of the structurally novel 2,3-dihydroimidazo[1,2-<i>c</i>]quinazoline <b>116</b> (PI3Kγ IC<sub>50</sub> = 810 nM, PI3Kβ IC<sub>50</sub> = 4000 nM). In the lead optimization phase, the enol moiety of <b>116</b> could be replaced with an amide moiety giving <b>117</b> (PI3Kγ IC<sub>50</sub> = 60 nM, PI3Kβ IC<sub>50</sub> = 1 nM), and further substitutions on the phenyl ring led to <b>118</b> (PI3Kγ IC<sub>50</sub> = 60 nM, PI3Kβ IC<sub>50</sub> = 1700 nM), and both were shown to have an effect on isoform selectivity. Therefore, a program to optimize the PI3Kβ and PI3Kα activity of the 2,3-dihydroimidazo[1,2-<i>c</i>]quinazoline lead for potential use in cancer therapies was undertaken. Scott et al. reported on extensive SAR studies where multiple substitutions on the A ring in combination to changes in the B and C rings eventually led to the discovery of <b>119</b> (copanlisib).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> An X-ray crystal structure showed that the imidazoline N-1 nitrogen atom formed a critical hydrogen bond to Val882 in the adenine hinge pocket and the 4-aminopyrimiding group interacted in the affinity pocket, forming hydrogen bonds with Asp836 and Asp841 through the amino group and with Lys833 through a pyrimidine nitrogen atom (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G2N">5G2N</a>). Copanlisib was shown to be a potent PI3K inhibitor (PI3Kα IC<sub>50</sub> = 0.5 nM, PI3Kβ IC<sub>50</sub> = 3.7 nM, PI3Kγ IC<sub>50</sub> = 6.4 nM, PI3Kβ IC<sub>50</sub> = 45 nM) as well as inhibiting mTOR (IC<sub>50</sub> = 45 nM) and has potent cellular mechanistic activity, inhibiting both IGF-1-stimulated AKT phosphorylation in S473 cells and basal AKT phosphorylation in KPL4 cells. The intravenous first-in-human phase I study of copanlisib in patients with advanced solid tumors and non-Hodgkin’s lymphomas (NHL) showed that it was well tolerated with a MTD of 0.8 mg/kg. Copanlisib exhibited dose-proportional pharmacokinetics and promising antitumor activity, particularly in patients with NHL.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><figure id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Discovery of <b>119</b> (Copanlisib), a PI3K Inhibitor with Potential Antineoplastic Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">4,6-Disubstituted Indazole-Based Inhibitors (GSK2269557 and GSK2292767)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Down et al. reported on the discovery of a series of selective indazole-based PI3Kδ inhibitors for the treatment of respiratory diseases, culminating in the discovery of the development compound <b>122</b> (GSK2269557) and the back-up clinical candidate <b>124</b> (GSK2292767) (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Compound <b>120</b> was selected as a lead due to its favorable selectivity profile for PI3Kδ (PI3Kδ pIC<sub>50</sub> = 7.0; PI3Kβ pIC<sub>50</sub> = 5.2; PI3Kα pIC<sub>50</sub> = 5.0; PI3Kγ pIC<sub>50</sub> = 5.2), and to avoid any potential negative impact of broad systemic inhibition of this biology, a lead optimization program was initiated with the aim of delivering an inhaled clinical candidate. Inhibition of PI3K enzymatic activity was determined using a homogeneous time-resolved fluorescence (HTRF) assay format and to measure cellular activity for compounds of interest. In addition, a peripheral blood mononuclear (PBMC) assay was used, using cytostim to stimulate cytokine production from the T-lymphocyte compartment. Interferon γ (IFNγ) was selected as an optimal analyte owing to robust stimulation by cytostim and exquisite sensitivity to PI3Kδ inhibition. The target profile was established of high potency, which is a requirement for inhaled delivery due to dose limitations, and the target PK profile was intended to minimize systemic circulation after inhaled delivery. Therefore, moderate to high intrinsic clearance was required in order to ensure removal of drug once absorbed through the lung into the plasma and low oral bioavailability was required to limit absorption of the swallowed fraction of the inhaled dose. Exploration of the SAR at the two positions of substitution on the indazole core was examined, where initially group R<sub>2</sub> was fixed as indole and exploration of R<sub>1</sub> pursued. A set of 4-position amide modifications were prepared while keeping the 6-indole substituent fixed. Extensive SAR showed that in this position a planar amide conformation was important for potency and isoform selectivity, as typified by <b>121</b> (PI3Kδ pIC<sub>50</sub> = 7.3; PI3Kβ pIC<sub>50</sub> = 5.0; PI3Kα pIC<sub>50</sub> < 4.6; PI3Kγ pIC<sub>50</sub> = 5.4). The requirements for planarity to balance both isoform potency and pharmacokinetics led to the application of heteroaromatic bioisosteric replacements for the coplanar amide substitutent R<sup>1</sup>, leading to the eventual discovery of <b>122</b> (PI3Kδ p<i>K</i><sub>i</sub> = 9.9; PI3Kβ p<i>K</i><sub>i</sub> = 5.8; PI3Kα p<i>K</i><sub>i</sub> = 5.3; PI3Kγ p<i>K</i><sub>i</sub> = 5.2), a compound with excellent cellular activity (PBMC IFNγ p<i>K</i><sub>i</sub> = 9.7). The rat PK profile of <b>122</b> was encouraging, with low oral bioavailability (<i>F</i> = 2%) and in vivo clearance of 28 mL min<sup>–1</sup> kg<sup>–1</sup>, which met the criteria for progression. Importantly, due to the dibasic nature of <b>122</b> in combination with its moderate lipophilicity (cLogP = 4.4), <b>122</b> also had a high volume of distribution of 6.3 L/kg, which suggested a beneficial tissue retention when delivered topically to the lung. <b>122</b> was progressed to a human lung parenchyma assay where finely chopped lung tissue was incubated with the plant lectin phytohemagglutinin (PHA) for 72 h to induce production of cytokines including IFNγ and IL-2. This response was inhibited by <b>122</b> in a concentration-dependent manner, returning pIC<sub>50</sub> values of 8.2 (IFNγ) and 8.1 (IL-2). In a disease relevant brown Norway rat acute OVA model of Th2 driven lung inflammation, <b>122</b> was shown to protect against eosinophil recruitment, with an ED<sub>50</sub> of 67 μg/kg. In addition, the activity of <b>122</b> was assessed using other end points in this model, including leukocyte recruitment to the lung (neutrophils, macrophages, CD4 and CD8 T-lymphocytes at 48 h) and Th2 cytokines such as IL-13. Importantly, <b>122</b> was shown to dose-dependently reduce recruitment of all leukocyte subpopulations and IL-13 in the lungs. In light of all the data, <b>122</b> progressed to clinical evaluation as GSK2269557. In phase I studies, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients and resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor and further clinical trials are ongoing.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Replacing the indole in <b>121</b> with a pyridyl methylsulfonamide gave <b>123</b> (PI3Kδ pIC<sub>50</sub> = 8.7; PI3Kβ pIC<sub>50</sub> = 6.0; PI3Kα pIC<sub>50</sub> = 6.5; PI3Kγ pIC<sub>50</sub> = 7.3). Although this replacement resulted in a greater than 10-fold increase in potency for PI3Kδ, potency at the other PI3K isoforms was also significantly enhanced such that compound <b>123</b> was no more selective than compound <b>121</b>. However, further evolution of the sulfonamide group and bioisosteric replacement of the secondary amide resulted in <b>124</b> ((PI3Kδ p<i>K</i><sub>i</sub> = 10.1; PI3Kβ p<i>K</i><sub>i</sub> = 6.2; PI3Kα p<i>K</i><sub>i</sub> = 6.3; PI3Kγ p<i>K</i><sub>i</sub> = 6.3), with excellent cellular activity (PBMC IFNγ p<i>K</i><sub>i</sub> = 9.2). In a human lung parenchyma assay, <b>124</b> inhibited both IFNγ and IL-2 production in a concentration-dependent manner, with pIC<sub>50</sub> values of 8.7 and 8.5, respectively. In the brown Norway rat acute OVA model of Th2 driven inflammation in the lungs, <b>124</b> was shown to protect against eosinophil recruitment with an ED<sub>50</sub> of 35 μg/kg, similar to compound <b>122</b>. A PK study in rat, demonstrated a high in vivo clearance of 50 mL min<sup>–1</sup> kg<sup>–1</sup> which was significantly higher than that for compound <b>122</b> and fitted well for the target profile for a follow-up inhaled candidate. In addition, the oral bioavailability was low (<i>F</i> < 2%), in line with the data observed for compound <b>122</b>, and therefore <b>124</b> was progressed into preclinical development as a back-up for <b>122</b>.</div><figure id="sch7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Identification of <b>120</b> and the Evolution to <b>122</b> (GSK2269557) and <b>124</b> (GSK2292767)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">1,3-Dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>][1,5]naphthyridin-2-ones (BEZ235): Inspired Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0048.gif" alt="" id="dgr19" /></img>Starting from <b>125</b> (BEZ235, dactolisib),<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> the first PI3K inhibitor to enter clinical trials in 2006, Cheng et al. from Pfizer reported on a fast-follower approach to discover <b>126</b>, which exhibited excellent properties (mouse PI3Kα <i>K</i><sub>i</sub> = 1.41 nM, which translates to a ligand efficiency (LE) of 0.354). When tested in an mTOR kinase domain in vitro biochemical assay, <b>126</b> exhibited good activity with a <i>K</i><sub>i</sub> of 4.51 nM. However, in a BT20 cell assay, measuring inhibition of AKT phosphorylation at S473, <b>126</b> exhibited only moderate cellular potency with an IC<sub>50</sub> of 144 nM, which relates to a cell-based LipE of 2.15, due to high lipophilicity (cLogP = 4.69). Unsurprisingly, the combination of lack of sp<sup>3</sup> atoms and lipophilicity led to the reported poor solubility (2.0 μM).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> SAR studies, directed to increasing both PI3Kα and mTOR activity while reducing lipophilicity, led to the discovery of <b>127</b> (PF-04979064) as a structurally diverse back-up to their first development compound <b>79</b>.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Compound <b>127</b> (PI3Kα <i>K</i><sub>i</sub> = 0.3 nM; mTOR <i>K</i><sub>i</sub> = 1.42 nM), due in part to the reduction in lipophilicity (cLogP = 1.27) and increase in solubility (539 μM), had very good cellular potency (IC<sub>50</sub> = 9.1 nM), which relates to a cell-based improved LipE of 6.8. <b>127</b> progressed to pharmacokinetic studies (rat PK CL = 19.3 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>V</i><sub>dss</sub> = 5.23 L/kg; <i>F</i> = 61%) and progressed to mouse in vivo xenograft efficacy studies, where it exhibited dose proportional tumor growth inhibition (TGI) in a U87MG mouse xenograft model, achieving 88% TGI at the highest tolerated dose, 40 mg/kg QD.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">2,8-Disubstituted Pyrido[3,2-<i>d</i>]pyrimidine and Substituted 5,6,7,8-Tetrahydropyrido[4,3-<i>d</i>]pyrimidine Inhibitors (Leniolisib)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0049.gif" alt="" id="dgr20" /></img>Hoegenauer et al. from Novartis also used <b>125</b> as a starting point for the discovery of <b>131</b>.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In their first disclosure they reported on efforts to synthesize a PI3Kδ inhibitor. Guided by docking studies, they deconstructed the imidazolquinoline present in <b>125</b>, which they considered was contributing to the affinity of <b>125</b> for mTOR (mTOR IC<sub>50</sub> = 6 nM), to the simplified quinazoline fragment <b>128</b> (PI3Kα IC<sub>50</sub> = 0.65 μM; PI3Kδ IC<sub>50</sub> = 8.1 μM; PI3Kβ/γ and mTOR IC<sub>50</sub> ≥ 10 μM). Further SAR studies led to <b>129</b> (PI3Kα IC<sub>50</sub> = 0.262 μM; PI3Kδ IC<sub>50</sub> = 9 nM; PI3Kβ IC<sub>50</sub> = 1.65 μM; PI3Kγ IC<sub>50</sub> = 4.63 μM, cell activity PI3Kδ IC<sub>50</sub> = 0.049 μM). In rats, <b>129</b> showed a moderate 22% oral bioavailability. While a higher total exposure could be reached with increasing the dose to 30 mg/kg, this overall gain was not dose-linear and bioavailability dropped to 10%, likely due to solubility limited absorption. However, in dogs the overall pharmacokinetic properties for <b>129</b> were similar but with a better 42% oral bioavailability at 0.3 mg/kg. PK/PD studies were performed in rodents following a single oral dose of compound <b>129</b> (30 mg/kg) in male Lewis rats. Blood was collected at various time points, and changes for two PD biomarker expression profiles as well as drug levels were determined. A clear relationship of drug exposure, inhibition of Akt phosphorylation, and anti-IgM/rIL-4-induced CD86 expression was observed.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Further SAR was reported by Hoegenauer et al. to improve physicochemical properties of the quinazoline series, as typified by <b>129</b>, through reduction of the MW and fsp<sup>3</sup> which are known drivers of poor physicochemical properties. Further SAR studies resulted in the identification of <b>130</b> (PI3Kα IC<sub>50</sub> = 0.424 μM; PI3Kδ IC<sub>50</sub> = 22 nM; PI3Kβ IC<sub>50</sub> = 1.03 μM; PI3Kγ IC<sub>50</sub> = 2.94 μM). However, the improvement in physicochemical properties did not lead to an increase in cellular activity (IC<sub>50</sub> = 0.022 μM), due in part to the reduction in PI3Kδ activity.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In their final publication, further optimization led to the discovery of <b>131</b> (leniolisib PI3Kα IC<sub>50</sub> = 0.244 μM; PI3Kδ IC<sub>50</sub> = 11 nM; PI3Kβ IC<sub>50</sub> = 0.424 μM; PI3Kγ IC<sub>50</sub> = 2.23 μM). <b>131</b> demonstrated 30-fold cell activity over PI3Kα (PI3Kδ IC<sub>50</sub> = 56 nM). <b>131</b> was tested in a mouse ozone-induced lung inflammation model where it dose-dependently inhibited the increase in bronchoalveolar lavage (BAL) neutrophil and macrophage numbers with ED<sub>50</sub> values of 16 mg/kg and 40 mg/kg, respectively. In a rat model of collagen-induced arthritis (<i>r</i>CIA) it significantly inhibited pathogenic anti-rat collagen antibodies, paw swelling, inflammatory cell infiltration, proteoglycan loss, and joint erosion when dosing started, before disease onset and full efficacy was also observed with low doses (3 mg/kg b.i.d.). In a therapeutic setting when <b>131</b> was administered when significant paw swelling was present, a dose of 10 mg/kg b.i.d. significantly ameliorated disease parameters.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Currently <b>131</b> is undergoing phase II/III studies for activated PI3Kδ syndrome and primary Sjögren syndrome.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">Xin et al. reported on the synthesis of a range of 4-anilinequinazoline derivatives as PI3Kδ inhibitors designed as a fast follower approach.</div><div class="NLM_p">Changing the aromatic linkage present in the Novartis compound <b>132</b> generated a new series of 6-aryl substituted 4-anilinquinazoline derivatives (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>), which resulted in the identification of <b>133</b> (PI3Kδ IC<sub>50</sub> = 9.3 nM). <b>133</b> demonstrated similar antiproliferative profiles to idelalisib in several human B cell lines (e.g RPMI-8226 IC<sub>50</sub> = 6.61 μM; idelalisib IC<sub>50</sub> = 5.49 μM).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Further studies on changing the aniline group for less lipophilic moieties resulted in the identification of <b>134</b> (PI3Kδ IC<sub>50</sub> = 2.7 nM; PI3Kα IC<sub>50</sub> = 25.6 nM; PI3Kβ IC<sub>50</sub> = 263.8 nM; PI3Kγ IC<sub>50</sub> = 174.2 nM).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a><b>134</b> showed significant potent antiproliferative activity against human B cell line Ramos (IC<sub>50</sub> = 0.57 μM), moderate antiproliferation against RPMI-8226 (IC<sub>50</sub> = 4.34 μM) and SU-DHL-6 (IC<sub>50</sub> = 4.55 μM), but no activity against Raji (IC<sub>50</sub> > 10 μM).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0050.gif" alt="" id="dgr21" /></img></div><figure id="sch8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. 2,8-Disubstituted Pyrido[3,2-<i>d</i>]pyrimidine Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Hei et al. reported on a series of 4,6-disubstituted quinazoline derivatives, as typified by <b>135</b>, which displayed high potency against PI3K enzymes (PI3Kα IC<sub>50</sub> = 465 nM, PI3Kδ IC<sub>50</sub> = 37 nM) and antiproliferative activities against both HCT-116 (IC<sub>50</sub> = 0.51 μM) and MCF-7 (IC<sub>50</sub> = 2.10 μM) and could efficaciously inhibit tumor growth in a mice S-180 model.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> In a similar series of compounds, Xin et al. demonstrated that <b>136</b> had good PI3K enzyme activity (PI3Kδ IC<sub>50</sub> = 9.3 nM) and showed similar antiproliferative profiles to idelalisib in human B cell lines [e.g., RPMI-8226 cells IC<sub>50</sub> = 6.61 μM, idelalisib 5.49 μM].<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Zhang et al. reported on <b>137</b>, a potent PI3K/mTOR dual inhibitor that significantly inhibited class I PI3Ks (PI3Kδ IC<sub>50</sub> = 0.87 nM; PI3Kβ IC<sub>50</sub> = 3.9 nM; PI3Kα IC<sub>50</sub> = 1.7 nM; PI3Kγ IC<sub>50</sub> = 8.4 nM), mTOR (IC<sub>50</sub> = 10 nM) and phosphorylation of pAkt(Ser473) at low nanomolar level.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Moreover, <b>137</b> displayed high potency in an antiproliferative assay in PC-3 cells (IC<sub>50</sub> = 80 nM) and showed acceptable in vivo pharmacokinetic properties in mice after oral administration at 5 mg/kg as a crystalline suspension in 0.5% methylcellulose [CL = 0.42 L h<sup>–1</sup> kg<sup>–1</sup>, <i>V</i><sub>d</sub> = 1.0 L/kg, plasma terminal half-life (<i>T</i><sub>1/2</sub> = 1.6 h)]. Mah et al. reported the identification of 4-phenoxyquinoline based inhibitor for L1196 M mutant of anaplastic lymphoma kinase as typified by <b>138</b> discovered by a fragment growing strategy.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a><b>138</b> exhibited significant antiproliferative effects on H2228 CR crizotinib-resistant cells by decreasing PI3K/AKT and MAPK signaling. Fan et al. highlighted compound <b>139</b> with potent antiproliferative activity without cytotoxicity to human normal cells. <b>139</b> was reported to be selective for PI3Kα (IC<sub>50</sub> = 13.6 nM, selectivity of ∼10-fold), and in a Western blot assay, <b>138</b> demonstrated inhibition of cell proliferation via suppression of PI3Kα kinase activity (IC<sub>50</sub> of 13.6 nM) and subsequently blocked PI3K/Akt pathway activation in HCT116 cells.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">7,9-Disubstituted-2-morpholino-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one-Based Inhibitors: Evolution of AZD6482 and AZD8186</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">TGX-221 (<b>140</b>) was disclosed as a selective PI3Kβ inhibitor by Kinaacia Ply Ltd., a spin-out from Monash University, and has served as the inspiration of several drug discovery programs looking for potent and selective PI3Kβ inhibitors (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).</div><figure id="sch9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Evolution of 7,9-Disubstituted 2-Morpholino-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one-Based Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scientists at GSK separated the enantiomers by chiral HPLC and discovered that the biological activity resided in one enantiomer, with the (<i>R</i>)-enantiomer <b>141</b> (PI3Kβ IC<sub>50</sub> = 6 nM) being ∼30-fold more potent than the (<i>S</i>)-enantiomer (PI3Kβ IC<sub>50</sub> = 200 nM), suggesting that the aniline plays an important role in the interaction with PI3Kβ.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> It was suggested that imadazo[1,2-<i>a</i>]pyrimidine-5(1<i>H</i>)-one, with a N-1 substituted benzyl group, would be a replacement scaffold, and SAR demonstrated that a 2,3-disubstituted benzyl group was optimal for balancing potency and PI3Kβ isoform selectivity, <b>142</b> (PI3Kβ = 1 nM; PI3Kα = 2 μM; PI3Kδ = 8 nM; PI3Kγ = 1 μM), as well as demonstrating potent cell growth inhibition (EC<sub>50</sub> = 0.14 μM) against a PTEN-deficient breast cancer cell line (MDA-MB-468). In a follow-on publication, the core imadazo[1,2-<i>a</i>]pyrimidine-5(1<i>H</i>)-one was changed to a 1,2,4-triazolo[1,5-<i>a</i>]pyrimidin-7(3<i>H</i>)-one with similar activity, <b>143</b> (PI3Kβ = 1.5 nM; PI3Kδ = 4 nM), as well as demonstrating good cell growth inhibition (EC<sub>50</sub> = 0.1 μM) against a PTEN-deficient breast cancer cell line (MDA-MB-468). Substituting the morpholine ring with a 2-methyl group substantially increased potency and cell-based activity <b>144</b> (PI3Kβ = 0.3 nM; PI3Kδ = 4 nM; EC<sub>50</sub> = 0.5 nM). Unfortunately, the series of compounds suffered high rat clearance and was not progressed.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In light of the poor rat metabolic stability, a core change to a new thiazolopyrimidinone series was evolved.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Once more, extensive SAR studies identified <b>145</b> (PI3Kβ = 0.6 nM; PI3Kα = 2.5 μM; PI3Kδ = 20 nM; PI3Kγ = 0.79 μM; cell, MDA-MB-468 pAKT IC<sub>50</sub> = 24 nM; proliferation gIC<sub>50</sub> = 0.103 μM). Importantly, <b>145</b> showed good pharmacokinetics (mouse PK CL = 29.6 mL min<sup>–1</sup> kg<sup>–1</sup>); Vd<sub>ss</sub> = 2.8 L/kg; <i>F</i> = 49%) and progressed to a PTEN-deficient PC-3 prostate carcinoma xenograft mouse model, where it was dosed once-daily for 21 days at 100 and 300 mg/kg, demonstrating complete tumor growth inhibition relative to vehicle treated mice, with no effect on body weight. However, the authors conclude by stating that other unknown activities of PI3Kβ may be contributing to the effects on tumor growth. However, these studies represented a significant milestone toward validating PI3Kβ as a potential target for proliferative disorders.</div><div class="NLM_p">Once more taking inspiration from <b>141</b> and <b>146</b> (AZD6482), Barlaam et al. reported on the discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxopyrido[1,2-<i>a</i>]pyridine carboxamides as selective PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumors.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> With an aim of reducing lipophilicity and balancing PI3Kβ enzyme and cellular activity through increasing permeability, a series of 6-substituted carboxamides were synthesized which resulted in the identification of <b>147</b> (PI3Kβ IC<sub>50</sub> = 5 nM; PI3Kα IC<sub>50</sub> = 0.075 μM; PI3Kδ IC<sub>50</sub> = 32 nM; PI3Kγ IC<sub>50</sub> = 0.51 μM; cell, MDA-MB-468 pAKT IC<sub>50</sub> = 3 nM, mouse PK CL = 82 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 31%)). <b>147</b>, a compound with low/medium metabolic stability, showed profound pharmacodynamic modulation of phosphorylated Akt in a PC3 prostate tumor xenograft after a single oral dose. In addition, <b>148</b> (PI3Kβ IC<sub>50</sub> = 7 nM; PI3Kα = 0.34 μM; PI3Kδ IC<sub>50</sub> = 45 nM; PI3Kγ IC<sub>50</sub> = 3.0 μM; cell, MDA-MB-468 pAKT IC<sub>50</sub> = 34 nM, mouse PK CL = 74 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 35%) demonstrated significant inhibition of tumor growth in the PC3 prostate xenograft model after chronic oral dosing. In order to address the low/medium metabolic stability, improve solubility, and increase bioavailability, a reduction in lipophilicity was explored, where the core was changed to a 2-morpholino-4-oxo-4<i>H</i>-chromene-6-carboxamide scaffold to generate, after extensive SAR studies, <b>149</b> (PI3Kβ IC<sub>50</sub> = 4 nM; PI3Kα IC<sub>50</sub> = 35 nM; PI3Kδ IC<sub>50</sub> = 12 nM; PI3Kγ IC<sub>50</sub> = 0.675 μM; cell, MDA-MB-468 pAKT IC<sub>50</sub> = 3 nM, mouse PK CL = 77 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 18%) (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a><b>149</b> proved to be efficacious for p-Akt in PTEN-deficient PC3 prostate tumor bearing mice after oral administration and showed complete inhibition of tumor growth in a mouse PTEN-deficient PC3 prostate tumor xenograft model. <b>149</b> was selected as a clinical candidate for patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small-cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC), and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies as a monotherapy and in combination with vistusertib or abiraterone acetate. Further clinical studies are ongoing.</div><figure id="sch10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Chemical Modifications on <b>146</b> To Deliver AZD8186, a PI3Kβ Inhibitor for Use in Treating Patients with Advanced Solid Tumors with PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Marshall et al. reported on further SAR evaluation of pyrido[1,2-<i>a</i>]pyrimidinone-based class 1 PI3K inhibitors (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Extensive SAR, such as replacement of the group X by CH<sub>2</sub>O and CH<sub>2</sub>S, decreased both potency and selectivity as well as constrained the group X with NHSO<sub>2</sub>, NHCO, or CONH moieties, confirming the structural requirements for these “T-shaped” inhibitors.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Interestingly, in this report the <i>N</i>-methyl analog <b>150</b> showed the best potency (PI3Kβ IC<sub>50</sub> = 20 nM) but was not tested in a cell-based assay.</div><figure id="sch11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Pyrido[1,2-<i>a</i>]pyrimidinone-Based Class 1 PI3K Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>146</b> is an ATP-competitive PI3Kβ inhibitor, and the first human target validation of PI3Kβ inhibition with <b>2</b> was reported following a 3 h infusion of seven different doses of <b>146</b>; a wide separation between antithrombotic effect and bleeding was observed, demonstrating that previous pharmacodynamic findings in dog translated well to man. Whereas <b>146</b> was well tolerated in man, a weak but significant concentration-dependent increase in plasma insulin and corresponding homeostasis model analysis (HOMA) index was recorded. In the plasma concentration range tested, it was suggested that such an effect could be ascribed to the compound’s ability to inhibit PI3Kα (IC<sub>50</sub> = 0.87 μM). In addition, <b>146</b> had a short plasma half-life (5–43 min) due to high metabolic clearance and a relatively small distribution volume (40–68 L).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Thus, the pharmacokinetic and pharmacodynamic profile of <b>146</b> might limit its use to parenteral administration in situations where a low bleeding risk is desirable. Giordanetto et al. reported fragment-based drug discovery approaches<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> to reduce the PI3Kα inhibitory activity through investigation of the requirement of the aromatic carboxylic acid, the linking group to the aniline, and the incorporation of a group to improve water solubility. This extensive SAR resulted in <b>151</b> (PI3Kβ IC<sub>50</sub> = 100 nM; PI3Kα IC<sub>50</sub> = 3.5 μM; PI3Kδ IC<sub>50</sub> = 0.4 μM; PI3Kγ IC<sub>50</sub> = 83 μM; dog PK CL = 8 mL min<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 31%) as a novel orally bioavailable PI3Kβ inhibitor. <b>151</b> inhibited platelet activation in plasma and whole blood and was highly soluble and metabolically stable. Furthermore, no significant inhibition of Cyp450 enzymes and ion channels involved in cardiac function was recorded. Efficacy versus bleeding in anesthetized dogs showed <b>151</b> elicited a concentration-dependent inhibition of platelet aggregation ex vivo (EC<sub>80</sub> = 0.69 ± 0.06 μM), which well predicted its inhibition of thrombosis in vivo (EC<sub>80</sub> = 0.6 ± 0.05 μM). Importantly, no significant increase in bleeding time and blood loss was recorded at the observed maximum compound concentration (24.1 ± 2.3 μM). Finally, no significant increase of the homeostasis model analysis (HOMA index) from baseline was apparent at the maximum compound concentration (20.4 ± 2.1 μM). Therefore, the safety margin to compound concentrations resulting in full antithrombotic effect was acceptable, and <b>151</b> was selected as a preclinical candidate for further development (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><figure id="sch12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Extensive SAR To Deliver <b>151</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Starting from a high throughput screening campaign, Certal et al. identified <b>152</b> as an interesting lead due to its selectivity for PI3Kβ versus other PI3K isoforms (PI3Kβ IC<sub>50</sub> of 42–2133 nM in various screens and >10 μM on PI3Kα,δ,γ). Chemistry to exchange the potentially labile amide bond with heterocyclic replacements gave <b>153</b> (PI3Kβ IC<sub>50</sub> = 158 nM) and <b>154</b> (PI3Kβ IC<sub>50</sub> = 82 nM), and further SAR optimization resulted in <b>155</b> (PI3Kβ IC<sub>50</sub> = 99 nM; PI3Kδ IC<sub>50</sub> = 1395 nM and >10 μM on PI3Kα,γ), a compound with adequate in vitro pharmacokinetic properties and was shown to potently inhibit Akt phosphorylation in PTEN-deficient PC3 prostate carcinoma cell line when dosed at 300 mg/kg b.i.d. for 9 days.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0051.gif" alt="" id="dgr22" /></img></div><div class="NLM_p">In a continuation of their studies, Certal et al. reported on the identification of the clinical candidate <b>156</b> (SAR260301), a low molecular weight compound (MW 354 cLogP = 1.5) with improved physicochemical and in vitro pharmacokinetic properties (PI3Kβ IC<sub>50</sub> = 23 nM; PI3Kα IC<sub>50</sub> = 1.5 μM; PI3Kδ IC<sub>50</sub> = 0.47 μM; PI3Kγ IC<sub>50</sub> ≥ 10 μM; dog PK CL = 0.4 L h<sup>–1</sup> kg<sup>–1</sup>; <i>F</i> = 67%). The first X-ray cocrystal structure of P110β with the selective inhibitor <b>156</b> bound to the ATP site demonstrated the “T-shaped” nonplanar binding mode. The X-ray showed that the morpholine oxygen accepts a H-bond from Val848 in the hinge region.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The aniline generates an induced fit in the P-loop at the top of the ATP binding site creating a lipophilic pocket lined with Met771 and Trp781, and this was the reason for the β-isoform selectivity (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><figure id="fig11" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Binding of <b>156</b> to the ATP binding site of P110β (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR">4BFR</a>), visualized in PyMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>156</b> demonstrated significant in vivo activity in a mouse UACC-62 xenograft model and entered phase I/Ib clinical trials in patients with advanced cancer where <b>156</b> had an acceptable safety profile, but exposure sufficient to inhibit the PI3K pathway was unachievable because of rapid clearance, and clinical development was terminated.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Benzoxazepin-Based PI3Kδ Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2011, Staben et al. identified a benzopyran-based inhibitor <b>157</b> from a HTS.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0052.gif" alt="" id="dgr23" /></img></div><div class="NLM_p">Compound <b>157</b> exhibited reasonable potency for PI3Kα (IC<sub>50</sub> = 0.254 μΜ); however the physicochemical properties were not ideal (cLogP = 4.1, LE = 0.39, LipE = 2.5, MW = 356). Due to the structural novelty of the scaffold, a SAR study was initiated where the aryl substituent on the aniline amide revealed the importance of the <i>ortho-</i>halogen for PI3Kα activity. Additionally, a crystal structure of <b>158</b> (PI3Kα = 0.108 μM) indicated that the <i>N-</i>methylaniline amide bound in a <i>cis-</i>fashion in the activity pocket and that the hinge binding interaction of the pyran oxygen was suboptimal and could be potentially improved upon through ring expansion. This led to a seven-membered ring with a 4-fold increase in potency (PI3Kα = 0.024 μM), and subsequent expansion to an eight-membered ring, <b>159</b>, reduced potency drastically (>10 μM). Comparison of the crystal structures of <b>157</b> and <b>159</b> confirmed a shorter hydrogen bond and better angle for interaction with the hinge Val882 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Although potency had increased, the rate of clearance proved consistently high across the series of analogs. A metabolite identification experiment in human hepatocytes revealed hydrolysis of the aniline amide and an oxidative metabolite resulting from demethylation, aromatic oxidation, and glucoronindation of the aniline. <i>Para-</i>substitution with an electron withdrawing polar amide <b>161</b> (GNE-614) reduced lipophilicity (cLogP = 2.7), blocked <i>para-</i>oxidation, and decreased clearance in rat (36 mL min<sup>–1</sup> kg<sup>–1</sup>). Compound <b>161</b> exhibited good potency toward the class I PI3Ks (PI3Kα IC<sub>50</sub> = 4.6 nM, PI3Kβ IC<sub>50</sub> = 60 nM, PI3Kγ IC<sub>50</sub> = 5 nM, PI3Kδ IC<sub>50</sub> = 1.7 nM) and was relatively inactive against mTOR (IC<sub>50</sub> = 530 nM). However, <b>161</b> showed only a moderate PK profile, rat (CL = 36 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 50%, AUC = 39 μM/h), mouse (CL = 15 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 28%, AUC = 330 μM/h), and dog (CL = 5 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 120%, AUC = 17 μM/h), and was found to inhibit DNA-PK (IC<sub>50</sub> = 6 nM), a structurally similar countertarget.</div><figure id="fig12" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. X-ray crystal structures of <b>157</b> showing a shorter hydrogen bond and better angle for interaction with the hinge Val882 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R">3R7R</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a follow-up paper, Staben et al. aimed to improve the upon the PK profile of <b>161</b> by replacing the metabolically liable <i>cis-N-</i>methyl anilide with an appropriate bioisostere. After extensive SAR they discovered that replacing the aryl group with an alkyl group was not tolerated. However, replacement with heteroaryl groups led to the discovery of <b>162</b> (PI3Kα IC<sub>50</sub> = 4 nM) which showed improved properties for further optimization (rat CL = 13 mL min<sup>–1</sup> kg<sup>–1</sup>, AUC = 5.7–17.8 μM/h).<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0053.gif" alt="" id="dgr24" /></img></div><div class="NLM_p">Following the discovery of <b>162</b>, Staben et al. set out to further decrease the lipophilicity of the series by modification of the thiophene.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In addition, replacement of the thiophene would remove the potential oxidative metabolism of this group. After identifying a number of suitable heteroaryl groups, the group opted to select the thiazole <b>163</b> for further development. <b>163</b> was highly potent toward the class I PI3Ks (PI3Kα IC<sub>50</sub> = 0.27, PI3Kβ IC<sub>50</sub> = 15 nM, PI3Kγ IC<sub>50</sub> = 0.55 nM, PI3Kδ IC<sub>50</sub> = 0.61 nM), although they observed that potency toward PI3Kβ was consistently lower with specific substitutions at the 8-position of the benzoxepin. They hypothesized that this was due to a different conformation (in PI3Kβ) of the tryptophan residue that makes up the tryptophan shelf in the case of PI3Kδ. Compound <b>163</b> showed a suitable PK profile for further advancement as it had low clearance and high bioavailability in rodents (rat CL = 5.4 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 83%, mouse CL = 9.5 mg mL<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 110%), acceptable PK in dog (CL = 14 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 22%), and moderate predicted clearance in human (hepatocyte Clp = 12 mL min<sup>–1</sup> kg<sup>–1</sup>). In addition, <b>163</b> showed modest tumor growth inhibition in an MCF7-neo/HER2 xenograft breast cancer model, and activity against countertargets was also reduced (mTOR IC<sub>50</sub> > 4.3 μM and DNA-PK IC<sub>50</sub> = 0.34 μM).</div><div class="NLM_p">With <b>163</b> showing only modest tumor growth inhibition in a MCF7-neo/HER2 xenograft breast cancer model despite being highly potent and exhibiting a moderate PK profile, Staben et al. aimed to increase the unbound exposure by further reducing the lipophilicity. An extensive screen of heteroaryl isosteres was performed, with focus on lowering the lipophilicity, leading to the discovery of <b>164</b> (GDC-0032, clogD = 2.5). Compound <b>164</b> showed good activity toward the class I PI3Ks, with decreased PI3Kβ activity (PI3Kα IC<sub>50</sub> = 0.29 nM, PI3Kβ IC<sub>50</sub> = 9.1 nM, PI3Kγ IC<sub>50</sub> = 0.12 nM, PI3Kδ IC<sub>50</sub> = 0.97 nM). In addition, against a panel of 235 kinases, only 2 (not including the class I PI3Ks) exhibited greater than 50% inhibition at 10 μM concentration: C2β (80.4%), and Vps34 (69.9%). <b>164</b> also had a good PK profile, exhibiting low in vivo clearance in rat with high oral bioavailability (<i>F</i> = 99%). After toxicological and safety evaluations, <b>164</b> was progressed to clinical trials for PI3K-related cancers.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0054.gif" alt="" id="dgr25" /></img></div><div class="NLM_p">Having only reported pan or so-called β-sparing benzoxepins, in 2016, Heffron et al. moved the focus of their program toward the development of selective PI3Kα inhibitors.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> At the onset of their PI3Kα program, a crystal structure of one of their benzoxepin inhibitors was obtained, revealing two residues unique to the α-isoform, Gln859 and His855. From molecular modeling evidence the team decided to target Gln859 in order to gain selectivity toward PI3Kα. Extensive SAR, and monitoring of torsion angle at the 8-position, focused on optimizing hydrogen bonding with Gln859. This led to the discovery of <b>165</b> (GDC-0326), where the primary amide makes three concerted hydrogen bonds with Gln859 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). <b>165</b> is a PI3Kα-selective inhibitor (PI3Kα IC<sub>50</sub> = 0.2 nM, α/β = 133, α/γ = 51, α/δ = 20) and showed a comparable PK profile to <b>164</b> and was selected for further study, although it has not yet progressed into the clinic at the time of writing.</div><figure id="fig13" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <b>165</b> X-ray crystal structure in PI3Kα where the primary amide makes three concerted hydrogen bonds with Gln859 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In their most recent publication, Safina et al. used their previous experience with the design of selective PI3Kδ inhibitors in order to build-in PI3Kδ selectivity into the benzoxepin core.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Since the benzoxepin core was a result of ADME optimization, it possessed favorable drug-like properties, and therefore this was an attractive endeavor. They discovered <b>166</b> as a PI3Kδ-selective inhibitor (PI3Kδ IC<sub>50</sub> = 1.9 nM, δ/α = 113) through interaction via the tryptophan shelf.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Compound <b>166</b> had low lipophilicity (clogD = 1.29), yet maintained good permeability (MDCK(A to B) = 10 × 10<sup>–6</sup> cm/s).</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Aminothiazole and Aminobenzthiazole Urea-Based Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2012, scientists from Cellzome reported <b>167</b> (PI3Kα pIC<sub>50</sub> < 4, PI3Kβ pIC<sub>50</sub> < 4, PI3Kγ pIC<sub>50</sub> = 5.4, PI3Kδ pIC<sub>50</sub> = 4.5) and <b>168</b> (PI3Kα pIC<sub>50</sub> = 4.9, PI3Kβ pIC<sub>50</sub> = 4.7, PI3Kγ pIC<sub>50</sub> = 5.7, PI3Kδ pIC<sub>50</sub> = 5.2) as hits from an HTS of a kinase focused library of 16 000 compounds (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>).<a onclick="showRef(event, 'ref131 ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref131 ref132 ref133">(131−133)</a> SAR around the core led to <b>169</b> (CZC19945, PI3Kα pIC<sub>50</sub> = 5.6, PI3Kγ pIC<sub>50</sub> = 7.6, PI3Kδ pIC<sub>50</sub> = 5.8). Further SAR on the central core led to <b>170</b> (CZC24832, PI3Kα pIC<sub>50</sub> < 5, PI3Kγ pIC<sub>50</sub> = 7.6, PI3Kδ pIC<sub>50</sub> = 5.1). <b>170</b> showed moderate PK properties in mouse (CL = 11.5 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 37%), showed no inhibition of <i>h</i>ERG up to 100 μM and no CYP inhibition, and was negative in the Ames test. In addition, <b>170</b> demonstrated efficacy in a chronic model of inflammation, although poor aqueous solubility (5 μg/mL) made preclinical development problematic. Crystallographic studies show that these compounds bound to the hinge region of PI3Kγ via the donor/acceptor motif of the triazolopyridine with the pyridine sulphonamide interacting with the activity pocket. In a further publication, Ellard et al. detailed more SAR at the solvent exposed region, leading to PI3Kγ/δ compounds such as <b>171</b> (PI3Kα pIC<sub>50</sub> = 6.4, PI3Kγ pIC<sub>50</sub> = 8.4, PI3Kδ pIC<sub>50</sub> = 7.8, PI3K pIC<sub>50</sub> = 6.3), although poor physicochemical properties precluded them from oral absorption.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0055.gif" alt="" id="dgr26" /></img></div><figure id="sch13" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Discovery of the Urea-Based Inhibitor <b>171</b> from Early HTS of a Kinase Focused Library</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In parallel, Oka et al. identified <b>172</b> as a hit in their HTS with excellent enzymatic potency (PI3Kγ IC<sub>50</sub> = 5 nM). Through structural modification, struggling initially with permeability issues, they developed <b>173</b> (PI3Kγ IC<sub>50</sub> = 10 nM, α/γ = 4) and <b>174</b> (PI3Kγ IC<sub>50</sub> = 3 nM, α/γ = 5). However, although both demonstrated improved permeability leading to improved cellular potency, they showed low selectivity over PI3Kγ.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> In a later publication, it was reported that the deacetylated version of <b>173</b> was positive in the Ames test.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Although the deacetylated product was not found to be a major metabolite, they sought to mitigate mutagenic risk by replacing the oxazole ring with more π-electron deficient heterocycles. This led to the 2-amino-5-oxadiazolyl thiazole <b>175</b>, where both the acetylated and deacetylated analogs were negative in the Ames test. Being approximately equipotent in terms of PI3Kγ potency to <b>174</b>, they were able to explore <b>175</b> further, leading to the discovery of <b>176</b> (TASP0415914, PI3Kγ IC<sub>50</sub> = 29 nM). <b>176</b> exhibited a better PK profile, showed no CYP inhibition, and was progressed to in vivo studies in a mouse collagen-induced arthritis model and was effective in a dose-dependent manner.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0056.gif" alt="" id="dgr27" /></img></div><div class="NLM_p">Also, in 2012, Bruce et al. revealed <b>177</b> as a hit from a HTS targeting PI3Kγ.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> A docking study involving <b>177</b> showed that the thiazole nitrogen and amide hydrogen form a bidentate donor–acceptor pair with the hinge region, and the sulfonamide interacts with the activity pocket. They observed that residues lining the binding pocket were less conserved and hypothesized that isoform selectivity might be achievable by extending or replacing the acyl moiety with diverse substituents to exploit these differences. After developing a method of thiazole synthesis amenable to automation, they were able to generate approximately 400 analogs with replacements for the acyl moiety. Most of these compounds were found to be either inactive or weak pan-PI3K inhibitors. However, three types of amines were identified that led to potent isoform selective inhibitors. For example, (<i>S</i>)-pyrrolidine carboxamides such as <b>178</b> (NVS-PI3-1, PI3Kα <i>K</i><sub>i</sub> = 0.005 μM, PI3Kβ <i>K</i><sub>i</sub> = 2.0 μM, PI3Kγ <i>K</i><sub>i</sub> = 0.53 μM, PI3Kδ <i>K</i><sub>i</sub> = 0.22 μM) and <b>179</b> (NVS-PI3-2, PI3Kα IC<sub>50</sub> = 0.04 μM, PI3Kβ IC<sub>50</sub> = 22.94 μM, PI3Kγ IC<sub>50</sub> = 1.19 μM, PI3Kδ IC<sub>50</sub> = 0.54 μM) were the optimal compounds. A structurally related benzothiazole was shown to be selective toward PI3Kα, due to the carboxamide making favorable interactions with the nonconserved Gln859 of PI3Kα. Aminopropionic acid derivatives such as <b>180</b> (NVS-PI3-3, PI3Kα <i>K</i><sub>i</sub> = 0.15 μM, PI3Kβ <i>K</i><sub>i</sub> = 0.34 μM, PI3Kγ <i>K</i><sub>i</sub> = 1.02 μM, PI3Kδ <i>K</i><sub>i</sub> = 0.004 μM), <b>181</b> (NVS-PI3-4, PI3Kα <i>K</i><sub>i</sub> = 1.89 μM, PI3Kβ <i>K</i><sub>i</sub> = 0.25 μM, PI3Kγ <i>K</i><sub>i</sub> = 0.088 μM, PI3Kδ <i>K</i><sub>i</sub> = 0.74 μM), and <b>182</b> (NVS-PI3-5, PI3Kα <i>K</i><sub>i</sub> = 1.40 μM, PI3Kβ <i>K</i><sub>i</sub> = 0.32 μM, PI3Kγ <i>K</i><sub>i</sub> = 0.036 μM, PI3Kδ <i>K</i><sub>i</sub> = 0.47 μM) led to PI3Kδ selectivity (<b>180</b>) and PI3Kγ selectivity (<b>181</b> and <b>182</b>). The authors suggested that the PI3Kδ and PI3Kγ selectivity was most likely derived from interactions between the terminal functional groups of the urea side chain and nonconserved amino acids at the outer edge of the binding site. Additionally, all examples in the series were much less potent toward PI3Kβ than the other isoforms. However, the PK properties of <b>178</b>–<b>182</b> were not adequate for further progression, but this work led to some interesting observations toward selective inhibitors.</div><div class="NLM_p">Following this in 2013, Furet et al. disclosed the discovery of the PI3Kα selective inhibitor <b>183</b>, alpelisib (NVP-BYL719).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Addressing the poor PK and isoform selectivity within the series to date, extensive SAR studies around <b>178</b> led to the discovery of <b>183</b> (PI3Kα IC<sub>50</sub> = 0.005 μM, PI3Kβ IC<sub>50</sub> = 1.2 μM, PI3Kγ IC<sub>50</sub> = 0.25 μM, PI3Kδ IC<sub>50</sub> = 0.29 μM). Crystallographic evidence of <b>183</b> in complex with PI3Kα shows that <b>183</b> exhibited its excellent selectivity toward PI3Kα by exploiting the nonconserved Gln859 of PI3Kα. <b>183</b> had a suitable PK profile (rat CL = 10 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>V</i><sub>ss</sub> = 1.9 L/kg) and showed no significant CYP or related-kinase inhibition and was progressed to clinical development.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0057.gif" alt="" id="dgr28" /></img></div><div class="NLM_p">In 2014, Collier et al. analyzed the crystal structure of PIK-93 and observed that there was sufficient space in the ATP binding pocket to allow for a ring fusion of the thiazole into a benzothiazole where hinge binding could be achieved through the donor–acceptor motif of the nitrogen atoms of the aminobenzothiazole. <b>184</b> (PI3Kγ <i>K</i><sub>i</sub> = 0.004 μM, α/γ = 1, β/γ = 10, and δ/γ = 3) and <b>185 (</b>PI3Kγ <i>K</i><sub>i</sub> = 0.002 μM, α/γ = 66, β/γ = 21, and δ/γ = 61) were compounds that exhibited isoform selectivity toward PI3Kγ.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> After obtaining an X-ray crystal structure for <b>185</b> in PI3Kγ (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PS3">4PS3</a>), they hypothesized that this selectivity was a result of two nonconserved residues within the binding site. The first is Ala885, which is unique to PI3Kγ. In PI3Kα, β, and δ this is a serine residue where the OH of serine is involved in hydrogen bonding with the hinge valine residue. They proposed that introduction of urea functionality allows for the urea carbonyl to form an additional hydrogen bond to the hinge valine, which in turn breaks the serine–valine hydrogen bond, freeing up the OH group and thereby introducing a steric clash with the lipophilic side chain. This steric clash is unfavorable in the antitargets and does not happen in the case of PI3Kγ. The second nonconserved residue is Gly829, a glutamic acid residue in PI3Kα. This aids selectivity over PI3Kα upon increasing the length of the terminal alkyl chain. These compounds were not progressed further; however they were useful in determining important residues for identifying new approaches for PI3K isoform selectivity.</div><figure id="fig14" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. X-ray crystal structure of <b>185</b> in PI3Kγ, demonstrating new key interactions generating isoform selectivity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PS3">4PS3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To improve the overall physicochemical properties (as typified by <b>185</b>), Collier et al. aimed to reduce the overall lipophilicity in combination with increasing the fraction of sp<sup>3</sup> atoms (fsp<sup>3</sup>) within the series.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> In order to accomplish this, they replaced the central benzothiazole core with a thiazolopiperidine, leading to <b>186</b> (PI3Kγ <i>K</i><sub>i</sub> = 0.002 μM, α/γ = 228, β/γ = 105, and δ/γ = 395). In <b>186</b> they suggested that incorporating fluorine atoms onto the terminal alkyl chain increased selectivity markedly through increasing affinity for PI3Kγ, due to a C–F···C═O interaction with Thr827. Additionally, they suggested that the increase in selectivity was driven by a favorable interaction of the acidic methine proton of the fluoroethyl group with Glu814, a residue unique to PI3Kγ. Compound <b>186</b> showed no significant inhibition in a screen of structurally related kinases.</div><div class="NLM_p">In a recent publication, Come et al. disclosed further refinement of the core structure with a view to increasing blood–brain barrier penetration. The authors highlighted the general difficulty in designing CNS-penetrant kinase inhibitors due, in part, to the property space characteristics of the ATP-competitive kinase inhibitors, where hydrogen bond donor moieties are essential pharmacophoric elements required to bind to the kinase hinge region. They proposed a very elegant solution where an isoindolinone carbonyl group would provide a hydrogen bond acceptor to the backbone NH of the hinge residue Val882, and in addition, an aromatic proton would be positioned in place of the urea NH donor (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Further functionalization gave <b>187</b> as a selective, brain penetrant inhibitor of PI3Kγ (PI3Kγ <i>K</i><sub>i</sub> = 4 nM, α/γ = 60, β/γ = 10, and δ/γ = 14). <b>187</b> was an orally bioavailable compound (rat PK CL = 20 mL min<sup>–1</sup> kg<sup>–1</sup>, <i>F</i> = 100%, <i>T</i><sub>1/2</sub> = 5.1 h) that showed efficacy in murine experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0058.gif" alt="" id="dgr29" /></img></div><figure id="fig15" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Strategy employed to reduce the number of H-bond donor groups to aid CNS penetration and compound <b>187</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Pemberten et al. discovered <b>188</b> (PI3Kγ pIC<sub>50</sub> = 6.8) from a HTS. They showed that methylation of the acetamide <b>189</b> led to a large reduction in potency, suggesting that the acetamido-substituted isoxazole was the hinge binding motif.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> SAR to replace the isoxazole with amino heterocycles that are typical kinase hinge-binding motifs led to replacement of the isoxazole with a thiazole, <b>190</b> (<i>R</i>)-enantiomer PI3Kγ pIC<sub>50</sub> = 8.9. Failing to cocrystallize inhibitors of the series in PI3Kγ, the team looked to cocrystallize inhibitors in PI3Kδ. Successfully crystallizing <b>190</b> within PI3Kδ, they confirmed the aminothiazole forms hydrogen bonds to the hinge residue Val828 and that the carbonyl of the lactam interacts with Lys779. The <i>N-</i>alkyl tail is oriented perpendicular to the isoindolinone core and extends deep into the ATP-binding pocket. An interesting observation was that removal of the <i>N-</i>alkyl group led to a 100-fold decrease in PI3Kγ activity and a corresponding 15-fold increase in PI3Kα potency, suggesting that PI3Kγ selectivity seems to originate from the <i>N-</i>alkyl tail extending deep into the ATP-binding pocket. Compound <b>190</b> exhibited poor properties for oral administration due to a combination of poor solubility, high in vitro clearance, and high lipophilicity. Introduction of a sulfone led to the discovery of <b>191</b>, with excellent isoform selectivity (PI3Kα pIC<sub>50</sub> < 4.5, PI3Kβ pIC<sub>50</sub> < 4.5, PI3Kγ pIC<sub>50</sub> = 8.1, PI3Kδ pIC<sub>50</sub> = 6.0) and good bioavailability (<i>F</i> = 51%) and low in vivo clearance (rat 6.3 mL min<sup>–1</sup> kg<sup>–1</sup>). In a kinase screen only related kinases C2β (84%) and C2γ (71%) showed significant inhibition at 10 μM concentration. In a rat LPS-induced acute inflammation model, oral administration of <b>191</b> resulted in a dose-dependent inhibition of airway neutrophilia in rats.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">PI3K Dual Pharmacology Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0059.gif" alt="" id="dgr30" /></img>Qian et al. observed synergistic effects between PI3K inhibitors and HDAC inhibitors and therefore synthesized a novel series of dual-acting PI3K and HDAC inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> They incorporated the morpholine-pyrimidine core from <b>85</b> and <b>70</b> for PI3K inhibition and the hydroxamic acid from SAHA (vorinostat), LBH-589 (panobinostat), and JNJ-16241199 for HDAC inhibition to produce <b>192</b> (CUDC-907).<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a> They reported that <b>192</b> displayed potent anticancer activity in both cultured cancer cells and xenograft models and may offer therapeutic benefits in multiple cancers, through broad signaling network disruption. <b>192</b> is currently in phase I and phase II clinical trials. In a similar fashion, Chen et al. once more combined the PI3K and HDAC pharmacophores to generate a series of dual inhibitors typified by <b>193</b> (PI3Kα = 28 nM, HDAC1 = 1.1 nM, HDAC6 = 4.2 nM). Compound <b>193</b> demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors and, in particular, showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0060.gif" alt="" id="dgr31" /></img></div><div class="NLM_p">Ding et al. reported novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα. On the basis of the structural similarity to omipalisib and gefitinib, compound <b>194</b> was shown to possess reasonable PI3Kα activity (IC<sub>50</sub> = 317 nM) in combination with very high EGFR activity (IC<sub>50</sub> = 2.4 nM). Compound <b>194</b> could induce cell cycle arrest in G1 phase and apoptosis in BT549 cells. The Western blot assay indicated that <b>194</b> inhibited the proliferation of BT549 cell through EGFR and PI3Ka/Akt signaling pathway, suggesting that compound <b>194</b> could be a potential dual inhibitors of EGFR and PI3Kα.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0061.gif" alt="" id="dgr32" /></img></div><div class="NLM_p last">Pujala et al. reported a range of pyrazolopyrimidine derivatives, such as <b>195</b>, as dual inhibitors of Bruton’s tyrosine kinase (BTK, IC<sub>50</sub> = 32 nM) and PI3Kδ (IC<sub>50</sub> = 16 nM). <b>195</b> had a reasonable mouse pharmacokinetic profile [10 mg/kg po, CL = 0.59 L h<sup>–1</sup> kg<sup>–1</sup>, <i>V</i><sub><i>z</i></sub> = 3.44 L/kg, plasma terminal half-life of 1.3 h, <i>F</i> = 40%)]. No in vivo results were shown for the compound.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusion and Perspective Comment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The PI3K pathway has attracted enormous industrial and academic interest as a therapeutic target for clinical conditions, such as cancer, diabetes, and asthma. Idelalisib was the first PI3K inhibitor approved by the U.S. Food and Drug Administration (FDA) and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> However, the use of idelalisib may come with toxicities that are distinct from the side effects of immunochemotherapy and, as such, co-dosing strategies with steroids are currently being investigated in the clinic.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> Subsequently, copanlisib was approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> In addition, there is a wealth of PI3K agents currently in clinical development (38 at this present time), which target various combinations of the PI3K isoforms. While idelalisib has proven to be efficacious for patients, unexpected infectious and autoimmune toxicities have demonstrated the need for careful development and monitoring of new agents.</div><div class="NLM_p">The phosphatidylinositol 3-kinase family consists of highly conserved enzymes that are part of the intracellular PI3K/Akt/mammalian target of rapamycin (mTOR) signaling axis. As such, early medicinal chemistry strategies concentrated on the discovery of nonselective PI3K inhibitors. However, the identification of “propeller-shaped” PI3K inhibitors signaled a step-change in the design of isoform selective PI3Kδ inhibitors. This led to the identification of idelalisib, the first FDA-approved PI3K inhibitor.</div><div class="NLM_p">Concerns over isoform toxicity have led to groups exploring structural modification to synthesize compounds with PI3K isoform selectivity through subtle change in chemical structure. This led to the explosion of structural variation, with many changes to the core of the molecules mainly to secure intellectual property, but has also in some cases led to subtle changes in isoform selectivity. In general, the initial pan PI3K inhibitors suffered from poor physicochemical properties, such as poor solubility and permeability from the combination of multiple aromatic rings and lack of sp<sup>3</sup> carbons leading to compounds with poor pharmacokinetic properties.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a> These early issues were rapidly solved by medicinal chemists, through decreasing lipophilicity and adding ionizeable groups to deliver compounds with excellent permeability and good oral pharmacokinetic properties. Drug delivery has also been considered, with various groups exploring the design of compounds with improved pharmacokinetics for topical lung delivery, thus removing some of the safety issues involved with systemic exposure of the high affinity inhibitors.</div><div class="NLM_p">Running in parallel with the discovery of the propeller shaped inhibitors, the identification of “flat-shaped” pan PI3K inhibitors has resulted in the delivery of many potent clinical candidates. However, their inherent lack of three-dimensional structure resulted in compounds with higher lipophilicity, leading again to poor water solubility. These physicochemical properties resulted in compounds with reduced cellular potency and off-target toxicity in preclinical studies. Once more, concerns over pan-PI3K inhibition has, through careful consideration of ligand-bound X-ray structures, led to the creative design of inhibitors with good to excellent isoform selectivity. However, these highly selective inhibitors have generally gained their selectivity as a consequence of increased molecular weight resulting, in the case of PI3Kδ inhibitors, in movement toward topical (i.e., inhaled) delivery.</div><div class="NLM_p">Bivalent or dual pharmacology inhibitors have been disclosed, where secondary pharmacology has been built into the original PI3K core scaffold, such as the dual PI3K/HDAC inhibitors and more recently EGFR-PI3K dual inhibitors utilizing solvent-exposed positions of the PI3K scaffold to incorporate the secondary pharmacology.</div><div class="NLM_p">Finally, it should be noted the extremely positive effect that ligand-bound X-ray crystallography has had on the design and synthesis on new isoform selective PI3K inhibitors. Outputs from these studies have enabled medicinal chemistry groups to thoroughly explore structural diversity in pursuit of gaining freedom to operate in a very congested and narrow field. In addition, the often nonpredictive subtle targeting of specific residues inducing isoform selectivity was made possible through information gleaned from multiple ligand-bound X-ray crystal data, once more highlighting the importance of structure based drug design to increase isoform selectivity.</div><div class="NLM_p last">In conclusion, it is disappointing that many PI3K inhibitors have not met their true clinical potential due to the absence of reliable and effective biomarkers, the limited efficacy as single agents, and the lack of development of rational therapeutic combinations, off-target effects, and suboptimal therapeutic exposures.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therefore, it is hoped that with regard to current PI3K inhibitors in late-stage clinical trials, the identification of appropriate efficacy biomarkers and the development of optimal combination regimens will lead to future successful FDA drug approvals.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01492" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01492" class="ext-link">10.1021/acs.jmedchem.8b01492</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical structures of PI3K inhibitors in clinical development (Table ST1) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01492/suppl_file/jm8b01492_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01492/suppl_file/jm8b01492_si_001.pdf">jm8b01492_si_001.pdf (461.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01492" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Stocks</span> - <span class="hlFld-Affiliation affiliation">Centre for Biomolecular Sciences, University Park Nottingham, Nottingham NG7 2RD, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3046-137X" title="Orcid link">http://orcid.org/0000-0003-3046-137X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6f02060c070e0a03411c1b000c041c2f01001b1b060108070e02410e0c411a04"><span class="__cf_email__" data-cfemail="177a7e747f76727b39646378747c6457797863637e79707f767a39767439627c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aimie
E. Garces</span> - <span class="hlFld-Affiliation affiliation">Centre for Biomolecular Sciences, University Park Nottingham, Nottingham NG7 2RD, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Aimie
E. Garces</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=BIO-d7e5793-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Aimie E. Garces</b> received her first class Master’s degree in Chemistry (M.Sci.) from The University of Nottingham (U.K.) in 2015. During those studies, she undertook PI3K and αv integrin collaborative projects between GSK and The University of Nottingham. Currently she is a doctoral student within the Division of Biomolecular Science and Medicinal Chemistry at the University of Nottingham (U.K.) under the supervision of Dr. Michael Stocks and Dr. Tracey Bradshaw. Her current research focuses on the development of bifunctional prodrugs, incorporating PI3K inhibitors, for oncology use.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Michael J. Stocks</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=BIO-d7e5798-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michael J. Stocks</b> is an Associate Professor in Medicinal Chemistry within the School of Pharmacy at The University of Nottingham. He has over 20 years of industrial experience in drug discovery within Fison’s Pharmaceuticals, Astra Pharma, and AstraZeneca and was the lead scientist on multiple preclinical research projects. Since joining the School of Pharmacy in 2012, Michael has focused his research on the medicinal chemistry design and synthesis of compounds to study and modulate the function of biological targets. His recent research interests lie in combining chemical structures to discover dual inhibitors for cancer therapy; identification of inhibitors for disrupting bacterial quorum sensing; generation of fluorescent ligands to study GPCR function, topical drug delivery, and serine protease inhibitor design.</p></figure></div><div class="ack" id="notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the UK Medical Research Council funded Ph.D. research studentship (A.E.G.) (Reference Number 1648176).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton tyrosine kinase</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term"><i>h</i>ERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LIPE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">PIKK</td><td class="NLM_def"><p class="first last">phosphatidylinositol-like kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 154 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Signalling through the Lipid Products of Phosphoinositide-3-OH Kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>387</i></span> (<span class="NLM_issue">6634</span>),  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1038/42648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2F42648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=1997&pages=673-676&issue=6634&author=A.+Tokerauthor=L.+C.+Cantley&title=Signalling+through+the+Lipid+Products+of+Phosphoinositide-3-OH+Kinase&doi=10.1038%2F42648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F42648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F42648%26sid%3Dliteratum%253Aachs%26aulast%3DToker%26aufirst%3DA.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DSignalling%2520through%2520the%2520Lipid%2520Products%2520of%2520Phosphoinositide-3-OH%2520Kinase%26jtitle%3DNature%26date%3D1997%26volume%3D387%26issue%3D6634%26spage%3D673%26epage%3D676%26doi%3D10.1038%2F42648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&issue=2&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lghxK2grEDK2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span> <span> </span><span class="NLM_article-title">Class I Phosphatidylinositol 3-Kinase Inhibitors for Cancer Therapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.apsb.2016.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28119806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=27-37&issue=1&author=W.+Zhaoauthor=Y.+Qiuauthor=D.+Kong&title=Class+I+Phosphatidylinositol+3-Kinase+Inhibitors+for+Cancer+Therapy&doi=10.1016%2Fj.apsb.2016.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Zhao Wennan; Qiu Yuling; Kong Dexin</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers.  Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis.  Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors.  Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy.  Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials.  Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc.  This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfpaqoNC7CEjAyhZbj3lKdfW6udTcc2eb16E3hSEiZSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D&md5=9506d6088eb6f72dc579ece97bb19930</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DD.%26atitle%3DClass%2520I%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520for%2520Cancer%2520Therapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2016.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Use of PI3K Inhibitors for Glioblastoma Multiforme: Current Preclinical and Clinical Development</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0670-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1186%2Fs12943-017-0670-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28592260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC1cnmtVyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=100&issue=1&author=H.+Zhaoauthor=J.+Wangauthor=W.+Shaoauthor=C.+Wuauthor=Z.+Chenauthor=S.+T.+Toauthor=W.+Li&title=Recent+Advances+in+the+Use+of+PI3K+Inhibitors+for+Glioblastoma+Multiforme%3A+Current+Preclinical+and+Clinical+Development&doi=10.1186%2Fs12943-017-0670-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development</span></div><div class="casAuthors">Zhao Hua-Fu; Wu Chang-Peng; Li Wei-Ping; Zhao Hua-Fu; Wang Jing; Chen Zhong-Ping; Shao Wei; To Shing-Shun Tony; Wu Chang-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system.  One of the most widely used chemotherapeutic drugs for GBM is temozolomide, which is a DNA-alkylating agent and its efficacy is dependent on MGMT methylation status.  Little progress in improving the prognosis of GBM patients has been made in the past ten years, urging the development of more effective molecular targeted therapies.  Hyper-activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is frequently found in a variety of cancers including GBM, and it plays a central role in the regulation of tumor cell survival, growth, motility, angiogenesis and metabolism.  Numerous PI3K inhibitors including pan-PI3K, isoform-selective and dual PI3K/mammalian target of rapamycin (mTOR) inhibitors have exhibited favorable preclinical results and entered clinical trials in a range of hematologic malignancies and solid tumors.  Furthermore, combination of inhibitors targeting PI3K and other related pathways may exert synergism on suppressing tumor growth and improving patients' prognosis.  Currently, only a handful of PI3K inhibitors are in phase I/II clinical trials for GBM treatment.  In this review, we focus on the importance of PI3K/Akt pathway in GBM, and summarize the current development of PI3K inhibitors alone or in combination with other inhibitors for GBM treatment from preclinical to clinical studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoYdXHzx6A1kGy1nwu7K2mfW6udTcc2eb16E3hSEiZSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnmtVyluw%253D%253D&md5=9d329ca3e72fd5e88b57588574bce2bb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0670-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0670-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTo%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Use%2520of%2520PI3K%2520Inhibitors%2520for%2520Glioblastoma%2520Multiforme%253A%2520Current%2520Preclinical%2520and%2520Clinical%2520Development%26jtitle%3DMol.%2520Cancer%26date%3D2017%26volume%3D16%26issue%3D1%26spage%3D100%26doi%3D10.1186%2Fs12943-017-0670-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzugullu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">PI3K in Cancer: Divergent Roles of Isoforms, Modes of Activation and Therapeutic Targeting</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1038/nrc3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnrc3860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=25533673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=7-24&issue=1&author=L.+M.+Thorpeauthor=H.+Yuzugulluauthor=J.+J.+Zhao&title=PI3K+in+Cancer%3A+Divergent+Roles+of+Isoforms%2C+Modes+of+Activation+and+Therapeutic+Targeting&doi=10.1038%2Fnrc3860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span></div><div class="casAuthors">Thorpe, Lauren M.; Yuzugullu, Haluk; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli.  Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers.  In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxh6fOPe86x7Vg90H21EOLACvtfcHk0lgaoDJWjAf0fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N&md5=0b609a62c2ec9fcc6efae437d2ed7a24</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3860%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DL.%2BM.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DPI3K%2520in%2520Cancer%253A%2520Divergent%2520Roles%2520of%2520Isoforms%252C%2520Modes%2520of%2520Activation%2520and%2520Therapeutic%2520Targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26issue%3D1%26spage%3D7%26epage%3D24%26doi%3D10.1038%2Fnrc3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span> <span> </span><span class="NLM_article-title">PI3K Inhibitors in Inflammation, Autoimmunity and Cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.coph.2015.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=26093105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=82-91&author=A.+K.+Starkauthor=S.+Sriskantharajahauthor=E.+M.+Hesselauthor=K.+Okkenhaug&title=PI3K+Inhibitors+in+Inflammation%2C+Autoimmunity+and+Cancer&doi=10.1016%2Fj.coph.2015.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K inhibitors in inflammation, autoimmunity and cancer</span></div><div class="casAuthors">Stark, Anne-Katrien; Sriskantharajah, Srividya; Hessel, Edith M.; Okkenhaug, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-91</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues.  Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer.  Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research.  In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small mol. inhibitors, of which several are currently in clin. trials for the treatment of immune-related disorders and cancer.  The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clin. and clin. development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNWPQZuO9fE7Vg90H21EOLACvtfcHk0lgaoDJWjAf0fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM&md5=382eb159c8ec5e3a4bc14f71f54dd295</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DA.%2BK.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%2520Inhibitors%2520in%2520Inflammation%252C%2520Autoimmunity%2520and%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D82%26epage%3D91%26doi%3D10.1016%2Fj.coph.2015.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase (PI3K) Pathway Inhibitors in Solid Tumors: From Laboratory to Patients</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ctrv.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28779636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WgtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=93-101&author=F.+Janku&title=Phosphoinositide+3-Kinase+%28PI3K%29+Pathway+Inhibitors+in+Solid+Tumors%3A+From+Laboratory+to+Patients&doi=10.1016%2Fj.ctrv.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients</span></div><div class="casAuthors">Janku, Filip</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K) pathway is an intracellular signaling pathway that has regulatory roles in cell survival, proliferation, and differentiation, and a crit. role in tumorigenesis.  In cancer, multiple studies have investigated the therapeutic targeting of the PI3K pathway, and multiple inhibitors targeting PI3K and its isoforms, protein kinase B/AKT, mammalian target of rapamycin (mTOR), and other pathway proteins have been developed.  For the treatment of solid tumors, only allosteric mTOR inhibitors, such as everolimus and temsirolimus, are currently approved for clin. use.  This review describes the PI3K inhibitors that have progressed from the lab. to late-stage clin. trials, and discusses the challenges that have prevented other compds. from doing the same.  Challenges to the therapeutic effectiveness of some PI3K inhibitors include the absence of reliable and effective biomarkers, their limited efficacy as single agents, insufficient development of rational therapeutic combinations, the use of schedules with a variety of off-target effects, and suboptimal therapeutic exposures.  Therefore, with regard to PI3K inhibitors currently in late-stage clin. trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQhlVdFU8NPrVg90H21EOLACvtfcHk0lgaoDJWjAf0fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WgtbrJ&md5=5b60a21296fea87bffc4e691f9e5c7be</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DJanku%26aufirst%3DF.%26atitle%3DPhosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520Pathway%2520Inhibitors%2520in%2520Solid%2520Tumors%253A%2520From%2520Laboratory%2520to%2520Patients%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2017%26volume%3D59%26spage%3D93%26epage%3D101%26doi%3D10.1016%2Fj.ctrv.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunder, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for P110α in Insulin Signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&issue=4&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+P110%CE%B1+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0li3IFwa3yX6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520P110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26issue%3D4%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span> <span> </span><span class="NLM_article-title">The PI3K/AKT Pathway in Obesity and Type 2 Diabetes</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.7150/ijbs.27173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.7150%2Fijbs.27173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=30263000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVyqsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1483-1496&issue=11&author=X.+Huangauthor=G.+Liuauthor=J.+Guoauthor=Z.+Su&title=The+PI3K%2FAKT+Pathway+in+Obesity+and+Type+2+Diabetes&doi=10.7150%2Fijbs.27173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K/AKT pathway in obesity and type 2 diabetes</span></div><div class="casAuthors">Huang, Xingjun; Liu, Guihua; Guo, Jiao; Su, Zhengquan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1483-1496</span>CODEN:
                <span class="NLM_cas:coden">IJBSB9</span>;
        ISSN:<span class="NLM_cas:issn">1449-2288</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Obesity and type 2 diabetes mellitus are complicated metabolic diseases that affect multiple organs and are characterized by hyperglycemia.  Currently, stable and effective treatments for obesity and type 2 diabetes mellitus are not available.  Therefore, the mechanisms leading to obesity and diabetes and more effective ways to treat obesity and diabetes should be identified.  Based on accumulated evidences, the PI3K/AKT signalling pathway is required for normal metab. due to its characteristics, and its imbalance leads to the development of obesity and type 2 diabetes mellitus.  This review focuses on the role of PI3K/AKT signalling in the skeletal muscle, adipose tissue, liver, brain and pancreas, and discusses how this signalling pathway affects the development of the aforementioned diseases.  We also summarize evidences for recently identified therapeutic targets of the PI3K/AKT pathway as treatments for obesity and type 2 diabetes mellitus.  PI3K/AKT pathway damaged in various tissues of the body leads to obesity and type 2 diabetes as the result of insulin resistance, and in turn, insulin resistance exacerbates the PI3K/AKT pathway, forming a vicious circle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRWKUROIFqVbVg90H21EOLACvtfcHk0li3IFwa3yX6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVyqsbbJ&md5=8aa3b9f581f25e971f689164b0ac2505</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7150%2Fijbs.27173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.27173%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26atitle%3DThe%2520PI3K%252FAKT%2520Pathway%2520in%2520Obesity%2520and%2520Type%25202%2520Diabetes%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2018%26volume%3D14%26issue%3D11%26spage%3D1483%26epage%3D1496%26doi%3D10.7150%2Fijbs.27173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenwaelder, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesbitt, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dopheide, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgeon, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabaharan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, H. H.</span></span> <span> </span><span class="NLM_article-title">PI 3-Kinase P110β: A New Target for Antithrombotic Therapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/nm1232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnm1232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=15834429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=507-514&issue=5&author=S.%0AP.+Jacksonauthor=S.+M.+Schoenwaelderauthor=I.+Goncalvesauthor=W.+S.+Nesbittauthor=C.+L.+Yapauthor=C.+E.+Wrightauthor=V.+Kencheauthor=K.+E.+Andersonauthor=S.+M.+Dopheideauthor=Y.+Yuanauthor=S.+A.+Sturgeonauthor=H.+Prabaharanauthor=P.+E.+Thompsonauthor=G.+D.+Smithauthor=P.+R.+Shepherdauthor=N.+Danieleauthor=S.+Kulkarniauthor=B.+Abbottauthor=D.+Saylikauthor=C.+Jonesauthor=L.+Luauthor=S.+Giulianoauthor=S.+C.+Hughanauthor=J.+A.+Angusauthor=A.+D.+Robertsonauthor=H.+H.+Salem&title=PI+3-Kinase+P110%CE%B2%3A+A+New+Target+for+Antithrombotic+Therapy&doi=10.1038%2Fnm1232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PI 3-kinase p110β: a new target for antithrombotic therapy</span></div><div class="casAuthors">Jackson, Shaun P.; Schoenwaelder, Simone M.; Goncalves, Isaac; Nesbitt, Warwick S.; Yap, Cindy L.; Wright, Christine E.; Kenche, Vijaya; Anderson, Karen E.; Dopheide, Sacha M.; Yuan, Yuping; Sturgeon, Sharelle A.; Prabaharan, Hishani; Thompson, Philip E.; Smith, Gregg D.; Shepherd, Peter R.; Daniele, Nathalie; Kulkarni, Suhasini; Abbott, Belinda; Saylik, Dilek; Jones, Catherine; Lu, Lucy; Giuliano, Simon; Hughan, Sascha C.; Angus, James A.; Robertson, Alan D.; Salem, Hatem H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-514</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, pptg. diseases such as acute myocardial infarction and ischemic stroke.  Rheol. disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin αIIbβ3 (GPIIb-IIIa).  In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110β isoform in regulating the formation and stability of integrin αIIbβ3 adhesion bonds, necessary for shear activation of platelets.  Isoform-selective PI3K p110β inhibitors have been developed which prevent formation of stable integrin αIIbβ3 adhesion contacts, leading to defective platelet thrombus formation.  In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time.  These studies define PI3K p110β as an important new target for antithrombotic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYnYolzsDrrVg90H21EOLACvtfcHk0li3IFwa3yX6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D&md5=c8dc7ba1955e86104ae913d39f22674b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm1232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1232%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26aulast%3DGoncalves%26aufirst%3DI.%26aulast%3DNesbitt%26aufirst%3DW.%2BS.%26aulast%3DYap%26aufirst%3DC.%2BL.%26aulast%3DWright%26aufirst%3DC.%2BE.%26aulast%3DKenche%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DDopheide%26aufirst%3DS.%2BM.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DSturgeon%26aufirst%3DS.%2BA.%26aulast%3DPrabaharan%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DSmith%26aufirst%3DG.%2BD.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDaniele%26aufirst%3DN.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DAbbott%26aufirst%3DB.%26aulast%3DSaylik%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DGiuliano%26aufirst%3DS.%26aulast%3DHughan%26aufirst%3DS.%2BC.%26aulast%3DAngus%26aufirst%3DJ.%2BA.%26aulast%3DRobertson%26aufirst%3DA.%2BD.%26aulast%3DSalem%26aufirst%3DH.%2BH.%26atitle%3DPI%25203-Kinase%2520P110%25CE%25B2%253A%2520A%2520New%2520Target%2520for%2520Antithrombotic%2520Therapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26issue%3D5%26spage%3D507%26epage%3D514%26doi%3D10.1038%2Fnm1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenwaelder, S. M.</span></span> <span> </span><span class="NLM_article-title">Antithrombotic Phosphoinositide 3-Kinase β Inhibitors in Humans: A ‘Shear’ Delight!</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2123</span>– <span class="NLM_lpage">2126</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2012.04912.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1111%2Fj.1538-7836.2012.04912.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22943292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSku77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2123-2126&issue=10&author=S.+P.+Jacksonauthor=S.+M.+Schoenwaelder&title=Antithrombotic+Phosphoinositide+3-Kinase+%CE%B2+Inhibitors+in+Humans%3A+A+%E2%80%98Shear%E2%80%99+Delight%21&doi=10.1111%2Fj.1538-7836.2012.04912.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a 'shear' delight" Comments</span></div><div class="casAuthors">Jackson, S. P.; Schoenwaelder, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2123-2126</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The research of Nylander et al. (2012) entitled, 'Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor' is reviewed with commentary and refs.  Nylander et al. performed a preclin. and phase I human study investigating the effects of a phosphoinositide 3-kinase (PI3K) inhibitor (AZD6482), selective for the p110β isoform (PI3Kβ), on platelet function, thrombosis, and bleeding.  Their findings generally provided important validation of PI3Kβ as a potentially important antithrombotic target in humans, and provided further support for the concept that PI3Kβ inhibitors may have a wide therapeutic window and represent a potentially safe antithrombotic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGv1NpKZjxOrVg90H21EOLACvtfcHk0lgPmlU34TPdlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSku77P&md5=036329b65e313de7d3d02c98b2068bdd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2012.04912.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2012.04912.x%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26atitle%3DAntithrombotic%2520Phosphoinositide%25203-Kinase%2520%25CE%25B2%2520Inhibitors%2520in%2520Humans%253A%2520A%2520%25E2%2580%2598Shear%25E2%2580%2599%2520Delight%2521%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2012%26volume%3D10%26issue%3D10%26spage%3D2123%26epage%3D2126%26doi%3D10.1111%2Fj.1538-7836.2012.04912.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8559</span>– <span class="NLM_lpage">8581</span>, <span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&issue=20&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0lgPmlU34TPdlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affleck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span> <span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase δ for Allergic Asthma</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1042/BST20110665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1042%2FBST20110665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22260698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=240-245&issue=1&author=W.+C.+Rowanauthor=J.+L.+Smithauthor=K.+Affleckauthor=A.+Amour&title=Targeting+Phosphoinositide+3-Kinase+%CE%B4+for+Allergic+Asthma&doi=10.1042%2FBST20110665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase δ for allergic asthma</span></div><div class="casAuthors">Rowan, Wendy C.; Smith, Janet L.; Affleck, Karen; Amour, Augustin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">240-245</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic inflammation in the lung has long been linked to the pathogenesis of asthma.  Central to this airway inflammation is a T-cell response to allergens, with Th2 cytokines driving the differentiation, survival and function of the major inflammatory cells involved in the allergic cascade.  PI3Kδ (phosphoinositide 3-kinase δ) is a lipid kinase, expressed predominantly in leukocytes, where it plays a crit. role in immune receptor signalling.  A selective PI3Kδ inhibitor is predicted to block T-cell activation in the lung, reducing the prodn. of pro-inflammatory Th2 cytokines.  PI3Kδ is also involved in B-cell and mast cell activation.  Therefore the inhibition of PI3Kδ should dampen down the inflammatory cascade involved in the asthmatic response through a wide breadth of pharmacol.  Current anti-inflammatory therapies, which are based on corticosteroids, are effective in controlling inflammation in mild asthmatics, but moderate/severe asthmatic patients remain poorly controlled, experiencing recurrent exacerbations.  Corticosteroids have no effect on mast cell degranulation and do not act directly on B-cells, so, overall, a PI3Kδ inhibitor has the potential to deliver improvements in onset of action, efficacy and reduced exacerbations in moderate/severe asthmatics.  Addnl., PI3Kδ inhibition is expected to block effects of Th17 cells, which are increasingly implicated in steroid-insensitive asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwu2SYlFjDbVg90H21EOLACvtfcHk0lj4Ly6HW5VAnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D&md5=db36bc8f79c70e0817e00fb9b04f10ff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1042%2FBST20110665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20110665%26sid%3Dliteratum%253Aachs%26aulast%3DRowan%26aufirst%3DW.%2BC.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520Allergic%2520Asthma%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2012%26volume%3D40%26issue%3D1%26spage%3D240%26epage%3D245%26doi%3D10.1042%2FBST20110665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojiaku, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2016-0308TR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1165%2Frcmb.2016-0308TR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27977296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1artrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=700-707&issue=6&author=E.+J.+Yooauthor=C.+A.+Ojiakuauthor=K.+Sunderauthor=R.+A.+Panettieri&title=Phosphoinositide+3-Kinase+in+Asthma%3A+Novel+Roles+and+Therapeutic+Approaches&doi=10.1165%2Frcmb.2016-0308TR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase in asthma: novel roles and therapeutic approaches</span></div><div class="casAuthors">Yoo, Edwin J.; Ojiaku, Christie A.; Sunder, Krishna; Panettieri, Reynold A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">700-707</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Asthma manifests as airway hyperresponsiveness and inflammation, including coughing, wheezing, and shortness of breath.  Immune cells and airway structural cells orchestrate asthma pathophysiol., leading to mucus secretion, airway narrowing, and obstruction.  Phosphoinositide 3-kinase, a lipid kinase, plays a crucial role in many of the cellular and mol. mechanisms driving asthma pathophysiol. and represents an attractive therapeutic target.  Here, we summarize the diverse roles of phosphoinositide 3-kinase in the pathogenesis of asthma and discuss novel therapeutic approaches to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraWH_Lnj-6X7Vg90H21EOLACvtfcHk0lj4Ly6HW5VAnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1artrrI&md5=67d7e791406eae6be3ebb2a352a13e9d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2016-0308TR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2016-0308TR%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DE.%2BJ.%26aulast%3DOjiaku%26aufirst%3DC.%2BA.%26aulast%3DSunder%26aufirst%3DK.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26atitle%3DPhosphoinositide%25203-Kinase%2520in%2520Asthma%253A%2520Novel%2520Roles%2520and%2520Therapeutic%2520Approaches%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2017%26volume%3D56%26issue%3D6%26spage%3D700%26epage%3D707%26doi%3D10.1165%2Frcmb.2016-0308TR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemela, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deenick, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palendira, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannons, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancalana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frucht, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agharahimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folio, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleisher, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittaluga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangye, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzel, G.</span></span> <span> </span><span class="NLM_article-title">Dominant-Activating Germline Mutations in the Gene Encoding the PI(3)K Catalytic Subunit P110δ Result in T Cell Senescence and Human Immunodeficiency</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1038/ni.2771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fni.2771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24165795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=88-97&issue=1&author=C.+L.+Lucasauthor=H.+S.+Kuehnauthor=F.+Zhaoauthor=J.+E.+Niemelaauthor=E.+K.+Deenickauthor=U.+Palendiraauthor=D.+T.+Averyauthor=L.+Moensauthor=J.+L.+Cannonsauthor=M.+Biancalanaauthor=J.+Stoddardauthor=W.+Ouyangauthor=D.+M.+Fruchtauthor=V.+K.+Raoauthor=T.+P.+Atkinsonauthor=A.+Agharahimiauthor=A.+A.+Husseyauthor=L.+R.+Folioauthor=K.+N.+Olivierauthor=T.+A.+Fleisherauthor=S.+Pittalugaauthor=S.+M.+Hollandauthor=J.+I.+Cohenauthor=J.+B.+Oliveiraauthor=S.+G.+Tangyeauthor=P.+L.+Schwartzbergauthor=M.+J.+Lenardoauthor=G.+Uzel&title=Dominant-Activating+Germline+Mutations+in+the+Gene+Encoding+the+PI%283%29K+Catalytic+Subunit+P110%CE%B4+Result+in+T+Cell+Senescence+and+Human+Immunodeficiency&doi=10.1038%2Fni.2771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</span></div><div class="casAuthors">Lucas, Carrie L.; Kuehn, Hye Sun; Zhao, Fang; Niemela, Julie E.; Deenick, Elissa K.; Palendira, Umaimainthan; Avery, Danielle T.; Moens, Leen; Cannons, Jennifer L.; Biancalana, Matthew; Stoddard, Jennifer; Ouyang, Weiming; Frucht, David M.; Rao, V. Koneti; Atkinson, T. Prescott; Agharahimi, Anahita; Hussey, Ashleigh A.; Folio, Les R.; Olivier, Kenneth N.; Fleisher, Thomas A.; Pittaluga, Stefania; Holland, Steven M.; Cohen, Jeffrey I.; Oliveira, Joao B.; Tangye, Stuart G.; Schwartzberg, Pamela L.; Lenardo, Michael J.; Uzel, Gulbu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-97</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The p110δ subunit of phosphatidylinositol-3-OH kinase (PI(3)K) is selectively expressed in leukocytes and is crit. for lymphocyte biol.  Here we report fourteen patients from seven families who were heterozygous for three different germline, gain-of-function mutations in PIK3CD (which encodes p110δ).  These patients presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremia due to cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV).  Strikingly, they had a substantial deficiency in naive T cells but an over-representation of senescent effector T cells.  In vitro, T cells from patients exhibited increased phosphorylation of the kinase Akt and hyperactivation of the metabolic checkpoint kinase mTOR, enhanced glucose uptake and terminal effector differentiation.  Notably, treatment with rapamycin to inhibit mTOR activity in vivo partially restored the abundance of naive T cells, largely 'rescued' the in vitro T cell defects and improved the clin. course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFA88fwwfZf7Vg90H21EOLACvtfcHk0lj4Ly6HW5VAnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L&md5=4bfccb05603009684ca01f893b29adc8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fni.2771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2771%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DNiemela%26aufirst%3DJ.%2BE.%26aulast%3DDeenick%26aufirst%3DE.%2BK.%26aulast%3DPalendira%26aufirst%3DU.%26aulast%3DAvery%26aufirst%3DD.%2BT.%26aulast%3DMoens%26aufirst%3DL.%26aulast%3DCannons%26aufirst%3DJ.%2BL.%26aulast%3DBiancalana%26aufirst%3DM.%26aulast%3DStoddard%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DFrucht%26aufirst%3DD.%2BM.%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DAtkinson%26aufirst%3DT.%2BP.%26aulast%3DAgharahimi%26aufirst%3DA.%26aulast%3DHussey%26aufirst%3DA.%2BA.%26aulast%3DFolio%26aufirst%3DL.%2BR.%26aulast%3DOlivier%26aufirst%3DK.%2BN.%26aulast%3DFleisher%26aufirst%3DT.%2BA.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BI.%26aulast%3DOliveira%26aufirst%3DJ.%2BB.%26aulast%3DTangye%26aufirst%3DS.%2BG.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DUzel%26aufirst%3DG.%26atitle%3DDominant-Activating%2520Germline%2520Mutations%2520in%2520the%2520Gene%2520Encoding%2520the%2520PI%25283%2529K%2520Catalytic%2520Subunit%2520P110%25CE%25B4%2520Result%2520in%2520T%2520Cell%2520Senescence%2520and%2520Human%2520Immunodeficiency%26jtitle%3DNat.%2520Immunol.%26date%3D2014%26volume%3D15%26issue%3D1%26spage%3D88%26epage%3D97%26doi%3D10.1038%2Fni.2771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banham-Hall, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plagnol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxendale, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake-Palmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perisic, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiddler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilliers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kielkowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcenas-Morales, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clatworthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilvers, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cant, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumararatne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condliffe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Gene Mutation Predisposes to Respiratory Infection and Airway Damage</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span> (<span class="NLM_issue">6160</span>),  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1126/science.1243292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1126%2Fscience.1243292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24136356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCrsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=866-871&issue=6160&author=I.+Anguloauthor=O.+Vadasauthor=F.+Garconauthor=E.+Banham-Hallauthor=V.+Plagnolauthor=T.+R.+Leahyauthor=H.+Baxendaleauthor=T.+Coulterauthor=J.+Curtisauthor=C.+Wuauthor=K.+Blake-Palmerauthor=O.+Perisicauthor=D.+Smythauthor=M.+Maesauthor=C.+Fiddlerauthor=J.+Jussauthor=D.+Cilliersauthor=G.+Markeljauthor=A.+Chandraauthor=G.+Farmerauthor=A.+Kielkowskaauthor=J.+Clarkauthor=S.+Krackerauthor=M.+Debreauthor=C.+Picardauthor=I.+Pellierauthor=N.+Jabadoauthor=J.+A.+Morrisauthor=G.+Barcenas-Moralesauthor=A.+Fischerauthor=L.+Stephensauthor=P.+Hawkinsauthor=J.+C.+Barrettauthor=M.+Abinunauthor=M.+Clatworthyauthor=A.+Durandyauthor=R.+Doffingerauthor=E.+R.+Chilversauthor=A.+J.+Cantauthor=D.+Kumararatneauthor=K.+Okkenhaugauthor=R.+L.+Williamsauthor=A.+Condliffeauthor=S.+Nejentsev&title=Phosphoinositide+3-Kinase+Gene+Mutation+Predisposes+to+Respiratory+Infection+and+Airway+Damage&doi=10.1126%2Fscience.1243292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage</span></div><div class="casAuthors">Angulo, Ivan; Vadas, Oscar; Garcon, Fabien; Banham-Hall, Edward; Plagnol, Vincent; Leahy, Timothy R.; Baxendale, Helen; Coulter, Tanya; Curtis, James; Wu, Changxin; Blake-Palmer, Katherine; Perisic, Olga; Smyth, Deborah; Maes, Mailis; Fiddler, Christine; Juss, Jatinder; Cilliers, Deirdre; Markelj, Gasper; Chandra, Anita; Farmer, George; Kielkowska, Anna; Clark, Jonathan; Kracker, Sven; Debre, Marianne; Picard, Capucine; Pellier, Isabelle; Jabado, Nada; Morris, James A.; Barcenas-Morales, Gabriela; Fischer, Alain; Stephens, Len; Hawkins, Phillip; Barrett, Jeffrey C.; Abinun, Mario; Clatworthy, Menna; Durandy, Anne; Doffinger, Rainer; Chilvers, Edwin R.; Cant, Andrew J.; Kumararatne, Dinakantha; Okkenhaug, Klaus; Williams, Roger L.; Condliffe, Alison; Nejentsev, Sergey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6160</span>),
    <span class="NLM_cas:pages">866-871</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Genetic mutations cause primary immunodeficiencies (PIDs) that predispose to infections.  Here, the authors describe activated PI3K-δ syndrome (APDS), a PID assocd. with a dominant gain-of-function mutation in which lysine replaced glutamic acid at residue 1021 (E1021K) in the p110δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ), encoded by the PIK3CD gene.  The authors found E1021K in 17 patients from seven unrelated families, but not among 3346 healthy subjects.  APDS was characterized by recurrent respiratory infections, progressive airway damage, lymphopenia, increased circulating transitional B cells, increased IgM, and reduced IgG2 levels in serum and impaired vaccine responses.  The E1021K mutation enhanced membrane assocn. and kinase activity of p110δ.  Patient-derived lymphocytes had increased levels of phosphatidylinositol 3,4,5-trisphosphate and phosphorylated AKT protein and were prone to activation-induced cell death.  Selective p110δ inhibitors IC87114 and GS-1101 reduced the activity of the mutant enzyme in vitro, which suggested a therapeutic approach for patients with APDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox6rTR4UfkVbVg90H21EOLACvtfcHk0lgmUOfCEyXG7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCrsrbL&md5=7e5ed81697a879ef0bf8fb332f188400</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.1243292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1243292%26sid%3Dliteratum%253Aachs%26aulast%3DAngulo%26aufirst%3DI.%26aulast%3DVadas%26aufirst%3DO.%26aulast%3DGarcon%26aufirst%3DF.%26aulast%3DBanham-Hall%26aufirst%3DE.%26aulast%3DPlagnol%26aufirst%3DV.%26aulast%3DLeahy%26aufirst%3DT.%2BR.%26aulast%3DBaxendale%26aufirst%3DH.%26aulast%3DCoulter%26aufirst%3DT.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBlake-Palmer%26aufirst%3DK.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DSmyth%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DM.%26aulast%3DFiddler%26aufirst%3DC.%26aulast%3DJuss%26aufirst%3DJ.%26aulast%3DCilliers%26aufirst%3DD.%26aulast%3DMarkelj%26aufirst%3DG.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DFarmer%26aufirst%3DG.%26aulast%3DKielkowska%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DDebre%26aufirst%3DM.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DPellier%26aufirst%3DI.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DJ.%2BA.%26aulast%3DBarcenas-Morales%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DClatworthy%26aufirst%3DM.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DChilvers%26aufirst%3DE.%2BR.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26aulast%3DKumararatne%26aufirst%3DD.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DCondliffe%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26atitle%3DPhosphoinositide%25203-Kinase%2520Gene%2520Mutation%2520Predisposes%2520to%2520Respiratory%2520Infection%2520and%2520Airway%2520Damage%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D342%26issue%3D6160%26spage%3D866%26epage%3D871%26doi%3D10.1126%2Fscience.1243292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sediva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debré, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, J. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span> <span> </span><span class="NLM_article-title">Occurrence of B-Cell Lymphomas in Patients with Activated Phosphoinositide 3-Kinase δ Syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.jaci.2014.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24698326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltl2ksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=233-236&issue=1&author=S.+Krackerauthor=J.+Curtisauthor=M.+A.+A.+Ibrahimauthor=A.+Sedivaauthor=J.+Salisburyauthor=V.+Camprauthor=M.+Debr%C3%A9author=J.+D.+M.+Edgarauthor=K.+Imaiauthor=C.+Picardauthor=J.-L.+Casanovaauthor=A.+Fischerauthor=S.+Nejentsevauthor=A.+Durandy&title=Occurrence+of+B-Cell+Lymphomas+in+Patients+with+Activated+Phosphoinositide+3-Kinase+%CE%B4+Syndrome&doi=10.1016%2Fj.jaci.2014.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome</span></div><div class="casAuthors">Kracker, Sven; Curtis, James; Ibrahim, Mohammad A. A.; Sediva, Anna; Salisbury, Jon; Campr, Vit; Debre, Marianne; Edgar, J. David M.; Imai, Kohsuke; Picard, Capucine; Casanova, Jean-Laurent; Fischer, Alain; Nejentsev, Sergey; Durandy, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">233-236.e3</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Activated phosphoinositide 3-kinase δ syndrome (APDS) is a novel autosomal-dominant primary immunodeficiency (PID) caused by a heterozygous gain-of-function mutation in the PIK3CD gene encoding the p110δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ).  This article discusses the occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhInUP8M7s9LVg90H21EOLACvtfcHk0lgmUOfCEyXG7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltl2ksbY%253D&md5=effd7e1d392375ce9fdfe55ce0942c72</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%2BA.%26aulast%3DSediva%26aufirst%3DA.%26aulast%3DSalisbury%26aufirst%3DJ.%26aulast%3DCampr%26aufirst%3DV.%26aulast%3DDebr%25C3%25A9%26aufirst%3DM.%26aulast%3DEdgar%26aufirst%3DJ.%2BD.%2BM.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DDurandy%26aufirst%3DA.%26atitle%3DOccurrence%2520of%2520B-Cell%2520Lymphomas%2520in%2520Patients%2520with%2520Activated%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2014%26volume%3D134%26issue%3D1%26spage%3D233%26epage%3D236%26doi%3D10.1016%2Fj.jaci.2014.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Screaton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodlad, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxendale, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatoniene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, J. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhurst, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speckmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimbacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sediva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucuk, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hague, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herriot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancrini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariganello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feighery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieux-Laucat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touzot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumararatne, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshous, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condliffe, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cant, A. J.</span></span> <span> </span><span class="NLM_article-title">Clinical Spectrum and Features of Activated Phosphoinositide 3-Kinase δ Syndrome: A Large Patient Cohort Study</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.jaci.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27555459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyqt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=597-606&issue=2&author=T.+I.+Coulterauthor=A.+Chandraauthor=C.+M.+Baconauthor=J.+Babarauthor=J.+Curtisauthor=N.+Screatonauthor=J.+R.+Goodladauthor=G.+Farmerauthor=C.+L.+Steeleauthor=T.+R.+Leahyauthor=R.+Doffingerauthor=H.+Baxendaleauthor=J.+Bernatonieneauthor=J.+D.+M.+Edgarauthor=H.+J.+Longhurstauthor=S.+Ehlauthor=C.+Speckmannauthor=B.+Grimbacherauthor=A.+Sedivaauthor=T.+Milotaauthor=S.+N.+Faustauthor=A.+P.+Williamsauthor=G.+Haymanauthor=Z.+Y.+Kucukauthor=R.+Hagueauthor=P.+Frenchauthor=R.+Brookerauthor=P.+Forsythauthor=R.+Herriotauthor=C.+Cancriniauthor=P.+Palmaauthor=P.+Ariganelloauthor=N.+Conlonauthor=C.+Feigheryauthor=P.+J.+Gavinauthor=A.+Jonesauthor=K.+Imaiauthor=M.+A.+A.+Ibrahimauthor=G.+Markeljauthor=M.+Abinunauthor=F.+Rieux-Laucatauthor=S.+Latourauthor=I.+Pellierauthor=A.+Fischerauthor=F.+Touzotauthor=J.-L.+Casanovaauthor=A.+Durandyauthor=S.+O.+Burnsauthor=S.+Savicauthor=D.+S.+Kumararatneauthor=D.+Moshousauthor=S.+Krackerauthor=B.+Vanhaesebroeckauthor=K.+Okkenhaugauthor=C.+Picardauthor=S.+Nejentsevauthor=A.+M.+Condliffeauthor=A.+J.+Cant&title=Clinical+Spectrum+and+Features+of+Activated+Phosphoinositide+3-Kinase+%CE%B4+Syndrome%3A+A+Large+Patient+Cohort+Study&doi=10.1016%2Fj.jaci.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study</span></div><div class="casAuthors">Coulter, Tanya I.; Chandra, Anita; Bacon, Chris M.; Babar, Judith; Curtis, James; Screaton, Nick; Goodlad, John R.; Farmer, George; Steele, Cathal Laurence; Leahy, Timothy Ronan; Doffinger, Rainer; Baxendale, Helen; Bernatoniene, Jolanta; Edgar, J. David M.; Longhurst, Hilary J.; Ehl, Stephan; Speckmann, Carsten; Grimbacher, Bodo; Sediva, Anna; Milota, Tomas; Faust, Saul N.; Williams, Anthony P.; Hayman, Grant; Kucuk, Zeynep Yesim; Hague, Rosie; French, Paul; Brooker, Richard; Forsyth, Peter; Herriot, Richard; Cancrini, Caterina; Palma, Paolo; Ariganello, Paola; Conlon, Niall; Feighery, Conleth; Gavin, Patrick J.; Jones, Alison; Imai, Kohsuke; Ibrahim, Mohammad A. A.; Markelj, Gasper; Abinun, Mario; Rieux-Laucat, Frederic; Latour, Sylvain; Pellier, Isabelle; Fischer, Alain; Touzot, Fabien; Casanova, Jean-Laurent; Durandy, Anne; Burns, Siobhan O.; Savic, Sinisa; Kumararatne, D. S.; Moshous, Despina; Kracker, Sven; Vanhaesebroeck, Bart; Okkenhaug, Klaus; Picard, Capucine; Nejentsev, Sergey; Condliffe, Alison M.; Cant, Andrew James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">597-606.e4</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ).  We sought to review the clin., immunol., histopathol., and radiol. features of APDS in a large genetically defined international cohort.  We applied a clin. questionnaire and performed review of medical notes, radiol., histopathol., and lab. investigations of 53 patients with APDS.  Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood.  Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%).  Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for PI3Kδ in the central nervous system; consistent with this, PI3Kδ is broadly expressed in the developing murine central nervous system.  Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%).  Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunol. features.  No immunol. marker reliably predicted clin. severity, which ranged from asymptomatic to death in early childhood.  The majority of patients received Ig replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation.  Five patients died from complications of APDS.  APDS is a combined immunodeficiency with multiple clin. manifestations, many with incomplete penetrance and others with variable expressivity.  The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease.  Clin. trials of selective PI3Kδ inhibitors offer new prospects for APDS treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorhoMuz1hapLVg90H21EOLACvtfcHk0lidXfapDXCSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyqt7jF&md5=26f3181a3b523a4af2e32eed1b950a6a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DCoulter%26aufirst%3DT.%2BI.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DBabar%26aufirst%3DJ.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DScreaton%26aufirst%3DN.%26aulast%3DGoodlad%26aufirst%3DJ.%2BR.%26aulast%3DFarmer%26aufirst%3DG.%26aulast%3DSteele%26aufirst%3DC.%2BL.%26aulast%3DLeahy%26aufirst%3DT.%2BR.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DBaxendale%26aufirst%3DH.%26aulast%3DBernatoniene%26aufirst%3DJ.%26aulast%3DEdgar%26aufirst%3DJ.%2BD.%2BM.%26aulast%3DLonghurst%26aufirst%3DH.%2BJ.%26aulast%3DEhl%26aufirst%3DS.%26aulast%3DSpeckmann%26aufirst%3DC.%26aulast%3DGrimbacher%26aufirst%3DB.%26aulast%3DSediva%26aufirst%3DA.%26aulast%3DMilota%26aufirst%3DT.%26aulast%3DFaust%26aufirst%3DS.%2BN.%26aulast%3DWilliams%26aufirst%3DA.%2BP.%26aulast%3DHayman%26aufirst%3DG.%26aulast%3DKucuk%26aufirst%3DZ.%2BY.%26aulast%3DHague%26aufirst%3DR.%26aulast%3DFrench%26aufirst%3DP.%26aulast%3DBrooker%26aufirst%3DR.%26aulast%3DForsyth%26aufirst%3DP.%26aulast%3DHerriot%26aufirst%3DR.%26aulast%3DCancrini%26aufirst%3DC.%26aulast%3DPalma%26aufirst%3DP.%26aulast%3DAriganello%26aufirst%3DP.%26aulast%3DConlon%26aufirst%3DN.%26aulast%3DFeighery%26aufirst%3DC.%26aulast%3DGavin%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%2BA.%26aulast%3DMarkelj%26aufirst%3DG.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DRieux-Laucat%26aufirst%3DF.%26aulast%3DLatour%26aufirst%3DS.%26aulast%3DPellier%26aufirst%3DI.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DTouzot%26aufirst%3DF.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DBurns%26aufirst%3DS.%2BO.%26aulast%3DSavic%26aufirst%3DS.%26aulast%3DKumararatne%26aufirst%3DD.%2BS.%26aulast%3DMoshous%26aufirst%3DD.%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DCondliffe%26aufirst%3DA.%2BM.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26atitle%3DClinical%2520Spectrum%2520and%2520Features%2520of%2520Activated%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Syndrome%253A%2520A%2520Large%2520Patient%2520Cohort%2520Study%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2017%26volume%3D139%26issue%3D2%26spage%3D597%26epage%3D606%26doi%3D10.1016%2Fj.jaci.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkaim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui-Sekinaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heurtier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deau, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharapova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glastre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugakani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshous, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamrini, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otremba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougaris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodszki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlogis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutboul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span> <span> </span><span class="NLM_article-title">Clinical and Immunologic Phenotype Associated with Activated Phosphoinositide 3-Kinase δ Syndrome 2: A Cohort Study</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2016.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.jaci.2016.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27221134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVSmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=210-218&issue=1&author=E.+Elkaimauthor=B.+Nevenauthor=J.+Bruneauauthor=K.+Mitsui-Sekinakaauthor=A.+Stanislasauthor=L.+Heurtierauthor=C.+L.+Lucasauthor=H.+Matthewsauthor=M.-C.+Deauauthor=S.+Sharapovaauthor=J.+Curtisauthor=J.+Reichenbachauthor=C.+Glastreauthor=D.+A.+Parryauthor=G.+Arumugakaniauthor=E.+McDermottauthor=S.+S.+Kilicauthor=M.+Yamashitaauthor=D.+Moshousauthor=H.+Lamriniauthor=B.+Otrembaauthor=A.+Genneryauthor=T.+Coulterauthor=I.+Quintiauthor=J.-L.+Stephanauthor=V.+Lougarisauthor=N.+Brodszkiauthor=V.+Barlogisauthor=T.+Asanoauthor=L.+Galicierauthor=D.+Boutboulauthor=S.+Nonoyamaauthor=A.+Cantauthor=K.+Imaiauthor=C.+Picardauthor=S.+Nejentsevauthor=T.+J.+Molinaauthor=M.+Lenardoauthor=S.+Savicauthor=M.+Cavazzanaauthor=A.+Fischerauthor=A.+Durandyauthor=S.+Kracker&title=Clinical+and+Immunologic+Phenotype+Associated+with+Activated+Phosphoinositide+3-Kinase+%CE%B4+Syndrome+2%3A+A+Cohort+Study&doi=10.1016%2Fj.jaci.2016.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study</span></div><div class="casAuthors">Elkaim, Elodie; Neven, Benedicte; Bruneau, Julie; Mitsui-Sekinaka, Kanako; Stanislas, Aurelie; Heurtier, Lucie; Lucas, Carrie L.; Matthews, Helen; Deau, Marie-Celine; Sharapova, Svetlana; Curtis, James; Reichenbach, Janine; Glastre, Catherine; Parry, David A.; Arumugakani, Gururaj; McDermott, Elizabeth; Kilic, Sara Sebnem; Yamashita, Motoi; Moshous, Despina; Lamrini, Hicham; Otremba, Burkhard; Gennery, Andrew; Coulter, Tanya; Quinti, Isabella; Stephan, Jean-Louis; Lougaris, Vassilios; Brodszki, Nicholas; Barlogis, Vincent; Asano, Takaki; Galicier, Lionel; Boutboul, David; Nonoyama, Shigeaki; Cant, Andrew; Imai, Kohsuke; Picard, Capucine; Nejentsev, Sergey; Molina, Thierry Jo; Lenardo, Michael; Savic, Sinisa; Cavazzana, Marina; Fischer, Alain; Durandy, Anne; Kracker, Sven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-218.e9</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases.  We sought to review the clin., immunol., and histopathol. phenotypes of APDS2 in a genetically defined international patient cohort.  The medical and biol. records of 36 patients with genetically diagnosed APDS2 were collected and reviewed.  Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2.  Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features.  Growth retardation was frequently noticed (45%).  Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%).  Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) assocd. with an increased frequency of transitional B cells (93%), and decreased nos. of naive CD4 and naive CD8 cells but increased nos. of CD8 effector/memory T cells were predominant immunol. features.  The majority of patients (89%) received Ig replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2.  Five patients died from APDS2-related complications.  APDS2 is a combined immunodeficiency with a variable clin. phenotype.  Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD.  Ig replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWsgjSs8Vh2bVg90H21EOLACvtfcHk0lidXfapDXCSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVSmtb0%253D&md5=b2ddcbd533e9c2ddefa6a0fcc09bc514</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2016.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2016.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DElkaim%26aufirst%3DE.%26aulast%3DNeven%26aufirst%3DB.%26aulast%3DBruneau%26aufirst%3DJ.%26aulast%3DMitsui-Sekinaka%26aufirst%3DK.%26aulast%3DStanislas%26aufirst%3DA.%26aulast%3DHeurtier%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DDeau%26aufirst%3DM.-C.%26aulast%3DSharapova%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DReichenbach%26aufirst%3DJ.%26aulast%3DGlastre%26aufirst%3DC.%26aulast%3DParry%26aufirst%3DD.%2BA.%26aulast%3DArumugakani%26aufirst%3DG.%26aulast%3DMcDermott%26aufirst%3DE.%26aulast%3DKilic%26aufirst%3DS.%2BS.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DMoshous%26aufirst%3DD.%26aulast%3DLamrini%26aufirst%3DH.%26aulast%3DOtremba%26aufirst%3DB.%26aulast%3DGennery%26aufirst%3DA.%26aulast%3DCoulter%26aufirst%3DT.%26aulast%3DQuinti%26aufirst%3DI.%26aulast%3DStephan%26aufirst%3DJ.-L.%26aulast%3DLougaris%26aufirst%3DV.%26aulast%3DBrodszki%26aufirst%3DN.%26aulast%3DBarlogis%26aufirst%3DV.%26aulast%3DAsano%26aufirst%3DT.%26aulast%3DGalicier%26aufirst%3DL.%26aulast%3DBoutboul%26aufirst%3DD.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DCant%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DMolina%26aufirst%3DT.%2BJ.%26aulast%3DLenardo%26aufirst%3DM.%26aulast%3DSavic%26aufirst%3DS.%26aulast%3DCavazzana%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DKracker%26aufirst%3DS.%26atitle%3DClinical%2520and%2520Immunologic%2520Phenotype%2520Associated%2520with%2520Activated%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Syndrome%25202%253A%2520A%2520Cohort%2520Study%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2016%26volume%3D138%26issue%3D1%26spage%3D210%26epage%3D218%26doi%3D10.1016%2Fj.jaci.2016.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gili, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruciano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korfei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iemmolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Furno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuffrida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vancheri, C.</span></span> <span> </span><span class="NLM_article-title">PI3K P110γ Overexpression in Idiopathic Pulmonary Fibrosis Lung Tissue and Fibroblast Cells: In Vitro Effects of Its Inhibition</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1038/labinvest.2013.6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Flabinvest.2013.6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=566-576&issue=5&author=E.+Conteauthor=E.+Giliauthor=M.+Frucianoauthor=M.+Korfeiauthor=E.+Fagoneauthor=M.+Iemmoloauthor=D.+Lo+Furnoauthor=R.+Giuffridaauthor=N.+Crimiauthor=A.+Guentherauthor=C.+Vancheri&title=PI3K+P110%CE%B3+Overexpression+in+Idiopathic+Pulmonary+Fibrosis+Lung+Tissue+and+Fibroblast+Cells%3A+In+Vitro+Effects+of+Its+Inhibition&doi=10.1038%2Flabinvest.2013.6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2013.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2013.6%26sid%3Dliteratum%253Aachs%26aulast%3DConte%26aufirst%3DE.%26aulast%3DGili%26aufirst%3DE.%26aulast%3DFruciano%26aufirst%3DM.%26aulast%3DKorfei%26aufirst%3DM.%26aulast%3DFagone%26aufirst%3DE.%26aulast%3DIemmolo%26aufirst%3DM.%26aulast%3DLo%2BFurno%26aufirst%3DD.%26aulast%3DGiuffrida%26aufirst%3DR.%26aulast%3DCrimi%26aufirst%3DN.%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DVancheri%26aufirst%3DC.%26atitle%3DPI3K%2520P110%25CE%25B3%2520Overexpression%2520in%2520Idiopathic%2520Pulmonary%2520Fibrosis%2520Lung%2520Tissue%2520and%2520Fibroblast%2520Cells%253A%2520In%2520Vitro%2520Effects%2520of%2520Its%2520Inhibition%26jtitle%3DLab.%2520Invest.%26date%3D2013%26volume%3D93%26issue%3D5%26spage%3D566%26epage%3D576%26doi%3D10.1038%2Flabinvest.2013.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">The PI3K Pathway in Human Disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.cell.2017.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28802037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=605-635&issue=4&author=D.+A.+Frumanauthor=H.+Chiuauthor=B.+D.+Hopkinsauthor=S.+Bagrodiaauthor=L.+C.+Cantleyauthor=R.+T.+Abraham&title=The+PI3K+Pathway+in+Human+Disease&doi=10.1016%2Fj.cell.2017.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway in Human Disease</span></div><div class="casAuthors">Fruman, David A.; Chiu, Honyin; Hopkins, Benjamin D.; Bagrodia, Shubha; Cantley, Lewis C.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-635</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is considered a hallmark of cancer.  Many PI3K pathway-targeted therapies have been tested in oncol. trials, resulting in regulatory approval of one isoform-selective inhibitor (idelalisib) for treatment of certain blood cancers and a variety of other agents at different stages of development.  In parallel to PI3K research by cancer biologists, investigations in other fields have uncovered exciting and often unpredicted roles for PI3K catalytic and regulatory subunits in normal cell function and in disease.  Many of these functions impinge upon oncol. by influencing the efficacy and toxicity of PI3K-targeted therapies.  Here we provide a perspective on the roles of class I PI3Ks in the regulation of cellular metab. and in immune system functions, two topics closely intertwined with cancer biol.  We also discuss recent progress developing PI3K-targeted therapies for treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX1NPtgicD_rVg90H21EOLACvtfcHk0ljrpWVUNWDkoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL&md5=a5a5c06960587cefa95a6fb8cc647c7f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DChiu%26aufirst%3DH.%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DThe%2520PI3K%2520Pathway%2520in%2520Human%2520Disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26issue%3D4%26spage%3D605%26epage%3D635%26doi%3D10.1016%2Fj.cell.2017.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Montfort, R. L. M.</span></span> <span> </span><span class="NLM_article-title">Revealing the Delta Lady</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1038/nchembio.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnchembio.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=20081818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=82&author=P.+Workmanauthor=R.+L.+M.+van+Montfort&title=Revealing+the+Delta+Lady&doi=10.1038%2Fnchembio.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing the delta lady</span></div><div class="casAuthors">Workman, Paul; van Montfort, Rob L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">82-83</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-OH kinases (PI(3)Ks) are important lipid signaling enzymes and exciting drug targets for a no. of human diseases.  The 1st, much anticipated crystal structure of the δ isoform of PI(3)K recently reported by A. Berndt et al. (2010) has provided surprising new insights into the selectivity of inhibitors for this vs. other PI(3)K isoforms and facilitates the design of improved drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgWqq4U-FSC7Vg90H21EOLACvtfcHk0ljrpWVUNWDkoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGmtQ%253D%253D&md5=89a6a30c3fc8673821c9cc829583d185</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.305%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26atitle%3DRevealing%2520the%2520Delta%2520Lady%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D82%26doi%3D10.1038%2Fnchembio.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houseman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hon, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rückle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span> <span> </span><span class="NLM_article-title">The P110δ Structure: Mechanisms for Selectivity and Potency of New PI(3)K Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1038/nchembio.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&issue=2&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D.+Leauthor=B.+T.+Housemanauthor=J.+I.+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=P.+Renauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+R%C3%BCckleauthor=M.+K.+Schwarzauthor=K.+M.+Shokatauthor=J.+P.+Shawauthor=R.+L.+Williams&title=The+P110%CE%B4+Structure%3A+Mechanisms+for+Selectivity+and+Potency+of+New+PI%283%29K+Inhibitors&doi=10.1038%2Fnchembio.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0lip4N1EWBXV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DPacold%26aufirst%3DJ.%2BI.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DThe%2520P110%25CE%25B4%2520Structure%253A%2520Mechanisms%2520for%2520Selectivity%2520and%2520Potency%2520of%2520New%2520PI%25283%2529K%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26issue%3D2%26spage%3D117%26epage%3D124%26doi%3D10.1038%2Fnchembio.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span> <i>PyMOL Molecular
Graphics System</i>, version <span class="NLM_edition">2.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMOL+Molecular%0AGraphics+System%2C+version+2.0%3B+Schr%C3%B6dinger%2C+LLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%2520Molecular%250AGraphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Potential Value and Limitation of Dual Inhibitors of PI3K and MTOR in the Treatment of Cancer</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2174/1568009611313020001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.2174%2F1568009611313020001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=23215718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFWhsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=117-120&issue=2&author=J.+Chen&title=Potential+Value+and+Limitation+of+Dual+Inhibitors+of+PI3K+and+MTOR+in+the+Treatment+of+Cancer&doi=10.2174%2F1568009611313020001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer</span></div><div class="casAuthors">Chen, Jiezhong</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-120</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At present, the most effective inhibitors developed for the phosphoinositide 3-kinase (PI3K) pathway are dual inhibitors of PI3K and mammalian target of rapamycin (mTOR), a downstream target of PI3K.  PI3K/Akt/mTOR is a major signaling pathway activated in many cancers.  This special issue presents review articles that summarize the implications of the dual inhibitors of PI3K/mTOR in several cancers including melanoma, leukemia, breast cancer, prostate cancer, gastric cancer and cervical cancer.  These articles reflect the most recent progress in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8rNpnggFtcLVg90H21EOLACvtfcHk0lip4N1EWBXV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFWhsrY%253D&md5=6e729b1d223a8b919690dfdd3bbee349</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1568009611313020001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009611313020001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DPotential%2520Value%2520and%2520Limitation%2520of%2520Dual%2520Inhibitors%2520of%2520PI3K%2520and%2520MTOR%2520in%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2013%26volume%3D13%26issue%3D2%26spage%3D117%26epage%3D120%26doi%3D10.2174%2F1568009611313020001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and Regulation of Akt/PKB by the Rictor-MTOR Complex</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span> (<span class="NLM_issue">5712</span>),  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&issue=5712&author=D.+D.+Sarbassov&title=Phosphorylation+and+Regulation+of+Akt%2FPKB+by+the+Rictor-MTOR+Complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lip4N1EWBXV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26atitle%3DPhosphorylation%2520and%2520Regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520Rictor-MTOR%2520Complex%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2005%26volume%3D307%26issue%3D5712%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">ATP-Competitive Inhibitors of MTOR: An Update</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2995</span>– <span class="NLM_lpage">3014</span>, <span class="refDoi"> DOI: 10.2174/092986711796391651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.2174%2F092986711796391651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=21651476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2995-3014&issue=20&author=S.+Schenoneauthor=C.+Brulloauthor=F.+Musumeciauthor=M.+Radiauthor=M.+Botta&title=ATP-Competitive+Inhibitors+of+MTOR%3A+An+Update&doi=10.2174%2F092986711796391651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-competitive inhibitors of mTOR: an update</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Musumeci, F.; Radi, M.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2995-3014</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  MTOR (mammalian target of rapamycin) is a serine-threonine kinase belonging to the PI3K/Akt/mTOR signalling pathway that is involved in several cell functions, including growth, proliferation, apoptosis and autophagy.  MTOR hyperactivation has been detected in several human cancers, thus representing, together with its upstream effectors, an important target for cancer therapy.  MTOR exists in two different complexes in cells, mTORC1 and mTORC2 which could both be targeted by potential anticancer agents.  Rapamycin, the selective and allosteric inhibitor of mTOR, inhibits the enzyme in mTORC1, but not in mTORC2.  In the last few years a no. of mTOR ATP-competitive inhibitors has been reported acting on mTOR in both complexes and possessing a more complete anticancer activity in comparison with that of rapamycin and its derivs.  MTOR shares high sequence homol. in the hinge-region with PI3K that is a lipid kinase upstream to mTOR in the same signalling pathway; for this reason some compds. originally developed as PI3K inhibitors later showed to also target mTOR.  As indicated by preclin. and clin. studies, compds. acting on more than one target could result in a better biol. response and in enhanced therapeutic potential and also dual PI3K/mTOR inhibitors result of great interest as potential antitumor agents.  This review mainly reports the recently discovered mTOR ATP-competitive inhibitors in terms of medicinal chem., classified by their chem. structures, focusing on SAR and modeling studies that led to the discovery of very potent and selective agents, such as AZD-8055, OSI-027 and INK128, already entered clin. trials, or WYE-132, Torin1 and others in preclin. studies.  Also some examples of dual PI3K/mTOR inhibitors, including PI-103, GNE477, WJD008 and GSK2126458 are reported together with their biol. and clin. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu7yn-FHwtVbVg90H21EOLACvtfcHk0liegG54kahKmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7o%253D&md5=bc3786d2c4e703558cffa34a9657b7d5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F092986711796391651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391651%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DATP-Competitive%2520Inhibitors%2520of%2520MTOR%253A%2520An%2520Update%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D20%26spage%3D2995%26epage%3D3014%26doi%3D10.2174%2F092986711796391651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span>PubChem. <a href="https://pubchem.ncbi.nlm.nih.gov/" class="extLink">https://pubchem.ncbi.nlm.nih.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PubChem.+https%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, K. W.</span>; <span class="NLM_string-name">Huang, D.</span>; <span class="NLM_string-name">Kesicki, E. A.</span>; <span class="NLM_string-name">Ooi, H. C.</span>; <span class="NLM_string-name">Oliver, A. R.</span>; <span class="NLM_string-name">Ruan, F.</span>; <span class="NLM_string-name">Treiberg, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Purine Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta</span>. <span class="NLM_patent">WO2005113556A1</span>, December 1, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+W.+Fowler&author=D.+Huang&author=E.+A.+Kesicki&author=H.+C.+Ooi&author=A.+R.+Oliver&author=F.+Ruan&author=J.+Treiberg&title=Preparation+of+Purine+Quinazolinones+as+Inhibitors+of+Human+Phosphatidylinositol+3-Kinase+Delta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFowler%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Purine%2520Quinazolinones%2520as%2520Inhibitors%2520of%2520Human%2520Phosphatidylinositol%25203-Kinase%2520Delta%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagpacan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papalia, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">8439</span>– <span class="NLM_lpage">8446</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&issue=13&author=J.%0AR.+Somozaauthor=D.+Koditekauthor=A.%0AG.+Villase%C3%B1orauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+Biochemical%2C+and+Biophysical+Characterization+of+Idelalisib+Binding+to+Phosphoinositide+3-Kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520Biochemical%252C%2520and%2520Biophysical%2520Characterization%2520of%2520Idelalisib%2520Binding%2520to%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D13%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, B. P.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1007/s40262-015-0304-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1007%2Fs40262-015-0304-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=26242379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=33-45&issue=1&author=S.+Ramanathanauthor=F.+Jinauthor=S.+Sharmaauthor=B.+P.+Kearney&title=Clinical+Pharmacokinetic+and+Pharmacodynamic+Profile+of+Idelalisib&doi=10.1007%2Fs40262-015-0304-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib</span></div><div class="casAuthors">Ramanathan, Srinivasan; Jin, Feng; Sharma, Shringi; Kearney, Brian P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Idelalisib is a potent and selective phosphatidylinositol 3-kinase-δ inhibitor, which is a first-in-class agent to be approved for the treatment of relapsed chronic lymphocytic leukemia, follicular B cell non-Hodgkin's lymphoma and small lymphocytic lymphoma.  In dose-ranging studies, idelalisib exposure increased in a less than dose-proportional manner, likely because of soly.-limited absorption.  The approved starting dose of 150 mg twice daily was supported by extensive exposure-response evaluations, with dose redn. to 100 mg twice daily being allowed for specific toxicities.  Idelalisib may be administered without regard to food on the basis of the absence of clin. relevant food effects, and was accordingly dosed in primary efficacy/safety studies.  Idelalisib is metabolized primarily via aldehyde oxidase (AO) and, to a lesser extent, via cytochrome P 450 (CYP) 3A.  Coadministration with the strong CYP3A inhibitor ketoconazole 400 mg once daily resulted in a ∼79 % increase in the idelalisib area under the plasma concn.-time curve (AUC).  Administration with the potent inducer rifampin resulted in a 75 % decrease in idelalisib exposure (AUC) and, as such, coadministration with strong inducers should be avoided.  GS-563117 is an inactive primary circulating metabolite of idelalisib formed mainly via AO.  Unlike idelalisib, GS-563117 is a mechanism-based inhibitor of CYP3A.  Accordingly, idelalisib 150 mg twice-daily dosing increases the midazolam AUC 5.4-fold.  Clin., idelalisib is not an inhibitor of the transporters P-glycoprotein, breast cancer resistance protein, org. anion-transporting polypeptide (OATP) 1B1 or OAPT1B3.  In a population pharmacokinetic model, no meaningful impact on idelalisib pharmacokinetics was noted for any of the covariates tested.  Idelalisib exposure was ∼60 % higher with moderate/severe hepatic impairment; no relevant changes were obsd. with severe renal impairment.  This article reviews a comprehensive pharmacol. program, including drug-drug interaction studies and mechanistic and special population studies, which has allowed a thorough understanding of idelalisib clin. pharmacokinetics and their impact on clin. safety and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSL8hV_Gha7Vg90H21EOLACvtfcHk0liegG54kahKmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D&md5=df1082fcbb0e1a9aa941769ade9fe962</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0304-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0304-0%26sid%3Dliteratum%253Aachs%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKearney%26aufirst%3DB.%2BP.%26atitle%3DClinical%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Profile%2520of%2520Idelalisib%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26issue%3D1%26spage%3D33%26epage%3D45%26doi%3D10.1007%2Fs40262-015-0304-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3532</span>– <span class="NLM_lpage">3548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3532-3548&issue=7&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=A.+C.+Haranauthor=C.+Ipauthor=J.+A.+Kaplanauthor=M.+Kimauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=N.+Novikovauthor=S.+Perreaultauthor=K.+D.+Puriauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=K.+L.+Stevensauthor=J.+Therrienauthor=J.+Treibergauthor=A.+G.+Villase%C3%B1orauthor=A.+Yeungauthor=G.+Phillips&title=2%2C4%2C6-Triaminopyrimidine+as+a+Novel+Hinge+Binder+in+a+Series+of+PI3K%CE%B4+Selective+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00213"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3D2%252C4%252C6-Triaminopyrimidine%2520as%2520a%2520Novel%2520Hinge%2520Binder%2520in%2520a%2520Series%2520of%2520PI3K%25CE%25B4%2520Selective%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D3532%26epage%3D3548%26doi%3D10.1021%2Facs.jmedchem.6b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">9228</span>– <span class="NLM_lpage">9242</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9228-9242&issue=19&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=K.+Forsethauthor=A.+C.+Haranauthor=C.+Ipauthor=A.+Kashishianauthor=M.+Kimauthor=D.+Koditekauthor=S.+Koppenolauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=S.+Perreaultauthor=K.+D.+Puriauthor=A.%0AG.+Villase%C3%B1orauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=G.+Phillips&title=Discovery+of+Orally+Efficacious+Phosphoinositide+3-Kinase+%CE%B4+Inhibitors+with+Improved+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.6b01169"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01169%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DForseth%26aufirst%3DK.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DKoppenol%26aufirst%3DS.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Orally%2520Efficacious%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Inhibitors%2520with%2520Improved%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D19%26spage%3D9228%26epage%3D9242%26doi%3D10.1021%2Facs.jmedchem.6b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahiaoui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1567</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01821</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1555-1567&issue=4&author=S.+Perreaultauthor=J.+Chandrasekharauthor=Z.-H.+Cuiauthor=J.+Evartsauthor=J.+Haoauthor=J.+A.+Kaplanauthor=A.+Kashishianauthor=K.+S.+Keeganauthor=T.+Kenneyauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=L.+Patelauthor=B.+Phillipsauthor=J.+Therrienauthor=J.+Treibergauthor=A.+Yahiaouiauthor=G.+Phillips&title=Discovery+of+a+Phosphoinositide+3-Kinase+%28PI3K%29+%CE%B2%2F%CE%B4+Inhibitor+for+the+Treatment+of+Phosphatase+and+Tensin+Homolog+%28PTEN%29+Deficient+Tumors%3A+Building+PI3K%CE%B2+Potency+in+a+PI3K%CE%B4-Selective+Template+by+Targeting+Nonconserved+Asp856&doi=10.1021%2Facs.jmedchem.6b01821"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01821%26sid%3Dliteratum%253Aachs%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.-H.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DKenney%26aufirst%3DT.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DPhillips%26aufirst%3DB.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DYahiaoui%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520%25CE%25B2%252F%25CE%25B4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Phosphatase%2520and%2520Tensin%2520Homolog%2520%2528PTEN%2529%2520Deficient%2520Tumors%253A%2520Building%2520PI3K%25CE%25B2%2520Potency%2520in%2520a%2520PI3K%25CE%25B4-Selective%2520Template%2520by%2520Targeting%2520Nonconserved%2520Asp856%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1555%26epage%3D1567%26doi%3D10.1021%2Facs.jmedchem.6b01821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcbride, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcgee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of Dual PI3K β/δ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7667</span>– <span class="NLM_lpage">7685</span>, <span class="refDoi"> DOI: 10.1021/jm300679u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300679u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7667-7685&author=F.+Gonzalez-Lopez%0Ade+Turisoauthor=Y.+Shinauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=D.+Fongauthor=X.+Haoauthor=X.+Heauthor=K.+Henneauthor=Y.+Huauthor=M.+G.+Johnsonauthor=T.+Kohnauthor=J.+Lohmanauthor=H.+J.+Mcbrideauthor=L.+R.+Mcgeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=K.+Minerauthor=D.+Mohnauthor=V.+Pattaropongauthor=J.+Seganishauthor=J.+L.+Simardauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=G.+Yuauthor=T.+D.+Cushing&title=Discovery+and+in+Vivo+Evaluation+of+Dual+PI3K+%CE%B2%2F%CE%B4+Inhibitors&doi=10.1021%2Fjm300679u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm300679u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300679u%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKohn%26aufirst%3DT.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DMcbride%26aufirst%3DH.%2BJ.%26aulast%3DMcgee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMiner%26aufirst%3DK.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Dual%2520PI3K%2520%25CE%25B2%252F%25CE%25B4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7667%26epage%3D7685%26doi%3D10.1021%2Fjm300679u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzasa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(Pyridin-2-Yl)Quinolin-3-Yl)Ethyl)-9 H -Purin-6-Amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&issue=1&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.-L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+in+Vivo+Evaluation+of+%28S%29-N-%281-%287-Fluoro-2-%28Pyridin-2-Yl%29Quinolin-3-Yl%29Ethyl%29-9+H+-Purin-6-Amine+%28AMG319%29+and+Related+PI3K%CE%B4+Inhibitors+for+Inflammation+and+Autoimmune+Disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520%2528S%2529-N-%25281-%25287-Fluoro-2-%2528Pyridin-2-Yl%2529Quinolin-3-Yl%2529Ethyl%2529-9%2520H%2520-Purin-6-Amine%2520%2528AMG319%2529%2520and%2520Related%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Inflammation%2520and%2520Autoimmune%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vissinga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01651</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01651" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=431-447&issue=1&author=Y.+Shinauthor=J.+Suchomelauthor=M.+Cardozoauthor=J.+Duquetteauthor=X.+Heauthor=K.+Henneauthor=Y.+Huauthor=R.+C.+Kellyauthor=J.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=T.+San+Miguelauthor=D.+Mohnauthor=T.+Tranauthor=C.+Vissingaauthor=S.+Wongauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=X.+Zhangauthor=T.+D.+Cushing&title=Discovery%2C+Optimization%2C+and+in+Vivo+Evaluation+of+Benzimidazole+Derivatives+AM-8508+and+AM-9635+as+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01651%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DVissinga%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%252C%2520Optimization%252C%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Benzimidazole%2520Derivatives%2520AM-8508%2520and%2520AM-9635%2520as%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D431%26epage%3D447%26doi%3D10.1021%2Facs.jmedchem.5b01651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR Study of Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1109</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2015.01.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1104-1109&issue=5&author=M.+Buiauthor=X.+Haoauthor=Y.+Shinauthor=M.+Cardozoauthor=X.+Heauthor=K.+Henneauthor=J.+Suchomelauthor=J.+McCarterauthor=L.+R.+McGeeauthor=T.+San+Miguelauthor=J.+C.+Medinaauthor=D.+Mohnauthor=T.+Tranauthor=S.+Wannbergauthor=J.+Wongauthor=S.+Wongauthor=L.+Zalamedaauthor=D.+Metzauthor=T.+D.+Cushing&title=Synthesis+and+SAR+Study+of+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520Study%2520of%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D5%26spage%3D1104%26epage%3D1109%26doi%3D10.1016%2Fj.bmcl.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campuzano, I. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vissinga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-Cyano-4-Pyrimidinyl)Amino)Ethyl)-6-Fluoro-N-Methyl-3-(2-Pyridinyl)-4-Quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-Cyano-4-Pyrimidinyl)Amino)Eth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7252</span>– <span class="NLM_lpage">7267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00827</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00827" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7252-7267&issue=15&author=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Haoauthor=Y.+Shinauthor=M.+Buiauthor=I.+D.+G.+Campuzanoauthor=M.+Cardozoauthor=M.+C.+Dunnauthor=J.+Duquetteauthor=B.+Fisherauthor=R.+S.+Fotiauthor=K.+Henneauthor=X.+Heauthor=Y.-L.+Huauthor=R.+C.+Kellyauthor=M.+G.+Johnsonauthor=B.+S.+Lucasauthor=J.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=T.+San+Miguelauthor=D.+Mohnauthor=T.+Tranauthor=C.+Vissingaauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=X.+Zhangauthor=T.+D.+Cushing&title=Discovery+and+in+Vivo+Evaluation+of+the+Potent+and+Selective+PI3K%CE%B4+Inhibitors+2-%28%281S%29-1-%28%286-Amino-5-Cyano-4-Pyrimidinyl%29Amino%29Ethyl%29-6-Fluoro-N-Methyl-3-%282-Pyridinyl%29-4-Quinolinecarboxamide+%28AM-0687%29+and+2-%28%281S%29-1-%28%286-Amino-5-Cyano-4-Pyrimidinyl%29Amino%29Eth&doi=10.1021%2Facs.jmedchem.6b00827"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00827%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DCampuzano%26aufirst%3DI.%2BD.%2BG.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DM.%2BC.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DLucas%26aufirst%3DB.%2BS.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DVissinga%26aufirst%3DC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520the%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%25202-%2528%25281S%2529-1-%2528%25286-Amino-5-Cyano-4-Pyrimidinyl%2529Amino%2529Ethyl%2529-6-Fluoro-N-Methyl-3-%25282-Pyridinyl%2529-4-Quinolinecarboxamide%2520%2528AM-0687%2529%2520and%25202-%2528%25281S%2529-1-%2528%25286-Amino-5-Cyano-4-Pyrimidinyl%2529Amino%2529Eth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D15%26spage%3D7252%26epage%3D7267%26doi%3D10.1021%2Facs.jmedchem.6b00827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armengol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00438</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00438" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=118-123&issue=1&author=M.+Erraauthor=J.+Taltavullauthor=A.+Grecoauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=J.+Graciaauthor=M.+Dominguezauthor=M.+Sabateauthor=S.+Parisauthor=S.+Soriaauthor=B.+Hernandezauthor=C.+Armengolauthor=J.+Cabedoauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehner&title=Discovery+of+a+Potent%2C+Selective%2C+and+Orally+Available+PI3K%CE%B4+Inhibitor+for+the+Treatment+of+Inflammatory+Diseases&doi=10.1021%2Facsmedchemlett.6b00438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00438%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DDominguez%26aufirst%3DM.%26aulast%3DSabate%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DArmengol%26aufirst%3DC.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520PI3K%25CE%25B4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D118%26epage%3D123%26doi%3D10.1021%2Facsmedchemlett.6b00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">SAR Study of 5-Alkynyl Substituted Quinazolin-4(3H)-Ones as Phosphoinositide 3-Kinase Delta (PI3Kδ) Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2016.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27846451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVChsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=1156-1171&author=M.+Weiauthor=X.+Zhangauthor=X.+Wangauthor=Z.+Songauthor=J.+Dingauthor=L.-H.+Mengauthor=A.+Zhang&title=SAR+Study+of+5-Alkynyl+Substituted+Quinazolin-4%283H%29-Ones+as+Phosphoinositide+3-Kinase+Delta+%28PI3K%CE%B4%29+Inhibitors&doi=10.1016%2Fj.ejmech.2016.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors</span></div><div class="casAuthors">Wei, Manman; Zhang, Xi; Wang, Xiang; Song, Zilan; Ding, Jian; Meng, Ling-Hua; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1156-1171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">PI3Kδ is a key component in the aberrant signaling transduction in B cell malignancy, therefore specific targeting PI3Kδ has become an attractive molecularly targeted therapy for chronic lymphocytic leukemia (CLL).  Herein, we describe the discovery and optimization of a series of 5-alkynyl substituted PI3Kδ inhibitors based on the first FDA-approved inhibitor idelalisib.  Compd. 8d bearing the 1-morpholinohex-5-yn-1-one moiety as the C5-substituent was identified to have high potency against PI3Kδ (3.82 nM) and SU-DHL-6 cells (7.60 nM), resp.  It was 154-fold selective over PI3Kα, 133-fold selective against PI3Kβ, and 24-fold selective against PI3Kγ.  Treatment of MOLT-4 and SU-DHL-6 cells with compd. 8d for 1 h resulted in redn. of phosphorylation of both Akt (S473) and its downstream S6k1 (T389) in a concn.-dependent manner.  Compd. 8d showed potent anti-proliferative activity as well against T lymphoblast MOLT-4, suggesting its potential activity in T-cell leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYWHSwSiMyQrVg90H21EOLACvtfcHk0lip9rVVCGJNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVChsbjJ&md5=809c50e6dc45e1e4871af760fe27cefc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DL.-H.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSAR%2520Study%2520of%25205-Alkynyl%2520Substituted%2520Quinazolin-4%25283H%2529-Ones%2520as%2520Phosphoinositide%25203-Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D1156%26epage%3D1171%26doi%3D10.1016%2Fj.ejmech.2016.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescarbeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeilles, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenadel, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Hearn, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Hearn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=862-867&issue=9&author=C.+A.+Evansauthor=T.+Liuauthor=A.+Lescarbeauauthor=S.+J.+Nairauthor=L.+Grenierauthor=J.+A.+Pradeillesauthor=Q.+Glenadelauthor=T.+Tibbittsauthor=A.+M.+Rowleyauthor=J.+P.+DiNittoauthor=E.+E.+Brophyauthor=E.+L.+O%27Hearnauthor=J.+A.+Aliauthor=D.+G.+Winklerauthor=S.+I.+Goldsteinauthor=P.+O%27Hearnauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=J.+R.+Sogliaauthor=C.+Cheungauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=V.+J.+Palombellaauthor=M.+R.+Tremblayauthor=A.+C.+Castro&title=Discovery+of+a+Selective+Phosphoinositide-3-Kinase+%28PI3K%29-%CE%B3+Inhibitor+%28IPI-549%29+as+an+Immuno-Oncology+Clinical+Candidate&doi=10.1021%2Facsmedchemlett.6b00238"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00238%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLescarbeau%26aufirst%3DA.%26aulast%3DNair%26aufirst%3DS.%2BJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPradeilles%26aufirst%3DJ.%2BA.%26aulast%3DGlenadel%26aufirst%3DQ.%26aulast%3DTibbitts%26aufirst%3DT.%26aulast%3DRowley%26aufirst%3DA.%2BM.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DO%2527Hearn%26aufirst%3DE.%2BL.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DGoldstein%26aufirst%3DS.%2BI.%26aulast%3DO%2527Hearn%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DCheung%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DTremblay%26aufirst%3DM.%2BR.%26aulast%3DCastro%26aufirst%3DA.%2BC.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Phosphoinositide-3-Kinase%2520%2528PI3K%2529-%25CE%25B3%2520Inhibitor%2520%2528IPI-549%2529%2520as%2520an%2520Immuno-Oncology%2520Clinical%2520Candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D9%26spage%3D862%26epage%3D867%26doi%3D10.1021%2Facsmedchemlett.6b00238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh Pathania, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobe, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargotra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, S. D.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of 1,4-Substituted 1H-1,2,3-Triazolo-Quinazolin-4(3H)-Ones by Huisgen 1,3-Dipolar Cycloaddition with PI3Kγ Isoform Selective Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2018.02.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1005-1010&issue=6&author=M.+Srinivasauthor=A.+Singh+Pathaniaauthor=P.+Mahajanauthor=P.+K.+Vermaauthor=S.+S.+Chobeauthor=F.+A.+Malikauthor=A.+Nargotraauthor=R.+A.+Vishwakarmaauthor=S.+D.+Sawant&title=Design+and+Synthesis+of+1%2C4-Substituted+1H-1%2C2%2C3-Triazolo-Quinazolin-4%283H%29-Ones+by+Huisgen+1%2C3-Dipolar+Cycloaddition+with+PI3K%CE%B3+Isoform+Selective+Activity&doi=10.1016%2Fj.bmcl.2018.02.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivas%26aufirst%3DM.%26aulast%3DSingh%2BPathania%26aufirst%3DA.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DVerma%26aufirst%3DP.%2BK.%26aulast%3DChobe%26aufirst%3DS.%2BS.%26aulast%3DMalik%26aufirst%3DF.%2BA.%26aulast%3DNargotra%26aufirst%3DA.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DSawant%26aufirst%3DS.%2BD.%26atitle%3DDesign%2520and%2520Synthesis%2520of%25201%252C4-Substituted%25201H-1%252C2%252C3-Triazolo-Quinazolin-4%25283H%2529-Ones%2520by%2520Huisgen%25201%252C3-Dipolar%2520Cycloaddition%2520with%2520PI3K%25CE%25B3%2520Isoform%2520Selective%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D1005%26epage%3D1010%26doi%3D10.1016%2Fj.bmcl.2018.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björhall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredlund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terstiege, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5057</span>– <span class="NLM_lpage">5071</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00401</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00401" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5057-5071&issue=12&author=M.+W.+D.+Perryauthor=K.+Bj%C3%B6rhallauthor=B.+Bonnauthor=J.+Carlssonauthor=Y.+Chenauthor=A.+Erikssonauthor=L.+Fredlundauthor=H.+Haoauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=H.+Lindmarkauthor=F.+Liuauthor=N.+Pembertonauthor=J.+Petersenauthor=S.+Rodrigo+Blomqvistauthor=R.+W.+Smithauthor=T.+Svenssonauthor=I.+Terstiegeauthor=C.+Tyrchanauthor=W.+Yangauthor=S.+Zhaoauthor=L.+%C3%96ster&title=Design+and+Synthesis+of+Soluble+and+Cell-Permeable+PI3K%CE%B4+Inhibitors+for+Long-Acting+Inhaled+Administration&doi=10.1021%2Facs.jmedchem.7b00401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span></div><div class="casAuthors">Perry, Matthew W. D.; Bjoerhall, Karin; Bonn, Britta; Carlsson, Johan; Chen, Yunhua; Eriksson, Anders; Fredlund, Linda; Hao, Hai'e; Holden, Neil S.; Karabelas, Kostas; Lindmark, Helena; Liu, Feifei; Pemberton, Nils; Petersen, Jens; Rodrigo Blomqvist, Sandra; Smith, Reed W.; Svensson, Tor; Terstiege, Ina; Tyrchan, Christian; Yang, Wenzhen; Zhao, Shuchun; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5057-5071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system.  Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis.  In this work, identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation is described.  The initially identified compd. I had good potency and isoform selectivity but was not suitable for inhalation.  Addn. of basic substituents to a region of the mol. pointing to solvent was tolerated (enzyme inhibition pIC50 > 9), and by careful manipulation of the pKa and lipophilicity, the authors were able to discover compds. II (R = Me or i-Bu) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lo9sRrhhb7Vg90H21EOLACvtfcHk0lip9rVVCGJNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D&md5=dafb9cfdf6c06e30c599dcceec85497a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00401%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DBj%25C3%25B6rhall%26aufirst%3DK.%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEriksson%26aufirst%3DA.%26aulast%3DFredlund%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DR.%2BW.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Soluble%2520and%2520Cell-Permeable%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Long-Acting%2520Inhaled%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D5057%26epage%3D5071%26doi%3D10.1021%2Facs.jmedchem.7b00401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the Inhaled Route: Challenges and Approaches</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&issue=4&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+Inhaled+Route%3A+Challenges+and+Approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lhgMqP0btnniQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520Inhaled%2520Route%253A%2520Challenges%2520and%2520Approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26issue%3D4%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD3199, An Inhaled Ultralong Acting β 2 Receptor Agonist with Rapid Onset of Action</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1021/ml4005232</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4005232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=416-421&issue=4&author=M.+J.+Stocksauthor=L.+Alcarazauthor=A.+Baileyauthor=R.+Bonnertauthor=E.+Cadoganauthor=J.+Christieauthor=J.+Dixonauthor=S.+Connollyauthor=A.+Cookauthor=A.+Fisherauthor=A.+Flahertyauthor=A.+Humphriesauthor=A.+Ingallauthor=S.+Jordanauthor=M.+Lawsonauthor=A.+Mullenauthor=D.+Nichollsauthor=S.+Paineauthor=G.+Pairaudeauauthor=A.+Young&title=Discovery+of+AZD3199%2C+An+Inhaled+Ultralong+Acting+%CE%B2+2+Receptor+Agonist+with+Rapid+Onset+of+Action&doi=10.1021%2Fml4005232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action</span></div><div class="casAuthors">Stocks, Michael J.; Alcaraz, Lilian; Bailey, Andrew; Bonnert, Roger; Cadogan, Elaine; Christie, Jadeen; Dixon, John; Connolly, Stephen; Cook, Anthony; Fisher, Adrian; Flaherty, Alice; Humphries, Alexander; Ingall, Anthony; Jordan, Stephen; Lawson, Mandy; Mullen, Alex; Nicholls, David; Paine, Stuart; Pairaudeau, Garry; Young, Alan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of dibasic des-hydroxy β2 receptor agonists has been prepd. and evaluated for potential as inhaled ultralong acting bronchodilators.  Detn. of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model.  Following further assessment by onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i.t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clin. evaluation as a new ultralong acting inhaled β2 receptor agonist with rapid onset of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqROqAoAEVIvbVg90H21EOLACvtfcHk0lhgMqP0btnniQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKgu7o%253D&md5=c07077547e5d948ea027919240e78768</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fml4005232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4005232%26sid%3Dliteratum%253Aachs%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBonnert%26aufirst%3DR.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DFisher%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DA.%26aulast%3DHumphries%26aufirst%3DA.%26aulast%3DIngall%26aufirst%3DA.%26aulast%3DJordan%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DMullen%26aufirst%3DA.%26aulast%3DNicholls%26aufirst%3DD.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520AZD3199%252C%2520An%2520Inhaled%2520Ultralong%2520Acting%2520%25CE%25B2%25202%2520Receptor%2520Agonist%2520with%2520Rapid%2520Onset%2520of%2520Action%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D4%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml4005232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alderton, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugendradas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lensun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergl-Wilson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghir, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhyvoloup, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S. J.</span></span> <span> </span><span class="NLM_article-title">The Identification of 2-(1 H -Indazol-4-Yl)-6-(4-Methanesulfonyl-Piperazin-1-Ylmethyl)-4-Morpholin-4-Yl-Thieno[3,2- d ]Pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer †</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5522</span>– <span class="NLM_lpage">5532</span>, <span class="refDoi"> DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&issue=18&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+Identification+of+2-%281+H+-Indazol-4-Yl%29-6-%284-Methanesulfonyl-Piperazin-1-Ylmethyl%29-4-Morpholin-4-Yl-Thieno%5B3%2C2-+d+%5DPyrimidine+%28GDC-0941%29+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Inhibitor+of+Class+I+PI3+Kinase+for+the+Treatment+of+Cancer+%E2%80%A0&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lhgMqP0btnniQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Identification%2520of%25202-%25281%2520H%2520-Indazol-4-Yl%2529-6-%25284-Methanesulfonyl-Piperazin-1-Ylmethyl%2529-4-Morpholin-4-Yl-Thieno%255B3%252C2-%2520d%2520%255DPyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitor%2520of%2520Class%2520I%2520PI3%2520Kinase%2520for%2520the%2520Treatment%2520of%2520Cancer%2520%25E2%2580%25A0%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D18%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of 4-Morpholino-2-Phenylquinazolines and Related Derivatives as Novel PI3 Kinase P110α Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6847</span>– <span class="NLM_lpage">6858</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2006.06.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=6847-6858&issue=20&author=M.+Hayakawaauthor=H.+Kaizawaauthor=H.+Moritomoauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+Tsukamotoauthor=P.+Parkerauthor=P.+Workmanauthor=M.+Waterfield&title=Synthesis+and+Biological+Evaluation+of+4-Morpholino-2-Phenylquinazolines+and+Related+Derivatives+as+Novel+PI3+Kinase+P110%CE%B1+Inhibitors&doi=10.1016%2Fj.bmc.2006.06.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DMoritomo%26aufirst%3DH.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWaterfield%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%25204-Morpholino-2-Phenylquinazolines%2520and%2520Related%2520Derivatives%2520as%2520Novel%2520PI3%2520Kinase%2520P110%25CE%25B1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26issue%3D20%26spage%3D6847%26epage%3D6858%26doi%3D10.1016%2Fj.bmc.2006.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodny, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3 - Kinase (PI3K) and Phosphatidylinositol 3 - Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3+-+Kinase+%28PI3K%29+and+Phosphatidylinositol+3+-+Kinase-Related+Kinase+%28PIKK%29+Inhibitors%3A+Importance+of+the+Morpholine+Ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203%2520-%2520Kinase%2520%2528PI3K%2529%2520and%2520Phosphatidylinositol%25203%2520-%2520Kinase-Related%2520Kinase%2520%2528PIKK%2529%2520Inhibitors%253A%2520Importance%2520of%2520the%2520Morpholine%2520Ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">7579</span>– <span class="NLM_lpage">7587</span>, <span class="refDoi"> DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&issue=21&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+Potent%2C+Selective%2C+and+Orally+Available+Class+I+Phosphatidylinositol+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28MTOR%29+Kinase+Inhibitor+%28GDC-0980%29+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528MTOR%2529%2520Kinase%2520Inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D21%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span> <span> </span><span class="NLM_article-title">Identification of GNE-477, a Potent and Efficacious Dual PI3K/MTOR Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2411</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2010.03.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2408-2411&issue=8&author=T.+P.+Heffronauthor=M.+Berryauthor=G.+Castanedoauthor=C.+Changauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folkesauthor=J.+Gunznerauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=A.+Oliveroauthor=J.+Pangauthor=D.+Petersonauthor=L.+Salphatiauthor=D.+Sampathauthor=S.+Siderisauthor=D.+P.+Sutherlinauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=S.+Wongauthor=B.+Zhu&title=Identification+of+GNE-477%2C+a+Potent+and+Efficacious+Dual+PI3K%2FMTOR+Inhibitor&doi=10.1016%2Fj.bmcl.2010.03.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DD.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520GNE-477%252C%2520a%2520Potent%2520and%2520Efficacious%2520Dual%2520PI3K%252FMTOR%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D8%26spage%3D2408%26epage%3D2411%26doi%3D10.1016%2Fj.bmcl.2010.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartwright, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheguillaume, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krintel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukadam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tivitmahaisoon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5887</span>– <span class="NLM_lpage">5900</span>, <span class="refDoi"> DOI: 10.1021/jm3003747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5887-5900&issue=12&author=B.+S.+Safinaauthor=S.+Bakerauthor=M.+Baumgardnerauthor=P.+M.+Blaneyauthor=B.+K.+Chanauthor=Y.-H.+Chenauthor=M.+W.+Cartwrightauthor=G.+Castanedoauthor=C.+Chabotauthor=A.+J.+Cheguillaumeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=B.+Goyalauthor=T.+Hancoxauthor=R.+K.+Handaauthor=P.+S.+Iyerauthor=J.+Kaurauthor=R.+Kondruauthor=J.+R.+Kennyauthor=S.+L.+Krintelauthor=J.+Liauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=S.+Mukadamauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=F.+Padillaauthor=W.+S.+Palmerauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=L.+Salphatiauthor=P.+A.+Savyauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=S.+Tayauthor=P.+Tivitmahaisoonauthor=B.+Waszkowyczauthor=B.+Weiauthor=Q.+Yueauthor=C.+Zhangauthor=D.+P.+Sutherlin&title=Discovery+of+Novel+PI3-Kinase+%CE%B4+Specific+Inhibitors+for+the+Treatment+of+Rheumatoid+Arthritis%3A+Taming+CYP3A4+Time-Dependent+Inhibition&doi=10.1021%2Fjm3003747"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm3003747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003747%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.-H.%26aulast%3DCartwright%26aufirst%3DM.%2BW.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DCheguillaume%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DHanda%26aufirst%3DR.%2BK.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKrintel%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPadilla%26aufirst%3DF.%26aulast%3DPalmer%26aufirst%3DW.%2BS.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSavy%26aufirst%3DP.%2BA.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DTivitmahaisoon%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520of%2520Novel%2520PI3-Kinase%2520%25CE%25B4%2520Specific%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520Taming%2520CYP3A4%2520Time-Dependent%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D12%26spage%3D5887%26epage%3D5900%26doi%3D10.1021%2Fjm3003747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8007</span>– <span class="NLM_lpage">8020</span>, <span class="refDoi"> DOI: 10.1021/jm300867c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300867c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8007-8020&issue=18&author=T.+P.+Heffronauthor=L.+Salphatiauthor=B.+Alickeauthor=J.+Cheongauthor=J.+Dotsonauthor=K.+Edgarauthor=R.+Goldsmithauthor=S.+E.+Gouldauthor=L.+B.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=C.+Ndubakuauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=J.+Pangauthor=E.+G.+Pliseauthor=S.+Siderisauthor=S.+Trappauthor=J.+Wallinauthor=L.+Wangauthor=X.+Zhang&title=The+Design+and+Identification+of+Brain+Penetrant+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B1&doi=10.1021%2Fjm300867c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300867c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300867c%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DJ.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPlise%26aufirst%3DE.%2BG.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTrapp%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DThe%2520Design%2520and%2520Identification%2520of%2520Brain%2520Penetrant%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D18%26spage%3D8007%26epage%3D8020%26doi%3D10.1021%2Fjm300867c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Inhibitors of PI3Kδ: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4296</span>– <span class="NLM_lpage">4302</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.05.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4296-4302&issue=13&author=D.+P.+Sutherlinauthor=S.+Bakerauthor=A.+Bisconteauthor=P.+M.+Blaneyauthor=A.+Brownauthor=B.+K.+Chanauthor=D.+Chantryauthor=G.+Castanedoauthor=P.+DePledgeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=T.+Hancoxauthor=J.+Kaurauthor=D.+Knowlesauthor=R.+Kondruauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=B.+S.+Safinaauthor=L.+Salphatiauthor=S.+Stabenauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=M.+Ultschauthor=B.+Waszkowyczauthor=B.+Wei&title=Potent+and+Selective+Inhibitors+of+PI3K%CE%B4%3A+Obtaining+Isoform+Selectivity+from+the+Affinity+Pocket+and+Tryptophan+Shelf&doi=10.1016%2Fj.bmcl.2012.05.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DDePledge%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKnowles%26aufirst%3DD.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26atitle%3DPotent%2520and%2520Selective%2520Inhibitors%2520of%2520PI3K%25CE%25B4%253A%2520Obtaining%2520Isoform%2520Selectivity%2520from%2520the%2520Affinity%2520Pocket%2520and%2520Tryptophan%2520Shelf%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D13%26spage%3D4296%26epage%3D4302%26doi%3D10.1016%2Fj.bmcl.2012.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savy, P. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7686</span>– <span class="NLM_lpage">7695</span>, <span class="refDoi"> DOI: 10.1021/jm300717c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300717c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7686-7695&issue=17&author=J.+M.+Murrayauthor=Z.+K.+Sweeneyauthor=B.+K.+Chanauthor=M.+Balazsauthor=E.+Bradleyauthor=G.+Castanedoauthor=C.+Chabotauthor=D.+Chantryauthor=M.+Flagellaauthor=D.+M.+Goldsteinauthor=R.+Kondruauthor=J.+Lesnickauthor=J.+Liauthor=M.+C.+Lucasauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=L.+Salphatiauthor=B.+Safinaauthor=P.+P.+A.+Savyauthor=E.+M.+Sewardauthor=M.+Ultschauthor=D.+P.+Sutherlin&title=Potent+and+Highly+Selective+Benzimidazole+Inhibitors+of+PI3-Kinase+Delta&doi=10.1021%2Fjm300717c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm300717c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300717c%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSafina%26aufirst%3DB.%26aulast%3DSavy%26aufirst%3DP.%2BP.%2BA.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DPotent%2520and%2520Highly%2520Selective%2520Benzimidazole%2520Inhibitors%2520of%2520PI3-Kinase%2520Delta%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7686%26epage%3D7695%26doi%3D10.1021%2Fjm300717c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Identification of GNE-293, a Potent and Selective PI3Kδ Inhibitor: Navigating in Vitro Genotoxicity While Improving Potency and Selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4953</span>– <span class="NLM_lpage">4959</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2013.06.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4953-4959&issue=17&author=B.%0AS.+Safinaauthor=Z.+K.+Sweeneyauthor=J.+Liauthor=B.+K.+Chanauthor=A.+Bisconteauthor=D.+Carreraauthor=G.+Castanedoauthor=M.+Flagellaauthor=R.+Healdauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=K.+Reifauthor=L.+Salphatiauthor=E.+M.+Sewardauthor=B.+Weiauthor=D.+P.+Sutherlin&title=Identification+of+GNE-293%2C+a+Potent+and+Selective+PI3K%CE%B4+Inhibitor%3A+Navigating+in+Vitro+Genotoxicity+While+Improving+Potency+and+Selectivity&doi=10.1016%2Fj.bmcl.2013.06.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DCarrera%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DIdentification%2520of%2520GNE-293%252C%2520a%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitor%253A%2520Navigating%2520in%2520Vitro%2520Genotoxicity%2520While%2520Improving%2520Potency%2520and%2520Selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D17%26spage%3D4953%26epage%3D4959%26doi%3D10.1016%2Fj.bmcl.2013.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yaguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshimizu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamori, T.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor</span>. <i>JNCI J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1093/jnci/djj133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1093%2Fjnci%2Fdjj133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=16622124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=545-556&issue=8&author=S.+Yaguchiauthor=Y.+Fukuiauthor=I.+Koshimizuauthor=H.+Yoshimiauthor=T.+Matsunoauthor=H.+Goudaauthor=S.+Hironoauthor=K.+Yamazakiauthor=T.+Yamori&title=Antitumor+Activity+of+ZSTK474%2C+a+New+Phosphatidylinositol+3-Kinase+Inhibitor&doi=10.1093%2Fjnci%2Fdjj133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor</span></div><div class="casAuthors">Yaguchi, Shin-ichi; Fukui, Yasuhisa; Koshimizu, Ichiro; Yoshimi, Hisashi; Matsuno, Toshiyuki; Gouda, Hiroaki; Hirono, Shuichi; Yamazaki, Kanami; Yamori, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously synthesized a novel s-triazine deriv., ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells.  We identified its mol. target, investigated its effects on cellular signaling pathways, and examd. its antitumor efficacy and toxicity in vivo.  Methods: We used COMPARE anal. of chemosensitivity measurements from 39 human cancer cell lines and identified phosphatidylinositol 3-kinase (PI3K) as a mol. target for ZSTK474.  PI3K was immunopptd. from A549 cell lysates, and its activity was measured by assessing the incorporation of 32P into phosphatidylinositol.  We used the crystal structure of the PI3K-LY294002 complex to model the binding of ZSTK474 to PI3K (where LY294002 is a known PI3K inhibitor).  PI3K downstream activity was analyzed by immunoblotting.  Antitumor activity of ZSTK474 was examd. against A549, PC-3, and WiDr xenografts in nude mice.  Phosphorylation of Akt, a serine/threonine protein kinase and a major signaling component downstream of PI3K, was assessed in vivo by immunohistochem.  Results: PI3K was identified as a mol. target for ZSTK474 by COMPARE anal.  We confirmed that ZSTK474 directly inhibited PI3K activity more efficiently than the PI3K inhibitor LY294002.  At concns. of 1 μM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), resp., of the untreated control level.  Mol. modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K.  ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3β, and mediated a decrease in cyclin D1 levels.  ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474.  Conclusion: ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  ZSTK474 merits further investigation as an anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0v8LFKdruLVg90H21EOLACvtfcHk0li2I41_O_DbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D&md5=a2593024975536089ab2ee7e53234ebc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj133%26sid%3Dliteratum%253Aachs%26aulast%3DYaguchi%26aufirst%3DS.%26aulast%3DFukui%26aufirst%3DY.%26aulast%3DKoshimizu%26aufirst%3DI.%26aulast%3DYoshimi%26aufirst%3DH.%26aulast%3DMatsuno%26aufirst%3DT.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DYamori%26aufirst%3DT.%26atitle%3DAntitumor%2520Activity%2520of%2520ZSTK474%252C%2520a%2520New%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%26jtitle%3DJNCI%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26issue%3D8%26spage%3D545%26epage%3D556%26doi%3D10.1093%2Fjnci%2Fdjj133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&issue=10&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Class+I+PI3+Kinase+Inhibitor+for+Treating+Cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0liPC5EV9q51LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Class%2520I%2520PI3%2520Kinase%2520Inhibitor%2520for%2520Treating%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D10%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification and Structure–activity Relationship of 2-Morpholino 6-(3-Hydroxyphenyl) Pyrimidines, a Class of Potent and Selective PI3 Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6895</span>– <span class="NLM_lpage">6898</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2010.10.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6895-6898&issue=23&author=S.+Pecchiauthor=P.+A.+Renhoweauthor=C.+Taylorauthor=S.+Kaufmanauthor=H.+Merrittauthor=M.+Wiesmannauthor=K.+R.+Shoemakerauthor=M.+S.+Knappauthor=E.+Ornelasauthor=T.+F.+Hendricksonauthor=W.+Fantlauthor=C.+F.+Voliva&title=Identification+and+Structure%E2%80%93activity+Relationship+of+2-Morpholino+6-%283-Hydroxyphenyl%29+Pyrimidines%2C+a+Class+of+Potent+and+Selective+PI3+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2010.10.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DShoemaker%26aufirst%3DK.%2BR.%26aulast%3DKnapp%26aufirst%3DM.%2BS.%26aulast%3DOrnelas%26aufirst%3DE.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DFantl%26aufirst%3DW.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520and%2520Structure%25E2%2580%2593activity%2520Relationship%2520of%25202-Morpholino%25206-%25283-Hydroxyphenyl%2529%2520Pyrimidines%252C%2520a%2520Class%2520of%2520Potent%2520and%2520Selective%2520PI3%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D23%26spage%3D6895%26epage%3D6898%26doi%3D10.1016%2Fj.bmcl.2010.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleylein-Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blommers, M. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazic-Legueux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laborde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaxelaire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummendorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1747</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1158%2F1535-7163.MCT-11-1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22653967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1747-1757&issue=8&author=S.+M.+Brachmannauthor=J.+Kleylein-Sohnauthor=S.+Gaulisauthor=A.+Kauffmannauthor=M.+J.+J.+Blommersauthor=M.+Kazic-Legueuxauthor=L.+Labordeauthor=M.+Hattenbergerauthor=F.+Staufferauthor=J.+Vaxelaireauthor=V.+Romanetauthor=C.+Henryauthor=M.+Murakamiauthor=D.+A.+Guthyauthor=D.+Sterkerauthor=S.+Berglingauthor=C.+Wilsonauthor=T.+Brummendorfauthor=C.+Fritschauthor=C.+Garcia-Echeverriaauthor=W.+R.+Sellersauthor=F.+Hofmannauthor=S.-M.+Maira&title=Characterization+of+the+Mechanism+of+Action+of+the+Pan+Class+I+PI3K+Inhibitor+NVP-BKM120+across+a+Broad+Range+of+Concentrations&doi=10.1158%2F1535-7163.MCT-11-1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations</span></div><div class="casAuthors">Brachmann, Saskia M.; Kleylein-Sohn, Julia; Gaulis, Swann; Kauffmann, Audrey; Blommers, Marcel J. J.; Kazic-Legueux, Malika; Laborde, Laurent; Hattenberger, Marc; Stauffer, Fabian; Vaxelaire, Juliane; Romanet, Vincent; Henry, Chrystele; Murakami, Masato; Guthy, Daniel Alexander; Sterker, Dario; Bergling, Sebastian; Wilson, Christopher; Bruemmendorf, Thomas; Fritsch, Christine; Garcia-Echeverria, Carlos; Sellers, William R.; Hofmann, Francesco; Maira, Sauveur-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1747-1757</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The pan-phosphoinositide 3-kinase (PI3K) inhibitor BKM120 was found, at high concns., to cause cell death in various cellular systems, irresp. of their level of PI3K addiction.  Transcriptional and biochem. profiling studies were used to identify the origin of these unexpected and apparently PI3K-independent effects.  At 5- to 10-fold, the concn. needed to half-maximally inhibit PI3K signaling.  BKM120 treatment caused changes in expression of mitotic genes and the induction of a robust G2-M arrest.  Tubulin polymn. assays and NMR-binding studies revealed that BKM120 inhibited microtubule dynamics upon direct binding to tubulin.  To assess the contribution of this off-target activity vis-a-vis the antitumor activity of BKM120 in PI3K-dependent tumors, we used a mechanistic PI3K-α-dependent model.  We obsd. that, in vivo, daily treatment of mice with doses of BKM120 up to 40 mg/kg led to tumor regressions with no increase in the mitotic index.  Thus, strong antitumor activity can be achieved in PI3K-dependent models at exposures that are below those necessary to engage the off-target activity.  In comparison, the clin. data indicate that it is unlikely that BKM120 will achieve exposures sufficient to significantly engage the off-target activity at tolerated doses and schedules.  However, in preclin. settings, the consequences of the off-target activity start to manifest themselves at concns. above 1 μmol/L in vitro and doses above 50 mg/kg in efficacy studies using s.c. tumor-bearing mice.  Hence, careful concn. and dose range selection is required to ensure that any observation can be correctly attributed to BKM120 inhibition of PI3K.  Mol Cancer Ther; 11(8); 1747-57. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKHhs5m02qfrVg90H21EOLACvtfcHk0liPC5EV9q51LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM&md5=26f5cd3377b49f9e61a092191d86194b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1021%26sid%3Dliteratum%253Aachs%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DKleylein-Sohn%26aufirst%3DJ.%26aulast%3DGaulis%26aufirst%3DS.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DBlommers%26aufirst%3DM.%2BJ.%2BJ.%26aulast%3DKazic-Legueux%26aufirst%3DM.%26aulast%3DLaborde%26aufirst%3DL.%26aulast%3DHattenberger%26aufirst%3DM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DVaxelaire%26aufirst%3DJ.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DGuthy%26aufirst%3DD.%2BA.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DBergling%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBrummendorf%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMaira%26aufirst%3DS.-M.%26atitle%3DCharacterization%2520of%2520the%2520Mechanism%2520of%2520Action%2520of%2520the%2520Pan%2520Class%2520I%2520PI3K%2520Inhibitor%2520NVP-BKM120%2520across%2520a%2520Broad%2520Range%2520of%2520Concentrations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D8%26spage%3D1747%26epage%3D1757%26doi%3D10.1158%2F1535-7163.MCT-11-1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s Mechanism of Action Defines Specific PI3K and Tubulin Inhibitors for Therapeutic Intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+Mechanism+of+Action+Defines+Specific+PI3K+and+Tubulin+Inhibitors+for+Therapeutic+Intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eYMCxiEpGFcpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520Mechanism%2520of%2520Action%2520Defines%2520Specific%2520PI3K%2520and%2520Tubulin%2520Inhibitors%2520for%2520Therapeutic%2520Intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7268</span>– <span class="NLM_lpage">7274</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00235</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00235" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7268-7274&issue=15&author=J.-Q.+Zhangauthor=Y.-J.+Luoauthor=Y.-S.+Xiongauthor=Y.+Yuauthor=Z.-C.+Tuauthor=Z.-J.+Longauthor=X.-J.+Laiauthor=H.-X.+Chenauthor=Y.+Luoauthor=J.+Wengauthor=G.+Lu&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Substituted+Pyrimidines+as+Potential+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00235"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00235%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-Q.%26aulast%3DLuo%26aufirst%3DY.-J.%26aulast%3DXiong%26aufirst%3DY.-S.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLong%26aufirst%3DZ.-J.%26aulast%3DLai%26aufirst%3DX.-J.%26aulast%3DChen%26aufirst%3DH.-X.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWeng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Substituted%2520Pyrimidines%2520as%2520Potential%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D15%26spage%3D7268%26epage%3D7274%26doi%3D10.1021%2Facs.jmedchem.6b00235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delos Santos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khafizova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1021/jm901830p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901830p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2636-2645&issue=6&author=A.+M.+Venkatesanauthor=C.+M.+Dehnhardtauthor=E.+Delos+Santosauthor=Z.+Chenauthor=O.+Dos+Santosauthor=S.+Ayral-Kaloustianauthor=G.+Khafizovaauthor=N.+Brooijmansauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=K.+Yuauthor=J.+Gibbonsauthor=R.+T.+Abrahamauthor=I.+Chaudharyauthor=T.+S.+Mansour&title=Bis%28Morpholino-1%2C3%2C5-Triazine%29+Derivatives%3A+Potent+Adenosine+5%E2%80%B2-Triphosphate+Competitive+Phosphatidylinositol-3-Kinase%2FMammalian+Target+of+Rapamycin+Inhibitors%3A+Discovery+of+Compound+26+%28PKI-587%29%2C+a+Highly+Efficacious+Dual+Inhibitor&doi=10.1021%2Fjm901830p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm901830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901830p%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDos%2BSantos%26aufirst%3DO.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DKhafizova%26aufirst%3DG.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DBis%2528Morpholino-1%252C3%252C5-Triazine%2529%2520Derivatives%253A%2520Potent%2520Adenosine%25205%25E2%2580%25B2-Triphosphate%2520Competitive%2520Phosphatidylinositol-3-Kinase%252FMammalian%2520Target%2520of%2520Rapamycin%2520Inhibitors%253A%2520Discovery%2520of%2520Compound%252026%2520%2528PKI-587%2529%252C%2520a%2520Highly%2520Efficacious%2520Dual%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D6%26spage%3D2636%26epage%3D2645%26doi%3D10.1021%2Fjm901830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delos Santos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1021/jm9014982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9014982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=798-810&issue=2&author=C.+M.+Dehnhardtauthor=A.+M.+Venkatesanauthor=E.+Delos+Santosauthor=Z.+Chenauthor=O.+Santosauthor=S.+Ayral-Kaloustianauthor=N.+Brooijmansauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=I.+Chaudharyauthor=K.+Yuauthor=J.+Gibbonsauthor=R.+Abrahamauthor=T.+S.+Mansour&title=Lead+Optimization+of+N-3-Substituted+7-Morpholinotriazolopyrimidines+as+Dual+Phosphoinositide+3-Kinase%2FMammalian+Target+of+Rapamycin+Inhibitors%3A+Discovery+of+PKI-402&doi=10.1021%2Fjm9014982"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm9014982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9014982%26sid%3Dliteratum%253Aachs%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSantos%26aufirst%3DO.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DLead%2520Optimization%2520of%2520N-3-Substituted%25207-Morpholinotriazolopyrimidines%2520as%2520Dual%2520Phosphoinositide%25203-Kinase%252FMammalian%2520Target%2520of%2520Rapamycin%2520Inhibitors%253A%2520Discovery%2520of%2520PKI-402%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D2%26spage%3D798%26epage%3D810%26doi%3D10.1021%2Fjm9014982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span> <span> </span><span class="NLM_article-title">Regioselective Synthesis of 5- and 6-Methoxybenzimidazole-1,3,5-Triazines as Inhibitors of Phosphoinositide 3-Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">802</span>– <span class="NLM_lpage">805</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.11.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=802-805&issue=3&author=M.+S.+Millerauthor=J.-A.+Pinsonauthor=Z.+Zhengauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=Regioselective+Synthesis+of+5-+and+6-Methoxybenzimidazole-1%2C3%2C5-Triazines+as+Inhibitors+of+Phosphoinositide+3-Kinase&doi=10.1016%2Fj.bmcl.2012.11.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DRegioselective%2520Synthesis%2520of%25205-%2520and%25206-Methoxybenzimidazole-1%252C3%252C5-Triazines%2520as%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D802%26epage%3D805%26doi%3D10.1016%2Fj.bmcl.2012.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountford, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Künzli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span> <span> </span><span class="NLM_article-title">Development of Single and Mixed Isoform Selectivity PI3Kδ Inhibitors by Targeting Asn836 of PI3Kδ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4794</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.08.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4790-4794&issue=19&author=M.+S.+Millerauthor=S.+J.+Mountfordauthor=J.-A.+Pinsonauthor=Z.+Zhengauthor=M.+K%C3%BCnzliauthor=V.+Patelauthor=S.+J.+Hoggauthor=J.+Shorttauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=Development+of+Single+and+Mixed+Isoform+Selectivity+PI3K%CE%B4+Inhibitors+by+Targeting+Asn836+of+PI3K%CE%B4&doi=10.1016%2Fj.bmcl.2016.08.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DMountford%26aufirst%3DS.%2BJ.%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DK%25C3%25BCnzli%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DHogg%26aufirst%3DS.%2BJ.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DDevelopment%2520of%2520Single%2520and%2520Mixed%2520Isoform%2520Selectivity%2520PI3K%25CE%25B4%2520Inhibitors%2520by%2520Targeting%2520Asn836%2520of%2520PI3K%25CE%25B4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D19%26spage%3D4790%26epage%3D4794%26doi%3D10.1016%2Fj.bmcl.2016.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span> <span> </span><span class="NLM_article-title">L-Aminoacyl-Triazine Derivatives Are Isoform-Selective PI3Kβ Inhibitors That Target Nonconserved Asp862 of PI3Kβ</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1021/ml300336j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300336j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=206-210&issue=2&author=J.-A.+Pinsonauthor=Z.+Zhengauthor=M.+S.+Millerauthor=D.+K.+Chalmersauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=L-Aminoacyl-Triazine+Derivatives+Are+Isoform-Selective+PI3K%CE%B2+Inhibitors+That+Target+Nonconserved+Asp862+of+PI3K%CE%B2&doi=10.1021%2Fml300336j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fml300336j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300336j%26sid%3Dliteratum%253Aachs%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DL-Aminoacyl-Triazine%2520Derivatives%2520Are%2520Isoform-Selective%2520PI3K%25CE%25B2%2520Inhibitors%2520That%2520Target%2520Nonconserved%2520Asp862%2520of%2520PI3K%25CE%25B2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D2%26spage%3D206%26epage%3D210%26doi%3D10.1021%2Fml300336j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollinger, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuila, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahinj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhumkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00322</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00322" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1190-1194&issue=12&author=S.+Dugarauthor=F.+P.+Hollingerauthor=D.+Mahajanauthor=S.+Senauthor=B.+Kuilaauthor=R.+Aroraauthor=Y.+Pawarauthor=V.+Shindeauthor=M.+Rahinjauthor=K.+K.+Kapoorauthor=R.+Bhumkarauthor=S.+Raiauthor=R.+Kulkarni&title=Discovery+of+Novel+and+Orally+Bioavailable+Inhibitors+of+PI3+Kinase+Based+on+Indazole+Substituted+Morpholino-Triazines&doi=10.1021%2Facsmedchemlett.5b00322"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00322%26sid%3Dliteratum%253Aachs%26aulast%3DDugar%26aufirst%3DS.%26aulast%3DHollinger%26aufirst%3DF.%2BP.%26aulast%3DMahajan%26aufirst%3DD.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DKuila%26aufirst%3DB.%26aulast%3DArora%26aufirst%3DR.%26aulast%3DPawar%26aufirst%3DY.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DRahinj%26aufirst%3DM.%26aulast%3DKapoor%26aufirst%3DK.%2BK.%26aulast%3DBhumkar%26aufirst%3DR.%26aulast%3DRai%26aufirst%3DS.%26aulast%3DKulkarni%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520Novel%2520and%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520PI3%2520Kinase%2520Based%2520on%2520Indazole%2520Substituted%2520Morpholino-Triazines%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D12%26spage%3D1190%26epage%3D1194%26doi%3D10.1021%2Facsmedchemlett.5b00322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamage, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giddens, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, S. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Sulfonamide Analogues of the Phosphatidylinositol 3-Kinase Inhibitor ZSTK474</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5859</span>– <span class="NLM_lpage">5874</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2017.09.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5859-5874&issue=20&author=S.+A.+Gamageauthor=A.+C.+Giddensauthor=K.+Y.+Tsangauthor=J.+U.+Flanaganauthor=J.+D.+Kendallauthor=W.-J.+Leeauthor=B.+C.+Baguleyauthor=C.+M.+Buchananauthor=S.+M.+F.+Jamiesonauthor=P.+R.+Shepherdauthor=W.+A.+Dennyauthor=G.+W.+Rewcastle&title=Synthesis+and+Biological+Evaluation+of+Sulfonamide+Analogues+of+the+Phosphatidylinositol+3-Kinase+Inhibitor+ZSTK474&doi=10.1016%2Fj.bmc.2017.09.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DGamage%26aufirst%3DS.%2BA.%26aulast%3DGiddens%26aufirst%3DA.%2BC.%26aulast%3DTsang%26aufirst%3DK.%2BY.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DBuchanan%26aufirst%3DC.%2BM.%26aulast%3DJamieson%26aufirst%3DS.%2BM.%2BF.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Sulfonamide%2520Analogues%2520of%2520the%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%2520ZSTK474%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5859%26epage%3D5874%26doi%3D10.1016%2Fj.bmc.2017.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and Biological Activity of a Novel Class I PI3K Inhibitor, CH5132799</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1772</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.01.065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1767-1772&issue=6&author=J.+Ohwadaauthor=H.+Ebiikeauthor=H.+Kawadaauthor=M.+Tsukazakiauthor=M.+Nakamuraauthor=T.+Miyazakiauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=O.+Kondohauthor=S.+Kuramotoauthor=K.+Ogawaauthor=Y.+Aokiauthor=N.+Shimma&title=Discovery+and+Biological+Activity+of+a+Novel+Class+I+PI3K+Inhibitor%2C+CH5132799&doi=10.1016%2Fj.bmcl.2011.01.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DKuramoto%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DShimma%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520Biological%2520Activity%2520of%2520a%2520Novel%2520Class%2520I%2520PI3K%2520Inhibitor%252C%2520CH5132799%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D6%26spage%3D1767%26epage%3D1772%26doi%3D10.1016%2Fj.bmcl.2011.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of a Dihydropyrrolopyrimidine Inhibitor against Phosphoinositide 3-Kinase (PI3K) to Improve the Phenol Glucuronic Acid Conjugation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.11.112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=673-678&issue=3&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shimmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Lead+Optimization+of+a+Dihydropyrrolopyrimidine+Inhibitor+against+Phosphoinositide+3-Kinase+%28PI3K%29+to+Improve+the+Phenol+Glucuronic+Acid+Conjugation&doi=10.1016%2Fj.bmcl.2012.11.112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.112%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DLead%2520Optimization%2520of%2520a%2520Dihydropyrrolopyrimidine%2520Inhibitor%2520against%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520to%2520Improve%2520the%2520Phenol%2520Glucuronic%2520Acid%2520Conjugation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D673%26epage%3D678%26doi%3D10.1016%2Fj.bmcl.2012.11.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Modification of a Dihydropyrrolopyrimidine Phosphoinositide 3-Kinase (PI3K) Inhibitor to Improve Oral Bioavailability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7650</span>– <span class="NLM_lpage">7660</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2015.11.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=7650-7660&issue=24&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=S.+Yamamotoauthor=K.+Koyamaauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shinmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Modification+of+a+Dihydropyrrolopyrimidine+Phosphoinositide+3-Kinase+%28PI3K%29+Inhibitor+to+Improve+Oral+Bioavailability&doi=10.1016%2Fj.bmc.2015.11.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShinma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DModification%2520of%2520a%2520Dihydropyrrolopyrimidine%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520Inhibitor%2520to%2520Improve%2520Oral%2520Bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D24%26spage%3D7650%26epage%3D7660%26doi%3D10.1016%2Fj.bmc.2015.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Optimization of the Phenylurea Moiety in a Phosphoinositide 3-Kinase (PI3K) Inhibitor to Improve Water Solubility and the PK Profile by Introducing a Solubilizing Group and Ortho Substituents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2016.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2897-2906&issue=13&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=S.+Yamamotoauthor=K.+Koyamaauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shimmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Optimization+of+the+Phenylurea+Moiety+in+a+Phosphoinositide+3-Kinase+%28PI3K%29+Inhibitor+to+Improve+Water+Solubility+and+the+PK+Profile+by+Introducing+a+Solubilizing+Group+and+Ortho+Substituents&doi=10.1016%2Fj.bmc.2016.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520the%2520Phenylurea%2520Moiety%2520in%2520a%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520Inhibitor%2520to%2520Improve%2520Water%2520Solubility%2520and%2520the%2520PK%2520Profile%2520by%2520Introducing%2520a%2520Solubilizing%2520Group%2520and%2520Ortho%2520Substituents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D13%26spage%3D2897%26epage%3D2906%26doi%3D10.1016%2Fj.bmc.2016.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Bioactivity of 4-(2-Arylpyrido[3′,2′:3,4]Pyrrolo[1,2-f][1,2,4]Triazin-4-Yl) Morpholine Derivatives as Novel PI3K Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.11.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=339-342&issue=1&author=J.+Wangauthor=X.+Wangauthor=Y.+Chenauthor=S.+Chenauthor=G.+Chenauthor=L.+Tongauthor=L.+Mengauthor=Y.+Xieauthor=J.+Dingauthor=C.+Yang&title=Discovery+and+Bioactivity+of+4-%282-Arylpyrido%5B3%E2%80%B2%2C2%E2%80%B2%3A3%2C4%5DPyrrolo%5B1%2C2-f%5D%5B1%2C2%2C4%5DTriazin-4-Yl%29+Morpholine+Derivatives+as+Novel+PI3K+Inhibitors&doi=10.1016%2Fj.bmcl.2011.11.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520Bioactivity%2520of%25204-%25282-Arylpyrido%255B3%25E2%2580%25B2%252C2%25E2%2580%25B2%253A3%252C4%255DPyrrolo%255B1%252C2-f%255D%255B1%252C2%252C4%255DTriazin-4-Yl%2529%2520Morpholine%2520Derivatives%2520as%2520Novel%2520PI3K%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D1%26spage%3D339%26epage%3D342%26doi%3D10.1016%2Fj.bmcl.2011.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez
González, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Arístegui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González Cantalapiedra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez Hergueta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarrán, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebriá, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendón, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrián, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span> <span> </span><span class="NLM_article-title">Generation of Tricyclic Imidazo[1,2- a ]Pyrazines as Novel PI3K Inhibitors by Application of a Conformational Restriction Strategy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2536</span>– <span class="NLM_lpage">2543</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.03.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2536-2543&issue=11&author=S.+Mart%C3%ADnez%0AGonz%C3%A1lezauthor=S.+Rodr%C3%ADguez-Ar%C3%ADsteguiauthor=A.+I.+Hern%C3%A1ndezauthor=C.+Varelaauthor=E.+Gonz%C3%A1lez+Cantalapiedraauthor=R.+M.+%C3%81lvarezauthor=A.+Rodr%C3%ADguez+Herguetaauthor=J.+R.+Bischoffauthor=M.+I.+Albarr%C3%A1nauthor=A.+Cebri%C3%A1author=E.+Cend%C3%B3nauthor=D.+Cebri%C3%A1nauthor=P.+Alfonsoauthor=J.+Pastor&title=Generation+of+Tricyclic+Imidazo%5B1%2C2-+a+%5DPyrazines+as+Novel+PI3K+Inhibitors+by+Application+of+a+Conformational+Restriction+Strategy&doi=10.1016%2Fj.bmcl.2017.03.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.090%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez%2BGonz%25C3%25A1lez%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-Ar%25C3%25ADstegui%26aufirst%3DS.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DA.%2BI.%26aulast%3DVarela%26aufirst%3DC.%26aulast%3DGonz%25C3%25A1lez%2BCantalapiedra%26aufirst%3DE.%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%2BM.%26aulast%3DRodr%25C3%25ADguez%2BHergueta%26aufirst%3DA.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26aulast%3DAlbarr%25C3%25A1n%26aufirst%3DM.%2BI.%26aulast%3DCebri%25C3%25A1%26aufirst%3DA.%26aulast%3DCend%25C3%25B3n%26aufirst%3DE.%26aulast%3DCebri%25C3%25A1n%26aufirst%3DD.%26aulast%3DAlfonso%26aufirst%3DP.%26aulast%3DPastor%26aufirst%3DJ.%26atitle%3DGeneration%2520of%2520Tricyclic%2520Imidazo%255B1%252C2-%2520a%2520%255DPyrazines%2520as%2520Novel%2520PI3K%2520Inhibitors%2520by%2520Application%2520of%2520a%2520Conformational%2520Restriction%2520Strategy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2536%26epage%3D2543%26doi%3D10.1016%2Fj.bmcl.2017.03.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez
González, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Lima, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarrán, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebriá, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Encinas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Arocha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrián, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Aparicio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel PI3K Inhibitors through a Scaffold Hopping Strategy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4794</span>– <span class="NLM_lpage">4799</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.09.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.09.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4794-4799&issue=21&author=S.+Mart%C3%ADnez%0AGonz%C3%A1lezauthor=A.+I.+Hern%C3%A1ndezauthor=R.+M.+%C3%81lvarezauthor=A.+Rodr%C3%ADguezauthor=F.+Ramos-Limaauthor=J.+R.+Bischoffauthor=M.+I.+Albarr%C3%A1nauthor=A.+Cebri%C3%A1author=E.+Hern%C3%A1ndez-Encinasauthor=J.+Garc%C3%ADa-Arochaauthor=D.+Cebri%C3%A1nauthor=C.+Blanco-Aparicioauthor=J.+Pastor&title=Identification+of+Novel+PI3K+Inhibitors+through+a+Scaffold+Hopping+Strategy&doi=10.1016%2Fj.bmcl.2017.09.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.09.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.09.059%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez%2BGonz%25C3%25A1lez%26aufirst%3DS.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DA.%2BI.%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%2BM.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DA.%26aulast%3DRamos-Lima%26aufirst%3DF.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26aulast%3DAlbarr%25C3%25A1n%26aufirst%3DM.%2BI.%26aulast%3DCebri%25C3%25A1%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez-Encinas%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa-Arocha%26aufirst%3DJ.%26aulast%3DCebri%25C3%25A1n%26aufirst%3DD.%26aulast%3DBlanco-Aparicio%26aufirst%3DC.%26aulast%3DPastor%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520Novel%2520PI3K%2520Inhibitors%2520through%2520a%2520Scaffold%2520Hopping%2520Strategy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D21%26spage%3D4794%26epage%3D4799%26doi%3D10.1016%2Fj.bmcl.2017.09.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhavsar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medikonda, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1021/jm3008745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=712-721&issue=3&author=M.+Nachtauthor=L.+Qiaoauthor=M.+P.+Sheetsauthor=T.+St.+Martinauthor=M.+Labenskiauthor=H.+Mazdiyasniauthor=R.+Karpauthor=Z.+Zhuauthor=P.+Chaturvediauthor=D.+Bhavsarauthor=D.+Niuauthor=W.+Westlinauthor=R.+C.+Petterauthor=A.+P.+Medikondaauthor=J.+Singh&title=Discovery+of+a+Potent+and+Isoform-Selective+Targeted+Covalent+Inhibitor+of+the+Lipid+Kinase+PI3K%CE%B1&doi=10.1021%2Fjm3008745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm3008745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008745%26sid%3Dliteratum%253Aachs%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DSheets%26aufirst%3DM.%2BP.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DBhavsar%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DMedikonda%26aufirst%3DA.%2BP.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Isoform-Selective%2520Targeted%2520Covalent%2520Inhibitor%2520of%2520the%2520Lipid%2520Kinase%2520PI3K%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D3%26spage%3D712%26epage%3D721%26doi%3D10.1021%2Fjm3008745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saurat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Tauzia, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colliandre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akssira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corlu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bénédetti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/MTOR Dual Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1021/jm401138v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401138v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=613-631&issue=3&author=T.+Sauratauthor=F.+Buronauthor=N.+Rodriguesauthor=M.-L.+de+Tauziaauthor=L.+Colliandreauthor=S.+Bourgauthor=P.+Bonnetauthor=G.+Guillaumetauthor=M.+Akssiraauthor=A.+Corluauthor=C.+Guillouzoauthor=P.+Berthierauthor=P.+Rioauthor=M.-L.+Jourdanauthor=H.+B%C3%A9n%C3%A9dettiauthor=S.+Routier&title=Design%2C+Synthesis%2C+and+Biological+Activity+of+Pyridopyrimidine+Scaffolds+as+Novel+PI3K%2FMTOR+Dual+Inhibitors&doi=10.1021%2Fjm401138v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors</span></div><div class="casAuthors">Saurat, Thibault; Buron, Frederic; Rodrigues, Nuno; de Tauzia, Marie-Ludivine; Colliandre, Lionel; Bourg, Stephane; Bonnet, Pascal; Guillaumet, Gerald; Akssira, Mohamed; Corlu, Anne; Guillouzo, Christiane; Berthier, Pauline; Rio, Pascale; Jourdan, Marie-Lise; Benedetti, Helene; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">613-631</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and screening of dual PI3K/mTOR inhibitors that gave nanomolar enzymic and cellular activities on both targets with an acceptable kinase selectivity profile are described.  A docking study was performed to understand the binding mode of the compds. and to explain the differences in biol. activity.  In addn., cellular effects of the best dual inhibitors were detd. on six cancer cell lines and compared to those on a healthy diploid cell line for cellular cytotoxicity.  Two compds. are highly potent on cancer cells in the submicromolar range without any toxicity on healthy cells.  A more detailed anal. of the cellular effect of these PI3K/mTOR dual inhibitors demonstrated that they induce G1-phase cell cycle arrest in breast cancer cells and trigger apoptosis.  These compds. show an interesting kinase profile as dual PI3K/mTOR tool compds. or as a chem. series for further optimization to progress into in vivo expts.  Compd. I was found to display the most interesting pharmacol. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZi2SpToKDBrVg90H21EOLACvtfcHk0lj12l0-3xUJ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtrrE&md5=4ca2c231e2fd5289704aa7eb4ef79cce</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm401138v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401138v%26sid%3Dliteratum%253Aachs%26aulast%3DSaurat%26aufirst%3DT.%26aulast%3DBuron%26aufirst%3DF.%26aulast%3DRodrigues%26aufirst%3DN.%26aulast%3Dde%2BTauzia%26aufirst%3DM.-L.%26aulast%3DColliandre%26aufirst%3DL.%26aulast%3DBourg%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DCorlu%26aufirst%3DA.%26aulast%3DGuillouzo%26aufirst%3DC.%26aulast%3DBerthier%26aufirst%3DP.%26aulast%3DRio%26aufirst%3DP.%26aulast%3DJourdan%26aufirst%3DM.-L.%26aulast%3DB%25C3%25A9n%25C3%25A9detti%26aufirst%3DH.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Activity%2520of%2520Pyridopyrimidine%2520Scaffolds%2520as%2520Novel%2520PI3K%252FMTOR%2520Dual%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D613%26epage%3D631%26doi%3D10.1021%2Fjm401138v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollinger, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuila, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Pyrrolotriazine Based Molecules as PI3 Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3142</span>– <span class="NLM_lpage">3146</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2015.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3142-3146&issue=16&author=S.+Dugarauthor=F.+P.+Hollingerauthor=B.+Kuilaauthor=R.+Aroraauthor=S.+Senauthor=D.+Mahajan&title=Synthesis+and+Evaluation+of+Pyrrolotriazine+Based+Molecules+as+PI3+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2015.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DDugar%26aufirst%3DS.%26aulast%3DHollinger%26aufirst%3DF.%2BP.%26aulast%3DKuila%26aufirst%3DB.%26aulast%3DArora%26aufirst%3DR.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Pyrrolotriazine%2520Based%2520Molecules%2520as%2520PI3%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D16%26spage%3D3142%26epage%3D3146%26doi%3D10.1016%2Fj.bmcl.2015.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antitumor Activities Evaluation of M-(4-Morpholinoquinazolin-2-Yl)Benzamides in Vitro and in Vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.04.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2015.04.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=25911625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslels7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=382-395&author=X.-M.+Wangauthor=M.-H.+Xinauthor=J.+Xuauthor=B.-R.+Kangauthor=Y.+Liauthor=S.-M.+Luauthor=S.-Q.+Zhang&title=Synthesis+and+Antitumor+Activities+Evaluation+of+M-%284-Morpholinoquinazolin-2-Yl%29Benzamides+in+Vitro+and+in+Vivo&doi=10.1016%2Fj.ejmech.2015.04.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo</span></div><div class="casAuthors">Wang, Xiao-Meng; Xin, Min-Hang; Xu, Jing; Kang, Bo-Rui; Li, Yan; Lu, She-Min; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">382-395</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the present study, a series of m-(4-morpholinoquinazolin-2-yl)benzamides were designed, synthesized, and characterized.  The antiproliferative activities of the synthesized compds. were evaluated against two human cell lines (HCT-116 and MCF-7).  Compds. with IC50 values below 4 μM were further evaluated against U-87 MG and A549 cell lines.  Among these evaluated compds., compd. I displayed a remarkable antiproliferative effect in vitro.  The hoechst staining assay showed that compd. I caused morphol. changes.  The cell cycle and apoptosis assay further indicated that compd. I can arrest HCT-116 cells in G2/M and G0/G1 phase and induce apoptosis.  PI3K enzyme assays indicated that compds. I and II selectively inhibit PI3Kα.  A Western bolt assay further suggested that compd. I can block the PI3K/Akt/mTOR pathway.  Moreover, compd. I inhibited tumor growth on a mice S180 homograft model.  These findings directly identify m-(4-morpholinoquinazolin-2-yl)benzamide derivs. as novel anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBXC2Y2RqANbVg90H21EOLACvtfcHk0lj12l0-3xUJ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslels7o%253D&md5=45220465aa034e09de8288d3f94dded7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.037%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-M.%26aulast%3DXin%26aufirst%3DM.-H.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DB.-R.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DS.-M.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activities%2520Evaluation%2520of%2520M-%25284-Morpholinoquinazolin-2-Yl%2529Benzamides%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D96%26spage%3D382%26epage%3D395%26doi%3D10.1016%2Fj.ejmech.2015.04.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]Pyrimidine Derivatives Bearing Pyrazoline Scaffold</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1870</span>, <span class="refDoi"> DOI: 10.3390/molecules22111870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3390%2Fmolecules22111870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1870&issue=11&author=Q.+Wangauthor=X.+Liauthor=C.+Sunauthor=B.+Zhangauthor=P.+Zhengauthor=W.+Zhuauthor=S.+Xu&title=Synthesis+and+Structure%E2%80%93Activity+Relationships+of+4-Morpholino-7%2C8-Dihydro-5H-Thiopyrano%5B4%2C3-d%5DPyrimidine+Derivatives+Bearing+Pyrazoline+Scaffold&doi=10.3390%2Fmolecules22111870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22111870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22111870%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%25204-Morpholino-7%252C8-Dihydro-5H-Thiopyrano%255B4%252C3-d%255DPyrimidine%2520Derivatives%2520Bearing%2520Pyrazoline%2520Scaffold%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D11%26spage%3D1870%26doi%3D10.3390%2Fmolecules22111870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]Pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">310</span>, <span class="refDoi"> DOI: 10.3390/molecules22020310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3390%2Fmolecules22020310" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=310&issue=2&author=S.+Xuauthor=C.+Sunauthor=C.+Chenauthor=P.+Zhengauthor=Y.+Zhouauthor=H.+Zhouauthor=W.+Zhu&title=Synthesis+and+Biological+Evaluation+of+Novel+8-Morpholinoimidazo%5B1%2C2-a%5DPyrazine+Derivatives+Bearing+Phenylpyridine%2FPhenylpyrimidine-Carboxamides&doi=10.3390%2Fmolecules22020310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22020310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22020310%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25208-Morpholinoimidazo%255B1%252C2-a%255DPyrazine%2520Derivatives%2520Bearing%2520Phenylpyridine%252FPhenylpyrimidine-Carboxamides%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D310%26doi%3D10.3390%2Fmolecules22020310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwehm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowedder, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C–C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1534</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01801</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01801" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1534-1554&issue=4&author=C.+Schwehmauthor=B.+Kellamauthor=A.+E.+Garcesauthor=S.+J.+Hillauthor=N.+D.+Kindonauthor=T.+D.+Bradshawauthor=J.+Liauthor=S.+J.+F.+Macdonaldauthor=J.+E.+Rowedderauthor=L.+A.+Stoddartauthor=M.+J.+Stocks&title=Design+and+Elaboration+of+a+Tractable+Tricyclic+Scaffold+To+Synthesize+Druglike+Inhibitors+of+Dipeptidyl+Peptidase-4+%28DPP-4%29%2C+Antagonists+of+the+C%E2%80%93C+Chemokine+Receptor+Type+5+%28CCR5%29%2C+and+Highly+Potent+and+Selective+Phosphoinositol-3+Kinase+%CE%B4+%28PI3K%CE%B4%29+Inhib&doi=10.1021%2Facs.jmedchem.6b01801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01801%26sid%3Dliteratum%253Aachs%26aulast%3DSchwehm%26aufirst%3DC.%26aulast%3DKellam%26aufirst%3DB.%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26aulast%3DKindon%26aufirst%3DN.%2BD.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DRowedder%26aufirst%3DJ.%2BE.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DDesign%2520and%2520Elaboration%2520of%2520a%2520Tractable%2520Tricyclic%2520Scaffold%2520To%2520Synthesize%2520Druglike%2520Inhibitors%2520of%2520Dipeptidyl%2520Peptidase-4%2520%2528DPP-4%2529%252C%2520Antagonists%2520of%2520the%2520C%25E2%2580%2593C%2520Chemokine%2520Receptor%2520Type%25205%2520%2528CCR5%2529%252C%2520and%2520Highly%2520Potent%2520and%2520Selective%2520Phosphoinositol-3%2520Kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520Inhib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1534%26epage%3D1554%26doi%3D10.1021%2Facs.jmedchem.6b01801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1021/ci800429e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800429e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVShs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1025-1032&issue=4&author=T.+J.+Ritchieauthor=C.+N.+Luscombeauthor=S.+J.+F.+Macdonald&title=Analysis+of+the+Calculated+Physicochemical+Properties+of+Respiratory+Drugs%3A+Can+We+Design+for+Inhaled+Drugs+Yet%3F&doi=10.1021%2Fci800429e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?</span></div><div class="casAuthors">Ritchie, Timothy J.; Luscombe, Christopher N.; Macdonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1025-1032</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From an anal. of calcd. physicochem. properties for 81 currently marketed respiratory drugs, compds. administered via the inhaled/intranasal routes have a higher polar surface area, a higher mol. wt., and a trend toward lower lipophilicity, when compared with their orally administered counterparts.  Ranges of physicochem. space are described for the 29 drugs administered by the inhaled or intranasal routes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvP2GM6OuLlrVg90H21EOLACvtfcHk0lgHOU10WJQpYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVShs7w%253D&md5=d85e39ce2ebea1d42be67103edac1b8d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fci800429e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800429e%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DAnalysis%2520of%2520the%2520Calculated%2520Physicochemical%2520Properties%2520of%2520Respiratory%2520Drugs%253A%2520Can%2520We%2520Design%2520for%2520Inhaled%2520Drugs%2520Yet%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D4%26spage%3D1025%26epage%3D1032%26doi%3D10.1021%2Fci800429e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of Pyrrolo[2,1-f][1,2,4]Triazin-4-Amines as Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4260</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.07.047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4256-4260&issue=17&author=R.+S.+Bhideauthor=J.+Neelsauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=S.+Stachuraauthor=C.+Weigeltauthor=J.+S.+Sackauthor=K.+Stefanskiauthor=X.+Guauthor=J.+H.+Xieauthor=C.+B.+Goldstineauthor=S.+Skalaauthor=D.+L.+Pedicordauthor=S.+Rueppauthor=T.+G.+M.+Dharauthor=P.+H.+Carterauthor=L.+M.+Salter-Cidauthor=M.+A.+Possauthor=P.+Davies&title=Discovery+and+SAR+of+Pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5DTriazin-4-Amines+as+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2016.07.047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DGoldstine%26aufirst%3DC.%2BB.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DPedicord%26aufirst%3DD.%2BL.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520Pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255DTriazin-4-Amines%2520as%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4256%26epage%3D4260%26doi%3D10.1016%2Fj.bmcl.2016.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susulic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde-Chinn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosnius, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(3-(Piperazin-1-Yl)Phenyl)Pyrrolo[2,1-f][1,2,4]Triazin-4-Amine Derivatives as Highly Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.01.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=855-861&issue=4&author=L.-Y.+Qinauthor=Z.+Ruanauthor=R.+J.+Cherneyauthor=T.+G.+M.+Dharauthor=J.+Neelsauthor=C.+A.+Weigeltauthor=J.+S.+Sackauthor=A.+S.+Srivastavaauthor=L.+A.+M.+Corneliusauthor=J.+A.+Tinoauthor=K.+Stefanskiauthor=X.+Guauthor=J.+Xieauthor=V.+Susulicauthor=X.+Yangauthor=M.+Yarde-Chinnauthor=S.+Skalaauthor=R.+Bosniusauthor=C.+Goldsteinauthor=P.+Daviesauthor=S.+Rueppauthor=L.+Salter-Cidauthor=R.+S.+Bhideauthor=M.+A.+Poss&title=Discovery+of+7-%283-%28Piperazin-1-Yl%29Phenyl%29Pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5DTriazin-4-Amine+Derivatives+as+Highly+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DSusulic%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYarde-Chinn%26aufirst%3DM.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DBosnius%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26atitle%3DDiscovery%2520of%25207-%25283-%2528Piperazin-1-Yl%2529Phenyl%2529Pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255DTriazin-4-Amine%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D855%26epage%3D861%26doi%3D10.1016%2Fj.bmcl.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J.</span></span> <span> </span><span class="NLM_article-title">Identification of Highly Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2853</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.01.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2849-2853&issue=13&author=D.+Marcouxauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=Q.+Shiauthor=Q.+Ruanauthor=C.+Weigeltauthor=H.+Qiuauthor=G.+Schievenauthor=J.+Hynesauthor=R.+Bhideauthor=M.+Possauthor=J.+Tino&title=Identification+of+Highly+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.01.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.077%26sid%3Dliteratum%253Aachs%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DSchieven%26aufirst%3DG.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%26aulast%3DPoss%26aufirst%3DM.%26aulast%3DTino%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520Highly%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D13%26spage%3D2849%26epage%3D2853%26doi%3D10.1016%2Fj.bmcl.2017.01.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin-Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fancher, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RP, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajareddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5193</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5193-5208&issue=12&author=Q.+Liuauthor=Q.+Shiauthor=D.+Marcouxauthor=D.+G.+Battauthor=L.+Corneliusauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=J.+Neelsauthor=M.+Beaudoin-Bertrandauthor=A.+S.+Srivastavaauthor=L.+Liauthor=R.+J.+Cherneyauthor=H.+Gongauthor=S.+H.+Wattersonauthor=C.+Weigeltauthor=K.+M.+Gilloolyauthor=K.+W.+McIntyreauthor=J.+H.+Xieauthor=M.+T.+Obermeierauthor=A.+Furaauthor=B.+Sleczkaauthor=K.+Stefanskiauthor=R.+M.+Fancherauthor=S.+Padmanabhanauthor=T.+RPauthor=I.+Kunduauthor=K.+Rajareddyauthor=R.+Smithauthor=J.+K.+Hennanauthor=D.+Xingauthor=J.+Fanauthor=P.+C.+Levesqueauthor=Q.+Ruanauthor=S.+Pittauthor=R.+Zhangauthor=D.+Pedicordauthor=J.+Panauthor=M.+Yardeauthor=H.+Luauthor=J.+Lippyauthor=C.+Goldstineauthor=S.+Skalaauthor=R.+A.+Rampullaauthor=A.+Mathurauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=M.+E.+Cvijicauthor=L.+M.+Salter-Cidauthor=R.+S.+Bhideauthor=M.+A.+Possauthor=J.+Hynesauthor=P.+H.+Carterauthor=J.+E.+Macorauthor=S.+Rueppauthor=G.+L.+Schievenauthor=J.+A.+Tino&title=Identification+of+a+Potent%2C+Selective%2C+and+Efficacious+Phosphatidylinositol+3-Kinase+%CE%B4+%28PI3K%CE%B4%29+Inhibitor+for+the+Treatment+of+Immunological+Disorders&doi=10.1021%2Facs.jmedchem.7b00618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00618%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DCornelius%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DBeaudoin-Bertrand%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DFancher%26aufirst%3DR.%2BM.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DRP%26aufirst%3DT.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DRajareddy%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DHennan%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DGoldstine%26aufirst%3DC.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DRampulla%26aufirst%3DR.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Phosphatidylinositol%25203-Kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Immunological%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D5193%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.7b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Be, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPont, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubinska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkel, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Triazine-Benzimidazoles as Selective Inhibitors of MTOR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2070</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2064-2070&issue=7&author=E.+A.+Petersonauthor=P.+S.+Andrewsauthor=X.+Beauthor=A.+A.+Boezioauthor=T.+L.+Bushauthor=A.+C.+Chengauthor=J.+R.+Coatsauthor=A.+E.+Collettiauthor=K.+W.+Copelandauthor=M.+DuPontauthor=R.+Graceffaauthor=B.+Grubinskaauthor=J.-C.+Harmangeauthor=J.+L.+Kimauthor=E.+L.+Mulladyauthor=P.+Olivieriauthor=L.+B.+Schenkelauthor=M.+K.+Stantonauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=T.+Caiauthor=D.+S.+La&title=Discovery+of+Triazine-Benzimidazoles+as+Selective+Inhibitors+of+MTOR&doi=10.1016%2Fj.bmcl.2011.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DBe%26aufirst%3DX.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCoats%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDuPont%26aufirst%3DM.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGrubinska%26aufirst%3DB.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DOlivieri%26aufirst%3DP.%26aulast%3DSchenkel%26aufirst%3DL.%2BB.%26aulast%3DStanton%26aufirst%3DM.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DLa%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520of%2520Triazine-Benzimidazoles%2520as%2520Selective%2520Inhibitors%2520of%2520MTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D2064%26epage%3D2070%26doi%3D10.1016%2Fj.bmcl.2011.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5188</span>– <span class="NLM_lpage">5219</span>, <span class="refDoi"> DOI: 10.1021/jm300184s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300184s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5188-5219&issue=11&author=A.+L.+Smithauthor=N.+D.+D%E2%80%99Angeloauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=V.+J.+Ceeauthor=B.+Herberichauthor=F.-T.+Hongauthor=C.+L.+M.+Jacksonauthor=B.+A.+Lanmanauthor=L.+Liuauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=S.+Tadesseauthor=N.+A.+Tamayoauthor=R.+P.+Wurzauthor=K.+Yangauthor=K.+L.+Andrewsauthor=D.+A.+Whittingtonauthor=J.+D.+McCarterauthor=T.+S.+Miguelauthor=L.+Zalamedaauthor=J.+Jiangauthor=R.+Subramanianauthor=E.+L.+Mulladyauthor=S.+Caenepeelauthor=D.+J.+Freemanauthor=L.+Wangauthor=N.+Zhangauthor=T.+Wuauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Structure-Based+Design+of+a+Novel+Series+of+Potent%2C+Selective+Inhibitors+of+the+Class+I+Phosphatidylinositol+3-Kinases&doi=10.1021%2Fjm300184s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm300184s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300184s%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHong%26aufirst%3DF.-T.%26aulast%3DJackson%26aufirst%3DC.%2BL.%2BM.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMiguel%26aufirst%3DT.%2BS.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DStructure-Based%2520Design%2520of%2520a%2520Novel%2520Series%2520of%2520Potent%252C%2520Selective%2520Inhibitors%2520of%2520the%2520Class%2520I%2520Phosphatidylinositol%25203-Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D11%26spage%3D5188%26epage%3D5219%26doi%3D10.1021%2Fjm300184s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amico, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakowec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Dual Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1811</span>, <span class="refDoi"> DOI: 10.1021/jm1014605</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1014605" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1789-1811&issue=6&author=N.+D.+D%E2%80%99Angeloauthor=T.-S.+Kimauthor=K.+Andrewsauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=K.+Chenauthor=D.+D%E2%80%99Amicoauthor=D.+Freemanauthor=J.+Jiangauthor=L.+Liuauthor=J.+D.+McCarterauthor=T.+San+Miguelauthor=E.+L.+Mulladyauthor=M.+Schragauthor=R.+Subramanianauthor=J.+Tangauthor=R.+C.+Wahlauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=T.+Wuauthor=N.+Xiauthor=Y.+Xuauthor=P.+Yakowecauthor=K.+Yangauthor=L.+P.+Zalamedaauthor=N.+Zhangauthor=P.+Hughesauthor=M.+H.+Norman&title=Discovery+and+Optimization+of+a+Series+of+Benzothiazole+Phosphoinositide+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28MTOR%29+Dual+Inhibitors&doi=10.1021%2Fjm1014605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm1014605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014605%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DD.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYakowec%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%2BP.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Series%2520of%2520Benzothiazole%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528MTOR%2529%2520Dual%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D6%26spage%3D1789%26epage%3D1811%26doi%3D10.1021%2Fjm1014605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Dual PI3K/MTOR Inhibitors Based on a 4-Amino-6-Methyl-1,3,5-Triazine Sulfonamide Scaffold</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5714</span>– <span class="NLM_lpage">5720</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.06.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5714-5720&issue=17&author=R.+P.+Wurzauthor=L.+Liuauthor=K.+Yangauthor=N.+Nishimuraauthor=Y.+Boauthor=L.+H.+Pettusauthor=S.+Caenepeelauthor=D.+J.+Freemanauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=T.+San+Miguelauthor=L.+Wangauthor=N.+Zhangauthor=K.+L.+Andrewsauthor=D.+A.+Whittingtonauthor=J.+Jiangauthor=R.+Subramanianauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Synthesis+and+Structure-Activity+Relationships+of+Dual+PI3K%2FMTOR+Inhibitors+Based+on+a+4-Amino-6-Methyl-1%2C3%2C5-Triazine+Sulfonamide+Scaffold&doi=10.1016%2Fj.bmcl.2012.06.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.078%26sid%3Dliteratum%253Aachs%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Dual%2520PI3K%252FMTOR%2520Inhibitors%2520Based%2520on%2520a%25204-Amino-6-Methyl-1%252C3%252C5-Triazine%2520Sulfonamide%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D17%26spage%3D5714%26epage%3D5720%26doi%3D10.1016%2Fj.bmcl.2012.06.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidasani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 [Erratum to Document Cited in CA157:426662]</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7796</span>– <span class="NLM_lpage">7816</span>, <span class="refDoi"> DOI: 10.1021/jm300846z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300846z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7796-7816&issue=17&author=M.+H.+Normanauthor=K.+L.+Andrewsauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=N.+D.+D%E2%80%99Angeloauthor=D.+J.+Freemanauthor=B.+J.+Herberichauthor=F.-T.+Hongauthor=C.+L.+M.+Jacksonauthor=J.+Jiangauthor=B.+A.+Lanmanauthor=L.+Liuauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=T.+San+Miguelauthor=A.+L.+Smithauthor=M.+M.+Stecauthor=S.+Tadesseauthor=A.+Taskerauthor=D.+Aidasaniauthor=X.+Zhuauthor=R.+Subramanianauthor=N.+A.+Tamayoauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=B.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=K.+Yangauthor=L.+Zalamedaauthor=N.+Zhangauthor=P.+E.+Hughes&title=Selective+Class+I+Phosphoinositide+3-Kinase+Inhibitors%3A+Optimization+of+a+Series+of+Pyridyltriazines+Leading+to+the+Identification+of+a+Clinical+Candidate%2C+AMG+511+%5BErratum+to+Document+Cited+in+CA157%3A426662%5D&doi=10.1021%2Fjm300846z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm300846z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300846z%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%2BJ.%26aulast%3DHong%26aufirst%3DF.-T.%26aulast%3DJackson%26aufirst%3DC.%2BL.%2BM.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DAidasani%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DSelective%2520Class%2520I%2520Phosphoinositide%25203-Kinase%2520Inhibitors%253A%2520Optimization%2520of%2520a%2520Series%2520of%2520Pyridyltriazines%2520Leading%2520to%2520the%2520Identification%2520of%2520a%2520Clinical%2520Candidate%252C%2520AMG%2520511%2520%255BErratum%2520to%2520Document%2520Cited%2520in%2520CA157%253A426662%255D%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7796%26epage%3D7816%26doi%3D10.1021%2Fjm300846z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit94b"><span>Erratum cited in  <i>J. Med.
Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume">55</span>, (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8975</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Erratum+cited+in+J.+Med.%0AChem.+2012%2C+55%2C+%2820%29%2C+8975."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Med.%250AChem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3-Kinase Inhibitors: Evaluation of Substituted Alcohols as Replacements for the Piperazine Sulfonamide Portion of AMG 511</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5630</span>– <span class="NLM_lpage">5634</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2014.10.085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5630-5634&issue=24&author=B.%0AA.+Lanmanauthor=A.+B.+Reedauthor=V.+J.+Ceeauthor=F.-T.+Hongauthor=L.+H.+Pettusauthor=R.+P.+Wurzauthor=K.+L.+Andrewsauthor=J.+Jiangauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=T.+San+Miguelauthor=R.+Subramanianauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=T.+Wuauthor=L.+Zalamedaauthor=N.+Zhangauthor=A.+S.+Taskerauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Phosphoinositide-3-Kinase+Inhibitors%3A+Evaluation+of+Substituted+Alcohols+as+Replacements+for+the+Piperazine+Sulfonamide+Portion+of+AMG+511&doi=10.1016%2Fj.bmcl.2014.10.085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.085%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DHong%26aufirst%3DF.-T.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DPhosphoinositide-3-Kinase%2520Inhibitors%253A%2520Evaluation%2520of%2520Substituted%2520Alcohols%2520as%2520Replacements%2520for%2520the%2520Piperazine%2520Sulfonamide%2520Portion%2520of%2520AMG%2520511%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D24%26spage%3D5630%26epage%3D5634%26doi%3D10.1016%2Fj.bmcl.2014.10.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span> <span> </span><span class="NLM_article-title">The Imidazo[1,2-a]Pyridine Ring System as a Scaffold for Potent Dual Phosphoinositide-3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4136</span>– <span class="NLM_lpage">4142</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2015.08.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4136-4142&issue=19&author=M.+M.+Stecauthor=K.+L.+Andrewsauthor=Y.+Boauthor=H.+Liaoauthor=N.+Tamayoauthor=M.+H.+Normanauthor=S.+Caenepeelauthor=L.+Wangauthor=N.+Zhangauthor=P.+E.+Hughesauthor=J.+McCarterauthor=T.+San+Miguelauthor=L.+P.+Zalamedaauthor=E.+L.+Mulladyauthor=R.+Subramanianauthor=D.+A.+Whittingtonauthor=T.+Wu&title=The+Imidazo%5B1%2C2-a%5DPyridine+Ring+System+as+a+Scaffold+for+Potent+Dual+Phosphoinositide-3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28MTOR%29+Inhibitors&doi=10.1016%2Fj.bmcl.2015.08.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DZalameda%26aufirst%3DL.%2BP.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26atitle%3DThe%2520Imidazo%255B1%252C2-a%255DPyridine%2520Ring%2520System%2520as%2520a%2520Scaffold%2520for%2520Potent%2520Dual%2520Phosphoinositide-3-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528MTOR%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4136%26epage%3D4142%26doi%3D10.1016%2Fj.bmcl.2015.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullion, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fracasso, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]Quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1530</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1002%2Fcmdc.201600148" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1517-1530&author=W.+J.+Scottauthor=M.+F.+Hentemannauthor=R.+B.+Rowleyauthor=C.+O.+Bullauthor=S.+Jenkinsauthor=A.+M.+Bullionauthor=J.+Johnsonauthor=A.+Redmanauthor=A.+H.+Robbinsauthor=W.+Eslerauthor=R.+P.+Fracassoauthor=T.+Garrisonauthor=M.+Hamiltonauthor=M.+Michelsauthor=J.+E.+Woodauthor=D.+P.+Wilkieauthor=H.+Xiaoauthor=J.+Levyauthor=E.+Stasikauthor=N.+Liuauthor=M.+Schaeferauthor=M.+Brandsauthor=J.+Lefranc&title=Discovery+and+SAR+of+Novel+2%2C3-Dihydroimidazo%5B1%2C2-c%5DQuinazoline+PI3K+Inhibitors%3A+Identification+of+Copanlisib+%28BAY+80-6946%29&doi=10.1002%2Fcmdc.201600148"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600148%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DW.%2BJ.%26aulast%3DHentemann%26aufirst%3DM.%2BF.%26aulast%3DRowley%26aufirst%3DR.%2BB.%26aulast%3DBull%26aufirst%3DC.%2BO.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DBullion%26aufirst%3DA.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DRedman%26aufirst%3DA.%26aulast%3DRobbins%26aufirst%3DA.%2BH.%26aulast%3DEsler%26aufirst%3DW.%26aulast%3DFracasso%26aufirst%3DR.%2BP.%26aulast%3DGarrison%26aufirst%3DT.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%2BE.%26aulast%3DWilkie%26aufirst%3DD.%2BP.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLevy%26aufirst%3DJ.%26aulast%3DStasik%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DLefranc%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520Novel%25202%252C3-Dihydroimidazo%255B1%252C2-c%255DQuinazoline%2520PI3K%2520Inhibitors%253A%2520Identification%2520of%2520Copanlisib%2520%2528BAY%252080-6946%2529%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1517%26epage%3D1530%26doi%3D10.1002%2Fcmdc.201600148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Copanlisib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2057</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0838-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1007%2Fs40265-017-0838-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2057-2062&issue=18&author=A.+Markham&title=Copanlisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0838-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0838-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0838-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DCopanlisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26issue%3D18%26spage%3D2057%26epage%3D2062%26doi%3D10.1007%2Fs40265-017-0838-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, F. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peña, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genvresse, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Phase I Study of Copanlisib (BAY 80-6946), an Intravenous Pan-Class I Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphomas</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1928</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1093%2Fannonc%2Fmdw282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27672108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1928-1940&issue=10&author=A.+Patnaikauthor=L.+J.+Applemanauthor=A.+W.+Tolcherauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=G.+J.+Weissauthor=J.+C.+Sachdevauthor=M.+Chadhaauthor=M.+Fulkauthor=S.+Ejadiauthor=J.+M.+Mountzauthor=M.+T.+Lotzeauthor=F.+G.+S.+Toledoauthor=E.+Chuauthor=M.+Jeffersauthor=C.+Pe%C3%B1aauthor=C.+Xiaauthor=S.+Reifauthor=I.+Genvresseauthor=R.+K.+Ramanathan&title=First-in-Human+Phase+I+Study+of+Copanlisib+%28BAY+80-6946%29%2C+an+Intravenous+Pan-Class+I+Phosphatidylinositol+3-Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+and+Non-Hodgkin%E2%80%99s+Lymphomas&doi=10.1093%2Fannonc%2Fmdw282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas</span></div><div class="casAuthors">Patnaik A; Tolcher A W; Papadopoulos K P; Beeram M; Rasco D W; Appleman L J; Mountz J M; Lotze M T; Toledo F G S; Chu E; Weiss G J; Sachdev J C; Chadha M; Fulk M; Ejadi S; Ramanathan R K; Jeffers M; Pena C; Xia C; Reif S; Genvresse I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1928-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).  PATIENTS AND METHODS:  Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus.  Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the dose range 0.1-1.2 mg/kg.  Plasma copanlisib levels were analyzed for pharmacokinetics.  Biomarker analysis included PIK3CA, KRAS, BRAF, and PTEN mutational status and PTEN immunohistochemistry.  Whole-body [(18)F]-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) was carried out at baseline and following the first dose to assess early pharmacodynamic effects.  Plasma glucose and insulin levels were evaluated serially.  RESULTS:  Fifty-seven patients received treatment.  The MTD was 0.8 mg/kg copanlisib.  The most frequent treatment-related adverse events were nausea and transient hyperglycemia.  Copanlisib exposure was dose-proportional with no accumulation; peak exposure positively correlated with transient hyperglycemia post-infusion.  Sixteen of 20 patients treated at the MTD had reduced (18)FDG-PET uptake; 7 (33%) had a reduction >25%.  One patient achieved a complete response (CR; endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss) and two had a partial response (PR; both metastatic breast cancer).  Among the nine NHL patients, all six with follicular lymphoma (FL) responded (one CR and five PRs) and one patient with diffuse large B-cell lymphoma had a PR by investigator assessment; two patients with FL who achieved CR (per post hoc independent radiologic review) were on treatment >3 years.  CONCLUSION:  Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg.  Copanlisib exhibited dose-proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with NHL.  CLINICALTRIALSGOV:  NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5iDaGefdSJNFxYDaSSP8XfW6udTcc2eY1lDWQ0tPJ67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D&md5=219db9cc72ca2493834406a977141667</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw282%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DFulk%26aufirst%3DM.%26aulast%3DEjadi%26aufirst%3DS.%26aulast%3DMountz%26aufirst%3DJ.%2BM.%26aulast%3DLotze%26aufirst%3DM.%2BT.%26aulast%3DToledo%26aufirst%3DF.%2BG.%2BS.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DPe%25C3%25B1a%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DReif%26aufirst%3DS.%26aulast%3DGenvresse%26aufirst%3DI.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DFirst-in-Human%2520Phase%2520I%2520Study%2520of%2520Copanlisib%2520%2528BAY%252080-6946%2529%252C%2520an%2520Intravenous%2520Pan-Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520and%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphomas%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3D10%26spage%3D1928%26epage%3D1940%26doi%3D10.1093%2Fannonc%2Fmdw282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&issue=18&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+J.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+Novel+Indazoles+as+Highly+Potent+and+Selective+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B4+for+the+Treatment+of+Respiratory+Disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0ljEOgYtZQcz5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520Novel%2520Indazoles%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520Respiratory%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D18%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunsire, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montembault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leemereise, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinanes-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span> <span> </span><span class="NLM_article-title">Safety, Pharmacokinetics and Dose-Response Characteristics of GSK2269557, an Inhaled PI3Kδ Inhibitor under Development for the Treatment of COPD</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.pupt.2017.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28823947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=69-77&author=A.+Cahnauthor=J.+N.+Hamblinauthor=M.+Beggauthor=R.+Wilsonauthor=L.+Dunsireauthor=S.+Sriskantharajahauthor=M.+Montembaultauthor=C.+N.+Leemereiseauthor=L.+Galinanes-Garciaauthor=H.+Watzauthor=A.+M.+Kirstenauthor=R.+Fuhrauthor=E.+M.+Hessel&title=Safety%2C+Pharmacokinetics+and+Dose-Response+Characteristics+of+GSK2269557%2C+an+Inhaled+PI3K%CE%B4+Inhibitor+under+Development+for+the+Treatment+of+COPD&doi=10.1016%2Fj.pupt.2017.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD</span></div><div class="casAuthors">Cahn, A.; Hamblin, J. N.; Begg, M.; Wilson, R.; Dunsire, L.; Sriskantharajah, S.; Montembault, M.; Leemereise, C. N.; Galinanes-Garcia, L.; Watz, H.; Kirsten, A. M.; Fuhr, R.; Hessel, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">While current therapies reduce symptoms in chronic obstructive pulmonary disease (COPD) patients, substantial unmet need remains and novel treatments are highly desired.  Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase specifically expressed in leukocytes and involved in their recruitment and activation.  This study evaluated the safety, pharmacokinetics (PK) and dose-response characteristics of inhaled GSK2269557, a PI3Kδ inhibitor, in moderate-to-severe COPD patients with stable disease.  In this randomised, double-blind, placebo controlled, parallel group study, patients received once daily inhaled treatment with GSK2269557 1000 μg or placebo for 14 days (Part A, primary aim safety, N = 28 patients).  In part B of the study (primary aim pharmacodynamic dose-response, N = 36 patients), GSK2269557 100, 200, 500, 700, 1000, 2000 μg or placebo was given for 14 days.  In both Part A and B, GSK2269557 was added to the usual maintenance therapy.  Safety, PK assessments and induced sputum collection for cytokine anal. were conducted at baseline and after 7 and 14 days of treatment.  Adverse events (AEs) were monitored throughout.In Part A, mean age was 61.7 years (SD 6.7), 29% were females, and mean FEV1% predicted was 59.7% (SD 11.4)2.  In Part B, mean age was 63.3 years (SD 6.3), 44% were females, and mean FEV1% predicted was 56.5% (SD 11.5)2.  GSK2269557 was well tolerated in both parts of the study; the most commonly reported AEs were cough and headache, with cough being reported with a greater incidence in the GSK2269557 groups vs. placebo (Part A: 19% vs. 14% and Part B: range of 0-80% for different doses vs. 0% on placebo).  No drug-related serious AEs or clin. significant changes in any other safety parameters were reported.  GSK2269557 was rapidly absorbed into plasma following all doses with a max. peak at approx. 2 h.  Following repeat administration, accumulation in plasma was approx. 2-3 fold from Day 1 to Day 7.  At Day 14, relative to placebo, sputum interleukin (IL)-8 and IL-6 levels were reduced on av. by 32% and 29% resp. after inhalation of GSK2269557 1000 μg in Part A.  In Part B, although inhibition of both IL-8 and IL-6 levels was obsd., the levels were variable and there was insufficient evidence to support a monotonic dose-response.  In this study, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients.  Moreover, inhalation of GSK2269557 resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor.  Inhibition of inflammatory cytokines in the airway compartment may contribute to the potential therapeutic benefit of a PI3Kδ inhibitor in chronically inflamed COPD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLev2M055yDLVg90H21EOLACvtfcHk0lj7Z7v5vH_9yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M&md5=bf5733fdf1e02f3804724f1a523c758b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DDunsire%26aufirst%3DL.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DMontembault%26aufirst%3DM.%26aulast%3DLeemereise%26aufirst%3DC.%2BN.%26aulast%3DGalinanes-Garcia%26aufirst%3DL.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DKirsten%26aufirst%3DA.%2BM.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26atitle%3DSafety%252C%2520Pharmacokinetics%2520and%2520Dose-Response%2520Characteristics%2520of%2520GSK2269557%252C%2520an%2520Inhaled%2520PI3K%25CE%25B4%2520Inhibitor%2520under%2520Development%2520for%2520the%2520Treatment%2520of%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.pupt.2017.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Highly Potent PI3K/MTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1021/ml300309h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300309h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=91-97&issue=1&author=H.+Chengauthor=C.+Liauthor=S.+Baileyauthor=S.+M.+Baxiauthor=L.+Gouletauthor=L.+Guoauthor=J.+Hoffmanauthor=Y.+Jiangauthor=T.+O.+Johnsonauthor=T.+W.+Johnsonauthor=D.+R.+Knightonauthor=J.+Liauthor=K.+K.-C.+Liuauthor=Z.+Liuauthor=M.+A.+Marxauthor=M.+Wallsauthor=P.+A.+Wellsauthor=M.-J.+Yinauthor=J.+Zhuauthor=M.+Zientek&title=Discovery+of+the+Highly+Potent+PI3K%2FMTOR+Dual+Inhibitor+PF-04979064+through+Structure-Based+Drug+Design&doi=10.1021%2Fml300309h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design</span></div><div class="casAuthors">Cheng, Hengmiao; Li, Chunze; Bailey, Simon; Baxi, Sangita M.; Goulet, Lance; Guo, Lisa; Hoffman, Jacqui; Jiang, Ying; Johnson, Theodore Otto; Johnson, Ted W.; Knighton, Daniel R.; Li, John; Liu, Kevin K.-C.; Liu, Zhengyu; Marx, Matthew A.; Walls, Marlena; Wells, Peter A.; Yin, Min-Jean; Zhu, Jinjiang; Zientek, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-97</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncol.  To search for a structurally differentiated back-up candidate to PF-04691502, which is currently in phase I/II clin. trials for treating solid tumors, a lead optimization effort was carried out with a tricyclic imidazo[1,5]naphthyridine series.  Integration of structure-based drug design and phys. properties-based optimization yielded a potent and selective PI3K/mTOR dual kinase inhibitor PF-04979064 (I).  This manuscript discusses the lead optimization for the tricyclic series, which both improved the in vitro potency and addressed a no. of ADMET issues including high metabolic clearance mediated by both P 450 and aldehyde oxidase (AO), poor permeability, and poor soly.  An empirical scaling tool was developed to predict human clearance from in vitro human liver S9 assay data for tricyclic derivs. that were AO substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsQSJqL-ssP7Vg90H21EOLACvtfcHk0lj7Z7v5vH_9yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I&md5=0059c9c220419aad748b4fcde92c28bb</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fml300309h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300309h%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%2BM.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZientek%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520Highly%2520Potent%2520PI3K%252FMTOR%2520Dual%2520Inhibitor%2520PF-04979064%2520through%2520Structure-Based%2520Drug%2520Design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D91%26epage%3D97%26doi%3D10.1021%2Fml300309h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoegenauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveleau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingworth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=975-980&issue=9&author=K.+Hoegenauerauthor=N.+Soldermannauthor=F.+Zecriauthor=R.+S.+Strangauthor=N.+Graveleauauthor=R.+M.+Wolfauthor=N.+G.+Cookeauthor=A.+B.+Smithauthor=G.+J.+Hollingworthauthor=J.+Blanzauthor=S.+Gutmannauthor=G.+Rummelauthor=A.+Littlewood-Evansauthor=C.+Burkhart&title=Discovery+of+CDZ173+%28Leniolisib%29%2C+Representing+a+Structurally+Novel+Class+of+PI3K+Delta-Selective+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DHoegenauer%26aufirst%3DK.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DZecri%26aufirst%3DF.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DGraveleau%26aufirst%3DN.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DHollingworth%26aufirst%3DG.%2BJ.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DBurkhart%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520CDZ173%2520%2528Leniolisib%2529%252C%2520Representing%2520a%2520Structurally%2520Novel%2520Class%2520of%2520PI3K%2520Delta-Selective%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D975%26epage%3D980%26doi%3D10.1021%2Facsmedchemlett.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoegenauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveleau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingworth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feifel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecri, F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=762-767&issue=8&author=K.+Hoegenauerauthor=N.+Soldermannauthor=F.+Staufferauthor=P.+Furetauthor=N.+Graveleauauthor=A.+B.+Smithauthor=C.+Hebachauthor=G.+J.+Hollingworthauthor=I.+Lewisauthor=S.+Gutmannauthor=G.+Rummelauthor=M.+Knappauthor=R.+M.+Wolfauthor=J.+Blanzauthor=R.+Feifelauthor=C.+Burkhartauthor=F.+Zecri&title=Discovery+and+Pharmacological+Characterization+of+Novel+Quinazoline-Based+PI3K+Delta-Selective+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00119%26sid%3Dliteratum%253Aachs%26aulast%3DHoegenauer%26aufirst%3DK.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGraveleau%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DHebach%26aufirst%3DC.%26aulast%3DHollingworth%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DFeifel%26aufirst%3DR.%26aulast%3DBurkhart%26aufirst%3DC.%26aulast%3DZecri%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Characterization%2520of%2520Novel%2520Quinazoline-Based%2520PI3K%2520Delta-Selective%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D8%26spage%3D762%26epage%3D767%26doi%3D10.1021%2Facsmedchemlett.6b00119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoegenauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingworth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Matt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haasen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Pyrrolidineoxy-Substituted Heteroaromatics as Potent and Selective PI3K Delta Inhibitors with Improved Physicochemical Properties</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5657</span>– <span class="NLM_lpage">5662</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.10.069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5657-5662&issue=23&author=K.+Hoegenauerauthor=N.+Soldermannauthor=C.+Hebachauthor=G.+J.+Hollingworthauthor=I.+Lewisauthor=A.+von+Mattauthor=A.+B.+Smithauthor=R.+M.+Wolfauthor=R.+Wilckenauthor=F.+Zecriauthor=D.+Haasenauthor=C.+Burkhart&title=Discovery+of+Novel+Pyrrolidineoxy-Substituted+Heteroaromatics+as+Potent+and+Selective+PI3K+Delta+Inhibitors+with+Improved+Physicochemical+Properties&doi=10.1016%2Fj.bmcl.2016.10.069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.069%26sid%3Dliteratum%253Aachs%26aulast%3DHoegenauer%26aufirst%3DK.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DHebach%26aufirst%3DC.%26aulast%3DHollingworth%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3Dvon%2BMatt%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZecri%26aufirst%3DF.%26aulast%3DHaasen%26aufirst%3DD.%26aulast%3DBurkhart%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Novel%2520Pyrrolidineoxy-Substituted%2520Heteroaromatics%2520as%2520Potent%2520and%2520Selective%2520PI3K%2520Delta%2520Inhibitors%2520with%2520Improved%2520Physicochemical%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D23%26spage%3D5657%26epage%3D5662%26doi%3D10.1016%2Fj.bmcl.2016.10.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalm, V. A. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šedivá, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hagen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Buck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pylvaenaeinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span> <span> </span><span class="NLM_article-title">Effective “Activated PI3Kδ Syndrome”-targeted Therapy with the PI3Kδ Inhibitor Leniolisib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2316</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-08-801191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1182%2Fblood-2017-08-801191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2307-2316&issue=21&author=V.+K.+Raoauthor=S.+Websterauthor=V.+A.+S.+H.+Dalmauthor=A.+%C5%A0ediv%C3%A1author=P.+M.+van+Hagenauthor=S.+Hollandauthor=S.+D.+Rosenzweigauthor=A.+D.+Christauthor=B.+Slothauthor=M.+Cabanskiauthor=A.+D.+Joshiauthor=S.+de+Buckauthor=J.+Doucetauthor=D.+Gueriniauthor=C.+Kalisauthor=I.+Pylvaenaeinenauthor=N.+Soldermannauthor=A.+Kashyapauthor=G.+Uzelauthor=M.+J.+Lenardoauthor=D.+D.+Patelauthor=C.+L.+Lucasauthor=C.+Burkhart&title=Effective+%E2%80%9CActivated+PI3K%CE%B4+Syndrome%E2%80%9D-targeted+Therapy+with+the+PI3K%CE%B4+Inhibitor+Leniolisib&doi=10.1182%2Fblood-2017-08-801191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-08-801191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-08-801191%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DWebster%26aufirst%3DS.%26aulast%3DDalm%26aufirst%3DV.%2BA.%2BS.%2BH.%26aulast%3D%25C5%25A0ediv%25C3%25A1%26aufirst%3DA.%26aulast%3Dvan%2BHagen%26aufirst%3DP.%2BM.%26aulast%3DHolland%26aufirst%3DS.%26aulast%3DRosenzweig%26aufirst%3DS.%2BD.%26aulast%3DChrist%26aufirst%3DA.%2BD.%26aulast%3DSloth%26aufirst%3DB.%26aulast%3DCabanski%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DA.%2BD.%26aulast%3Dde%2BBuck%26aufirst%3DS.%26aulast%3DDoucet%26aufirst%3DJ.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DKalis%26aufirst%3DC.%26aulast%3DPylvaenaeinen%26aufirst%3DI.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DKashyap%26aufirst%3DA.%26aulast%3DUzel%26aufirst%3DG.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DPatel%26aufirst%3DD.%2BD.%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DBurkhart%26aufirst%3DC.%26atitle%3DEffective%2520%25E2%2580%259CActivated%2520PI3K%25CE%25B4%2520Syndrome%25E2%2580%259D-targeted%2520Therapy%2520with%2520the%2520PI3K%25CE%25B4%2520Inhibitor%2520Leniolisib%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26issue%3D21%26spage%3D2307%26epage%3D2316%26doi%3D10.1182%2Fblood-2017-08-801191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel 6-Aryl Substituted 4-Anilinequinazoline Derivatives as Potential PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1972</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.03.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1972-1977&issue=9&author=M.+Xinauthor=Y.-Y.+Heiauthor=H.+Zhangauthor=Y.+Shenauthor=S.-Q.+Zhang&title=Design+and+Synthesis+of+Novel+6-Aryl+Substituted+4-Anilinequinazoline+Derivatives+as+Potential+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.03.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DM.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25206-Aryl%2520Substituted%25204-Anilinequinazoline%2520Derivatives%2520as%2520Potential%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D9%26spage%3D1972%26epage%3D1977%26doi%3D10.1016%2Fj.bmcl.2017.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Novel 6-Aryl Substituted 4-Pyrrolidineaminoquinazoline Derivatives as Potent Phosphoinositide 3-Kinase Delta (PI3Kδ) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2040</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2018.03.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2028-2040&issue=8&author=M.+Xinauthor=W.+Duanauthor=Y.+Fengauthor=Y.-Y.+Heiauthor=H.+Zhangauthor=Y.+Shenauthor=H.-Y.+Zhaoauthor=S.+Maoauthor=S.-Q.+Zhang&title=Novel+6-Aryl+Substituted+4-Pyrrolidineaminoquinazoline+Derivatives+as+Potent+Phosphoinositide+3-Kinase+Delta+%28PI3K%CE%B4%29+Inhibitors&doi=10.1016%2Fj.bmc.2018.03.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.-Y.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DNovel%25206-Aryl%2520Substituted%25204-Pyrrolidineaminoquinazoline%2520Derivatives%2520as%2520Potent%2520Phosphoinositide%25203-Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2028%26epage%3D2040%26doi%3D10.1016%2Fj.bmc.2018.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antitumor Activity Evaluation of 4,6-Disubstituted Quinazoline Derivatives as Novel PI3K Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4413</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.08.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4408-4413&issue=18&author=Y.-Y.+Heiauthor=M.+Xinauthor=H.+Zhangauthor=X.-X.+Xieauthor=S.+Maoauthor=S.-Q.+Zhang&title=Synthesis+and+Antitumor+Activity+Evaluation+of+4%2C6-Disubstituted+Quinazoline+Derivatives+as+Novel+PI3K+Inhibitors&doi=10.1016%2Fj.bmcl.2016.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DX.-X.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activity%2520Evaluation%2520of%25204%252C6-Disubstituted%2520Quinazoline%2520Derivatives%2520as%2520Novel%2520PI3K%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D18%26spage%3D4408%26epage%3D4413%26doi%3D10.1016%2Fj.bmcl.2016.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel 6-Aryl Substituted 4-Anilinequinazoline Derivatives as Potential PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1972</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.03.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1972-1977&issue=9&author=M.+Xinauthor=Y.-Y.+Heiauthor=H.+Zhangauthor=Y.+Shenauthor=S.-Q.+Zhang&title=Design+and+Synthesis+of+Novel+6-Aryl+Substituted+4-Anilinequinazoline+Derivatives+as+Potential+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.03.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DM.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25206-Aryl%2520Substituted%25204-Anilinequinazoline%2520Derivatives%2520as%2520Potential%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D9%26spage%3D1972%26epage%3D1977%26doi%3D10.1016%2Fj.bmcl.2017.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Series of N-(5-(Quinolin-6-Yl)Pyridin-3-Yl)Benzenesulfonamides as PI3K/MTOR Dual Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2017.01.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=509-520&author=J.+Zhangauthor=X.+Lvauthor=X.+Maauthor=Y.+Hu&title=Discovery+of+a+Series+of+N-%285-%28Quinolin-6-Yl%29Pyridin-3-Yl%29Benzenesulfonamides+as+PI3K%2FMTOR+Dual+Inhibitors&doi=10.1016%2Fj.ejmech.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Series%2520of%2520N-%25285-%2528Quinolin-6-Yl%2529Pyridin-3-Yl%2529Benzenesulfonamides%2520as%2520PI3K%252FMTOR%2520Dual%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D509%26epage%3D520%26doi%3D10.1016%2Fj.ejmech.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9205</span>– <span class="NLM_lpage">9221</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9205-9221&issue=22&author=S.+Mahauthor=J.+H.+Parkauthor=H.-Y.+Jungauthor=K.+Ahnauthor=S.+Choiauthor=H.+S.+Taeauthor=K.+H.+Jungauthor=J.+K.+Rhoauthor=J.+C.+Leeauthor=S.-S.+Hongauthor=S.+Hong&title=Identification+of+4-Phenoxyquinoline+Based+Inhibitors+for+L1196M+Mutant+of+Anaplastic+Lymphoma+Kinase+by+Structure-Based+Design&doi=10.1021%2Facs.jmedchem.7b01039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DIdentification%2520of%25204-Phenoxyquinoline%2520Based%2520Inhibitors%2520for%2520L1196M%2520Mutant%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520by%2520Structure-Based%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221%26doi%3D10.1021%2Facs.jmedchem.7b01039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Novel 4-Aminoquinazoline Derivatives Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis via PI3Kα Inhibition</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1675</span>– <span class="NLM_lpage">1685</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2018.02.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1675-1685&issue=8&author=Y.-H.+Fanauthor=H.-W.+Dingauthor=D.-D.+Liuauthor=H.-R.+Songauthor=Y.-N.+Xuauthor=J.+Wang&title=Novel+4-Aminoquinazoline+Derivatives+Induce+Growth+Inhibition%2C+Cell+Cycle+Arrest+and+Apoptosis+via+PI3K%CE%B1+Inhibition&doi=10.1016%2Fj.bmc.2018.02.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.-H.%26aulast%3DDing%26aufirst%3DH.-W.%26aulast%3DLiu%26aufirst%3DD.-D.%26aulast%3DSong%26aufirst%3DH.-R.%26aulast%3DXu%26aufirst%3DY.-N.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DNovel%25204-Aminoquinazoline%2520Derivatives%2520Induce%2520Growth%2520Inhibition%252C%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%2520via%2520PI3K%25CE%25B1%2520Inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1675%26epage%3D1685%26doi%3D10.1016%2Fj.bmc.2018.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwicke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSurdy-Freed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–activity Relationships of Imidazo[1,2-a]Pyrimidin-5(1H)-Ones as a Novel Series of Beta Isoform Selective Phosphatidylinositol 3-Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.01.092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2230-2234&issue=6&author=H.+Linauthor=K.+Erhardauthor=M.+A.+Hardwickeauthor=J.+I.+Luengoauthor=J.+F.+Mackauthor=J.+McSurdy-Freedauthor=R.+Plantauthor=K.+Rahaauthor=C.+M.+Romingerauthor=R.+M.+Sanchezauthor=M.+D.+Schaberauthor=M.+J.+Schulzauthor=M.+D.+Spenglerauthor=R.+Tedescoauthor=R.+Xieauthor=J.+J.+Zengauthor=R.+A.+Rivero&title=Synthesis+and+Structure%E2%80%93activity+Relationships+of+Imidazo%5B1%2C2-a%5DPyrimidin-5%281H%29-Ones+as+a+Novel+Series+of+Beta+Isoform+Selective+Phosphatidylinositol+3-Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2012.01.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.092%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DMack%26aufirst%3DJ.%2BF.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSanchez%26aufirst%3DR.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DSchulz%26aufirst%3DM.%2BJ.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%2BJ.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593activity%2520Relationships%2520of%2520Imidazo%255B1%252C2-a%255DPyrimidin-5%25281H%2529-Ones%2520as%2520a%2520Novel%2520Series%2520of%2520Beta%2520Isoform%2520Selective%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D6%26spage%3D2230%26epage%3D2234%26doi%3D10.1016%2Fj.bmcl.2012.01.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwicke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSurdy-Freed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–activity Relationships of 1,2,4-Triazolo[1,5-a]Pyrimidin-7(3H)-Ones as Novel Series of Potent β Isoform Selective Phosphatidylinositol 3-Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3198</span>– <span class="NLM_lpage">3202</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.03.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3198-3202&issue=9&author=R.+M.+Sanchezauthor=K.+Erhardauthor=M.+A.+Hardwickeauthor=H.+Linauthor=J.+McSurdy-Freedauthor=R.+Plantauthor=K.+Rahaauthor=C.+M.+Romingerauthor=M.+D.+Schaberauthor=M.+D.+Spenglerauthor=M.+L.+Mooreauthor=H.+Yuauthor=J.+I.+Luengoauthor=R.+Tedescoauthor=R.+A.+Rivero&title=Synthesis+and+Structure%E2%80%93activity+Relationships+of+1%2C2%2C4-Triazolo%5B1%2C5-a%5DPyrimidin-7%283H%29-Ones+as+Novel+Series+of+Potent+%CE%B2+Isoform+Selective+Phosphatidylinositol+3-Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2012.03.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DR.%2BM.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DMoore%26aufirst%3DM.%2BL.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593activity%2520Relationships%2520of%25201%252C2%252C4-Triazolo%255B1%252C5-a%255DPyrimidin-7%25283H%2529-Ones%2520as%2520Novel%2520Series%2520of%2520Potent%2520%25CE%25B2%2520Isoform%2520Selective%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D9%26spage%3D3198%26epage%3D3202%26doi%3D10.1016%2Fj.bmcl.2012.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 9-(1-Anilinoethyl)-2-Morpholino-4-Oxo-Pyrido[1,2-a]Pyrimidine-7-Carboxamides as PI3Kβ/δ Inhibitors for the Treatment of PTEN-Deficient Tumours</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3928</span>– <span class="NLM_lpage">3935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2014.06.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3928-3935&issue=16&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=F.+Giordanettoauthor=S.+Greenauthor=T.+Inghardtauthor=L.+Hennequinauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=S.+Passauthor=P.+Pleauthor=T.+Salehauthor=L.+Ward&title=Discovery+of+9-%281-Anilinoethyl%29-2-Morpholino-4-Oxo-Pyrido%5B1%2C2-a%5DPyrimidine-7-Carboxamides+as+PI3K%CE%B2%2F%CE%B4+Inhibitors+for+the+Treatment+of+PTEN-Deficient+Tumours&doi=10.1016%2Fj.bmcl.2014.06.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPass%26aufirst%3DS.%26aulast%3DPle%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25209-%25281-Anilinoethyl%2529-2-Morpholino-4-Oxo-Pyrido%255B1%252C2-a%255DPyrimidine-7-Carboxamides%2520as%2520PI3K%25CE%25B2%252F%25CE%25B4%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520PTEN-Deficient%2520Tumours%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3928%26epage%3D3935%26doi%3D10.1016%2Fj.bmcl.2014.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquet, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Péru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vautier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warin, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-8-(1-(3,5-Difluorophenylamino)Ethyl)-N,N-Dimethyl-2-Morpholino-4-Oxo-4 H-Chromene-6-Carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&issue=2&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=J.-J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.-J.+Pasquetauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-Difluorophenylamino%29Ethyl%29-N%2CN-Dimethyl-2-Morpholino-4-Oxo-4+H-Chromene-6-Carboxamide+%28AZD8186%29%3A+A+Potent+and+Selective+Inhibitor+of+PI3K%CE%B2+and+PI3K%CE%B4+for+the+Treatment+of+PTEN-Deficient+Cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.-J.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.-J.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-Difluorophenylamino%2529Ethyl%2529-N%252CN-Dimethyl-2-Morpholino-4-Oxo-4%2520H-Chromene-6-Carboxamide%2520%2528AZD8186%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520PI3K%25CE%25B2%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520PTEN-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D2%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolekar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span> <span> </span><span class="NLM_article-title">Exploring the Isoform Selectivity of TGX-221 Related Pyrido[1,2- a ]Pyrimidinone-Based Class IA PI 3-Kinase Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3808</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2015.03.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3796-3808&issue=13&author=A.+J.+Marshallauthor=C.+L.+Lillauthor=M.+Chaoauthor=S.+V.+Kolekarauthor=W.-J.+Leeauthor=E.+S.+Marshallauthor=B.+C.+Baguleyauthor=P.+R.+Shepherdauthor=W.+A.+Dennyauthor=J.+U.+Flanaganauthor=G.+W.+Rewcastle&title=Exploring+the+Isoform+Selectivity+of+TGX-221+Related+Pyrido%5B1%2C2-+a+%5DPyrimidinone-Based+Class+IA+PI+3-Kinase+Inhibitors%3A+Synthesis%2C+Biological+Evaluation+and+Molecular+Modelling&doi=10.1016%2Fj.bmc.2015.03.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.073%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DA.%2BJ.%26aulast%3DLill%26aufirst%3DC.%2BL.%26aulast%3DChao%26aufirst%3DM.%26aulast%3DKolekar%26aufirst%3DS.%2BV.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26atitle%3DExploring%2520the%2520Isoform%2520Selectivity%2520of%2520TGX-221%2520Related%2520Pyrido%255B1%252C2-%2520a%2520%255DPyrimidinone-Based%2520Class%2520IA%2520PI%25203-Kinase%2520Inhibitors%253A%2520Synthesis%252C%2520Biological%2520Evaluation%2520and%2520Molecular%2520Modelling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3796%26epage%3D3808%26doi%3D10.1016%2Fj.bmc.2015.03.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wållberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenjans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Morpholino-Pyrimidin-6-One and 4-Morpholino-Pyrimidin-2-One-Containing Phosphoinositide 3-Kinase (PI3K) P110β Isoform Inhibitors through Structure-Based Fragment Optimisation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6665</span>– <span class="NLM_lpage">6670</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.08.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6665-6670&issue=21&author=F.+Giordanettoauthor=A.+W%C3%A5llbergauthor=J.+Casselauthor=S.+Ghosalauthor=M.+Kossenjansauthor=Z.-Q.+Yuanauthor=X.+Wangauthor=L.+Liang&title=Discovery+of+4-Morpholino-Pyrimidin-6-One+and+4-Morpholino-Pyrimidin-2-One-Containing+Phosphoinositide+3-Kinase+%28PI3K%29+P110%CE%B2+Isoform+Inhibitors+through+Structure-Based+Fragment+Optimisation&doi=10.1016%2Fj.bmcl.2012.08.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.101%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DA.%26aulast%3DCassel%26aufirst%3DJ.%26aulast%3DGhosal%26aufirst%3DS.%26aulast%3DKossenjans%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DZ.-Q.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204-Morpholino-Pyrimidin-6-One%2520and%25204-Morpholino-Pyrimidin-2-One-Containing%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520P110%25CE%25B2%2520Isoform%2520Inhibitors%2520through%2520Structure-Based%2520Fragment%2520Optimisation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D21%26spage%3D6665%26epage%3D6670%26doi%3D10.1016%2Fj.bmcl.2012.08.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wållberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliefski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Wachenfeldt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Phosphoinositide 3-Kinases (PI3K) P110β Isoform Inhibitor 4-[2-Hydroxyethyl(1-Naphthylmethyl)Amino]-6-[(2S)-2-Methylmorpholin-4-Yl]-1H-Pyrimidin-2-One, an Effective Antithrombotic Agent without Associated Bleeding and Insulin Resistance</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6671</span>– <span class="NLM_lpage">6676</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.08.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6671-6676&issue=21&author=F.+Giordanettoauthor=A.+W%C3%A5llbergauthor=S.+Ghosalauthor=T.+Iliefskiauthor=J.+Casselauthor=Z.-Q.+Yuanauthor=H.+von+Wachenfeldtauthor=S.+M.+Andersenauthor=T.+Inghardtauthor=A.+Tunekauthor=S.+Nylander&title=Discovery+of+Phosphoinositide+3-Kinases+%28PI3K%29+P110%CE%B2+Isoform+Inhibitor+4-%5B2-Hydroxyethyl%281-Naphthylmethyl%29Amino%5D-6-%5B%282S%29-2-Methylmorpholin-4-Yl%5D-1H-Pyrimidin-2-One%2C+an+Effective+Antithrombotic+Agent+without+Associated+Bleeding+and+Insulin+Resistance&doi=10.1016%2Fj.bmcl.2012.08.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.102%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DA.%26aulast%3DGhosal%26aufirst%3DS.%26aulast%3DIliefski%26aufirst%3DT.%26aulast%3DCassel%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DZ.-Q.%26aulast%3Dvon%2BWachenfeldt%26aufirst%3DH.%26aulast%3DAndersen%26aufirst%3DS.%2BM.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DTunek%26aufirst%3DA.%26aulast%3DNylander%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Phosphoinositide%25203-Kinases%2520%2528PI3K%2529%2520P110%25CE%25B2%2520Isoform%2520Inhibitor%25204-%255B2-Hydroxyethyl%25281-Naphthylmethyl%2529Amino%255D-6-%255B%25282S%2529-2-Methylmorpholin-4-Yl%255D-1H-Pyrimidin-2-One%252C%2520an%2520Effective%2520Antithrombotic%2520Agent%2520without%2520Associated%2520Bleeding%2520and%2520Insulin%2520Resistance%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D21%26spage%3D6671%26epage%3D6676%26doi%3D10.1016%2Fj.bmcl.2012.08.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 9-(1-Phenoxyethyl)-2-Morpholino-4-Oxo-Pyrido[1,2-a]Pyrimidine-7-Carboxamides as Oral PI3Kβ Inhibitors, Useful as Antiplatelet Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3936</span>– <span class="NLM_lpage">3943</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2014.07.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3936-3943&issue=16&author=F.+Giordanettoauthor=B.+Barlaamauthor=S.+Berglundauthor=K.+Edmanauthor=O.+Karlssonauthor=J.+Lindbergauthor=S.+Nylanderauthor=T.+Inghardt&title=Discovery+of+9-%281-Phenoxyethyl%29-2-Morpholino-4-Oxo-Pyrido%5B1%2C2-a%5DPyrimidine-7-Carboxamides+as+Oral+PI3K%CE%B2+Inhibitors%2C+Useful+as+Antiplatelet+Agents&doi=10.1016%2Fj.bmcl.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DBerglund%26aufirst%3DS.%26aulast%3DEdman%26aufirst%3DK.%26aulast%3DKarlsson%26aufirst%3DO.%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DInghardt%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25209-%25281-Phenoxyethyl%2529-2-Morpholino-4-Oxo-Pyrido%255B1%252C2-a%255DPyrimidine-7-Carboxamides%2520as%2520Oral%2520PI3K%25CE%25B2%2520Inhibitors%252C%2520Useful%2520as%2520Antiplatelet%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3936%26epage%3D3943%26doi%3D10.1016%2Fj.bmcl.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virone-Oddos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Romme, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carry, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnevaux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquette, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Below, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vade, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatreaux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angouillant-Boniface, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kβ Inhibitors for the Treatment of Phosphatase and TENsin Homologue (PTEN)-Deficient Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4788</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1021/jm300241b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300241b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4788-4805&issue=10&author=V.+Certalauthor=F.+Halleyauthor=A.+Virone-Oddosauthor=C.+Delormeauthor=A.+Karlssonauthor=A.+Rakauthor=F.+Thompsonauthor=B.+Filoche-Rommeauthor=Y.+El-Ahmadauthor=J.-C.+Carryauthor=P.-Y.+Abecassisauthor=P.+Lejeuneauthor=L.+Vincentauthor=H.+Bonnevauxauthor=J.-P.+Nicolasauthor=T.+Bertrandauthor=J.-P.+Marquetteauthor=N.+Michotauthor=T.+Benardauthor=P.+Belowauthor=I.+Vadeauthor=F.+Chatreauxauthor=G.+Lebourgauthor=F.+Pilorgeauthor=O.+Angouillant-Bonifaceauthor=A.+Louboutinauthor=C.+Lengauerauthor=L.+Schio&title=Discovery+and+Optimization+of+New+Benzimidazole-+and+Benzoxazole-Pyrimidone+Selective+PI3K%CE%B2+Inhibitors+for+the+Treatment+of+Phosphatase+and+TENsin+Homologue+%28PTEN%29-Deficient+Cancers&doi=10.1021%2Fjm300241b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm300241b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300241b%26sid%3Dliteratum%253Aachs%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DVirone-Oddos%26aufirst%3DA.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romme%26aufirst%3DB.%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DCarry%26aufirst%3DJ.-C.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DLejeune%26aufirst%3DP.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DBonnevaux%26aufirst%3DH.%26aulast%3DNicolas%26aufirst%3DJ.-P.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DMarquette%26aufirst%3DJ.-P.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBelow%26aufirst%3DP.%26aulast%3DVade%26aufirst%3DI.%26aulast%3DChatreaux%26aufirst%3DF.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DAngouillant-Boniface%26aufirst%3DO.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520New%2520Benzimidazole-%2520and%2520Benzoxazole-Pyrimidone%2520Selective%2520PI3K%25CE%25B2%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Phosphatase%2520and%2520TENsin%2520Homologue%2520%2528PTEN%2529-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4788%26epage%3D4805%26doi%3D10.1021%2Fjm300241b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carry, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virone-Oddos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnevaux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquette, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaitre, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerflinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guizani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1021/jm401642q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401642q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=903-920&issue=3&author=V.+Certalauthor=J.-C.+Carryauthor=F.+Halleyauthor=A.+Virone-Oddosauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=Y.+El-Ahmadauthor=A.+Karlssonauthor=V.+Charrierauthor=C.+Delormeauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=C.+Amaraauthor=L.+Vincentauthor=H.+Bonnevauxauthor=J.-P.+Nicolasauthor=M.+Mathieuauthor=T.+Bertrandauthor=J.-P.+Marquetteauthor=N.+Michotauthor=T.+Benardauthor=M.-A.+Perrinauthor=O.+Lemaitreauthor=S.+Guerifauthor=S.+Perronauthor=S.+Mongetauthor=F.+Gruss-Leleuauthor=G.+Doerflingerauthor=H.+Guizaniauthor=M.+Brolloauthor=L.+Delbarreauthor=L.+Bertinauthor=P.+Richepinauthor=V.+Loyauauthor=C.+Garcia-Echeverriaauthor=C.+Lengauerauthor=L.+Schio&title=Discovery+and+Optimization+of+Pyrimidone+Indoline+Amide+PI3K%CE%B2+Inhibitors+for+the+Treatment+of+Phosphatase+and+Tensin+Homologue+%28PTEN%29-Deficient+Cancers&doi=10.1021%2Fjm401642q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers</span></div><div class="casAuthors">Certal, Victor; Carry, Jean-Christophe; Halley, Frank; Virone-Oddos, Angela; Thompson, Fabienne; Filoche-Romme, Bruno; El-Ahmad, Youssef; Karlsson, Andreas; Charrier, Veronique; Delorme, Cecile; Rak, Alexey; Abecassis, Pierre-Yves; Amara, Celine; Vincent, Loic; Bonnevaux, Helene; Nicolas, Jean-Paul; Mathieu, Magali; Bertrand, Thomas; Marquette, Jean-Pierre; Michot, Nadine; Benard, Tsiala; Perrin, Marc-Antoine; Lemaitre, Olivier; Guerif, Stephane; Perron, Sebastien; Monget, Sylvie; Gruss-Leleu, Florence; Doerflinger, Gilles; Guizani, Houlfa; Brollo, Maurice; Delbarre, Laurence; Bertin, Luc; Richepin, Patrick; Loyau, Veronique; Garcia-Echeverria, Carlos; Lengauer, Christoph; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">903-920</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compelling mol. biol. publications have reported the implication of phosphoinositide kinase PI3Kβ in PTEN-deficient cell line growth and proliferation.  These findings supported a scientific rationale for the development of PI3Kβ-specific inhibitors for the treatment of PTEN-deficient cancers.  This paper describes the discovery of 2-[2-(2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one and the optimization of this new series of active and selective pyrimidone indoline amide PI3Kβ inhibitors. 2-[2-(2-Methyl-2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (I), identified following a carefully designed Me scan, displayed improved physicochem. and in vitro pharmacokinetic properties.  Structural biol. efforts enabled the acquisition of the first x-ray cocrystal structure of p110β with the selective inhibitor compd. I bound to the ATP site.  The nonplanar binding mode described herein is consistent with obsd. structure-activity relationship for the series.  Compd. I demonstrated significant in vivo activity in a UACC-62 xenograft model in mice, warranting further preclin. investigation.  Following successful development, compd. 28 entered phase I/Ib clin. trial in patients with advanced cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5QsHhXYO6d7Vg90H21EOLACvtfcHk0lgEcRV3wwnEMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFOjsw%253D%253D&md5=8141ae91a81b06ad129afd2263e2a007</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjm401642q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401642q%26sid%3Dliteratum%253Aachs%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DCarry%26aufirst%3DJ.-C.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DVirone-Oddos%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DCharrier%26aufirst%3DV.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DAmara%26aufirst%3DC.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DBonnevaux%26aufirst%3DH.%26aulast%3DNicolas%26aufirst%3DJ.-P.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DMarquette%26aufirst%3DJ.-P.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DM.-A.%26aulast%3DLemaitre%26aufirst%3DO.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DPerron%26aufirst%3DS.%26aulast%3DMonget%26aufirst%3DS.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DDoerflinger%26aufirst%3DG.%26aulast%3DGuizani%26aufirst%3DH.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DDelbarre%26aufirst%3DL.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Pyrimidone%2520Indoline%2520Amide%2520PI3K%25CE%25B2%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Phosphatase%2520and%2520Tensin%2520Homologue%2520%2528PTEN%2529-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D903%26epage%3D920%26doi%3D10.1021%2Fjm401642q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bédard, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreafico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartot-Cotton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazuir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micallef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients with Advanced Solid Tumors</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1002/cncr.31044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1002%2Fcncr.31044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=315-324&issue=2&author=P.+L.+B%C3%A9dardauthor=M.+A.+Daviesauthor=S.+Kopetzauthor=D.+Juricauthor=G.+I.+Shapiroauthor=J.+J.+Lukeauthor=A.+Spreaficoauthor=B.+Wuauthor=C.+Castellauthor=C.+Gomezauthor=S.+Cartot-Cottonauthor=F.+Mazuirauthor=M.+Dubarauthor=S.+Micallefauthor=B.+Demersauthor=K.+T.+Flaherty&title=First-in-Human+Trial+of+the+PI3K%CE%B2-Selective+Inhibitor+SAR260301+in+Patients+with+Advanced+Solid+Tumors&doi=10.1002%2Fcncr.31044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31044%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9dard%26aufirst%3DP.%2BL.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DSpreafico%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DCastell%26aufirst%3DC.%26aulast%3DGomez%26aufirst%3DC.%26aulast%3DCartot-Cotton%26aufirst%3DS.%26aulast%3DMazuir%26aufirst%3DF.%26aulast%3DDubar%26aufirst%3DM.%26aulast%3DMicallef%26aufirst%3DS.%26aulast%3DDemers%26aufirst%3DB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DFirst-in-Human%2520Trial%2520of%2520the%2520PI3K%25CE%25B2-Selective%2520Inhibitor%2520SAR260301%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26issue%3D2%26spage%3D315%26epage%3D324%26doi%3D10.1002%2Fcncr.31044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Thienobenzoxepin Inhibitors of PI3-Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4054</span>– <span class="NLM_lpage">4058</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&issue=13&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.-Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-Based+Design+of+Thienobenzoxepin+Inhibitors+of+PI3-Kinase&doi=10.1016%2Fj.bmcl.2011.04.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-Based%2520Design%2520of%2520Thienobenzoxepin%2520Inhibitors%2520of%2520PI3-Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D13%26spage%3D4054%26epage%3D4058%26doi%3D10.1016%2Fj.bmcl.2011.04.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span> <span> </span><span class="NLM_article-title">Cis-Amide Isosteric Replacement in Thienobenzoxepin Inhibitors of PI3-Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.10.121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=897-901&issue=3&author=S.+T.+Stabenauthor=N.+Blaquiereauthor=V.+Tsuiauthor=A.+Kolesnikovauthor=S.+Doauthor=E.+K.+Bradleyauthor=J.+Dotsonauthor=R.+Goldsmithauthor=T.+P.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=J.+Pangauthor=L.+Rougeauthor=L.+Salphatiauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wu&title=Cis-Amide+Isosteric+Replacement+in+Thienobenzoxepin+Inhibitors+of+PI3-Kinase&doi=10.1016%2Fj.bmcl.2012.10.121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.121%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DCis-Amide%2520Isosteric%2520Replacement%2520in%2520Thienobenzoxepin%2520Inhibitors%2520of%2520PI3-Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D897%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2012.10.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ord, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weismann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Thiazolobenzoxepin PI3-Kinase Inhibitors That Spare the PI3-Kinase β Isoform</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2606</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2013.02.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2606-2613&issue=9&author=S.+T.+Stabenauthor=C.+Ndubakuauthor=N.+Blaquiereauthor=M.+Belvinauthor=R.+J.+Bullauthor=D.+Dudleyauthor=K.+Edgarauthor=D.+Grayauthor=R.+Healdauthor=T.+P.+Heffronauthor=G.+E.+Jonesauthor=M.+Jonesauthor=A.+Kolesnikovauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=N.+J.+McLeanauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=R.+Ordauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=C.+Weismannauthor=P.+Wu&title=Discovery+of+Thiazolobenzoxepin+PI3-Kinase+Inhibitors+That+Spare+the+PI3-Kinase+%CE%B2+Isoform&doi=10.1016%2Fj.bmcl.2013.02.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.102%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DN.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DOrd%26aufirst%3DR.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWeismann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Thiazolobenzoxepin%2520PI3-Kinase%2520Inhibitors%2520That%2520Spare%2520the%2520PI3-Kinase%2520%25CE%25B2%2520Isoform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D9%26spage%3D2606%26epage%3D2613%26doi%3D10.1016%2Fj.bmcl.2013.02.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-Methyl-1H -1,2-4-Triazol-5-Yl)-5,6-Dihydrobenzo[f]Imidazo[1,2-d][1,4]Oxazepin-9-Yl]-1H -Pyrazol-1-Yl}-2-Methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Ro</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4597</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&issue=11&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-Methyl-1H+-1%2C2-4-Triazol-5-Yl%29-5%2C6-Dihydrobenzo%5Bf%5DImidazo%5B1%2C2-d%5D%5B1%2C4%5DOxazepin-9-Yl%5D-1H+-Pyrazol-1-Yl%7D-2-Methylpropanamide+%28GDC-0032%29%3A+A+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Ro&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-Methyl-1H%2520-1%252C2-4-Triazol-5-Yl%2529-5%252C6-Dihydrobenzo%255Bf%255DImidazo%255B1%252C2-d%255D%255B1%252C4%255DOxazepin-9-Yl%255D-1H%2520-Pyrazol-1-Yl%257D-2-Methylpropanamide%2520%2528GDC-0032%2529%253A%2520A%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Ro%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D11%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augistin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gancia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mörtl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[f]Imidazo[1,2-d][1,4]Oxazepin-9-Yl)Oxy)Propa</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01483</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01483" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=985-1002&issue=3&author=T.+P.+Heffronauthor=R.+A.+Healdauthor=C.+Ndubakuauthor=B.+Weiauthor=M.+Augistinauthor=S.+Doauthor=K.+Edgarauthor=C.+Eigenbrotauthor=L.+Friedmanauthor=E.+Ganciaauthor=P.+S.+Jacksonauthor=G.+Jonesauthor=A.+Kolesnikovauthor=L.+B.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=N.+McLeanauthor=M.+M%C3%B6rtlauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=S.+T.+Stabenauthor=S.+Steinbacherauthor=V.+Tsuiauthor=J.+Wallinauthor=D.+Sampathauthor=A.+G.+Olivero&title=The+Rational+Design+of+Selective+Benzoxazepin+Inhibitors+of+the+%CE%B1-Isoform+of+Phosphoinositide+3-Kinase+Culminating+in+the+Identification+of+%28S%29-2-%28%282-%281-Isopropyl-1H-1%2C2%2C4-Triazol-5-Yl%29-5%2C6-Dihydrobenzo%5Bf%5DImidazo%5B1%2C2-d%5D%5B1%2C4%5DOxazepin-9-Yl%29Oxy%29Propa&doi=10.1021%2Facs.jmedchem.5b01483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01483%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DAugistin%26aufirst%3DM.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGancia%26aufirst%3DE.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMcLean%26aufirst%3DN.%26aulast%3DM%25C3%25B6rtl%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DThe%2520Rational%2520Design%2520of%2520Selective%2520Benzoxazepin%2520Inhibitors%2520of%2520the%2520%25CE%25B1-Isoform%2520of%2520Phosphoinositide%25203-Kinase%2520Culminating%2520in%2520the%2520Identification%2520of%2520%2528S%2529-2-%2528%25282-%25281-Isopropyl-1H-1%252C2%252C4-Triazol-5-Yl%2529-5%252C6-Dihydrobenzo%255Bf%255DImidazo%255B1%252C2-d%255D%255B1%252C4%255DOxazepin-9-Yl%2529Oxy%2529Propa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D3%26spage%3D985%26epage%3D1002%26doi%3D10.1021%2Facs.jmedchem.5b01483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">936</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00170</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00170" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=936-940&issue=9&author=B.+S.+Safinaauthor=R.+L.+Elliottauthor=A.+K.+Forrestauthor=R.+A.+Healdauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=E.+M.+Sewardauthor=S.+T.+Stabenauthor=M.+Ultschauthor=B.+Weiauthor=W.+Yangauthor=D.+P.+Sutherlin&title=Design+of+Selective+Benzoxazepin+PI3K%CE%B4+Inhibitors+Through+Control+of+Dihedral+Angles&doi=10.1021%2Facsmedchemlett.7b00170"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00170%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DElliott%26aufirst%3DR.%2BL.%26aulast%3DForrest%26aufirst%3DA.%2BK.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DDesign%2520of%2520Selective%2520Benzoxazepin%2520PI3K%25CE%25B4%2520Inhibitors%2520Through%2520Control%2520of%2520Dihedral%2520Angles%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D936%26epage%3D940%26doi%3D10.1021%2Facsmedchemlett.7b00170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggate, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plavec, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rharbaoui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor Reveals PI3Kγ Dependence of TH17 Cell Differentiation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1038/nchembio.957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnchembio.957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22544264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Gqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=576-582&issue=6&author=G.+Bergaminiauthor=K.+Bellauthor=S.+Shimamuraauthor=T.+Wernerauthor=A.+Cansfieldauthor=K.+M%C3%BCllerauthor=J.+Perrinauthor=C.+Rauauthor=K.+Ellardauthor=C.+Hopfauthor=C.+Doceauthor=D.+Leggateauthor=R.+Manganoauthor=T.+Mathiesonauthor=A.+O%E2%80%99Mahonyauthor=I.+Plavecauthor=F.+Rharbaouiauthor=F.+Reinhardauthor=M.+M.+Savitskiauthor=N.+Ramsdenauthor=E.+Hirschauthor=G.+Drewesauthor=O.+Rauschauthor=M.+Bantscheffauthor=G.+Neubauer&title=A+Selective+Inhibitor+Reveals+PI3K%CE%B3+Dependence+of+TH17+Cell+Differentiation&doi=10.1038%2Fnchembio.957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation</span></div><div class="casAuthors">Bergamini, Giovanna; Bell, Kathryn; Shimamura, Satoko; Werner, Thilo; Cansfield, Andrew; Mueller, Katrin; Perrin, Jessica; Rau, Christina; Ellard, Katie; Hopf, Carsten; Doce, Carola; Leggate, Daniel; Mangano, Raffaella; Mathieson, Toby; O'Mahony, Alison; Plavec, Ivan; Rharbaoui, Faiza; Reinhard, Friedrich; Savitski, Mikhail M.; Ramsden, Nigel; Hirsch, Emilio; Drewes, Gerard; Rausch, Oliver; Bantscheff, Marcus; Neubauer, Gitte</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576-582</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We devised a high-throughput chemoproteomics method that enabled multiplexed screening of 16,000 compds. against native protein and lipid kinases in cell exts.  Optimization of one chem. series resulted in CZC24832, which is to our knowledge the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation.  Extensive target- and cell-based profiling of CZC24832 revealed regulation of interleukin-17-producing T helper cell (TH17) differentiation by PI3Kγ, thus reinforcing selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqinUn8kLqw_LVg90H21EOLACvtfcHk0lhRwG7w04_7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Gqt7c%253D&md5=0141d8596ee10d4d796de57fb87a2c19</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.957%26sid%3Dliteratum%253Aachs%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DShimamura%26aufirst%3DS.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DCansfield%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DDoce%26aufirst%3DC.%26aulast%3DLeggate%26aufirst%3DD.%26aulast%3DMangano%26aufirst%3DR.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DPlavec%26aufirst%3DI.%26aulast%3DRharbaoui%26aufirst%3DF.%26aulast%3DReinhard%26aufirst%3DF.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DG.%26atitle%3DA%2520Selective%2520Inhibitor%2520Reveals%2520PI3K%25CE%25B3%2520Dependence%2520of%2520TH17%2520Cell%2520Differentiation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D6%26spage%3D576%26epage%3D582%26doi%3D10.1038%2Fnchembio.957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(2-Amino-[1,2,4]Triazolo[1,5-a]Pyridin-7-Yl)-N-(Tert-Butyl)Pyridine-3-Sulfonamide (CZC24758), as a Potent, Orally Bioavailable and Selective Inhibitor of PI3K for the Treatment of Inflammatory Disease</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4613</span>– <span class="NLM_lpage">4618</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.05.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4613-4618&issue=14&author=M.+Sunoseauthor=K.+Bellauthor=K.+Ellardauthor=G.+Bergaminiauthor=G.+Neubauerauthor=T.+Wernerauthor=N.+Ramsden&title=Discovery+of+5-%282-Amino-%5B1%2C2%2C4%5DTriazolo%5B1%2C5-a%5DPyridin-7-Yl%29-N-%28Tert-Butyl%29Pyridine-3-Sulfonamide+%28CZC24758%29%2C+as+a+Potent%2C+Orally+Bioavailable+and+Selective+Inhibitor+of+PI3K+for+the+Treatment+of+Inflammatory+Disease&doi=10.1016%2Fj.bmcl.2012.05.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DSunose%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DRamsden%26aufirst%3DN.%26atitle%3DDiscovery%2520of%25205-%25282-Amino-%255B1%252C2%252C4%255DTriazolo%255B1%252C5-a%255DPyridin-7-Yl%2529-N-%2528Tert-Butyl%2529Pyridine-3-Sulfonamide%2520%2528CZC24758%2529%252C%2520as%2520a%2520Potent%252C%2520Orally%2520Bioavailable%2520and%2520Selective%2520Inhibitor%2520of%2520PI3K%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D14%26spage%3D4613%26epage%3D4618%26doi%3D10.1016%2Fj.bmcl.2012.05.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span> <span> </span><span class="NLM_article-title">SAR Studies around a Series of Triazolopyridines as Potent and Selective PI3Kγ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">5257</span>– <span class="NLM_lpage">5263</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.06.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5257-5263&issue=16&author=K.+Bellauthor=M.+Sunoseauthor=K.+Ellardauthor=A.+Cansfieldauthor=J.+Taylorauthor=W.+Millerauthor=N.+Ramsdenauthor=G.+Bergaminiauthor=G.+Neubauer&title=SAR+Studies+around+a+Series+of+Triazolopyridines+as+Potent+and+Selective+PI3K%CE%B3+Inhibitors&doi=10.1016%2Fj.bmcl.2012.06.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DK.%26aulast%3DSunose%26aufirst%3DM.%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DW.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DNeubauer%26aufirst%3DG.%26atitle%3DSAR%2520Studies%2520around%2520a%2520Series%2520of%2520Triazolopyridines%2520as%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B3%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D16%26spage%3D5257%26epage%3D5263%26doi%3D10.1016%2Fj.bmcl.2012.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel PI3Kγ/δ Inhibitors as Potential Agents for Inflammation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4546</span>– <span class="NLM_lpage">4549</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.05.121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4546-4549&issue=14&author=K.+Ellardauthor=M.+Sunoseauthor=K.+Bellauthor=N.+Ramsdenauthor=G.+Bergaminiauthor=G.+Neubauer&title=Discovery+of+Novel+PI3K%CE%B3%2F%CE%B4+Inhibitors+as+Potential+Agents+for+Inflammation&doi=10.1016%2Fj.bmcl.2012.05.121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.121%26sid%3Dliteratum%253Aachs%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DSunose%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DNeubauer%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Novel%2520PI3K%25CE%25B3%252F%25CE%25B4%2520Inhibitors%2520as%2520Potential%2520Agents%2520for%2520Inflammation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D14%26spage%3D4546%26epage%3D4549%26doi%3D10.1016%2Fj.bmcl.2012.05.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of a Series of 2-Aminothiazole-Oxazoles as Potent Phosphoinositide 3-Kinase γ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7534</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.10.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7534-7538&issue=24&author=Y.+Okaauthor=T.+Yabuuchiauthor=Y.+Fujiiauthor=H.+Ohtakeauthor=S.+Wakaharaauthor=K.+Matsumotoauthor=M.+Endoauthor=Y.+Tamuraauthor=Y.+Sekiguchi&title=Discovery+and+Optimization+of+a+Series+of+2-Aminothiazole-Oxazoles+as+Potent+Phosphoinositide+3-Kinase+%CE%B3+Inhibitors&doi=10.1016%2Fj.bmcl.2012.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DY.%26aulast%3DYabuuchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DWakahara%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Series%2520of%25202-Aminothiazole-Oxazoles%2520as%2520Potent%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D24%26spage%3D7534%26epage%3D7538%26doi%3D10.1016%2Fj.bmcl.2012.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-{5-[3-(3-Hydroxypiperidin-1-Yl)-1,2,4-Oxadiazol-5-Yl]-4-Methyl-1,3-Thiazol-2-Yl}acetamide (TASP0415914) as an Orally Potent Phosphoinositide 3-Kinase γ Inhibitor for the Treatment of Inflammatory Diseases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7578</span>– <span class="NLM_lpage">7583</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2013.10.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7578-7583&issue=24&author=Y.+Okaauthor=T.+Yabuuchiauthor=T.+Oiauthor=S.+Kurodaauthor=Y.+Fujiiauthor=H.+Ohtakeauthor=T.+Inoueauthor=S.+Wakaharaauthor=K.+Kimuraauthor=K.+Fujitaauthor=M.+Endoauthor=K.+Taguchiauthor=Y.+Sekiguchi&title=Discovery+of+N-%7B5-%5B3-%283-Hydroxypiperidin-1-Yl%29-1%2C2%2C4-Oxadiazol-5-Yl%5D-4-Methyl-1%2C3-Thiazol-2-Yl%7Dacetamide+%28TASP0415914%29+as+an+Orally+Potent+Phosphoinositide+3-Kinase+%CE%B3+Inhibitor+for+the+Treatment+of+Inflammatory+Diseases&doi=10.1016%2Fj.bmc.2013.10.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DY.%26aulast%3DYabuuchi%26aufirst%3DT.%26aulast%3DOi%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DS.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DWakahara%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DK.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520N-%257B5-%255B3-%25283-Hydroxypiperidin-1-Yl%2529-1%252C2%252C4-Oxadiazol-5-Yl%255D-4-Methyl-1%252C3-Thiazol-2-Yl%257Dacetamide%2520%2528TASP0415914%2529%2520as%2520an%2520Orally%2520Potent%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26issue%3D24%26spage%3D7578%26epage%3D7583%26doi%3D10.1016%2Fj.bmc.2013.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaq, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuenoud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand, D. Le</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilgrim, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sviridenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, L.</span></span> <span> </span><span class="NLM_article-title">Development of Isoform Selective PI3-Kinase Inhibitors as Pharmacological Tools for Elucidating the PI3K Pathway</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5445</span>– <span class="NLM_lpage">5450</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.07.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5445-5450&issue=17&author=I.+Bruceauthor=M.+Akhlaqauthor=G.+C.+Bloomfieldauthor=E.+Buddauthor=B.+Coxauthor=B.+Cuenoudauthor=P.+Finanauthor=P.+Gedeckauthor=J.+Hattoauthor=J.+F.+Haylerauthor=D.+Headauthor=T.+Kellerauthor=L.+Kirmanauthor=C.+Leblancauthor=D.+Le+Grandauthor=C.+McCarthyauthor=D.+O%E2%80%99Connorauthor=C.+Owenauthor=M.+S.+Ozaauthor=G.+Pilgrimauthor=N.+E.+Pressauthor=L.+Sviridenkoauthor=L.+Whitehead&title=Development+of+Isoform+Selective+PI3-Kinase+Inhibitors+as+Pharmacological+Tools+for+Elucidating+the+PI3K+Pathway&doi=10.1016%2Fj.bmcl.2012.07.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.042%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DAkhlaq%26aufirst%3DM.%26aulast%3DBloomfield%26aufirst%3DG.%2BC.%26aulast%3DBudd%26aufirst%3DE.%26aulast%3DCox%26aufirst%3DB.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayler%26aufirst%3DJ.%2BF.%26aulast%3DHead%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DKirman%26aufirst%3DL.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DGrand%26aufirst%3DD.%2BLe%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DOza%26aufirst%3DM.%2BS.%26aulast%3DPilgrim%26aufirst%3DG.%26aulast%3DPress%26aufirst%3DN.%2BE.%26aulast%3DSviridenko%26aufirst%3DL.%26aulast%3DWhitehead%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520Isoform%2520Selective%2520PI3-Kinase%2520Inhibitors%2520as%2520Pharmacological%2520Tools%2520for%2520Elucidating%2520the%2520PI3K%2520Pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D17%26spage%3D5445%26epage%3D5450%26doi%3D10.1016%2Fj.bmcl.2012.07.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&issue=13&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornebise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1021/jm500362j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500362j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=517-521&issue=1&author=P.+N.+Collierauthor=G.+Martinez-Botellaauthor=M.+Cornebiseauthor=K.+M.+Cottrellauthor=J.+D.+Doranauthor=J.+P.+Griffithauthor=S.+Mahajanauthor=F.+Maltaisauthor=C.+S.+Moodyauthor=E.+P.+Huckauthor=T.+Wangauthor=A.+M.+Aronov&title=Structural+Basis+for+Isoform+Selectivity+in+a+Class+of+Benzothiazole+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B3&doi=10.1021%2Fjm500362j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm500362j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500362j%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DCornebise%26aufirst%3DM.%26aulast%3DCottrell%26aufirst%3DK.%2BM.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DHuck%26aufirst%3DE.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DStructural%2520Basis%2520for%2520Isoform%2520Selectivity%2520in%2520a%2520Class%2520of%2520Benzothiazole%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D517%26epage%3D521%26doi%3D10.1021%2Fjm500362j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tiran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandarage, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damagnez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare-Pandit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledeboer, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roday, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5684</span>– <span class="NLM_lpage">5688</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5684-5688&issue=14&author=P.+N.+Collierauthor=D.+Messersmithauthor=A.+Le+Tiranauthor=U.+K.+Bandarageauthor=C.+Boucherauthor=J.+Comeauthor=K.+M.+Cottrellauthor=V.+Damagnezauthor=J.+D.+Doranauthor=J.+P.+Griffithauthor=S.+Khare-Panditauthor=E.+B.+Kruegerauthor=M.+W.+Ledeboerauthor=B.+Ledfordauthor=Y.+Liaoauthor=S.+Mahajanauthor=C.+S.+Moodyauthor=S.+Rodayauthor=T.+Wangauthor=J.+Xuauthor=A.+M.+Aronov&title=Discovery+of+Highly+Isoform+Selective+Thiazolopiperidine+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B3&doi=10.1021%2Facs.jmedchem.5b00498"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00498%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DLe%2BTiran%26aufirst%3DA.%26aulast%3DBandarage%26aufirst%3DU.%2BK.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DCome%26aufirst%3DJ.%26aulast%3DCottrell%26aufirst%3DK.%2BM.%26aulast%3DDamagnez%26aufirst%3DV.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DKhare-Pandit%26aufirst%3DS.%26aulast%3DKrueger%26aufirst%3DE.%2BB.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26aulast%3DLedford%26aufirst%3DB.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DRoday%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DDiscovery%2520of%2520Highly%2520Isoform%2520Selective%2520Thiazolopiperidine%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D14%26spage%3D5684%26epage%3D5688%26doi%3D10.1021%2Facs.jmedchem.5b00498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Come, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tiran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandarage, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizensky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damagnez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworakowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare-Pandit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5245</span>– <span class="NLM_lpage">5256</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5245-5256&issue=12&author=J.+H.+Comeauthor=P.+N.+Collierauthor=J.+A.+Hendersonauthor=A.+C.+Pierceauthor=R.+J.+Daviesauthor=A.+Le+Tiranauthor=H.+O%E2%80%99Dowdauthor=U.+K.+Bandarageauthor=J.+Caoauthor=D.+Deiningerauthor=R.+Greyauthor=E.+B.+Kruegerauthor=D.+B.+Loweauthor=J.+Liangauthor=Y.+Liaoauthor=D.+Messersmithauthor=S.+Nanthakumarauthor=E.+Sizenskyauthor=J.+Wangauthor=J.+Xuauthor=E.+Y.+Chinauthor=V.+Damagnezauthor=J.+D.+Doranauthor=W.+Dworakowskiauthor=J.+P.+Griffithauthor=M.+D.+Jacobsauthor=S.+Khare-Panditauthor=S.+Mahajanauthor=C.+S.+Moodyauthor=A.+M.+Aronov&title=Design+and+Synthesis+of+a+Novel+Series+of+Orally+Bioavailable%2C+CNS-Penetrant%2C+Isoform+Selective+Phosphoinositide+3-Kinase+%CE%B3+%28PI3K%CE%B3%29+Inhibitors+with+Potential+for+the+Treatment+of+Multiple+Sclerosis+%28MS%29&doi=10.1021%2Facs.jmedchem.8b00085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00085%26sid%3Dliteratum%253Aachs%26aulast%3DCome%26aufirst%3DJ.%2BH.%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DHenderson%26aufirst%3DJ.%2BA.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DDavies%26aufirst%3DR.%2BJ.%26aulast%3DLe%2BTiran%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DH.%26aulast%3DBandarage%26aufirst%3DU.%2BK.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DDeininger%26aufirst%3DD.%26aulast%3DGrey%26aufirst%3DR.%26aulast%3DKrueger%26aufirst%3DE.%2BB.%26aulast%3DLowe%26aufirst%3DD.%2BB.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DSizensky%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DChin%26aufirst%3DE.%2BY.%26aulast%3DDamagnez%26aufirst%3DV.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DDworakowski%26aufirst%3DW.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DJacobs%26aufirst%3DM.%2BD.%26aulast%3DKhare-Pandit%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Novel%2520Series%2520of%2520Orally%2520Bioavailable%252C%2520CNS-Penetrant%252C%2520Isoform%2520Selective%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520%2528PI3K%25CE%25B3%2529%2520Inhibitors%2520with%2520Potential%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Sclerosis%2520%2528MS%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5245%26epage%3D5256%26doi%3D10.1021%2Facs.jmedchem.8b00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlbrandt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatoidsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5435</span>– <span class="NLM_lpage">5441</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00447</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00447" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5435-5441&issue=12&author=N.+Pembertonauthor=M.+Mogemarkauthor=S.+Arlbrandtauthor=P.+Boldauthor=R.+J.+Coxauthor=C.+Gardelliauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=J.+Karlssonauthor=S.+Leverauthor=X.+Liauthor=H.+Lindmarkauthor=M.+Norbergauthor=M.+W.+D.+Perryauthor=J.+Petersenauthor=S.+Rodrigo+Blomqvistauthor=M.+Thomasauthor=C.+Tyrchanauthor=A.+Westin+Erikssonauthor=P.+Zlatoidskyauthor=L.+%C3%96ster&title=Discovery+of+Highly+Isoform+Selective+Orally+Bioavailable+Phosphoinositide+3-Kinase+%28PI3K%29-%CE%B3+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span></div><div class="casAuthors">Pemberton, Nils; Mogemark, Mickael; Arlbrandt, Susanne; Bold, Peter; Cox, Rhona J.; Gardelli, Cristina; Holden, Neil S.; Karabelas, Kostas; Karlsson, Johan; Lever, Sarah; Li, Xueshan; Lindmark, Helena; Norberg, Monica; Perry, Matthew W. D.; Petersen, Jens; Rodrigo Blomqvist, Sandra; Thomas, Matthew; Tyrchan, Christian; Westin Eriksson, Annika; Zlatoidsky, Pavol; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5435-5441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a new chemotype of isoform selective PI3Kγ inhibitors.  Starting from an HTS hit, potency and physicochem. properties could be improved to give compds. such as 15, which is a potent and remarkably selective PI3Kγ inhibitor with ADME properties suitable for oral administration.  Compd. 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo3fbsxDWowrVg90H21EOLACvtfcHk0ljdNZMjQBZWEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO&md5=da8067ecb7fff28145f1c2bf82f0a7e7</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00447%26sid%3Dliteratum%253Aachs%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DArlbrandt%26aufirst%3DS.%26aulast%3DBold%26aufirst%3DP.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DGardelli%26aufirst%3DC.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DKarlsson%26aufirst%3DJ.%26aulast%3DLever%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DNorberg%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26aulast%3DZlatoidsky%26aufirst%3DP.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Highly%2520Isoform%2520Selective%2520Orally%2520Bioavailable%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529-%25CE%25B3%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5435%26epage%3D5441%26doi%3D10.1021%2Facs.jmedchem.8b00447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4104</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&issue=15&author=C.+Qianauthor=C.-J.+Laiauthor=R.+Baoauthor=D.-G.+Wangauthor=J.+Wangauthor=G.-X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+S.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.-X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+Network+Disruption+by+a+Single+Molecule+Inhibitor+Targeting+Both+Histone+Deacetylase+Activity+and+Phosphatidylinositol+3-Kinase+Signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lhtYqm11CWznw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%2BS.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520Network%2520Disruption%2520by%2520a%2520Single%2520Molecule%2520Inhibitor%2520Targeting%2520Both%2520Histone%2520Deacetylase%2520Activity%2520and%2520Phosphatidylinositol%25203-Kinase%2520Signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D15%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, Tolerability, and Preliminary Activity of CUDC-907, a First-in-Class, Oral, Dual Inhibitor of HDAC and PI3K, in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma: An Open-Label, Dose-Escalation, Phase 1 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&issue=5&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+Tolerability%2C+and+Preliminary+Activity+of+CUDC-907%2C+a+First-in-Class%2C+Oral%2C+Dual+Inhibitor+of+HDAC+and+PI3K%2C+in+Patients+with+Relapsed+or+Refractory+Lymphoma+or+Multiple+Myeloma%3A+An+Open-Label%2C+Dose-Escalation%2C+Phase+1+Trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0lhtYqm11CWznw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520Tolerability%252C%2520and%2520Preliminary%2520Activity%2520of%2520CUDC-907%252C%2520a%2520First-in-Class%252C%2520Oral%252C%2520Dual%2520Inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Lymphoma%2520or%2520Multiple%2520Myeloma%253A%2520An%2520Open-Label%252C%2520Dose-Escalation%252C%2520Phase%25201%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-Dependent Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&issue=2&author=K.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+S.+Samsonauthor=A.+W.+Maauthor=G.-X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+HDAC+and+PI3K+Inhibitor+CUDC-907+Downregulates+MYC+and+Suppresses+Growth+of+MYC-Dependent+Cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0lhtYqm11CWznw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%2BS.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520HDAC%2520and%2520PI3K%2520Inhibitor%2520CUDC-907%2520Downregulates%2520MYC%2520and%2520Suppresses%2520Growth%2520of%2520MYC-Dependent%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1552-1575&issue=4&author=D.+Chenauthor=C.+K.+Sohauthor=W.+H.+Gohauthor=H.+Wang&title=Design%2C+Synthesis%2C+and+Preclinical+Evaluation+of+Fused+Pyrimidine-Based+Hydroxamates+for+the+Treatment+of+Hepatocellular+Carcinoma&doi=10.1021%2Facs.jmedchem.7b01465"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01465%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSoh%26aufirst%3DC.%2BK.%26aulast%3DGoh%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Preclinical%2520Evaluation%2520of%2520Fused%2520Pyrimidine-Based%2520Hydroxamates%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1552%26epage%3D1575%26doi%3D10.1021%2Facs.jmedchem.7b01465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-R.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Novel 4-Aminoquinazolines as Dual Target Inhibitors of EGFR-PI3Kα</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2018.01.081" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=460-470&author=H.-W.+Dingauthor=C.-L.+Dengauthor=D.-D.+Liauthor=D.-D.+Liuauthor=S.-M.+Chaiauthor=W.+Wangauthor=Y.+Zhangauthor=K.+Chenauthor=X.+Liauthor=J.+Wangauthor=S.-J.+Songauthor=H.-R.+Song&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+4-Aminoquinazolines+as+Dual+Target+Inhibitors+of+EGFR-PI3K%CE%B1&doi=10.1016%2Fj.ejmech.2018.01.081"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.081%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.-W.%26aulast%3DDeng%26aufirst%3DC.-L.%26aulast%3DLi%26aufirst%3DD.-D.%26aulast%3DLiu%26aufirst%3DD.-D.%26aulast%3DChai%26aufirst%3DS.-M.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DS.-J.%26aulast%3DSong%26aufirst%3DH.-R.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25204-Aminoquinazolines%2520as%2520Dual%2520Target%2520Inhibitors%2520of%2520EGFR-PI3K%25CE%25B1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D460%26epage%3D470%26doi%3D10.1016%2Fj.ejmech.2018.01.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pujala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguloth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randive, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez de Arce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirez, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCullagh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00356</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00356" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1161-1166&issue=12&author=B.+Pujalaauthor=A.+K.+Agarwalauthor=S.+Middyaauthor=M.+Banerjeeauthor=A.+Suryaauthor=A.+K.+Nayakauthor=A.+Guptaauthor=S.+Khareauthor=R.+Gugulothauthor=N.+A.+Randiveauthor=B.+U.+Shindeauthor=A.+Thakurauthor=D.+I.+Patelauthor=M.+Rajaauthor=M.+J.+Greenauthor=J.+Alfaroauthor=P.+Avilaauthor=F.+Perez+de+Arceauthor=R.+G.+Almirezauthor=S.+Kannoauthor=S.+Bernalesauthor=D.+T.+Hungauthor=S.+Chakravartyauthor=E.+McCullaghauthor=K.+P.+Quinnauthor=R.+Raiauthor=S.+M.+Pham&title=Discovery+of+Pyrazolopyrimidine+Derivatives+as+Novel+Dual+Inhibitors+of+BTK+and+PI3K%CE%B4&doi=10.1021%2Facsmedchemlett.6b00356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ</span></div><div class="casAuthors">Pujala, Brahmam; Agarwal, Anil K.; Middya, Sandip; Banerjee, Monali; Surya, Arjun; Nayak, Anjan K.; Gupta, Ashu; Khare, Sweta; Guguloth, Rambabu; Randive, Nitin A.; Shinde, Bharat U.; Thakur, Anamika; Patel, Dhananjay I.; Raja, Mohd.; Green, Michael J.; Alfaro, Jennifer; Avila, Patricio; Perez de Arce, Felipe; Almirez, Ramona G.; Kanno, Stacy; Bernales, Sebastian; Hung, David T.; Chakravarty, Sarvajit; McCullagh, Emma; Quinn, Kevin P.; Rai, Roopa; Pham, Son M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1161-1166</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aberrant activation of B-cells has been implicated in several types of cancers and hematol. disorders.  BTK and PI3Kδ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clin. benefit in certain types of lymphoma.  Simultaneous inhibition of these pathways could result in more robust responses or overcome resistance as obsd. in single agent use.  The authors report a series of novel compds. that have low nanomolar potency against both BTK and PI3Kδ as well as acceptable PK properties that could be useful in the development of treatments against B-cell related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WMataMc2hbVg90H21EOLACvtfcHk0lh4j9QK-FwEaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL&md5=2a977a59c1bd1ccc5682405628990617</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00356%26sid%3Dliteratum%253Aachs%26aulast%3DPujala%26aufirst%3DB.%26aulast%3DAgarwal%26aufirst%3DA.%2BK.%26aulast%3DMiddya%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DSurya%26aufirst%3DA.%26aulast%3DNayak%26aufirst%3DA.%2BK.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DGuguloth%26aufirst%3DR.%26aulast%3DRandive%26aufirst%3DN.%2BA.%26aulast%3DShinde%26aufirst%3DB.%2BU.%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DD.%2BI.%26aulast%3DRaja%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DAlfaro%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DP.%26aulast%3DPerez%2Bde%2BArce%26aufirst%3DF.%26aulast%3DAlmirez%26aufirst%3DR.%2BG.%26aulast%3DKanno%26aufirst%3DS.%26aulast%3DBernales%26aufirst%3DS.%26aulast%3DHung%26aufirst%3DD.%2BT.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DMcCullagh%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DK.%2BP.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520Pyrazolopyrimidine%2520Derivatives%2520as%2520Novel%2520Dual%2520Inhibitors%2520of%2520BTK%2520and%2520PI3K%25CE%25B4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D1161%26epage%3D1166%26doi%3D10.1021%2Facsmedchemlett.6b00356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eradat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ervin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coiffier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettitt, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahn, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span> <span> </span><span class="NLM_article-title">Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1315226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1056%2FNEJMoa1315226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24450857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVyqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=997-1007&issue=11&author=R.+R.+Furmanauthor=J.+P.+Sharmanauthor=S.+E.+Coutreauthor=B.+D.+Chesonauthor=J.+M.+Pagelauthor=P.+Hillmenauthor=J.+C.+Barrientosauthor=A.+D.+Zelenetzauthor=T.+J.+Kippsauthor=I.+Flinnauthor=P.+Ghiaauthor=H.+Eradatauthor=T.+Ervinauthor=N.+Lamannaauthor=B.+Coiffierauthor=A.+R.+Pettittauthor=S.+Maauthor=S.+Stilgenbauerauthor=P.+Cramerauthor=M.+Aielloauthor=D.+M.+Johnsonauthor=L.+L.+Millerauthor=D.+Liauthor=T.+M.+Jahnauthor=R.+D.+Danseyauthor=M.+Hallekauthor=S.+M.+O%E2%80%99Brien&title=Idelalisib+and+Rituximab+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1315226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib and rituximab in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Furman, Richard R.; Sharman, Jeff P.; Coutre, Steven E.; Cheson, Bruce D.; Pagel, John M.; Hillmen, Peter; Barrientos, Jacqueline C.; Zelenetz, Andrew D.; Kipps, Thomas J.; Flinn, Ian; Ghia, Paolo; Eradat, Herbert; Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; Pettitt, Andrew R.; Ma, Shuo; Stilgenbauer, Stephan; Cramer, Paula; Aiello, Maria; Johnson, Dave M.; Miller, Langdon L.; Li, Daniel; Jahn, Thomas M.; Dansey, Roger D.; Hallek, Michael; O'Brien, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">997-1007</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with relapsed chronic lymphocytic leukemia (CLL) who have clin. significant coexisting medical conditions are less able to undergo std. chemotherapy.  Effective therapies with acceptable side-effect profiles are needed for this patient population.  In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, the authors assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab vs. rituximab plus placebo.  The authors randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily.  The primary end point was progression-free survival.  At the first prespecified interim anal., the study was stopped early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy.  The median progression-free survival was 5.5 mo in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001).  Patients receiving idelalisib vs. those receiving placebo had improved rates of overall response (81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 mo (92% vs. 80%; hazard ratio for death, 0.28; P = 0.02).  Serious adverse events occurred in 40% of the patients receiving idelalisib and rituximab and in 35% of those receiving placebo and rituximab.  The combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOhnTsUaIOybVg90H21EOLACvtfcHk0lgk8ZgAP1TMDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVyqtLs%253D&md5=4bce9ab0dae94360abfcd4f312691503</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315226%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DCheson%26aufirst%3DB.%2BD.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DEradat%26aufirst%3DH.%26aulast%3DErvin%26aufirst%3DT.%26aulast%3DLamanna%26aufirst%3DN.%26aulast%3DCoiffier%26aufirst%3DB.%26aulast%3DPettitt%26aufirst%3DA.%2BR.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DCramer%26aufirst%3DP.%26aulast%3DAiello%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DJahn%26aufirst%3DT.%2BM.%26aulast%3DDansey%26aufirst%3DR.%2BD.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26atitle%3DIdelalisib%2520and%2520Rituximab%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D11%26spage%3D997%26epage%3D1007%26doi%3D10.1056%2FNEJMoa1315226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Weerdt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopmans, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kater, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gelder, M.</span></span> <span> </span><span class="NLM_article-title">Incidence and Management of Toxicity Associated with Ibrutinib and Idelalisib: A Practical Approach</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1629</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.164103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3324%2Fhaematol.2017.164103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1629-1639&issue=10&author=I.+de+Weerdtauthor=S.+M.+Koopmansauthor=A.+P.+Katerauthor=M.+van+Gelder&title=Incidence+and+Management+of+Toxicity+Associated+with+Ibrutinib+and+Idelalisib%3A+A+Practical+Approach&doi=10.3324%2Fhaematol.2017.164103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.164103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.164103%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeerdt%26aufirst%3DI.%26aulast%3DKoopmans%26aufirst%3DS.%2BM.%26aulast%3DKater%26aufirst%3DA.%2BP.%26aulast%3Dvan%2BGelder%26aufirst%3DM.%26atitle%3DIncidence%2520and%2520Management%2520of%2520Toxicity%2520Associated%2520with%2520Ibrutinib%2520and%2520Idelalisib%253A%2520A%2520Practical%2520Approach%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26issue%3D10%26spage%3D1629%26epage%3D1639%26doi%3D10.3324%2Fhaematol.2017.164103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutré, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poleski, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A. D.</span></span> <span> </span><span class="NLM_article-title">Management of Adverse Events Associated with Idelalisib Treatment: Expert Panel Opinion</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2779</span>– <span class="NLM_lpage">2786</span>, <span class="refDoi"> DOI: 10.3109/10428194.2015.1022770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3109%2F10428194.2015.1022770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=25726955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=2779-2786&issue=10&author=S.+E.+Coutr%C3%A9author=J.+C.+Barrientosauthor=J.+R.+Brownauthor=S.+de+Vosauthor=R.+R.+Furmanauthor=M.+J.+Keatingauthor=D.+Liauthor=S.+M.+O%E2%80%99Brienauthor=J.+M.+Pagelauthor=M.+H.+Poleskiauthor=J.+P.+Sharmanauthor=N.-S.+Yaoauthor=A.+D.+Zelenetz&title=Management+of+Adverse+Events+Associated+with+Idelalisib+Treatment%3A+Expert+Panel+Opinion&doi=10.3109%2F10428194.2015.1022770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse events associated with idelalisib treatment: expert panel opinion</span></div><div class="casAuthors">Coutre, Steven E.; Barrientos, Jacqueline C.; Brown, Jennifer R.; de Vos, Sven; Furman, Richard R.; Keating, Michael J.; Li, Daniel; O'Brien, Susan M.; Pagel, John M.; Poleski, Martin H.; Sharman, Jeff P.; Yao, Nai-Shun; Zelenetz, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2779-2786</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer.  Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clin. trials.  However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.  An expert panel was convened to review the pathol. of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy.  This article provides an overview of idelalisib TEAEs reported in clin. trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis.  For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or i.v. steroid therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGi1H-woJu7Vg90H21EOLACvtfcHk0lgk8ZgAP1TMDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O&md5=649cb8c3d6fe0a60f74b3f9413e4706a</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1022770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1022770%26sid%3Dliteratum%253Aachs%26aulast%3DCoutr%25C3%25A9%26aufirst%3DS.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DPoleski%26aufirst%3DM.%2BH.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DN.-S.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26atitle%3DManagement%2520of%2520Adverse%2520Events%2520Associated%2520with%2520Idelalisib%2520Treatment%253A%2520Expert%2520Panel%2520Opinion%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2015%26volume%3D56%26issue%3D10%26spage%3D2779%26epage%3D2786%26doi%3D10.3109%2F10428194.2015.1022770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, F. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peña, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genvresse, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Phase I Study of Copanlisib (BAY 80-6946), an Intravenous Pan-Class I Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphomas</span>. <i>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1928</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1093%2Fannonc%2Fmdw282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27672108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1928-1940&issue=10&author=A.+Patnaikauthor=L.+J.+Applemanauthor=A.+W.+Tolcherauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=G.+J.+Weissauthor=J.+C.+Sachdevauthor=M.+Chadhaauthor=M.+Fulkauthor=S.+Ejadiauthor=J.+M.+Mountzauthor=M.+T.+Lotzeauthor=F.+G.+S.+Toledoauthor=E.+Chuauthor=M.+Jeffersauthor=C.+Pe%C3%B1aauthor=C.+Xiaauthor=S.+Reifauthor=I.+Genvresseauthor=R.+K.+Ramanathan&title=First-in-Human+Phase+I+Study+of+Copanlisib+%28BAY+80-6946%29%2C+an+Intravenous+Pan-Class+I+Phosphatidylinositol+3-Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+and+Non-Hodgkin%E2%80%99s+Lymphomas&doi=10.1093%2Fannonc%2Fmdw282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas</span></div><div class="casAuthors">Patnaik A; Tolcher A W; Papadopoulos K P; Beeram M; Rasco D W; Appleman L J; Mountz J M; Lotze M T; Toledo F G S; Chu E; Weiss G J; Sachdev J C; Chadha M; Fulk M; Ejadi S; Ramanathan R K; Jeffers M; Pena C; Xia C; Reif S; Genvresse I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1928-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).  PATIENTS AND METHODS:  Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus.  Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the dose range 0.1-1.2 mg/kg.  Plasma copanlisib levels were analyzed for pharmacokinetics.  Biomarker analysis included PIK3CA, KRAS, BRAF, and PTEN mutational status and PTEN immunohistochemistry.  Whole-body [(18)F]-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) was carried out at baseline and following the first dose to assess early pharmacodynamic effects.  Plasma glucose and insulin levels were evaluated serially.  RESULTS:  Fifty-seven patients received treatment.  The MTD was 0.8 mg/kg copanlisib.  The most frequent treatment-related adverse events were nausea and transient hyperglycemia.  Copanlisib exposure was dose-proportional with no accumulation; peak exposure positively correlated with transient hyperglycemia post-infusion.  Sixteen of 20 patients treated at the MTD had reduced (18)FDG-PET uptake; 7 (33%) had a reduction >25%.  One patient achieved a complete response (CR; endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss) and two had a partial response (PR; both metastatic breast cancer).  Among the nine NHL patients, all six with follicular lymphoma (FL) responded (one CR and five PRs) and one patient with diffuse large B-cell lymphoma had a PR by investigator assessment; two patients with FL who achieved CR (per post hoc independent radiologic review) were on treatment >3 years.  CONCLUSION:  Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg.  Copanlisib exhibited dose-proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with NHL.  CLINICALTRIALSGOV:  NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5iDaGefdSJNFxYDaSSP8XfW6udTcc2eaeJMkVd3PcLLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D&md5=219db9cc72ca2493834406a977141667</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw282%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DFulk%26aufirst%3DM.%26aulast%3DEjadi%26aufirst%3DS.%26aulast%3DMountz%26aufirst%3DJ.%2BM.%26aulast%3DLotze%26aufirst%3DM.%2BT.%26aulast%3DToledo%26aufirst%3DF.%2BG.%2BS.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DPe%25C3%25B1a%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DReif%26aufirst%3DS.%26aulast%3DGenvresse%26aufirst%3DI.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DFirst-in-Human%2520Phase%2520I%2520Study%2520of%2520Copanlisib%2520%2528BAY%252080-6946%2529%252C%2520an%2520Intravenous%2520Pan-Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520and%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphomas%26jtitle%3DAnn.%2520Oncol.%2520Off.%2520J.%2520Eur.%2520Soc.%2520Med.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3D10%26spage%3D1928%26epage%3D1940%26doi%3D10.1093%2Fannonc%2Fmdw282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&issue=17&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+Descriptors+of+Aromatic+Character+and+Their+Use+in+Drug+Discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520Descriptors%2520of%2520Aromatic%2520Character%2520and%2520Their%2520Use%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D17%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lit6ME5shlyLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94','cit94b'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 51 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kongjun Liu, Dan Li, Wei Zheng, Mingsong Shi, Yong Chen, Minghai Tang, Tao Yang, Min Zhao, Dexin Deng, Chufeng Zhang, Jiang Liu, Xue Yuan, Zhuang Yang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8951-8970. <a href="https://doi.org/10.1021/acs.jmedchem.1c00004" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252BOptimization%25252C%252Band%252BEvaluation%252Bof%252BQuinazolinone%252BDerivatives%252Bwith%252BNovel%252BLinkers%252Bas%252BOrally%252BEfficacious%252BPhosphoinositide-3-Kinase%252BDelta%252BInhibitors%252Bfor%252BTreatment%252Bof%252BInflammatory%252BDiseases%26aulast%3DLiu%26aufirst%3DKongjun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03012021%26date%3D17062021%26volume%3D64%26issue%3D13%26spage%3D8951%26epage%3D8970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Ming Ji, Songwen Lin, Shouguo Peng, Zhihui Zhang, Mingyi Zhang, Jingbo Zhang, Yan Zhang, Deyu Wu, Hua Tian, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7331-7340. <a href="https://doi.org/10.1021/acs.jmedchem.0c02186" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02186%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Ba%252BNovel%252BPhotocaged%252BPI3K%252BInhibitor%252Btoward%252BPrecise%252BCancer%252BTreatment%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D18122020%26date%3D20042021%26volume%3D64%26issue%3D11%26spage%3D7331%26epage%3D7340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Meredeth A. McGowan, Neville John Anthony, Matthew Christopher, Yudith Garcia, Abdelghani Achab, Kathryn Lipford, Benjamin Wesley Trotter, Michael D. Altman, Xavier Fradera, Charles A. Lesburg, Chaomin Li, Stephen Alves, Craig P. Chappell, Renu Jain, Ruban Mangado, Elaine Pinheiro, Sybill M. G. Williams, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vincent Tong, Robbie L. McLeod, Hyun-Hee Lee, Hongshi Yu, Sanjiv Shah, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 5137-5156. <a href="https://doi.org/10.1021/acs.jmedchem.1c00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProjected%252BDose%252BOptimization%252Bof%252BAmino-%252Band%252BHydroxypyrrolidine%252BPurine%252BPI3K%2525CE%2525B4%252BImmunomodulators%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06022021%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D5137%26epage%3D5156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hengmiao Cheng, Suvi T. M. Orr, Simon Bailey, Alexei Brooun, Ping Chen, Judith G. Deal, Yali L. Deng, Martin P. Edwards, Gary M. Gallego, Neil Grodsky, Buwen Huang, Mehran Jalaie, Stephen Kaiser, Robert S. Kania, Susan E. Kephart, Jennifer Lafontaine, Martha A. Ornelas, Mason Pairish, Simon Planken, Hong Shen, Scott Sutton, Luke Zehnder, Chau D. Almaden, Shubha Bagrodia, Matthew D. Falk, Hovhannes J. Gukasyan, Caroline Ho, Xiaolin Kang, Rachel E. Kosa, Ling Liu, Mary E. Spilker, Sergei Timofeevski, Ravi Visswanathan, Zhenxiong Wang, Fanxiu Meng, Shijian Ren, Li Shao, Feng Xu, <span class="NLM_string-name hlFld-ContribAuthor">John C. Kath</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 644-661. <a href="https://doi.org/10.1021/acs.jmedchem.0c01652" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDrug%252BDesign%252Band%252BSynthesis%252Bof%252BPI3K%2525CE%2525B1-Selective%252BInhibitor%252B%252528PF-06843195%252529%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D24122020%26volume%3D64%26issue%3D1%26spage%3D644%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Abdelghani Achab, Matthew Christopher, Hua Zhou, Meredeth A. McGowan, B. Wesley Trotter, Xavier Fradera, Charles A. Lesburg, Peter Goldenblatt, Armetta Hill, Dapeng Chen, Karin M. Otte, Martin Augustin, Sanjiv Shah, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2461-2469. <a href="https://doi.org/10.1021/acsmedchemlett.0c00441" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00441%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252BVersatile%252BOxindoles%252Bas%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitors%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12082020%26date%3D17112020%26date%3D19112020%26volume%3D11%26issue%3D12%26spage%3D2461%26epage%3D2469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng Li, Xiaofei Liang, Zongru Jiang, Aoli Wang, Junjie Wang, Cheng Chen, Wenliang Wang, Fengming Zou, Ziping Qi, Qingwang Liu, Zhenquan Hu, Jiangyan Cao, Hong Wu, Beilei Wang, Li Wang, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Qingsong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13973-13993. <a href="https://doi.org/10.1021/acs.jmedchem.0c01544" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01544%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-2-%2525281-%2525284-Amino-3-%2525283-fluoro-4-methoxyphenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529propyl%252529-3-cyclopropyl-5-fluoroquinazolin-4%2525283H%252529-one%252B%252528IHMT-PI3K%2525CE%2525B4-372%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DLi%26aufirst%3DFeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03092020%26date%3D12112020%26volume%3D63%26issue%3D22%26spage%3D13973%26epage%3D13993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dillon H. Miles, Xuelei Yan, Rhiannon Thomas-Tran, Jeremy Fournier, Ehesan U. Sharif, Samuel L. Drew, Guillaume Mata, Kenneth V. Lawson, Elaine Ginn, Kent Wong, Divyank Soni, Puja Dhanota, Stefan G. Shaqfeh, Cesar Meleza, Ada Chen, Amber T. Pham, Timothy Park, Debbie Swinarski, Jesus Banuelos, Ulrike Schindler, Matthew J. Walters, Nigel P. Walker, Xiaoning Zhao, Stephen W. Young, Jie Chen, Lixia Jin, Manmohan Reddy Leleti, Jay P. Powers, <span class="NLM_string-name hlFld-ContribAuthor">Jenna L. Jeffrey</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2244-2252. <a href="https://doi.org/10.1021/acsmedchemlett.0c00387" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00387</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00387%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252B7-Azaindole%252BIsoindolinone-Based%252BPI3K%2525CE%2525B3%252BInhibitors%26aulast%3DMiles%26aufirst%3DDillon%2BH.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11072020%26date%3D24092020%26date%3D30092020%26date%3D24092020%26volume%3D11%26issue%3D11%26spage%3D2244%26epage%3D2252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dinesh Mahajan, Somdutta Sen, Bilash Kuila, Amit Sharma, Reena Arora, Milind Sagar, Amal Ray Mahapatra, Lalita Babasaheb Gawade, <span class="NLM_string-name hlFld-ContribAuthor">Sundeep Dugar</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11121-11130. <a href="https://doi.org/10.1021/acs.jmedchem.0c01061" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01061%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BSPR519%252Bas%252Ba%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BInhibitor%252Bof%252BPI3K%2525CE%2525B1%252Band%252BmTOR%252BKinases%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumors%26aulast%3DMahajan%26aufirst%3DDinesh%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19062020%26date%3D23092020%26date%3D08092020%26volume%3D63%26issue%3D19%26spage%3D11121%26epage%3D11130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephane Perreault, Fatima Arjmand, Jayaraman Chandrasekhar, Jia Hao, Kathleen S. Keegan, David Koditek, Eve-Irene Lepist, Clinton K. Matson, Mary E. McGrath, Leena Patel, Kassandra Sedillo, Joseph Therrien, Nicholas A. Till, Adrian Tomkinson, Jennifer Treiberg, Yelena Zherebina, <span class="NLM_string-name hlFld-ContribAuthor">Gary Phillips</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1236-1243. <a href="https://doi.org/10.1021/acsmedchemlett.0c00095" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00095%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ban%252BAtropisomeric%252BPI3K%2525CE%2525B2%252BSelective%252BInhibitor%252Bthrough%252BOptimization%252Bof%252Bthe%252BHinge%252BBinding%252BMotif%26aulast%3DPerreault%26aufirst%3DStephane%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22022020%26date%3D13042020%26date%3D15042020%26date%3D13042020%26volume%3D11%26issue%3D6%26spage%3D1236%26epage%3D1243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Frederick W. Goldberg, M. Raymond V. Finlay, Attilla K. T. Ting, David Beattie, Gillian M. Lamont, Charlene Fallan, Gail L. Wrigley, Marianne Schimpl, Martin R. Howard, Beth Williamson, Mercedes Vazquez-Chantada, Derek G. Barratt, Barry R. Davies, Elaine B. Cadogan, Antonio Ramos-Montoya, <span class="NLM_string-name hlFld-ContribAuthor">Emma Dean</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (7)
                                     , 3461-3471. <a href="https://doi.org/10.1021/acs.jmedchem.9b01684" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Bof%252B7-Methyl-2-%25255B%2525287-methyl%25255B1%25252C2%25252C4%25255Dtriazolo%25255B1%25252C5-a%25255Dpyridin-6-yl%252529amino%25255D-9-%252528tetrahydro-2H-pyran-4-yl%252529-7%25252C9-dihydro-8H-purin-8-one%252B%252528AZD7648%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BDNA-Dependent%252BProtein%252BKinase%252B%252528DNA-PK%252529%252BInhibitor%26aulast%3DGoldberg%26aufirst%3DFrederick%2BW.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11102019%26date%3D15012020%26date%3D18122019%26volume%3D63%26issue%3D7%26spage%3D3461%26epage%3D3471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ya’nan Yu, Yuqiao Han, Fupo Zhang, Zhenmei Gao, Tong Zhu, Suzhen Dong, <span class="NLM_string-name hlFld-ContribAuthor">Mingliang Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3028-3046. <a href="https://doi.org/10.1021/acs.jmedchem.9b01736" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01736%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BImidazo%25255B1%25252C2-a%25255Dpyridine%252BDerivatives%252Bas%252BNovel%252BPI3K%25252FmTOR%252BDual%252BInhibitors%26aulast%3DYu%26aufirst%3DYa%25E2%2580%2599nan%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D28102019%26date%3D27022020%26date%3D18022020%26volume%3D63%26issue%3D6%26spage%3D3028%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lydia Barnes, Hollie Blaber, David T. K. Brooks, Lewis Byers, Daniel Buckley, Zoe C. Byron, Richard G. Chilvers, Liam Cochrane, Edward Cooney, Heather A. Damian, Luke Francis, Daniel Fu He, Jack M. J. Grace, Harley J. Green, Edmund J. P. Hogarth, Leyla Jusu, C. Elizabeth Killalea, Oliver King, Joseph Lambert, Zoe J. Lee, Nuria S. Lima, Christina L. Long, May-Li Mackinnon, Shusha Mahdy, Jolyon Matthews-Wright, Makenzie J. Millward, Matthew F. Meehan, Christopher Merrett, Lisa Morrison, Hal R. I. Parke, Charlotte Payne, Lawrence Payne, Craig Pike, Alexander Seal, Aaron J. Senior, Keenan M. Smith, Kamile Stanelyte, Joe Stillibrand, Rachel Szpara, Freya F. H. Taday, Antony M. Threadgould, Rohan J. Trainor, Jordan Waters, Oliver Williams, Carrie K. W. Wong, Katherine Wood, Nick Barton, Anna Gruszka, Zoe Henley, James E. Rowedder, Rosa Cookson, Katherine L. Jones, Alan Nadin, Ian E. Smith, Simon J. F. Macdonald, <span class="NLM_string-name hlFld-ContribAuthor">Andrew Nortcliffe</span>. </span><span class="cited-content_cbyCitation_article-title">Free–Wilson Analysis of Comprehensive Data on Phosphoinositide-3-kinase (PI3K) Inhibitors Reveals Importance of N-Methylation for PI3Kδ Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10402-10422. <a href="https://doi.org/10.1021/acs.jmedchem.9b01499" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01499%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFree%2525E2%252580%252593Wilson%252BAnalysis%252Bof%252BComprehensive%252BData%252Bon%252BPhosphoinositide-3-kinase%252B%252528PI3K%252529%252BInhibitors%252BReveals%252BImportance%252Bof%252BN-Methylation%252Bfor%252BPI3K%2525CE%2525B4%252BActivity%26aulast%3DBarnes%26aufirst%3DLydia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11092019%26date%3D06112019%26date%3D24102019%26volume%3D62%26issue%3D22%26spage%3D10402%26epage%3D10422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Songwen Lin, Jing Jin, Ying Liu, Hua Tian, Yan Zhang, Rong Fu, Jingbo Zhang, Mingjin Wang, Tingting Du, Ming Ji, Deyu Wu, Kehui Zhang, Li Sheng, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (19)
                                     , 8873-8879. <a href="https://doi.org/10.1021/acs.jmedchem.9b00969" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00969</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00969%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Methylquinazoline%252BBased%252BPI3K%252BInhibitors%252Bfor%252Bthe%252BPotential%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%26aulast%3DLin%26aufirst%3DSongwen%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18062019%26date%3D06082019%26date%3D23072019%26volume%3D62%26issue%3D19%26spage%3D8873%26epage%3D8879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Chengjun  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiao  He</span>, <span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingkang  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>49 </em>, 128286. <a href="https://doi.org/10.1016/j.bmcl.2021.128286" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128286%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bpotent%252BmTOR%25252FHDAC%252Bbi-functional%252Binhibitors%252Bvia%252Bpharmacophore-merging%252Bstrategy%26aulast%3DZhang%26aufirst%3DMingming%26date%3D2021%26volume%3D49%26spage%3D128286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yeon Su  Kim</span>, <span class="hlFld-ContribAuthor ">Min Gyeong  Cheon</span>, <span class="hlFld-ContribAuthor ">Pulla Reddy  Boggu</span>, <span class="hlFld-ContribAuthor ">Su Youn  Koh</span>, <span class="hlFld-ContribAuthor ">Gi Min  Park</span>, <span class="hlFld-ContribAuthor ">Gahee  Kim</span>, <span class="hlFld-ContribAuthor ">Seo Hyun  Park</span>, <span class="hlFld-ContribAuthor ">Sung Lyea  Park</span>, <span class="hlFld-ContribAuthor ">Chi Woo  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Woo  Kim</span>, <span class="hlFld-ContribAuthor ">Young Hoon  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>45 </em>, 116312. <a href="https://doi.org/10.1016/j.bmc.2021.116312" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116312%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpurinyl%252Bquinazolinone%252Bderivatives%252Bas%252BPI3K%2525CE%2525B4-specific%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bhematologic%252Bmalignancies%26aulast%3DKim%26aufirst%3DYeon%2BSu%26date%3D2021%26volume%3D45%26spage%3D116312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xavier  Fradera</span>, <span class="hlFld-ContribAuthor ">Qiaolin  Deng</span>, <span class="hlFld-ContribAuthor ">Abdelganhi  Achab</span>, <span class="hlFld-ContribAuthor ">Yudith  Garcia</span>, <span class="hlFld-ContribAuthor ">Solomon D.  Kattar</span>, <span class="hlFld-ContribAuthor ">Meredeth A.  McGowan</span>, <span class="hlFld-ContribAuthor ">Joey L.  Methot</span>, <span class="hlFld-ContribAuthor ">Kevin  Wilson</span>, <span class="hlFld-ContribAuthor ">Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Lynsey  Shaffer</span>, <span class="hlFld-ContribAuthor ">Peter  Goldenblatt</span>, <span class="hlFld-ContribAuthor ">Vincent  Tong</span>, <span class="hlFld-ContribAuthor ">Martin A  Augustin</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Charles A.  Lesburg</span>, <span class="hlFld-ContribAuthor ">Sanjiv  Shah</span>, <span class="hlFld-ContribAuthor ">Jason D.  Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a new series of PI3K-δ inhibitors from Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>42 </em>, 128046. <a href="https://doi.org/10.1016/j.bmcl.2021.128046" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnew%252Bseries%252Bof%252BPI3K-%2525CE%2525B4%252Binhibitors%252Bfrom%252BVirtual%252BScreening%26aulast%3DFradera%26aufirst%3DXavier%26date%3D2021%26volume%3D42%26spage%3D128046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suwen  Hu</span>, <span class="hlFld-ContribAuthor ">Zi  Hui</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (5)
                                     , 435-452. <a href="https://doi.org/10.1080/13543776.2021.1866540" title="DOI URL">https://doi.org/10.1080/13543776.2021.1866540</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1866540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1866540%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecule%252BDNA-PK%252Binhibitors%252Bas%252Bpotential%252Bcancer%252Btherapy%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%2525E2%252580%252593present%252529%26aulast%3DHu%26aufirst%3DSuwen%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D5%26spage%3D435%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Kan  Li</span>, <span class="hlFld-ContribAuthor ">Li  Yu</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Yanfei  Cai</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>41 </em>
                                    (3)
                                     , 1599-1621. <a href="https://doi.org/10.1002/med.21770" title="DOI URL">https://doi.org/10.1002/med.21770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21770%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252Bphosphatidylinositol%252B3%2525E2%252580%252590kinase%252Bgamma%252B%252528PI3K%2525CE%2525B3%252529%25253A%252BDiscovery%252Band%252Bdevelopment%252Bof%252Bits%252Bselective%252Binhibitors%26aulast%3DZhu%26aufirst%3DJingyu%26date%3D2021%26date%3D2020%26volume%3D41%26issue%3D3%26spage%3D1599%26epage%3D1621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyu  Li</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Golden</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of
              N
              ‐Boc‐2‐Alkylaminoquinazolin‐4(3
              H
              )‐Ones via a Three‐Component, One‐Pot Protocol Mediated by Copper(II) Chloride that Spares Enantiomeric Purity. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (6)
                                     , 1638-1645. <a href="https://doi.org/10.1002/adsc.202001279" title="DOI URL">https://doi.org/10.1002/adsc.202001279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001279%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DConstruction%252Bof%252BN%252B%2525E2%252580%252590Boc%2525E2%252580%2525902%2525E2%252580%252590Alkylaminoquinazolin%2525E2%252580%2525904%2525283%252BH%252B%252529%2525E2%252580%252590Ones%252Bvia%252Ba%252BThree%2525E2%252580%252590Component%25252C%252BOne%2525E2%252580%252590Pot%252BProtocol%252BMediated%252Bby%252BCopper%252528II%252529%252BChloride%252Bthat%252BSpares%252BEnantiomeric%252BPurity%26aulast%3DLi%26aufirst%3DXiaoyu%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D6%26spage%3D1638%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruoyu  He</span>, <span class="hlFld-ContribAuthor ">Bingyong  Xu</span>, <span class="hlFld-ContribAuthor ">Li  Ping</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113249. <a href="https://doi.org/10.1016/j.ejmech.2021.113249" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113249%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Btowards%252Bpromising%252B%2525CE%2525B2-methyl-4-acrylamido%252Bquinoline%252Bderivatives%252Bas%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%252Bfor%252Banti-cancer%252Btherapy%25253A%252BThe%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bbiological%252Bevaluation%26aulast%3DHe%26aufirst%3DRuoyu%26date%3D2021%26volume%3D214%26spage%3D113249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 448-457. <a href="https://doi.org/10.1002/cmdc.202000643" title="DOI URL">https://doi.org/10.1002/cmdc.202000643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000643%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMultitarget%252BInhibition%252Bof%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252Band%252BPhosphatidylinositol%2525E2%252580%2525903%2525E2%252580%252590kinase%252B%252528PI3K%252529%25253A%252BCurrent%252Band%252BFuture%252BProspects%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D448%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Pedicone</span>, <span class="hlFld-ContribAuthor ">Shea T.  Meyer</span>, <span class="hlFld-ContribAuthor ">John D.  Chisholm</span>, <span class="hlFld-ContribAuthor ">William G.  Kerr</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting SHIP1 and SHIP2 in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 890. <a href="https://doi.org/10.3390/cancers13040890" title="DOI URL">https://doi.org/10.3390/cancers13040890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040890%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BSHIP1%252Band%252BSHIP2%252Bin%252BCancer%26aulast%3DPedicone%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guirong  You</span>, <span class="hlFld-ContribAuthor ">Zhi-Xin  Chang</span>, <span class="hlFld-ContribAuthor ">Jizhong  Yan</span>, <span class="hlFld-ContribAuthor ">Chengcai  Xia</span>, <span class="hlFld-ContribAuthor ">Fu-Rong  Li</span>, <span class="hlFld-ContribAuthor ">Hong-Shuang  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium-catalyzed sequential intermolecular hydroacylation and deconjugative isomerization toward diversified diketones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (1)
                                     , 39-45. <a href="https://doi.org/10.1039/D0QO01174F" title="DOI URL">https://doi.org/10.1039/D0QO01174F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01174F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01174F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRhodium-catalyzed%252Bsequential%252Bintermolecular%252Bhydroacylation%252Band%252Bdeconjugative%252Bisomerization%252Btoward%252Bdiversified%252Bdiketones%26aulast%3DYou%26aufirst%3DGuirong%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D1%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongyan  Gu</span>, <span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Bo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115863. <a href="https://doi.org/10.1016/j.bmc.2020.115863" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115863%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%2525285-%252528quinolin-6-yl%252529-1%25252C3%25252C4-oxadiazol-2-yl%252529acetamide%252Bderivatives%252Bas%252Bnovel%252BPI3K%2525CE%2525B1%252Binhibitors%252Bvia%252Bdocking-based%252Bvirtual%252Bscreening%26aulast%3DGu%26aufirst%3DDongyan%26date%3D2021%26volume%3D29%26spage%3D115863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Sun</span>, <span class="hlFld-ContribAuthor ">Rong  Fu</span>, <span class="hlFld-ContribAuthor ">Songwen  Lin</span>, <span class="hlFld-ContribAuthor ">Jingbo  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Deyu  Wu</span>, <span class="hlFld-ContribAuthor ">Kehui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hua  Tian</span>, <span class="hlFld-ContribAuthor ">Mingyi  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Sheng</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Jin</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Heng  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115890. <a href="https://doi.org/10.1016/j.bmc.2020.115890" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115890%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnew%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine%252Band%252Bthiazolo%25255B5%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Borally%252Bactive%252Bphosphoinositide%252B3-kinase%252Binhibitors%26aulast%3DSun%26aufirst%3DYan%26date%3D2021%26volume%3D29%26spage%3D115890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Xiang  Wang</span>, <span class="hlFld-ContribAuthor ">Yan-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Xi  Zhang</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Zhi-Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Xiao-Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Zhao-Bing  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ling-Hua  Meng</span>, <span class="hlFld-ContribAuthor ">Chun-Hao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112913. <a href="https://doi.org/10.1016/j.ejmech.2020.112913" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112913%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bmethyl%252B%2525285-%2525286-%252528%2525284-%252528methylsulfonyl%252529piperazin-1-yl%252529methyl%252529-4-morpholinopyrrolo%25255B2%25252C1-f%25255D%25255B1%25252C2%25252C4%25255Dtriazin-2-yl%252529-4-%252528trifluoromethyl%252529pyridin-2-yl%252529carbamate%252B%252528CYH33%252529%252Bas%252Ban%252Borally%252Bbioavailable%25252C%252Bhighly%252Bpotent%25252C%252BPI3K%252Balpha%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Badvanced%252Bsolid%252Btumors%26aulast%3DXiang%26aufirst%3DHao-Yue%26date%3D2021%26volume%3D209%26spage%3D112913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">Keena L.  Green</span>, <span class="hlFld-ContribAuthor ">Barbara  Müller</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">David  Askin</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a practical synthesis to PI3K α-selective inhibitor GDC-0326. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>79 </em>, 131840. <a href="https://doi.org/10.1016/j.tet.2020.131840" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131840%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DDevelopment%252Bof%252Ba%252Bpractical%252Bsynthesis%252Bto%252BPI3K%252B%2525CE%2525B1-selective%252Binhibitor%252BGDC-0326%26aulast%3DKoenig%26aufirst%3DStefan%2BG.%26date%3D2021%26volume%3D79%26spage%3D131840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victoria Heather  Gilchrist</span>, <span class="hlFld-ContribAuthor ">Estephanie  Jémus-Gonzalez</span>, <span class="hlFld-ContribAuthor ">Aida  Said</span>, <span class="hlFld-ContribAuthor ">Tommy  Alain</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Cytokine & Growth Factor Reviews</span><span> <strong>2020,</strong> <em>56 </em>, 83-93. <a href="https://doi.org/10.1016/j.cytogfr.2020.07.008" title="DOI URL">https://doi.org/10.1016/j.cytogfr.2020.07.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cytogfr.2020.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cytogfr.2020.07.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCytokine%2520%2526%2520Growth%2520Factor%2520Reviews%26atitle%3DKinase%252Binhibitors%252Bwith%252Bviral%252Boncolysis%25253A%252BUnmasking%252Bpharmacoviral%252Bapproaches%252Bfor%252Bcancer%252Btherapy%26aulast%3DGilchrist%26aufirst%3DVictoria%2BHeather%26date%3D2020%26volume%3D56%26spage%3D83%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingzhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K inhibitors: review and new strategies. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (23)
                                     , 5855-5865. <a href="https://doi.org/10.1039/D0SC01676D" title="DOI URL">https://doi.org/10.1039/D0SC01676D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC01676D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC01676D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DPI3K%252Binhibitors%25253A%252Breview%252Band%252Bnew%252Bstrategies%26aulast%3DZhang%26aufirst%3DMingzhen%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D23%26spage%3D5855%26epage%3D5865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rammohan R.Y.  Bheemanaboina</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform-Selective PI3K Inhibitors for Various Diseases. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1074-1092. <a href="https://doi.org/10.2174/1568026620666200106141717" title="DOI URL">https://doi.org/10.2174/1568026620666200106141717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200106141717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200106141717%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DIsoform-Selective%252BPI3K%252BInhibitors%252Bfor%252BVarious%252BDiseases%26aulast%3DBheemanaboina%26aufirst%3DRammohan%2BR.Y.%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1074%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuanglei  Wang</span>, <span class="hlFld-ContribAuthor ">Hongxi  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongshou  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbamyl in structural optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103757. <a href="https://doi.org/10.1016/j.bioorg.2020.103757" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103757%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbamyl%252Bin%252Bstructural%252Boptimization%26aulast%3DWang%26aufirst%3DKuanglei%26date%3D2020%26volume%3D98%26spage%3D103757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiangqiang  Tao</span>, <span class="hlFld-ContribAuthor ">Yuqing  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao  Liang</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Jiaming  Li</span>, <span class="hlFld-ContribAuthor ">Fang  Fang</span>, <span class="hlFld-ContribAuthor ">Huchuan  Wang</span>, <span class="hlFld-ContribAuthor ">Chang  Meng</span>, <span class="hlFld-ContribAuthor ">Jingtai  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Shuangying  Gui</span>. </span><span class="cited-content_cbyCitation_article-title">Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>191 </em>, 112143. <a href="https://doi.org/10.1016/j.ejmech.2020.112143" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112143</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112143%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructurally%252Bnovel%252BPI3K%2525CE%2525B4%25252F%2525CE%2525B3%252Bdual%252Binhibitors%252Bcharacterized%252Bby%252Ba%252Bseven-membered%252Bspirocyclic%252Bspacer%25253A%252BThe%252BSARs%252Binvestigation%252Band%252BPK%252Bevaluation%26aulast%3DTao%26aufirst%3DQiangqiang%26date%3D2020%26volume%3D191%26spage%3D112143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sifan  Yu</span>, <span class="hlFld-ContribAuthor ">Jinzhou  Chen</span>, <span class="hlFld-ContribAuthor ">Gengxin  Liu</span>, <span class="hlFld-ContribAuthor ">Jinping  Lei</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>, <span class="hlFld-ContribAuthor ">Huang  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">A gold(
              i
              )-catalysed chemoselective three-component reaction between phenols, α-diazocarbonyl compounds and allenamides. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (11)
                                     , 1649-1652. <a href="https://doi.org/10.1039/C9CC09470A" title="DOI URL">https://doi.org/10.1039/C9CC09470A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC09470A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC09470A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DA%252Bgold%252528%252Bi%252B%252529-catalysed%252Bchemoselective%252Bthree-component%252Breaction%252Bbetween%252Bphenols%25252C%252B%2525CE%2525B1-diazocarbonyl%252Bcompounds%252Band%252Ballenamides%26aulast%3DYu%26aufirst%3DSifan%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D11%26spage%3D1649%26epage%3D1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob A.  McPhail</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 203-222. <a href="https://doi.org/10.1007/978-3-030-50621-6_9" title="DOI URL">https://doi.org/10.1007/978-3-030-50621-6_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-50621-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-50621-6_9%26sid%3Dliteratum%253Aachs%26atitle%3DDrugging%252Bthe%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252Band%252BPhosphatidylinositol%252B4-Kinase%252B%252528PI4K%252529%252BFamily%252Bof%252BEnzymes%252Bfor%252BTreatment%252Bof%252BCancer%25252C%252BImmune%252BDisorders%25252C%252Band%252BViral%25252FParasitic%252BInfections%26aulast%3DMcPhail%26aufirst%3DJacob%2BA.%26date%3D2020%26date%3D2020%26spage%3D203%26epage%3D222%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDruggable%252BLipid%252BSignaling%252BPathways%26aulast%3DKihara%26aufirst%3DYasuyuki%26date%3D2020%26volume%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Cu</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 925-941. <a href="https://doi.org/10.1080/13543776.2019.1687685" title="DOI URL">https://doi.org/10.1080/13543776.2019.1687685</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1687685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1687685%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPI3K%2525CE%2525B4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282015-present%252529%26aulast%3DFeng%26aufirst%3DYifan%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D925%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huai-Wei  Ding</span>, <span class="hlFld-ContribAuthor ">Lu  Yu</span>, <span class="hlFld-ContribAuthor ">Meng-xuan  Bai</span>, <span class="hlFld-ContribAuthor ">Xiao-Chun  Qin</span>, <span class="hlFld-ContribAuthor ">Man-tong  Song</span>, <span class="hlFld-ContribAuthor ">Qing-Chun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>93 </em>, 103283. <a href="https://doi.org/10.1016/j.bioorg.2019.103283" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103283%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bsome%252B1%25252C6-disubstituted-1H-benzo%25255Bd%25255Dimidazoles%252Bderivatives%252Btargeted%252BPI3K%252Bas%252Banticancer%252Bagents%26aulast%3DDing%26aufirst%3DHuai-Wei%26date%3D2019%26volume%3D93%26spage%3D103283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatma M.  Elmenier</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111718. <a href="https://doi.org/10.1016/j.ejmech.2019.111718" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111718%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPhosphatidylinositol%252B3%252Bkinase%252B%252528PI3K%252529%252Binhibitors%252Bas%252Bnew%252Bweapon%252Bto%252Bcombat%252Bcancer%26aulast%3DElmenier%26aufirst%3DFatma%2BM.%26date%3D2019%26volume%3D183%26spage%3D111718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gong</span>, <span class="hlFld-ContribAuthor ">Tang</span>, <span class="hlFld-ContribAuthor ">Liu</span>, <span class="hlFld-ContribAuthor ">Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (23)
                                     , 4299. <a href="https://doi.org/10.3390/molecules24234299" title="DOI URL">https://doi.org/10.3390/molecules24234299</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24234299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24234299%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BNovel%252B2H-Benzo%25255Be%25255D-%25255B1%25252C2%25252C4%25255Dthiadiazine%252B1%25252C1-Dioxide%252BDerivatives%252Bas%252BPI3K%2525CE%2525B4%252BInhibitors%26aulast%3DGong%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D23%26spage%3D4299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Yin</span>, <span class="hlFld-ContribAuthor ">Shao  Sha</span>, <span class="hlFld-ContribAuthor ">Xun  Wu</span>, <span class="hlFld-ContribAuthor ">She-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Fang  Qiao</span>, <span class="hlFld-ContribAuthor ">Zhong-Cheng  Song</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111630. <a href="https://doi.org/10.1016/j.ejmech.2019.111630" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111630%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252Bchromeno%25255B4%25252C3-c%25255Dpyrazol-4%2525282H%252529-one%252Bderivates%252Bbearing%252Bsulfonylpiperazine%252Bas%252Bantitumor%252Binhibitors%252Btargeting%252BPI3K%2525CE%2525B1%26aulast%3DYin%26aufirst%3DYong%26date%3D2019%26volume%3D182%26spage%3D111630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Weiming  Duan</span>, <span class="hlFld-ContribAuthor ">Shu  Fan</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (19)
                                     , 115035. <a href="https://doi.org/10.1016/j.bmc.2019.07.051" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.07.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.07.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.07.051%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-%252528piperid-3-yl%252529amino%252Bsubstituted%252B6-pyridylquinazolines%252Bas%252Bpotent%252BPI3K%2525CE%2525B4%252Binhibitors%26aulast%3DFeng%26aufirst%3DYifan%26date%3D2019%26volume%3D27%26issue%3D19%26spage%3D115035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Mu  Hu</span>, <span class="hlFld-ContribAuthor ">Hai  Dong</span>, <span class="hlFld-ContribAuthor ">Yue-Dan  Li</span>, <span class="hlFld-ContribAuthor ">Ping  Huang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Tian</span>, <span class="hlFld-ContribAuthor ">Ping-An  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Tandem grinding reactions involving aldol condensation and Michael addition in sequence for synthesis of 3,4,5-trisubstituted isoxazoles. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (48)
                                     , 27883-27887. <a href="https://doi.org/10.1039/C9RA04864B" title="DOI URL">https://doi.org/10.1039/C9RA04864B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA04864B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA04864B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DTandem%252Bgrinding%252Breactions%252Binvolving%252Baldol%252Bcondensation%252Band%252BMichael%252Baddition%252Bin%252Bsequence%252Bfor%252Bsynthesis%252Bof%252B3%25252C4%25252C5-trisubstituted%252Bisoxazoles%26aulast%3DHu%26aufirst%3DXiao-Mu%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D48%26spage%3D27883%26epage%3D27887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xavier  Fradera</span>, <span class="hlFld-ContribAuthor ">Joey L.  Methot</span>, <span class="hlFld-ContribAuthor ">Abdelghani  Achab</span>, <span class="hlFld-ContribAuthor ">Matthew  Christopher</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Meredeth A.  McGowan</span>, <span class="hlFld-ContribAuthor ">Sam D.  Kattar</span>, <span class="hlFld-ContribAuthor ">Kevin  Wilson</span>, <span class="hlFld-ContribAuthor ">Yudith  Garcia</span>, <span class="hlFld-ContribAuthor ">Martin A.  Augustin</span>, <span class="hlFld-ContribAuthor ">Charles A.  Lesburg</span>, <span class="hlFld-ContribAuthor ">Sanjiv  Shah</span>, <span class="hlFld-ContribAuthor ">Peter  Goldenblatt</span>, <span class="hlFld-ContribAuthor ">Jason D.  Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2575-2580. <a href="https://doi.org/10.1016/j.bmcl.2019.08.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.08.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.08.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bof%252Bselective%252BPI3K%2525CE%2525B4%252Binhibitors%252Busing%252Ban%252Biterative%252Bscaffold-hopping%252Bworkflow%26aulast%3DFradera%26aufirst%3DXavier%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2575%26epage%3D2580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernd  Nürnberg</span>, <span class="hlFld-ContribAuthor ">Sandra  Beer-Hammer</span>. </span><span class="cited-content_cbyCitation_article-title">Function, Regulation and Biological Roles of PI3Kγ Variants. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (9)
                                     , 427. <a href="https://doi.org/10.3390/biom9090427" title="DOI URL">https://doi.org/10.3390/biom9090427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9090427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9090427%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DFunction%25252C%252BRegulation%252Band%252BBiological%252BRoles%252Bof%252BPI3K%2525CE%2525B3%252BVariants%26aulast%3DN%25C3%25BCrnberg%26aufirst%3DBernd%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D9%26spage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2019,</strong> <em>12 </em>
                                    (2)
                                     , 69. <a href="https://doi.org/10.3390/ph12020069" title="DOI URL">https://doi.org/10.3390/ph12020069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph12020069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph12020069%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DDuvelisib%25253A%252BA%252B2018%252BNovel%252BFDA-Approved%252BSmall%252BMolecule%252BInhibiting%252BPhosphoinositide%252B3-Kinases%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D2%26spage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Fang  Fang</span>, <span class="hlFld-ContribAuthor ">Qiangqiang  Tao</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">Guochen  Zhong</span>, <span class="hlFld-ContribAuthor ">Tao  Qiao</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Jiaming  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Conformationally restricted quinazolone derivatives as PI3Kδ-selective inhibitors: the design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 413-420. <a href="https://doi.org/10.1039/C8MD00556G" title="DOI URL">https://doi.org/10.1039/C8MD00556G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00556G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00556G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DConformationally%252Brestricted%252Bquinazolone%252Bderivatives%252Bas%252BPI3K%2525CE%2525B4-selective%252Binhibitors%25253A%252Bthe%252Bdesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D3%26spage%3D413%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Miller</span>, <span class="hlFld-ContribAuthor ">Philip  Thompson</span>, <span class="hlFld-ContribAuthor ">Sandra  Gabelli</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Determinants of Isoform Selectivity in PI3K Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 82. <a href="https://doi.org/10.3390/biom9030082" title="DOI URL">https://doi.org/10.3390/biom9030082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9030082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9030082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DStructural%252BDeterminants%252Bof%252BIsoform%252BSelectivity%252Bin%252BPI3K%252BInhibitors%26aulast%3DMiller%26aufirst%3DMichelle%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PI3K medicinal-chemistry-based publications and PI3K chemical patents from 2012 to 2018 (source SciFinder).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ligand bound X-ray crystal structure of IC87114 in PI3Kδ showing the essential hinge binding interaction of Val828 and the specificity and affinity pockets as well as the hydrophobic region II (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X38">2X38</a>) visualized in PyMOL.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of <b>1</b> (PIK-39) in PI3Kδ demonstrating the propeller-shape conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF">2WXF</a>), visualized in PyMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of idelalisib bound to the ATP site of the P110 catalytic subunit of PI3Kδ showing the “propeller shape” adopted and the key hinge interactions with Val828 and Glu826 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XEO">4XEO</a>), visualized in PyMOL.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Exploration of the Hinge Binding Groups Present in <b>2</b> (Idelalisib)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Building on PI3Kδ inhibitor idealisib to generate the PI3Kα/β inhibitor <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Discovery of the selective PI3Kδ inhibitor <b>33</b> (AMG319).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Discovery of <b>41</b> (LAS191954) through an Extensive SAR Exploration</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Exploration of the Hinge Binding Regions and Introduction of a C-8 Alkynyl Substituent</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Huisgen Cycloaddition To Generate a Range of Analogs Such as <b>47</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Incorporation of dibasic groups to improve lung tissue retention after delivery through inhalation</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. X-ray crystal structure of <b>52</b> (GDC-0941) in PI3Kγ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS">3DBS</a>) visualized in PyMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Chemical Exploration of the Piperizine Group through Amidation To Deliver (<i>S</i>)-<b>61</b> (Apitoloisib)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. X-ray cocrystal structure of <b>106</b> bound into PI3Kδ. Key interactions between <b>106</b> and the hinge included Val828 and Glu826 and a close interaction between the carbonyl of the acetamide group and Thr750. The pyrazole group of <b>106</b> filled a hydrophobic pocket formed by Ile825 (not shown) and participated in an edge-to-face interaction with Tyr813 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VLR">5VLR</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Aminotriazine-based hinge binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Discovery of <b>119</b> (Copanlisib), a PI3K Inhibitor with Potential Antineoplastic Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Identification of <b>120</b> and the Evolution to <b>122</b> (GSK2269557) and <b>124</b> (GSK2292767)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. 2,8-Disubstituted Pyrido[3,2-<i>d</i>]pyrimidine Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Evolution of 7,9-Disubstituted 2-Morpholino-4<i>H</i>-pyrido[1,2-<i>a</i>]pyrimidin-4-one-Based Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Chemical Modifications on <b>146</b> To Deliver AZD8186, a PI3Kβ Inhibitor for Use in Treating Patients with Advanced Solid Tumors with PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Pyrido[1,2-<i>a</i>]pyrimidinone-Based Class 1 PI3K Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Extensive SAR To Deliver <b>151</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Binding of <b>156</b> to the ATP binding site of P110β (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR">4BFR</a>), visualized in PyMOL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. X-ray crystal structures of <b>157</b> showing a shorter hydrogen bond and better angle for interaction with the hinge Val882 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R">3R7R</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <b>165</b> X-ray crystal structure in PI3Kα where the primary amide makes three concerted hydrogen bonds with Gln859 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Discovery of the Urea-Based Inhibitor <b>171</b> from Early HTS of a Kinase Focused Library</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. X-ray crystal structure of <b>185</b> in PI3Kγ, demonstrating new key interactions generating isoform selectivity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PS3">4PS3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/medium/jm-2018-01492k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Strategy employed to reduce the number of H-bond donor groups to aid CNS penetration and compound <b>187</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01492/20190516/images/large/jm-2018-01492k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01492&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 154 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Signalling through the Lipid Products of Phosphoinositide-3-OH Kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>387</i></span> (<span class="NLM_issue">6634</span>),  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1038/42648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2F42648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=1997&pages=673-676&issue=6634&author=A.+Tokerauthor=L.+C.+Cantley&title=Signalling+through+the+Lipid+Products+of+Phosphoinositide-3-OH+Kinase&doi=10.1038%2F42648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F42648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F42648%26sid%3Dliteratum%253Aachs%26aulast%3DToker%26aufirst%3DA.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DSignalling%2520through%2520the%2520Lipid%2520Products%2520of%2520Phosphoinositide-3-OH%2520Kinase%26jtitle%3DNature%26date%3D1997%26volume%3D387%26issue%3D6634%26spage%3D673%26epage%3D676%26doi%3D10.1038%2F42648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&issue=2&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lhF3ll5mCY53g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span> <span> </span><span class="NLM_article-title">Class I Phosphatidylinositol 3-Kinase Inhibitors for Cancer Therapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.apsb.2016.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28119806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=27-37&issue=1&author=W.+Zhaoauthor=Y.+Qiuauthor=D.+Kong&title=Class+I+Phosphatidylinositol+3-Kinase+Inhibitors+for+Cancer+Therapy&doi=10.1016%2Fj.apsb.2016.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Zhao Wennan; Qiu Yuling; Kong Dexin</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers.  Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis.  Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors.  Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy.  Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials.  Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc.  This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfpaqoNC7CEjAyhZbj3lKdfW6udTcc2eb1_fcBuCZjCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ovFOrsg%253D%253D&md5=9506d6088eb6f72dc579ece97bb19930</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DD.%26atitle%3DClass%2520I%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520for%2520Cancer%2520Therapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.apsb.2016.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Use of PI3K Inhibitors for Glioblastoma Multiforme: Current Preclinical and Clinical Development</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0670-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1186%2Fs12943-017-0670-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28592260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC1cnmtVyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=100&issue=1&author=H.+Zhaoauthor=J.+Wangauthor=W.+Shaoauthor=C.+Wuauthor=Z.+Chenauthor=S.+T.+Toauthor=W.+Li&title=Recent+Advances+in+the+Use+of+PI3K+Inhibitors+for+Glioblastoma+Multiforme%3A+Current+Preclinical+and+Clinical+Development&doi=10.1186%2Fs12943-017-0670-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development</span></div><div class="casAuthors">Zhao Hua-Fu; Wu Chang-Peng; Li Wei-Ping; Zhao Hua-Fu; Wang Jing; Chen Zhong-Ping; Shao Wei; To Shing-Shun Tony; Wu Chang-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system.  One of the most widely used chemotherapeutic drugs for GBM is temozolomide, which is a DNA-alkylating agent and its efficacy is dependent on MGMT methylation status.  Little progress in improving the prognosis of GBM patients has been made in the past ten years, urging the development of more effective molecular targeted therapies.  Hyper-activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is frequently found in a variety of cancers including GBM, and it plays a central role in the regulation of tumor cell survival, growth, motility, angiogenesis and metabolism.  Numerous PI3K inhibitors including pan-PI3K, isoform-selective and dual PI3K/mammalian target of rapamycin (mTOR) inhibitors have exhibited favorable preclinical results and entered clinical trials in a range of hematologic malignancies and solid tumors.  Furthermore, combination of inhibitors targeting PI3K and other related pathways may exert synergism on suppressing tumor growth and improving patients' prognosis.  Currently, only a handful of PI3K inhibitors are in phase I/II clinical trials for GBM treatment.  In this review, we focus on the importance of PI3K/Akt pathway in GBM, and summarize the current development of PI3K inhibitors alone or in combination with other inhibitors for GBM treatment from preclinical to clinical studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoYdXHzx6A1kGy1nwu7K2mfW6udTcc2ea8lhEbUJJ257ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnmtVyluw%253D%253D&md5=9d329ca3e72fd5e88b57588574bce2bb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0670-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0670-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTo%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Use%2520of%2520PI3K%2520Inhibitors%2520for%2520Glioblastoma%2520Multiforme%253A%2520Current%2520Preclinical%2520and%2520Clinical%2520Development%26jtitle%3DMol.%2520Cancer%26date%3D2017%26volume%3D16%26issue%3D1%26spage%3D100%26doi%3D10.1186%2Fs12943-017-0670-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzugullu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">PI3K in Cancer: Divergent Roles of Isoforms, Modes of Activation and Therapeutic Targeting</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1038/nrc3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnrc3860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=25533673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=7-24&issue=1&author=L.+M.+Thorpeauthor=H.+Yuzugulluauthor=J.+J.+Zhao&title=PI3K+in+Cancer%3A+Divergent+Roles+of+Isoforms%2C+Modes+of+Activation+and+Therapeutic+Targeting&doi=10.1038%2Fnrc3860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting</span></div><div class="casAuthors">Thorpe, Lauren M.; Yuzugullu, Haluk; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli.  Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers.  In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxh6fOPe86x7Vg90H21EOLACvtfcHk0lgeAqfsMAmo5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb3N&md5=0b609a62c2ec9fcc6efae437d2ed7a24</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3860%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DL.%2BM.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DPI3K%2520in%2520Cancer%253A%2520Divergent%2520Roles%2520of%2520Isoforms%252C%2520Modes%2520of%2520Activation%2520and%2520Therapeutic%2520Targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26issue%3D1%26spage%3D7%26epage%3D24%26doi%3D10.1038%2Fnrc3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span> <span> </span><span class="NLM_article-title">PI3K Inhibitors in Inflammation, Autoimmunity and Cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.coph.2015.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=26093105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=82-91&author=A.+K.+Starkauthor=S.+Sriskantharajahauthor=E.+M.+Hesselauthor=K.+Okkenhaug&title=PI3K+Inhibitors+in+Inflammation%2C+Autoimmunity+and+Cancer&doi=10.1016%2Fj.coph.2015.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K inhibitors in inflammation, autoimmunity and cancer</span></div><div class="casAuthors">Stark, Anne-Katrien; Sriskantharajah, Srividya; Hessel, Edith M.; Okkenhaug, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-91</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues.  Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer.  Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research.  In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small mol. inhibitors, of which several are currently in clin. trials for the treatment of immune-related disorders and cancer.  The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clin. and clin. development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNWPQZuO9fE7Vg90H21EOLACvtfcHk0lgeAqfsMAmo5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM&md5=382eb159c8ec5e3a4bc14f71f54dd295</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DA.%2BK.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%2520Inhibitors%2520in%2520Inflammation%252C%2520Autoimmunity%2520and%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D82%26epage%3D91%26doi%3D10.1016%2Fj.coph.2015.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase (PI3K) Pathway Inhibitors in Solid Tumors: From Laboratory to Patients</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ctrv.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28779636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WgtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=93-101&author=F.+Janku&title=Phosphoinositide+3-Kinase+%28PI3K%29+Pathway+Inhibitors+in+Solid+Tumors%3A+From+Laboratory+to+Patients&doi=10.1016%2Fj.ctrv.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients</span></div><div class="casAuthors">Janku, Filip</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K) pathway is an intracellular signaling pathway that has regulatory roles in cell survival, proliferation, and differentiation, and a crit. role in tumorigenesis.  In cancer, multiple studies have investigated the therapeutic targeting of the PI3K pathway, and multiple inhibitors targeting PI3K and its isoforms, protein kinase B/AKT, mammalian target of rapamycin (mTOR), and other pathway proteins have been developed.  For the treatment of solid tumors, only allosteric mTOR inhibitors, such as everolimus and temsirolimus, are currently approved for clin. use.  This review describes the PI3K inhibitors that have progressed from the lab. to late-stage clin. trials, and discusses the challenges that have prevented other compds. from doing the same.  Challenges to the therapeutic effectiveness of some PI3K inhibitors include the absence of reliable and effective biomarkers, their limited efficacy as single agents, insufficient development of rational therapeutic combinations, the use of schedules with a variety of off-target effects, and suboptimal therapeutic exposures.  Therefore, with regard to PI3K inhibitors currently in late-stage clin. trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQhlVdFU8NPrVg90H21EOLACvtfcHk0lhzY16FfE_bNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WgtbrJ&md5=5b60a21296fea87bffc4e691f9e5c7be</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DJanku%26aufirst%3DF.%26atitle%3DPhosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520Pathway%2520Inhibitors%2520in%2520Solid%2520Tumors%253A%2520From%2520Laboratory%2520to%2520Patients%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2017%26volume%3D59%26spage%3D93%26epage%3D101%26doi%3D10.1016%2Fj.ctrv.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunder, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for P110α in Insulin Signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&issue=4&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+P110%CE%B1+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0lhzY16FfE_bNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520P110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26issue%3D4%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span> <span> </span><span class="NLM_article-title">The PI3K/AKT Pathway in Obesity and Type 2 Diabetes</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.7150/ijbs.27173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.7150%2Fijbs.27173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=30263000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVyqsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1483-1496&issue=11&author=X.+Huangauthor=G.+Liuauthor=J.+Guoauthor=Z.+Su&title=The+PI3K%2FAKT+Pathway+in+Obesity+and+Type+2+Diabetes&doi=10.7150%2Fijbs.27173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K/AKT pathway in obesity and type 2 diabetes</span></div><div class="casAuthors">Huang, Xingjun; Liu, Guihua; Guo, Jiao; Su, Zhengquan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1483-1496</span>CODEN:
                <span class="NLM_cas:coden">IJBSB9</span>;
        ISSN:<span class="NLM_cas:issn">1449-2288</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Obesity and type 2 diabetes mellitus are complicated metabolic diseases that affect multiple organs and are characterized by hyperglycemia.  Currently, stable and effective treatments for obesity and type 2 diabetes mellitus are not available.  Therefore, the mechanisms leading to obesity and diabetes and more effective ways to treat obesity and diabetes should be identified.  Based on accumulated evidences, the PI3K/AKT signalling pathway is required for normal metab. due to its characteristics, and its imbalance leads to the development of obesity and type 2 diabetes mellitus.  This review focuses on the role of PI3K/AKT signalling in the skeletal muscle, adipose tissue, liver, brain and pancreas, and discusses how this signalling pathway affects the development of the aforementioned diseases.  We also summarize evidences for recently identified therapeutic targets of the PI3K/AKT pathway as treatments for obesity and type 2 diabetes mellitus.  PI3K/AKT pathway damaged in various tissues of the body leads to obesity and type 2 diabetes as the result of insulin resistance, and in turn, insulin resistance exacerbates the PI3K/AKT pathway, forming a vicious circle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRWKUROIFqVbVg90H21EOLACvtfcHk0lhzY16FfE_bNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVyqsbbJ&md5=8aa3b9f581f25e971f689164b0ac2505</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7150%2Fijbs.27173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.27173%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26atitle%3DThe%2520PI3K%252FAKT%2520Pathway%2520in%2520Obesity%2520and%2520Type%25202%2520Diabetes%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2018%26volume%3D14%26issue%3D11%26spage%3D1483%26epage%3D1496%26doi%3D10.7150%2Fijbs.27173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenwaelder, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesbitt, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dopheide, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgeon, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabaharan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, H. H.</span></span> <span> </span><span class="NLM_article-title">PI 3-Kinase P110β: A New Target for Antithrombotic Therapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/nm1232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnm1232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=15834429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=507-514&issue=5&author=S.%0AP.+Jacksonauthor=S.+M.+Schoenwaelderauthor=I.+Goncalvesauthor=W.+S.+Nesbittauthor=C.+L.+Yapauthor=C.+E.+Wrightauthor=V.+Kencheauthor=K.+E.+Andersonauthor=S.+M.+Dopheideauthor=Y.+Yuanauthor=S.+A.+Sturgeonauthor=H.+Prabaharanauthor=P.+E.+Thompsonauthor=G.+D.+Smithauthor=P.+R.+Shepherdauthor=N.+Danieleauthor=S.+Kulkarniauthor=B.+Abbottauthor=D.+Saylikauthor=C.+Jonesauthor=L.+Luauthor=S.+Giulianoauthor=S.+C.+Hughanauthor=J.+A.+Angusauthor=A.+D.+Robertsonauthor=H.+H.+Salem&title=PI+3-Kinase+P110%CE%B2%3A+A+New+Target+for+Antithrombotic+Therapy&doi=10.1038%2Fnm1232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PI 3-kinase p110β: a new target for antithrombotic therapy</span></div><div class="casAuthors">Jackson, Shaun P.; Schoenwaelder, Simone M.; Goncalves, Isaac; Nesbitt, Warwick S.; Yap, Cindy L.; Wright, Christine E.; Kenche, Vijaya; Anderson, Karen E.; Dopheide, Sacha M.; Yuan, Yuping; Sturgeon, Sharelle A.; Prabaharan, Hishani; Thompson, Philip E.; Smith, Gregg D.; Shepherd, Peter R.; Daniele, Nathalie; Kulkarni, Suhasini; Abbott, Belinda; Saylik, Dilek; Jones, Catherine; Lu, Lucy; Giuliano, Simon; Hughan, Sascha C.; Angus, James A.; Robertson, Alan D.; Salem, Hatem H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-514</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, pptg. diseases such as acute myocardial infarction and ischemic stroke.  Rheol. disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin αIIbβ3 (GPIIb-IIIa).  In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110β isoform in regulating the formation and stability of integrin αIIbβ3 adhesion bonds, necessary for shear activation of platelets.  Isoform-selective PI3K p110β inhibitors have been developed which prevent formation of stable integrin αIIbβ3 adhesion contacts, leading to defective platelet thrombus formation.  In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time.  These studies define PI3K p110β as an important new target for antithrombotic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYnYolzsDrrVg90H21EOLACvtfcHk0lhn2iypLSSJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D&md5=c8dc7ba1955e86104ae913d39f22674b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm1232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1232%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26aulast%3DGoncalves%26aufirst%3DI.%26aulast%3DNesbitt%26aufirst%3DW.%2BS.%26aulast%3DYap%26aufirst%3DC.%2BL.%26aulast%3DWright%26aufirst%3DC.%2BE.%26aulast%3DKenche%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DDopheide%26aufirst%3DS.%2BM.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DSturgeon%26aufirst%3DS.%2BA.%26aulast%3DPrabaharan%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DSmith%26aufirst%3DG.%2BD.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDaniele%26aufirst%3DN.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DAbbott%26aufirst%3DB.%26aulast%3DSaylik%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DGiuliano%26aufirst%3DS.%26aulast%3DHughan%26aufirst%3DS.%2BC.%26aulast%3DAngus%26aufirst%3DJ.%2BA.%26aulast%3DRobertson%26aufirst%3DA.%2BD.%26aulast%3DSalem%26aufirst%3DH.%2BH.%26atitle%3DPI%25203-Kinase%2520P110%25CE%25B2%253A%2520A%2520New%2520Target%2520for%2520Antithrombotic%2520Therapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26issue%3D5%26spage%3D507%26epage%3D514%26doi%3D10.1038%2Fnm1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenwaelder, S. M.</span></span> <span> </span><span class="NLM_article-title">Antithrombotic Phosphoinositide 3-Kinase β Inhibitors in Humans: A ‘Shear’ Delight!</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2123</span>– <span class="NLM_lpage">2126</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2012.04912.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1111%2Fj.1538-7836.2012.04912.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22943292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSku77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2123-2126&issue=10&author=S.+P.+Jacksonauthor=S.+M.+Schoenwaelder&title=Antithrombotic+Phosphoinositide+3-Kinase+%CE%B2+Inhibitors+in+Humans%3A+A+%E2%80%98Shear%E2%80%99+Delight%21&doi=10.1111%2Fj.1538-7836.2012.04912.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a 'shear' delight" Comments</span></div><div class="casAuthors">Jackson, S. P.; Schoenwaelder, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2123-2126</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The research of Nylander et al. (2012) entitled, 'Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor' is reviewed with commentary and refs.  Nylander et al. performed a preclin. and phase I human study investigating the effects of a phosphoinositide 3-kinase (PI3K) inhibitor (AZD6482), selective for the p110β isoform (PI3Kβ), on platelet function, thrombosis, and bleeding.  Their findings generally provided important validation of PI3Kβ as a potentially important antithrombotic target in humans, and provided further support for the concept that PI3Kβ inhibitors may have a wide therapeutic window and represent a potentially safe antithrombotic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGv1NpKZjxOrVg90H21EOLACvtfcHk0lhn2iypLSSJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSku77P&md5=036329b65e313de7d3d02c98b2068bdd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2012.04912.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2012.04912.x%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26atitle%3DAntithrombotic%2520Phosphoinositide%25203-Kinase%2520%25CE%25B2%2520Inhibitors%2520in%2520Humans%253A%2520A%2520%25E2%2580%2598Shear%25E2%2580%2599%2520Delight%2521%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2012%26volume%3D10%26issue%3D10%26spage%3D2123%26epage%3D2126%26doi%3D10.1111%2Fj.1538-7836.2012.04912.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8559</span>– <span class="NLM_lpage">8581</span>, <span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&issue=20&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0lhn2iypLSSJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affleck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span> <span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase δ for Allergic Asthma</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1042/BST20110665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1042%2FBST20110665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22260698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=240-245&issue=1&author=W.+C.+Rowanauthor=J.+L.+Smithauthor=K.+Affleckauthor=A.+Amour&title=Targeting+Phosphoinositide+3-Kinase+%CE%B4+for+Allergic+Asthma&doi=10.1042%2FBST20110665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase δ for allergic asthma</span></div><div class="casAuthors">Rowan, Wendy C.; Smith, Janet L.; Affleck, Karen; Amour, Augustin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">240-245</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic inflammation in the lung has long been linked to the pathogenesis of asthma.  Central to this airway inflammation is a T-cell response to allergens, with Th2 cytokines driving the differentiation, survival and function of the major inflammatory cells involved in the allergic cascade.  PI3Kδ (phosphoinositide 3-kinase δ) is a lipid kinase, expressed predominantly in leukocytes, where it plays a crit. role in immune receptor signalling.  A selective PI3Kδ inhibitor is predicted to block T-cell activation in the lung, reducing the prodn. of pro-inflammatory Th2 cytokines.  PI3Kδ is also involved in B-cell and mast cell activation.  Therefore the inhibition of PI3Kδ should dampen down the inflammatory cascade involved in the asthmatic response through a wide breadth of pharmacol.  Current anti-inflammatory therapies, which are based on corticosteroids, are effective in controlling inflammation in mild asthmatics, but moderate/severe asthmatic patients remain poorly controlled, experiencing recurrent exacerbations.  Corticosteroids have no effect on mast cell degranulation and do not act directly on B-cells, so, overall, a PI3Kδ inhibitor has the potential to deliver improvements in onset of action, efficacy and reduced exacerbations in moderate/severe asthmatics.  Addnl., PI3Kδ inhibition is expected to block effects of Th17 cells, which are increasingly implicated in steroid-insensitive asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwu2SYlFjDbVg90H21EOLACvtfcHk0lhS_IB5n7QIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D&md5=db36bc8f79c70e0817e00fb9b04f10ff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1042%2FBST20110665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20110665%26sid%3Dliteratum%253Aachs%26aulast%3DRowan%26aufirst%3DW.%2BC.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520Allergic%2520Asthma%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2012%26volume%3D40%26issue%3D1%26spage%3D240%26epage%3D245%26doi%3D10.1042%2FBST20110665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojiaku, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2016-0308TR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1165%2Frcmb.2016-0308TR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27977296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1artrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=700-707&issue=6&author=E.+J.+Yooauthor=C.+A.+Ojiakuauthor=K.+Sunderauthor=R.+A.+Panettieri&title=Phosphoinositide+3-Kinase+in+Asthma%3A+Novel+Roles+and+Therapeutic+Approaches&doi=10.1165%2Frcmb.2016-0308TR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase in asthma: novel roles and therapeutic approaches</span></div><div class="casAuthors">Yoo, Edwin J.; Ojiaku, Christie A.; Sunder, Krishna; Panettieri, Reynold A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">700-707</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Asthma manifests as airway hyperresponsiveness and inflammation, including coughing, wheezing, and shortness of breath.  Immune cells and airway structural cells orchestrate asthma pathophysiol., leading to mucus secretion, airway narrowing, and obstruction.  Phosphoinositide 3-kinase, a lipid kinase, plays a crucial role in many of the cellular and mol. mechanisms driving asthma pathophysiol. and represents an attractive therapeutic target.  Here, we summarize the diverse roles of phosphoinositide 3-kinase in the pathogenesis of asthma and discuss novel therapeutic approaches to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraWH_Lnj-6X7Vg90H21EOLACvtfcHk0lhS_IB5n7QIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1artrrI&md5=67d7e791406eae6be3ebb2a352a13e9d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2016-0308TR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2016-0308TR%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DE.%2BJ.%26aulast%3DOjiaku%26aufirst%3DC.%2BA.%26aulast%3DSunder%26aufirst%3DK.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26atitle%3DPhosphoinositide%25203-Kinase%2520in%2520Asthma%253A%2520Novel%2520Roles%2520and%2520Therapeutic%2520Approaches%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2017%26volume%3D56%26issue%3D6%26spage%3D700%26epage%3D707%26doi%3D10.1165%2Frcmb.2016-0308TR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemela, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deenick, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palendira, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannons, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancalana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frucht, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agharahimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folio, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleisher, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittaluga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangye, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzel, G.</span></span> <span> </span><span class="NLM_article-title">Dominant-Activating Germline Mutations in the Gene Encoding the PI(3)K Catalytic Subunit P110δ Result in T Cell Senescence and Human Immunodeficiency</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1038/ni.2771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fni.2771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24165795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=88-97&issue=1&author=C.+L.+Lucasauthor=H.+S.+Kuehnauthor=F.+Zhaoauthor=J.+E.+Niemelaauthor=E.+K.+Deenickauthor=U.+Palendiraauthor=D.+T.+Averyauthor=L.+Moensauthor=J.+L.+Cannonsauthor=M.+Biancalanaauthor=J.+Stoddardauthor=W.+Ouyangauthor=D.+M.+Fruchtauthor=V.+K.+Raoauthor=T.+P.+Atkinsonauthor=A.+Agharahimiauthor=A.+A.+Husseyauthor=L.+R.+Folioauthor=K.+N.+Olivierauthor=T.+A.+Fleisherauthor=S.+Pittalugaauthor=S.+M.+Hollandauthor=J.+I.+Cohenauthor=J.+B.+Oliveiraauthor=S.+G.+Tangyeauthor=P.+L.+Schwartzbergauthor=M.+J.+Lenardoauthor=G.+Uzel&title=Dominant-Activating+Germline+Mutations+in+the+Gene+Encoding+the+PI%283%29K+Catalytic+Subunit+P110%CE%B4+Result+in+T+Cell+Senescence+and+Human+Immunodeficiency&doi=10.1038%2Fni.2771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</span></div><div class="casAuthors">Lucas, Carrie L.; Kuehn, Hye Sun; Zhao, Fang; Niemela, Julie E.; Deenick, Elissa K.; Palendira, Umaimainthan; Avery, Danielle T.; Moens, Leen; Cannons, Jennifer L.; Biancalana, Matthew; Stoddard, Jennifer; Ouyang, Weiming; Frucht, David M.; Rao, V. Koneti; Atkinson, T. Prescott; Agharahimi, Anahita; Hussey, Ashleigh A.; Folio, Les R.; Olivier, Kenneth N.; Fleisher, Thomas A.; Pittaluga, Stefania; Holland, Steven M.; Cohen, Jeffrey I.; Oliveira, Joao B.; Tangye, Stuart G.; Schwartzberg, Pamela L.; Lenardo, Michael J.; Uzel, Gulbu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-97</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The p110δ subunit of phosphatidylinositol-3-OH kinase (PI(3)K) is selectively expressed in leukocytes and is crit. for lymphocyte biol.  Here we report fourteen patients from seven families who were heterozygous for three different germline, gain-of-function mutations in PIK3CD (which encodes p110δ).  These patients presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremia due to cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV).  Strikingly, they had a substantial deficiency in naive T cells but an over-representation of senescent effector T cells.  In vitro, T cells from patients exhibited increased phosphorylation of the kinase Akt and hyperactivation of the metabolic checkpoint kinase mTOR, enhanced glucose uptake and terminal effector differentiation.  Notably, treatment with rapamycin to inhibit mTOR activity in vivo partially restored the abundance of naive T cells, largely 'rescued' the in vitro T cell defects and improved the clin. course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFA88fwwfZf7Vg90H21EOLACvtfcHk0lhS_IB5n7QIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yhsb3L&md5=4bfccb05603009684ca01f893b29adc8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fni.2771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2771%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DNiemela%26aufirst%3DJ.%2BE.%26aulast%3DDeenick%26aufirst%3DE.%2BK.%26aulast%3DPalendira%26aufirst%3DU.%26aulast%3DAvery%26aufirst%3DD.%2BT.%26aulast%3DMoens%26aufirst%3DL.%26aulast%3DCannons%26aufirst%3DJ.%2BL.%26aulast%3DBiancalana%26aufirst%3DM.%26aulast%3DStoddard%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DW.%26aulast%3DFrucht%26aufirst%3DD.%2BM.%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DAtkinson%26aufirst%3DT.%2BP.%26aulast%3DAgharahimi%26aufirst%3DA.%26aulast%3DHussey%26aufirst%3DA.%2BA.%26aulast%3DFolio%26aufirst%3DL.%2BR.%26aulast%3DOlivier%26aufirst%3DK.%2BN.%26aulast%3DFleisher%26aufirst%3DT.%2BA.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BI.%26aulast%3DOliveira%26aufirst%3DJ.%2BB.%26aulast%3DTangye%26aufirst%3DS.%2BG.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DUzel%26aufirst%3DG.%26atitle%3DDominant-Activating%2520Germline%2520Mutations%2520in%2520the%2520Gene%2520Encoding%2520the%2520PI%25283%2529K%2520Catalytic%2520Subunit%2520P110%25CE%25B4%2520Result%2520in%2520T%2520Cell%2520Senescence%2520and%2520Human%2520Immunodeficiency%26jtitle%3DNat.%2520Immunol.%26date%3D2014%26volume%3D15%26issue%3D1%26spage%3D88%26epage%3D97%26doi%3D10.1038%2Fni.2771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banham-Hall, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plagnol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxendale, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake-Palmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perisic, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiddler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilliers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kielkowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcenas-Morales, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clatworthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilvers, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cant, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumararatne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condliffe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Gene Mutation Predisposes to Respiratory Infection and Airway Damage</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span> (<span class="NLM_issue">6160</span>),  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1126/science.1243292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1126%2Fscience.1243292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24136356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCrsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=866-871&issue=6160&author=I.+Anguloauthor=O.+Vadasauthor=F.+Garconauthor=E.+Banham-Hallauthor=V.+Plagnolauthor=T.+R.+Leahyauthor=H.+Baxendaleauthor=T.+Coulterauthor=J.+Curtisauthor=C.+Wuauthor=K.+Blake-Palmerauthor=O.+Perisicauthor=D.+Smythauthor=M.+Maesauthor=C.+Fiddlerauthor=J.+Jussauthor=D.+Cilliersauthor=G.+Markeljauthor=A.+Chandraauthor=G.+Farmerauthor=A.+Kielkowskaauthor=J.+Clarkauthor=S.+Krackerauthor=M.+Debreauthor=C.+Picardauthor=I.+Pellierauthor=N.+Jabadoauthor=J.+A.+Morrisauthor=G.+Barcenas-Moralesauthor=A.+Fischerauthor=L.+Stephensauthor=P.+Hawkinsauthor=J.+C.+Barrettauthor=M.+Abinunauthor=M.+Clatworthyauthor=A.+Durandyauthor=R.+Doffingerauthor=E.+R.+Chilversauthor=A.+J.+Cantauthor=D.+Kumararatneauthor=K.+Okkenhaugauthor=R.+L.+Williamsauthor=A.+Condliffeauthor=S.+Nejentsev&title=Phosphoinositide+3-Kinase+Gene+Mutation+Predisposes+to+Respiratory+Infection+and+Airway+Damage&doi=10.1126%2Fscience.1243292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage</span></div><div class="casAuthors">Angulo, Ivan; Vadas, Oscar; Garcon, Fabien; Banham-Hall, Edward; Plagnol, Vincent; Leahy, Timothy R.; Baxendale, Helen; Coulter, Tanya; Curtis, James; Wu, Changxin; Blake-Palmer, Katherine; Perisic, Olga; Smyth, Deborah; Maes, Mailis; Fiddler, Christine; Juss, Jatinder; Cilliers, Deirdre; Markelj, Gasper; Chandra, Anita; Farmer, George; Kielkowska, Anna; Clark, Jonathan; Kracker, Sven; Debre, Marianne; Picard, Capucine; Pellier, Isabelle; Jabado, Nada; Morris, James A.; Barcenas-Morales, Gabriela; Fischer, Alain; Stephens, Len; Hawkins, Phillip; Barrett, Jeffrey C.; Abinun, Mario; Clatworthy, Menna; Durandy, Anne; Doffinger, Rainer; Chilvers, Edwin R.; Cant, Andrew J.; Kumararatne, Dinakantha; Okkenhaug, Klaus; Williams, Roger L.; Condliffe, Alison; Nejentsev, Sergey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6160</span>),
    <span class="NLM_cas:pages">866-871</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Genetic mutations cause primary immunodeficiencies (PIDs) that predispose to infections.  Here, the authors describe activated PI3K-δ syndrome (APDS), a PID assocd. with a dominant gain-of-function mutation in which lysine replaced glutamic acid at residue 1021 (E1021K) in the p110δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ), encoded by the PIK3CD gene.  The authors found E1021K in 17 patients from seven unrelated families, but not among 3346 healthy subjects.  APDS was characterized by recurrent respiratory infections, progressive airway damage, lymphopenia, increased circulating transitional B cells, increased IgM, and reduced IgG2 levels in serum and impaired vaccine responses.  The E1021K mutation enhanced membrane assocn. and kinase activity of p110δ.  Patient-derived lymphocytes had increased levels of phosphatidylinositol 3,4,5-trisphosphate and phosphorylated AKT protein and were prone to activation-induced cell death.  Selective p110δ inhibitors IC87114 and GS-1101 reduced the activity of the mutant enzyme in vitro, which suggested a therapeutic approach for patients with APDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox6rTR4UfkVbVg90H21EOLACvtfcHk0lgmTwrlUssgWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCrsrbL&md5=7e5ed81697a879ef0bf8fb332f188400</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.1243292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1243292%26sid%3Dliteratum%253Aachs%26aulast%3DAngulo%26aufirst%3DI.%26aulast%3DVadas%26aufirst%3DO.%26aulast%3DGarcon%26aufirst%3DF.%26aulast%3DBanham-Hall%26aufirst%3DE.%26aulast%3DPlagnol%26aufirst%3DV.%26aulast%3DLeahy%26aufirst%3DT.%2BR.%26aulast%3DBaxendale%26aufirst%3DH.%26aulast%3DCoulter%26aufirst%3DT.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBlake-Palmer%26aufirst%3DK.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DSmyth%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DM.%26aulast%3DFiddler%26aufirst%3DC.%26aulast%3DJuss%26aufirst%3DJ.%26aulast%3DCilliers%26aufirst%3DD.%26aulast%3DMarkelj%26aufirst%3DG.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DFarmer%26aufirst%3DG.%26aulast%3DKielkowska%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DDebre%26aufirst%3DM.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DPellier%26aufirst%3DI.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DJ.%2BA.%26aulast%3DBarcenas-Morales%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DClatworthy%26aufirst%3DM.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DChilvers%26aufirst%3DE.%2BR.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26aulast%3DKumararatne%26aufirst%3DD.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DCondliffe%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26atitle%3DPhosphoinositide%25203-Kinase%2520Gene%2520Mutation%2520Predisposes%2520to%2520Respiratory%2520Infection%2520and%2520Airway%2520Damage%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D342%26issue%3D6160%26spage%3D866%26epage%3D871%26doi%3D10.1126%2Fscience.1243292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sediva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debré, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, J. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span> <span> </span><span class="NLM_article-title">Occurrence of B-Cell Lymphomas in Patients with Activated Phosphoinositide 3-Kinase δ Syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.jaci.2014.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24698326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltl2ksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=233-236&issue=1&author=S.+Krackerauthor=J.+Curtisauthor=M.+A.+A.+Ibrahimauthor=A.+Sedivaauthor=J.+Salisburyauthor=V.+Camprauthor=M.+Debr%C3%A9author=J.+D.+M.+Edgarauthor=K.+Imaiauthor=C.+Picardauthor=J.-L.+Casanovaauthor=A.+Fischerauthor=S.+Nejentsevauthor=A.+Durandy&title=Occurrence+of+B-Cell+Lymphomas+in+Patients+with+Activated+Phosphoinositide+3-Kinase+%CE%B4+Syndrome&doi=10.1016%2Fj.jaci.2014.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome</span></div><div class="casAuthors">Kracker, Sven; Curtis, James; Ibrahim, Mohammad A. A.; Sediva, Anna; Salisbury, Jon; Campr, Vit; Debre, Marianne; Edgar, J. David M.; Imai, Kohsuke; Picard, Capucine; Casanova, Jean-Laurent; Fischer, Alain; Nejentsev, Sergey; Durandy, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">233-236.e3</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Activated phosphoinositide 3-kinase δ syndrome (APDS) is a novel autosomal-dominant primary immunodeficiency (PID) caused by a heterozygous gain-of-function mutation in the PIK3CD gene encoding the p110δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ).  This article discusses the occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhInUP8M7s9LVg90H21EOLACvtfcHk0lgmTwrlUssgWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltl2ksbY%253D&md5=effd7e1d392375ce9fdfe55ce0942c72</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%2BA.%26aulast%3DSediva%26aufirst%3DA.%26aulast%3DSalisbury%26aufirst%3DJ.%26aulast%3DCampr%26aufirst%3DV.%26aulast%3DDebr%25C3%25A9%26aufirst%3DM.%26aulast%3DEdgar%26aufirst%3DJ.%2BD.%2BM.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DDurandy%26aufirst%3DA.%26atitle%3DOccurrence%2520of%2520B-Cell%2520Lymphomas%2520in%2520Patients%2520with%2520Activated%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2014%26volume%3D134%26issue%3D1%26spage%3D233%26epage%3D236%26doi%3D10.1016%2Fj.jaci.2014.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Screaton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodlad, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxendale, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatoniene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, J. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhurst, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speckmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimbacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sediva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucuk, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hague, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herriot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancrini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariganello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feighery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieux-Laucat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touzot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumararatne, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshous, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condliffe, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cant, A. J.</span></span> <span> </span><span class="NLM_article-title">Clinical Spectrum and Features of Activated Phosphoinositide 3-Kinase δ Syndrome: A Large Patient Cohort Study</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.jaci.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27555459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyqt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=597-606&issue=2&author=T.+I.+Coulterauthor=A.+Chandraauthor=C.+M.+Baconauthor=J.+Babarauthor=J.+Curtisauthor=N.+Screatonauthor=J.+R.+Goodladauthor=G.+Farmerauthor=C.+L.+Steeleauthor=T.+R.+Leahyauthor=R.+Doffingerauthor=H.+Baxendaleauthor=J.+Bernatonieneauthor=J.+D.+M.+Edgarauthor=H.+J.+Longhurstauthor=S.+Ehlauthor=C.+Speckmannauthor=B.+Grimbacherauthor=A.+Sedivaauthor=T.+Milotaauthor=S.+N.+Faustauthor=A.+P.+Williamsauthor=G.+Haymanauthor=Z.+Y.+Kucukauthor=R.+Hagueauthor=P.+Frenchauthor=R.+Brookerauthor=P.+Forsythauthor=R.+Herriotauthor=C.+Cancriniauthor=P.+Palmaauthor=P.+Ariganelloauthor=N.+Conlonauthor=C.+Feigheryauthor=P.+J.+Gavinauthor=A.+Jonesauthor=K.+Imaiauthor=M.+A.+A.+Ibrahimauthor=G.+Markeljauthor=M.+Abinunauthor=F.+Rieux-Laucatauthor=S.+Latourauthor=I.+Pellierauthor=A.+Fischerauthor=F.+Touzotauthor=J.-L.+Casanovaauthor=A.+Durandyauthor=S.+O.+Burnsauthor=S.+Savicauthor=D.+S.+Kumararatneauthor=D.+Moshousauthor=S.+Krackerauthor=B.+Vanhaesebroeckauthor=K.+Okkenhaugauthor=C.+Picardauthor=S.+Nejentsevauthor=A.+M.+Condliffeauthor=A.+J.+Cant&title=Clinical+Spectrum+and+Features+of+Activated+Phosphoinositide+3-Kinase+%CE%B4+Syndrome%3A+A+Large+Patient+Cohort+Study&doi=10.1016%2Fj.jaci.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study</span></div><div class="casAuthors">Coulter, Tanya I.; Chandra, Anita; Bacon, Chris M.; Babar, Judith; Curtis, James; Screaton, Nick; Goodlad, John R.; Farmer, George; Steele, Cathal Laurence; Leahy, Timothy Ronan; Doffinger, Rainer; Baxendale, Helen; Bernatoniene, Jolanta; Edgar, J. David M.; Longhurst, Hilary J.; Ehl, Stephan; Speckmann, Carsten; Grimbacher, Bodo; Sediva, Anna; Milota, Tomas; Faust, Saul N.; Williams, Anthony P.; Hayman, Grant; Kucuk, Zeynep Yesim; Hague, Rosie; French, Paul; Brooker, Richard; Forsyth, Peter; Herriot, Richard; Cancrini, Caterina; Palma, Paolo; Ariganello, Paola; Conlon, Niall; Feighery, Conleth; Gavin, Patrick J.; Jones, Alison; Imai, Kohsuke; Ibrahim, Mohammad A. A.; Markelj, Gasper; Abinun, Mario; Rieux-Laucat, Frederic; Latour, Sylvain; Pellier, Isabelle; Fischer, Alain; Touzot, Fabien; Casanova, Jean-Laurent; Durandy, Anne; Burns, Siobhan O.; Savic, Sinisa; Kumararatne, D. S.; Moshous, Despina; Kracker, Sven; Vanhaesebroeck, Bart; Okkenhaug, Klaus; Picard, Capucine; Nejentsev, Sergey; Condliffe, Alison M.; Cant, Andrew James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">597-606.e4</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ).  We sought to review the clin., immunol., histopathol., and radiol. features of APDS in a large genetically defined international cohort.  We applied a clin. questionnaire and performed review of medical notes, radiol., histopathol., and lab. investigations of 53 patients with APDS.  Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood.  Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%).  Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for PI3Kδ in the central nervous system; consistent with this, PI3Kδ is broadly expressed in the developing murine central nervous system.  Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%).  Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunol. features.  No immunol. marker reliably predicted clin. severity, which ranged from asymptomatic to death in early childhood.  The majority of patients received Ig replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation.  Five patients died from complications of APDS.  APDS is a combined immunodeficiency with multiple clin. manifestations, many with incomplete penetrance and others with variable expressivity.  The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease.  Clin. trials of selective PI3Kδ inhibitors offer new prospects for APDS treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorhoMuz1hapLVg90H21EOLACvtfcHk0lhgDIO7GrjIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyqt7jF&md5=26f3181a3b523a4af2e32eed1b950a6a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DCoulter%26aufirst%3DT.%2BI.%26aulast%3DChandra%26aufirst%3DA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DBabar%26aufirst%3DJ.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DScreaton%26aufirst%3DN.%26aulast%3DGoodlad%26aufirst%3DJ.%2BR.%26aulast%3DFarmer%26aufirst%3DG.%26aulast%3DSteele%26aufirst%3DC.%2BL.%26aulast%3DLeahy%26aufirst%3DT.%2BR.%26aulast%3DDoffinger%26aufirst%3DR.%26aulast%3DBaxendale%26aufirst%3DH.%26aulast%3DBernatoniene%26aufirst%3DJ.%26aulast%3DEdgar%26aufirst%3DJ.%2BD.%2BM.%26aulast%3DLonghurst%26aufirst%3DH.%2BJ.%26aulast%3DEhl%26aufirst%3DS.%26aulast%3DSpeckmann%26aufirst%3DC.%26aulast%3DGrimbacher%26aufirst%3DB.%26aulast%3DSediva%26aufirst%3DA.%26aulast%3DMilota%26aufirst%3DT.%26aulast%3DFaust%26aufirst%3DS.%2BN.%26aulast%3DWilliams%26aufirst%3DA.%2BP.%26aulast%3DHayman%26aufirst%3DG.%26aulast%3DKucuk%26aufirst%3DZ.%2BY.%26aulast%3DHague%26aufirst%3DR.%26aulast%3DFrench%26aufirst%3DP.%26aulast%3DBrooker%26aufirst%3DR.%26aulast%3DForsyth%26aufirst%3DP.%26aulast%3DHerriot%26aufirst%3DR.%26aulast%3DCancrini%26aufirst%3DC.%26aulast%3DPalma%26aufirst%3DP.%26aulast%3DAriganello%26aufirst%3DP.%26aulast%3DConlon%26aufirst%3DN.%26aulast%3DFeighery%26aufirst%3DC.%26aulast%3DGavin%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%2BA.%26aulast%3DMarkelj%26aufirst%3DG.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DRieux-Laucat%26aufirst%3DF.%26aulast%3DLatour%26aufirst%3DS.%26aulast%3DPellier%26aufirst%3DI.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DTouzot%26aufirst%3DF.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DBurns%26aufirst%3DS.%2BO.%26aulast%3DSavic%26aufirst%3DS.%26aulast%3DKumararatne%26aufirst%3DD.%2BS.%26aulast%3DMoshous%26aufirst%3DD.%26aulast%3DKracker%26aufirst%3DS.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DCondliffe%26aufirst%3DA.%2BM.%26aulast%3DCant%26aufirst%3DA.%2BJ.%26atitle%3DClinical%2520Spectrum%2520and%2520Features%2520of%2520Activated%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Syndrome%253A%2520A%2520Large%2520Patient%2520Cohort%2520Study%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2017%26volume%3D139%26issue%3D2%26spage%3D597%26epage%3D606%26doi%3D10.1016%2Fj.jaci.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkaim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui-Sekinaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heurtier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deau, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharapova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glastre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugakani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshous, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamrini, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otremba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougaris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodszki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlogis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutboul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejentsev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kracker, S.</span></span> <span> </span><span class="NLM_article-title">Clinical and Immunologic Phenotype Associated with Activated Phosphoinositide 3-Kinase δ Syndrome 2: A Cohort Study</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2016.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.jaci.2016.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27221134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVSmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=210-218&issue=1&author=E.+Elkaimauthor=B.+Nevenauthor=J.+Bruneauauthor=K.+Mitsui-Sekinakaauthor=A.+Stanislasauthor=L.+Heurtierauthor=C.+L.+Lucasauthor=H.+Matthewsauthor=M.-C.+Deauauthor=S.+Sharapovaauthor=J.+Curtisauthor=J.+Reichenbachauthor=C.+Glastreauthor=D.+A.+Parryauthor=G.+Arumugakaniauthor=E.+McDermottauthor=S.+S.+Kilicauthor=M.+Yamashitaauthor=D.+Moshousauthor=H.+Lamriniauthor=B.+Otrembaauthor=A.+Genneryauthor=T.+Coulterauthor=I.+Quintiauthor=J.-L.+Stephanauthor=V.+Lougarisauthor=N.+Brodszkiauthor=V.+Barlogisauthor=T.+Asanoauthor=L.+Galicierauthor=D.+Boutboulauthor=S.+Nonoyamaauthor=A.+Cantauthor=K.+Imaiauthor=C.+Picardauthor=S.+Nejentsevauthor=T.+J.+Molinaauthor=M.+Lenardoauthor=S.+Savicauthor=M.+Cavazzanaauthor=A.+Fischerauthor=A.+Durandyauthor=S.+Kracker&title=Clinical+and+Immunologic+Phenotype+Associated+with+Activated+Phosphoinositide+3-Kinase+%CE%B4+Syndrome+2%3A+A+Cohort+Study&doi=10.1016%2Fj.jaci.2016.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study</span></div><div class="casAuthors">Elkaim, Elodie; Neven, Benedicte; Bruneau, Julie; Mitsui-Sekinaka, Kanako; Stanislas, Aurelie; Heurtier, Lucie; Lucas, Carrie L.; Matthews, Helen; Deau, Marie-Celine; Sharapova, Svetlana; Curtis, James; Reichenbach, Janine; Glastre, Catherine; Parry, David A.; Arumugakani, Gururaj; McDermott, Elizabeth; Kilic, Sara Sebnem; Yamashita, Motoi; Moshous, Despina; Lamrini, Hicham; Otremba, Burkhard; Gennery, Andrew; Coulter, Tanya; Quinti, Isabella; Stephan, Jean-Louis; Lougaris, Vassilios; Brodszki, Nicholas; Barlogis, Vincent; Asano, Takaki; Galicier, Lionel; Boutboul, David; Nonoyama, Shigeaki; Cant, Andrew; Imai, Kohsuke; Picard, Capucine; Nejentsev, Sergey; Molina, Thierry Jo; Lenardo, Michael; Savic, Sinisa; Cavazzana, Marina; Fischer, Alain; Durandy, Anne; Kracker, Sven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-218.e9</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases.  We sought to review the clin., immunol., and histopathol. phenotypes of APDS2 in a genetically defined international patient cohort.  The medical and biol. records of 36 patients with genetically diagnosed APDS2 were collected and reviewed.  Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2.  Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features.  Growth retardation was frequently noticed (45%).  Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%).  Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) assocd. with an increased frequency of transitional B cells (93%), and decreased nos. of naive CD4 and naive CD8 cells but increased nos. of CD8 effector/memory T cells were predominant immunol. features.  The majority of patients (89%) received Ig replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2.  Five patients died from APDS2-related complications.  APDS2 is a combined immunodeficiency with a variable clin. phenotype.  Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD.  Ig replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWsgjSs8Vh2bVg90H21EOLACvtfcHk0lhgDIO7GrjIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVSmtb0%253D&md5=b2ddcbd533e9c2ddefa6a0fcc09bc514</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2016.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2016.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DElkaim%26aufirst%3DE.%26aulast%3DNeven%26aufirst%3DB.%26aulast%3DBruneau%26aufirst%3DJ.%26aulast%3DMitsui-Sekinaka%26aufirst%3DK.%26aulast%3DStanislas%26aufirst%3DA.%26aulast%3DHeurtier%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DDeau%26aufirst%3DM.-C.%26aulast%3DSharapova%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DReichenbach%26aufirst%3DJ.%26aulast%3DGlastre%26aufirst%3DC.%26aulast%3DParry%26aufirst%3DD.%2BA.%26aulast%3DArumugakani%26aufirst%3DG.%26aulast%3DMcDermott%26aufirst%3DE.%26aulast%3DKilic%26aufirst%3DS.%2BS.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DMoshous%26aufirst%3DD.%26aulast%3DLamrini%26aufirst%3DH.%26aulast%3DOtremba%26aufirst%3DB.%26aulast%3DGennery%26aufirst%3DA.%26aulast%3DCoulter%26aufirst%3DT.%26aulast%3DQuinti%26aufirst%3DI.%26aulast%3DStephan%26aufirst%3DJ.-L.%26aulast%3DLougaris%26aufirst%3DV.%26aulast%3DBrodszki%26aufirst%3DN.%26aulast%3DBarlogis%26aufirst%3DV.%26aulast%3DAsano%26aufirst%3DT.%26aulast%3DGalicier%26aufirst%3DL.%26aulast%3DBoutboul%26aufirst%3DD.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DCant%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DNejentsev%26aufirst%3DS.%26aulast%3DMolina%26aufirst%3DT.%2BJ.%26aulast%3DLenardo%26aufirst%3DM.%26aulast%3DSavic%26aufirst%3DS.%26aulast%3DCavazzana%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DDurandy%26aufirst%3DA.%26aulast%3DKracker%26aufirst%3DS.%26atitle%3DClinical%2520and%2520Immunologic%2520Phenotype%2520Associated%2520with%2520Activated%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Syndrome%25202%253A%2520A%2520Cohort%2520Study%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2016%26volume%3D138%26issue%3D1%26spage%3D210%26epage%3D218%26doi%3D10.1016%2Fj.jaci.2016.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gili, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruciano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korfei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iemmolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Furno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuffrida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vancheri, C.</span></span> <span> </span><span class="NLM_article-title">PI3K P110γ Overexpression in Idiopathic Pulmonary Fibrosis Lung Tissue and Fibroblast Cells: In Vitro Effects of Its Inhibition</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1038/labinvest.2013.6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Flabinvest.2013.6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=566-576&issue=5&author=E.+Conteauthor=E.+Giliauthor=M.+Frucianoauthor=M.+Korfeiauthor=E.+Fagoneauthor=M.+Iemmoloauthor=D.+Lo+Furnoauthor=R.+Giuffridaauthor=N.+Crimiauthor=A.+Guentherauthor=C.+Vancheri&title=PI3K+P110%CE%B3+Overexpression+in+Idiopathic+Pulmonary+Fibrosis+Lung+Tissue+and+Fibroblast+Cells%3A+In+Vitro+Effects+of+Its+Inhibition&doi=10.1038%2Flabinvest.2013.6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2013.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2013.6%26sid%3Dliteratum%253Aachs%26aulast%3DConte%26aufirst%3DE.%26aulast%3DGili%26aufirst%3DE.%26aulast%3DFruciano%26aufirst%3DM.%26aulast%3DKorfei%26aufirst%3DM.%26aulast%3DFagone%26aufirst%3DE.%26aulast%3DIemmolo%26aufirst%3DM.%26aulast%3DLo%2BFurno%26aufirst%3DD.%26aulast%3DGiuffrida%26aufirst%3DR.%26aulast%3DCrimi%26aufirst%3DN.%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DVancheri%26aufirst%3DC.%26atitle%3DPI3K%2520P110%25CE%25B3%2520Overexpression%2520in%2520Idiopathic%2520Pulmonary%2520Fibrosis%2520Lung%2520Tissue%2520and%2520Fibroblast%2520Cells%253A%2520In%2520Vitro%2520Effects%2520of%2520Its%2520Inhibition%26jtitle%3DLab.%2520Invest.%26date%3D2013%26volume%3D93%26issue%3D5%26spage%3D566%26epage%3D576%26doi%3D10.1038%2Flabinvest.2013.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span> <span> </span><span class="NLM_article-title">The PI3K Pathway in Human Disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.cell.2017.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28802037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=605-635&issue=4&author=D.+A.+Frumanauthor=H.+Chiuauthor=B.+D.+Hopkinsauthor=S.+Bagrodiaauthor=L.+C.+Cantleyauthor=R.+T.+Abraham&title=The+PI3K+Pathway+in+Human+Disease&doi=10.1016%2Fj.cell.2017.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway in Human Disease</span></div><div class="casAuthors">Fruman, David A.; Chiu, Honyin; Hopkins, Benjamin D.; Bagrodia, Shubha; Cantley, Lewis C.; Abraham, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-635</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is considered a hallmark of cancer.  Many PI3K pathway-targeted therapies have been tested in oncol. trials, resulting in regulatory approval of one isoform-selective inhibitor (idelalisib) for treatment of certain blood cancers and a variety of other agents at different stages of development.  In parallel to PI3K research by cancer biologists, investigations in other fields have uncovered exciting and often unpredicted roles for PI3K catalytic and regulatory subunits in normal cell function and in disease.  Many of these functions impinge upon oncol. by influencing the efficacy and toxicity of PI3K-targeted therapies.  Here we provide a perspective on the roles of class I PI3Ks in the regulation of cellular metab. and in immune system functions, two topics closely intertwined with cancer biol.  We also discuss recent progress developing PI3K-targeted therapies for treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX1NPtgicD_rVg90H21EOLACvtfcHk0lg6cq43_DNcRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlWhu7bL&md5=a5a5c06960587cefa95a6fb8cc647c7f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DChiu%26aufirst%3DH.%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DThe%2520PI3K%2520Pathway%2520in%2520Human%2520Disease%26jtitle%3DCell%26date%3D2017%26volume%3D170%26issue%3D4%26spage%3D605%26epage%3D635%26doi%3D10.1016%2Fj.cell.2017.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Montfort, R. L. M.</span></span> <span> </span><span class="NLM_article-title">Revealing the Delta Lady</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1038/nchembio.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnchembio.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=20081818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=82&author=P.+Workmanauthor=R.+L.+M.+van+Montfort&title=Revealing+the+Delta+Lady&doi=10.1038%2Fnchembio.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing the delta lady</span></div><div class="casAuthors">Workman, Paul; van Montfort, Rob L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">82-83</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-OH kinases (PI(3)Ks) are important lipid signaling enzymes and exciting drug targets for a no. of human diseases.  The 1st, much anticipated crystal structure of the δ isoform of PI(3)K recently reported by A. Berndt et al. (2010) has provided surprising new insights into the selectivity of inhibitors for this vs. other PI(3)K isoforms and facilitates the design of improved drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgWqq4U-FSC7Vg90H21EOLACvtfcHk0lg6cq43_DNcRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGmtQ%253D%253D&md5=89a6a30c3fc8673821c9cc829583d185</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.305%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26atitle%3DRevealing%2520the%2520Delta%2520Lady%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D82%26doi%3D10.1038%2Fnchembio.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houseman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hon, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rückle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span> <span> </span><span class="NLM_article-title">The P110δ Structure: Mechanisms for Selectivity and Potency of New PI(3)K Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1038/nchembio.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&issue=2&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D.+Leauthor=B.+T.+Housemanauthor=J.+I.+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=P.+Renauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+R%C3%BCckleauthor=M.+K.+Schwarzauthor=K.+M.+Shokatauthor=J.+P.+Shawauthor=R.+L.+Williams&title=The+P110%CE%B4+Structure%3A+Mechanisms+for+Selectivity+and+Potency+of+New+PI%283%29K+Inhibitors&doi=10.1038%2Fnchembio.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0lg6cq43_DNcRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DPacold%26aufirst%3DJ.%2BI.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DThe%2520P110%25CE%25B4%2520Structure%253A%2520Mechanisms%2520for%2520Selectivity%2520and%2520Potency%2520of%2520New%2520PI%25283%2529K%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26issue%3D2%26spage%3D117%26epage%3D124%26doi%3D10.1038%2Fnchembio.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span> <i>PyMOL Molecular
Graphics System</i>, version <span class="NLM_edition">2.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMOL+Molecular%0AGraphics+System%2C+version+2.0%3B+Schr%C3%B6dinger%2C+LLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%2520Molecular%250AGraphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Potential Value and Limitation of Dual Inhibitors of PI3K and MTOR in the Treatment of Cancer</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2174/1568009611313020001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.2174%2F1568009611313020001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=23215718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFWhsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=117-120&issue=2&author=J.+Chen&title=Potential+Value+and+Limitation+of+Dual+Inhibitors+of+PI3K+and+MTOR+in+the+Treatment+of+Cancer&doi=10.2174%2F1568009611313020001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer</span></div><div class="casAuthors">Chen, Jiezhong</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-120</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At present, the most effective inhibitors developed for the phosphoinositide 3-kinase (PI3K) pathway are dual inhibitors of PI3K and mammalian target of rapamycin (mTOR), a downstream target of PI3K.  PI3K/Akt/mTOR is a major signaling pathway activated in many cancers.  This special issue presents review articles that summarize the implications of the dual inhibitors of PI3K/mTOR in several cancers including melanoma, leukemia, breast cancer, prostate cancer, gastric cancer and cervical cancer.  These articles reflect the most recent progress in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8rNpnggFtcLVg90H21EOLACvtfcHk0lj7whiqvuj3hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFWhsrY%253D&md5=6e729b1d223a8b919690dfdd3bbee349</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1568009611313020001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009611313020001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DPotential%2520Value%2520and%2520Limitation%2520of%2520Dual%2520Inhibitors%2520of%2520PI3K%2520and%2520MTOR%2520in%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2013%26volume%3D13%26issue%3D2%26spage%3D117%26epage%3D120%26doi%3D10.2174%2F1568009611313020001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and Regulation of Akt/PKB by the Rictor-MTOR Complex</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span> (<span class="NLM_issue">5712</span>),  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&issue=5712&author=D.+D.+Sarbassov&title=Phosphorylation+and+Regulation+of+Akt%2FPKB+by+the+Rictor-MTOR+Complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lj7whiqvuj3hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26atitle%3DPhosphorylation%2520and%2520Regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520Rictor-MTOR%2520Complex%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2005%26volume%3D307%26issue%3D5712%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">ATP-Competitive Inhibitors of MTOR: An Update</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2995</span>– <span class="NLM_lpage">3014</span>, <span class="refDoi"> DOI: 10.2174/092986711796391651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.2174%2F092986711796391651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=21651476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2995-3014&issue=20&author=S.+Schenoneauthor=C.+Brulloauthor=F.+Musumeciauthor=M.+Radiauthor=M.+Botta&title=ATP-Competitive+Inhibitors+of+MTOR%3A+An+Update&doi=10.2174%2F092986711796391651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-competitive inhibitors of mTOR: an update</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Musumeci, F.; Radi, M.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2995-3014</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  MTOR (mammalian target of rapamycin) is a serine-threonine kinase belonging to the PI3K/Akt/mTOR signalling pathway that is involved in several cell functions, including growth, proliferation, apoptosis and autophagy.  MTOR hyperactivation has been detected in several human cancers, thus representing, together with its upstream effectors, an important target for cancer therapy.  MTOR exists in two different complexes in cells, mTORC1 and mTORC2 which could both be targeted by potential anticancer agents.  Rapamycin, the selective and allosteric inhibitor of mTOR, inhibits the enzyme in mTORC1, but not in mTORC2.  In the last few years a no. of mTOR ATP-competitive inhibitors has been reported acting on mTOR in both complexes and possessing a more complete anticancer activity in comparison with that of rapamycin and its derivs.  MTOR shares high sequence homol. in the hinge-region with PI3K that is a lipid kinase upstream to mTOR in the same signalling pathway; for this reason some compds. originally developed as PI3K inhibitors later showed to also target mTOR.  As indicated by preclin. and clin. studies, compds. acting on more than one target could result in a better biol. response and in enhanced therapeutic potential and also dual PI3K/mTOR inhibitors result of great interest as potential antitumor agents.  This review mainly reports the recently discovered mTOR ATP-competitive inhibitors in terms of medicinal chem., classified by their chem. structures, focusing on SAR and modeling studies that led to the discovery of very potent and selective agents, such as AZD-8055, OSI-027 and INK128, already entered clin. trials, or WYE-132, Torin1 and others in preclin. studies.  Also some examples of dual PI3K/mTOR inhibitors, including PI-103, GNE477, WJD008 and GSK2126458 are reported together with their biol. and clin. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu7yn-FHwtVbVg90H21EOLACvtfcHk0lj_22KqJErimw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7o%253D&md5=bc3786d2c4e703558cffa34a9657b7d5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F092986711796391651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391651%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DATP-Competitive%2520Inhibitors%2520of%2520MTOR%253A%2520An%2520Update%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26issue%3D20%26spage%3D2995%26epage%3D3014%26doi%3D10.2174%2F092986711796391651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span>PubChem. <a href="https://pubchem.ncbi.nlm.nih.gov/" class="extLink">https://pubchem.ncbi.nlm.nih.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PubChem.+https%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, K. W.</span>; <span class="NLM_string-name">Huang, D.</span>; <span class="NLM_string-name">Kesicki, E. A.</span>; <span class="NLM_string-name">Ooi, H. C.</span>; <span class="NLM_string-name">Oliver, A. R.</span>; <span class="NLM_string-name">Ruan, F.</span>; <span class="NLM_string-name">Treiberg, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Purine Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta</span>. <span class="NLM_patent">WO2005113556A1</span>, December 1, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=K.+W.+Fowler&author=D.+Huang&author=E.+A.+Kesicki&author=H.+C.+Ooi&author=A.+R.+Oliver&author=F.+Ruan&author=J.+Treiberg&title=Preparation+of+Purine+Quinazolinones+as+Inhibitors+of+Human+Phosphatidylinositol+3-Kinase+Delta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFowler%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Purine%2520Quinazolinones%2520as%2520Inhibitors%2520of%2520Human%2520Phosphatidylinositol%25203-Kinase%2520Delta%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagpacan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papalia, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">8439</span>– <span class="NLM_lpage">8446</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&issue=13&author=J.%0AR.+Somozaauthor=D.+Koditekauthor=A.%0AG.+Villase%C3%B1orauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+Biochemical%2C+and+Biophysical+Characterization+of+Idelalisib+Binding+to+Phosphoinositide+3-Kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520Biochemical%252C%2520and%2520Biophysical%2520Characterization%2520of%2520Idelalisib%2520Binding%2520to%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D13%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, B. P.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1007/s40262-015-0304-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1007%2Fs40262-015-0304-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=26242379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=33-45&issue=1&author=S.+Ramanathanauthor=F.+Jinauthor=S.+Sharmaauthor=B.+P.+Kearney&title=Clinical+Pharmacokinetic+and+Pharmacodynamic+Profile+of+Idelalisib&doi=10.1007%2Fs40262-015-0304-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib</span></div><div class="casAuthors">Ramanathan, Srinivasan; Jin, Feng; Sharma, Shringi; Kearney, Brian P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Idelalisib is a potent and selective phosphatidylinositol 3-kinase-δ inhibitor, which is a first-in-class agent to be approved for the treatment of relapsed chronic lymphocytic leukemia, follicular B cell non-Hodgkin's lymphoma and small lymphocytic lymphoma.  In dose-ranging studies, idelalisib exposure increased in a less than dose-proportional manner, likely because of soly.-limited absorption.  The approved starting dose of 150 mg twice daily was supported by extensive exposure-response evaluations, with dose redn. to 100 mg twice daily being allowed for specific toxicities.  Idelalisib may be administered without regard to food on the basis of the absence of clin. relevant food effects, and was accordingly dosed in primary efficacy/safety studies.  Idelalisib is metabolized primarily via aldehyde oxidase (AO) and, to a lesser extent, via cytochrome P 450 (CYP) 3A.  Coadministration with the strong CYP3A inhibitor ketoconazole 400 mg once daily resulted in a ∼79 % increase in the idelalisib area under the plasma concn.-time curve (AUC).  Administration with the potent inducer rifampin resulted in a 75 % decrease in idelalisib exposure (AUC) and, as such, coadministration with strong inducers should be avoided.  GS-563117 is an inactive primary circulating metabolite of idelalisib formed mainly via AO.  Unlike idelalisib, GS-563117 is a mechanism-based inhibitor of CYP3A.  Accordingly, idelalisib 150 mg twice-daily dosing increases the midazolam AUC 5.4-fold.  Clin., idelalisib is not an inhibitor of the transporters P-glycoprotein, breast cancer resistance protein, org. anion-transporting polypeptide (OATP) 1B1 or OAPT1B3.  In a population pharmacokinetic model, no meaningful impact on idelalisib pharmacokinetics was noted for any of the covariates tested.  Idelalisib exposure was ∼60 % higher with moderate/severe hepatic impairment; no relevant changes were obsd. with severe renal impairment.  This article reviews a comprehensive pharmacol. program, including drug-drug interaction studies and mechanistic and special population studies, which has allowed a thorough understanding of idelalisib clin. pharmacokinetics and their impact on clin. safety and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSL8hV_Gha7Vg90H21EOLACvtfcHk0lj_22KqJErimw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D&md5=df1082fcbb0e1a9aa941769ade9fe962</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0304-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0304-0%26sid%3Dliteratum%253Aachs%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKearney%26aufirst%3DB.%2BP.%26atitle%3DClinical%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Profile%2520of%2520Idelalisib%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26issue%3D1%26spage%3D33%26epage%3D45%26doi%3D10.1007%2Fs40262-015-0304-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3532</span>– <span class="NLM_lpage">3548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3532-3548&issue=7&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=A.+C.+Haranauthor=C.+Ipauthor=J.+A.+Kaplanauthor=M.+Kimauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=N.+Novikovauthor=S.+Perreaultauthor=K.+D.+Puriauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=K.+L.+Stevensauthor=J.+Therrienauthor=J.+Treibergauthor=A.+G.+Villase%C3%B1orauthor=A.+Yeungauthor=G.+Phillips&title=2%2C4%2C6-Triaminopyrimidine+as+a+Novel+Hinge+Binder+in+a+Series+of+PI3K%CE%B4+Selective+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00213"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3D2%252C4%252C6-Triaminopyrimidine%2520as%2520a%2520Novel%2520Hinge%2520Binder%2520in%2520a%2520Series%2520of%2520PI3K%25CE%25B4%2520Selective%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D3532%26epage%3D3548%26doi%3D10.1021%2Facs.jmedchem.6b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">9228</span>– <span class="NLM_lpage">9242</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9228-9242&issue=19&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=K.+Forsethauthor=A.+C.+Haranauthor=C.+Ipauthor=A.+Kashishianauthor=M.+Kimauthor=D.+Koditekauthor=S.+Koppenolauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=S.+Perreaultauthor=K.+D.+Puriauthor=A.%0AG.+Villase%C3%B1orauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=G.+Phillips&title=Discovery+of+Orally+Efficacious+Phosphoinositide+3-Kinase+%CE%B4+Inhibitors+with+Improved+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.6b01169"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01169%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DForseth%26aufirst%3DK.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DKoppenol%26aufirst%3DS.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Orally%2520Efficacious%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520Inhibitors%2520with%2520Improved%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D19%26spage%3D9228%26epage%3D9242%26doi%3D10.1021%2Facs.jmedchem.6b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahiaoui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1567</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01821</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1555-1567&issue=4&author=S.+Perreaultauthor=J.+Chandrasekharauthor=Z.-H.+Cuiauthor=J.+Evartsauthor=J.+Haoauthor=J.+A.+Kaplanauthor=A.+Kashishianauthor=K.+S.+Keeganauthor=T.+Kenneyauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=L.+Patelauthor=B.+Phillipsauthor=J.+Therrienauthor=J.+Treibergauthor=A.+Yahiaouiauthor=G.+Phillips&title=Discovery+of+a+Phosphoinositide+3-Kinase+%28PI3K%29+%CE%B2%2F%CE%B4+Inhibitor+for+the+Treatment+of+Phosphatase+and+Tensin+Homolog+%28PTEN%29+Deficient+Tumors%3A+Building+PI3K%CE%B2+Potency+in+a+PI3K%CE%B4-Selective+Template+by+Targeting+Nonconserved+Asp856&doi=10.1021%2Facs.jmedchem.6b01821"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01821%26sid%3Dliteratum%253Aachs%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.-H.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DKenney%26aufirst%3DT.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DPhillips%26aufirst%3DB.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DYahiaoui%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520%25CE%25B2%252F%25CE%25B4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Phosphatase%2520and%2520Tensin%2520Homolog%2520%2528PTEN%2529%2520Deficient%2520Tumors%253A%2520Building%2520PI3K%25CE%25B2%2520Potency%2520in%2520a%2520PI3K%25CE%25B4-Selective%2520Template%2520by%2520Targeting%2520Nonconserved%2520Asp856%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1555%26epage%3D1567%26doi%3D10.1021%2Facs.jmedchem.6b01821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcbride, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcgee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of Dual PI3K β/δ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7667</span>– <span class="NLM_lpage">7685</span>, <span class="refDoi"> DOI: 10.1021/jm300679u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300679u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7667-7685&author=F.+Gonzalez-Lopez%0Ade+Turisoauthor=Y.+Shinauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=D.+Fongauthor=X.+Haoauthor=X.+Heauthor=K.+Henneauthor=Y.+Huauthor=M.+G.+Johnsonauthor=T.+Kohnauthor=J.+Lohmanauthor=H.+J.+Mcbrideauthor=L.+R.+Mcgeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=K.+Minerauthor=D.+Mohnauthor=V.+Pattaropongauthor=J.+Seganishauthor=J.+L.+Simardauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=G.+Yuauthor=T.+D.+Cushing&title=Discovery+and+in+Vivo+Evaluation+of+Dual+PI3K+%CE%B2%2F%CE%B4+Inhibitors&doi=10.1021%2Fjm300679u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm300679u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300679u%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKohn%26aufirst%3DT.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DMcbride%26aufirst%3DH.%2BJ.%26aulast%3DMcgee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMiner%26aufirst%3DK.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Dual%2520PI3K%2520%25CE%25B2%252F%25CE%25B4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7667%26epage%3D7685%26doi%3D10.1021%2Fjm300679u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzasa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(Pyridin-2-Yl)Quinolin-3-Yl)Ethyl)-9 H -Purin-6-Amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&issue=1&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.-L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+in+Vivo+Evaluation+of+%28S%29-N-%281-%287-Fluoro-2-%28Pyridin-2-Yl%29Quinolin-3-Yl%29Ethyl%29-9+H+-Purin-6-Amine+%28AMG319%29+and+Related+PI3K%CE%B4+Inhibitors+for+Inflammation+and+Autoimmune+Disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520%2528S%2529-N-%25281-%25287-Fluoro-2-%2528Pyridin-2-Yl%2529Quinolin-3-Yl%2529Ethyl%2529-9%2520H%2520-Purin-6-Amine%2520%2528AMG319%2529%2520and%2520Related%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Inflammation%2520and%2520Autoimmune%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vissinga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01651</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01651" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=431-447&issue=1&author=Y.+Shinauthor=J.+Suchomelauthor=M.+Cardozoauthor=J.+Duquetteauthor=X.+Heauthor=K.+Henneauthor=Y.+Huauthor=R.+C.+Kellyauthor=J.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=T.+San+Miguelauthor=D.+Mohnauthor=T.+Tranauthor=C.+Vissingaauthor=S.+Wongauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=X.+Zhangauthor=T.+D.+Cushing&title=Discovery%2C+Optimization%2C+and+in+Vivo+Evaluation+of+Benzimidazole+Derivatives+AM-8508+and+AM-9635+as+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01651%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DVissinga%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%252C%2520Optimization%252C%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Benzimidazole%2520Derivatives%2520AM-8508%2520and%2520AM-9635%2520as%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D431%26epage%3D447%26doi%3D10.1021%2Facs.jmedchem.5b01651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR Study of Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1109</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2015.01.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1104-1109&issue=5&author=M.+Buiauthor=X.+Haoauthor=Y.+Shinauthor=M.+Cardozoauthor=X.+Heauthor=K.+Henneauthor=J.+Suchomelauthor=J.+McCarterauthor=L.+R.+McGeeauthor=T.+San+Miguelauthor=J.+C.+Medinaauthor=D.+Mohnauthor=T.+Tranauthor=S.+Wannbergauthor=J.+Wongauthor=S.+Wongauthor=L.+Zalamedaauthor=D.+Metzauthor=T.+D.+Cushing&title=Synthesis+and+SAR+Study+of+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520Study%2520of%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D5%26spage%3D1104%26epage%3D1109%26doi%3D10.1016%2Fj.bmcl.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campuzano, I. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vissinga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-Cyano-4-Pyrimidinyl)Amino)Ethyl)-6-Fluoro-N-Methyl-3-(2-Pyridinyl)-4-Quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-Cyano-4-Pyrimidinyl)Amino)Eth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7252</span>– <span class="NLM_lpage">7267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00827</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00827" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7252-7267&issue=15&author=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Haoauthor=Y.+Shinauthor=M.+Buiauthor=I.+D.+G.+Campuzanoauthor=M.+Cardozoauthor=M.+C.+Dunnauthor=J.+Duquetteauthor=B.+Fisherauthor=R.+S.+Fotiauthor=K.+Henneauthor=X.+Heauthor=Y.-L.+Huauthor=R.+C.+Kellyauthor=M.+G.+Johnsonauthor=B.+S.+Lucasauthor=J.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=T.+San+Miguelauthor=D.+Mohnauthor=T.+Tranauthor=C.+Vissingaauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=X.+Zhangauthor=T.+D.+Cushing&title=Discovery+and+in+Vivo+Evaluation+of+the+Potent+and+Selective+PI3K%CE%B4+Inhibitors+2-%28%281S%29-1-%28%286-Amino-5-Cyano-4-Pyrimidinyl%29Amino%29Ethyl%29-6-Fluoro-N-Methyl-3-%282-Pyridinyl%29-4-Quinolinecarboxamide+%28AM-0687%29+and+2-%28%281S%29-1-%28%286-Amino-5-Cyano-4-Pyrimidinyl%29Amino%29Eth&doi=10.1021%2Facs.jmedchem.6b00827"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00827%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DCampuzano%26aufirst%3DI.%2BD.%2BG.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DM.%2BC.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFoti%26aufirst%3DR.%2BS.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DLucas%26aufirst%3DB.%2BS.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DVissinga%26aufirst%3DC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520the%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%25202-%2528%25281S%2529-1-%2528%25286-Amino-5-Cyano-4-Pyrimidinyl%2529Amino%2529Ethyl%2529-6-Fluoro-N-Methyl-3-%25282-Pyridinyl%2529-4-Quinolinecarboxamide%2520%2528AM-0687%2529%2520and%25202-%2528%25281S%2529-1-%2528%25286-Amino-5-Cyano-4-Pyrimidinyl%2529Amino%2529Eth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D15%26spage%3D7252%26epage%3D7267%26doi%3D10.1021%2Facs.jmedchem.6b00827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armengol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00438</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00438" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=118-123&issue=1&author=M.+Erraauthor=J.+Taltavullauthor=A.+Grecoauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=J.+Graciaauthor=M.+Dominguezauthor=M.+Sabateauthor=S.+Parisauthor=S.+Soriaauthor=B.+Hernandezauthor=C.+Armengolauthor=J.+Cabedoauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehner&title=Discovery+of+a+Potent%2C+Selective%2C+and+Orally+Available+PI3K%CE%B4+Inhibitor+for+the+Treatment+of+Inflammatory+Diseases&doi=10.1021%2Facsmedchemlett.6b00438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00438%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DDominguez%26aufirst%3DM.%26aulast%3DSabate%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DArmengol%26aufirst%3DC.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520PI3K%25CE%25B4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D118%26epage%3D123%26doi%3D10.1021%2Facsmedchemlett.6b00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">SAR Study of 5-Alkynyl Substituted Quinazolin-4(3H)-Ones as Phosphoinositide 3-Kinase Delta (PI3Kδ) Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2016.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27846451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVChsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=1156-1171&author=M.+Weiauthor=X.+Zhangauthor=X.+Wangauthor=Z.+Songauthor=J.+Dingauthor=L.-H.+Mengauthor=A.+Zhang&title=SAR+Study+of+5-Alkynyl+Substituted+Quinazolin-4%283H%29-Ones+as+Phosphoinositide+3-Kinase+Delta+%28PI3K%CE%B4%29+Inhibitors&doi=10.1016%2Fj.ejmech.2016.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors</span></div><div class="casAuthors">Wei, Manman; Zhang, Xi; Wang, Xiang; Song, Zilan; Ding, Jian; Meng, Ling-Hua; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1156-1171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">PI3Kδ is a key component in the aberrant signaling transduction in B cell malignancy, therefore specific targeting PI3Kδ has become an attractive molecularly targeted therapy for chronic lymphocytic leukemia (CLL).  Herein, we describe the discovery and optimization of a series of 5-alkynyl substituted PI3Kδ inhibitors based on the first FDA-approved inhibitor idelalisib.  Compd. 8d bearing the 1-morpholinohex-5-yn-1-one moiety as the C5-substituent was identified to have high potency against PI3Kδ (3.82 nM) and SU-DHL-6 cells (7.60 nM), resp.  It was 154-fold selective over PI3Kα, 133-fold selective against PI3Kβ, and 24-fold selective against PI3Kγ.  Treatment of MOLT-4 and SU-DHL-6 cells with compd. 8d for 1 h resulted in redn. of phosphorylation of both Akt (S473) and its downstream S6k1 (T389) in a concn.-dependent manner.  Compd. 8d showed potent anti-proliferative activity as well against T lymphoblast MOLT-4, suggesting its potential activity in T-cell leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYWHSwSiMyQrVg90H21EOLACvtfcHk0ljjUY6FmldTYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVChsbjJ&md5=809c50e6dc45e1e4871af760fe27cefc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DL.-H.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSAR%2520Study%2520of%25205-Alkynyl%2520Substituted%2520Quinazolin-4%25283H%2529-Ones%2520as%2520Phosphoinositide%25203-Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D1156%26epage%3D1171%26doi%3D10.1016%2Fj.ejmech.2016.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescarbeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeilles, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenadel, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Hearn, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Hearn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=862-867&issue=9&author=C.+A.+Evansauthor=T.+Liuauthor=A.+Lescarbeauauthor=S.+J.+Nairauthor=L.+Grenierauthor=J.+A.+Pradeillesauthor=Q.+Glenadelauthor=T.+Tibbittsauthor=A.+M.+Rowleyauthor=J.+P.+DiNittoauthor=E.+E.+Brophyauthor=E.+L.+O%27Hearnauthor=J.+A.+Aliauthor=D.+G.+Winklerauthor=S.+I.+Goldsteinauthor=P.+O%27Hearnauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=J.+R.+Sogliaauthor=C.+Cheungauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=V.+J.+Palombellaauthor=M.+R.+Tremblayauthor=A.+C.+Castro&title=Discovery+of+a+Selective+Phosphoinositide-3-Kinase+%28PI3K%29-%CE%B3+Inhibitor+%28IPI-549%29+as+an+Immuno-Oncology+Clinical+Candidate&doi=10.1021%2Facsmedchemlett.6b00238"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00238%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLescarbeau%26aufirst%3DA.%26aulast%3DNair%26aufirst%3DS.%2BJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPradeilles%26aufirst%3DJ.%2BA.%26aulast%3DGlenadel%26aufirst%3DQ.%26aulast%3DTibbitts%26aufirst%3DT.%26aulast%3DRowley%26aufirst%3DA.%2BM.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DO%2527Hearn%26aufirst%3DE.%2BL.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DGoldstein%26aufirst%3DS.%2BI.%26aulast%3DO%2527Hearn%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DCheung%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DTremblay%26aufirst%3DM.%2BR.%26aulast%3DCastro%26aufirst%3DA.%2BC.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Phosphoinositide-3-Kinase%2520%2528PI3K%2529-%25CE%25B3%2520Inhibitor%2520%2528IPI-549%2529%2520as%2520an%2520Immuno-Oncology%2520Clinical%2520Candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D9%26spage%3D862%26epage%3D867%26doi%3D10.1021%2Facsmedchemlett.6b00238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh Pathania, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chobe, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargotra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, S. D.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of 1,4-Substituted 1H-1,2,3-Triazolo-Quinazolin-4(3H)-Ones by Huisgen 1,3-Dipolar Cycloaddition with PI3Kγ Isoform Selective Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2018.02.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1005-1010&issue=6&author=M.+Srinivasauthor=A.+Singh+Pathaniaauthor=P.+Mahajanauthor=P.+K.+Vermaauthor=S.+S.+Chobeauthor=F.+A.+Malikauthor=A.+Nargotraauthor=R.+A.+Vishwakarmaauthor=S.+D.+Sawant&title=Design+and+Synthesis+of+1%2C4-Substituted+1H-1%2C2%2C3-Triazolo-Quinazolin-4%283H%29-Ones+by+Huisgen+1%2C3-Dipolar+Cycloaddition+with+PI3K%CE%B3+Isoform+Selective+Activity&doi=10.1016%2Fj.bmcl.2018.02.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivas%26aufirst%3DM.%26aulast%3DSingh%2BPathania%26aufirst%3DA.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DVerma%26aufirst%3DP.%2BK.%26aulast%3DChobe%26aufirst%3DS.%2BS.%26aulast%3DMalik%26aufirst%3DF.%2BA.%26aulast%3DNargotra%26aufirst%3DA.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DSawant%26aufirst%3DS.%2BD.%26atitle%3DDesign%2520and%2520Synthesis%2520of%25201%252C4-Substituted%25201H-1%252C2%252C3-Triazolo-Quinazolin-4%25283H%2529-Ones%2520by%2520Huisgen%25201%252C3-Dipolar%2520Cycloaddition%2520with%2520PI3K%25CE%25B3%2520Isoform%2520Selective%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D1005%26epage%3D1010%26doi%3D10.1016%2Fj.bmcl.2018.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björhall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredlund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terstiege, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5057</span>– <span class="NLM_lpage">5071</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00401</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00401" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5057-5071&issue=12&author=M.+W.+D.+Perryauthor=K.+Bj%C3%B6rhallauthor=B.+Bonnauthor=J.+Carlssonauthor=Y.+Chenauthor=A.+Erikssonauthor=L.+Fredlundauthor=H.+Haoauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=H.+Lindmarkauthor=F.+Liuauthor=N.+Pembertonauthor=J.+Petersenauthor=S.+Rodrigo+Blomqvistauthor=R.+W.+Smithauthor=T.+Svenssonauthor=I.+Terstiegeauthor=C.+Tyrchanauthor=W.+Yangauthor=S.+Zhaoauthor=L.+%C3%96ster&title=Design+and+Synthesis+of+Soluble+and+Cell-Permeable+PI3K%CE%B4+Inhibitors+for+Long-Acting+Inhaled+Administration&doi=10.1021%2Facs.jmedchem.7b00401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span></div><div class="casAuthors">Perry, Matthew W. D.; Bjoerhall, Karin; Bonn, Britta; Carlsson, Johan; Chen, Yunhua; Eriksson, Anders; Fredlund, Linda; Hao, Hai'e; Holden, Neil S.; Karabelas, Kostas; Lindmark, Helena; Liu, Feifei; Pemberton, Nils; Petersen, Jens; Rodrigo Blomqvist, Sandra; Smith, Reed W.; Svensson, Tor; Terstiege, Ina; Tyrchan, Christian; Yang, Wenzhen; Zhao, Shuchun; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5057-5071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system.  Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis.  In this work, identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation is described.  The initially identified compd. I had good potency and isoform selectivity but was not suitable for inhalation.  Addn. of basic substituents to a region of the mol. pointing to solvent was tolerated (enzyme inhibition pIC50 > 9), and by careful manipulation of the pKa and lipophilicity, the authors were able to discover compds. II (R = Me or i-Bu) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lo9sRrhhb7Vg90H21EOLACvtfcHk0ljjUY6FmldTYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D&md5=dafb9cfdf6c06e30c599dcceec85497a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00401%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DBj%25C3%25B6rhall%26aufirst%3DK.%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEriksson%26aufirst%3DA.%26aulast%3DFredlund%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DR.%2BW.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Soluble%2520and%2520Cell-Permeable%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Long-Acting%2520Inhaled%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D5057%26epage%3D5071%26doi%3D10.1021%2Facs.jmedchem.7b00401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the Inhaled Route: Challenges and Approaches</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&issue=4&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+Inhaled+Route%3A+Challenges+and+Approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0ljoOiywk8dAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520Inhaled%2520Route%253A%2520Challenges%2520and%2520Approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26issue%3D4%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD3199, An Inhaled Ultralong Acting β 2 Receptor Agonist with Rapid Onset of Action</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1021/ml4005232</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4005232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=416-421&issue=4&author=M.+J.+Stocksauthor=L.+Alcarazauthor=A.+Baileyauthor=R.+Bonnertauthor=E.+Cadoganauthor=J.+Christieauthor=J.+Dixonauthor=S.+Connollyauthor=A.+Cookauthor=A.+Fisherauthor=A.+Flahertyauthor=A.+Humphriesauthor=A.+Ingallauthor=S.+Jordanauthor=M.+Lawsonauthor=A.+Mullenauthor=D.+Nichollsauthor=S.+Paineauthor=G.+Pairaudeauauthor=A.+Young&title=Discovery+of+AZD3199%2C+An+Inhaled+Ultralong+Acting+%CE%B2+2+Receptor+Agonist+with+Rapid+Onset+of+Action&doi=10.1021%2Fml4005232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action</span></div><div class="casAuthors">Stocks, Michael J.; Alcaraz, Lilian; Bailey, Andrew; Bonnert, Roger; Cadogan, Elaine; Christie, Jadeen; Dixon, John; Connolly, Stephen; Cook, Anthony; Fisher, Adrian; Flaherty, Alice; Humphries, Alexander; Ingall, Anthony; Jordan, Stephen; Lawson, Mandy; Mullen, Alex; Nicholls, David; Paine, Stuart; Pairaudeau, Garry; Young, Alan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of dibasic des-hydroxy β2 receptor agonists has been prepd. and evaluated for potential as inhaled ultralong acting bronchodilators.  Detn. of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model.  Following further assessment by onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i.t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clin. evaluation as a new ultralong acting inhaled β2 receptor agonist with rapid onset of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqROqAoAEVIvbVg90H21EOLACvtfcHk0ljoOiywk8dAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKgu7o%253D&md5=c07077547e5d948ea027919240e78768</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fml4005232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4005232%26sid%3Dliteratum%253Aachs%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBonnert%26aufirst%3DR.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DFisher%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DA.%26aulast%3DHumphries%26aufirst%3DA.%26aulast%3DIngall%26aufirst%3DA.%26aulast%3DJordan%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DMullen%26aufirst%3DA.%26aulast%3DNicholls%26aufirst%3DD.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520AZD3199%252C%2520An%2520Inhaled%2520Ultralong%2520Acting%2520%25CE%25B2%25202%2520Receptor%2520Agonist%2520with%2520Rapid%2520Onset%2520of%2520Action%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D4%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml4005232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alderton, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugendradas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lensun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergl-Wilson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghir, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhyvoloup, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S. J.</span></span> <span> </span><span class="NLM_article-title">The Identification of 2-(1 H -Indazol-4-Yl)-6-(4-Methanesulfonyl-Piperazin-1-Ylmethyl)-4-Morpholin-4-Yl-Thieno[3,2- d ]Pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer †</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5522</span>– <span class="NLM_lpage">5532</span>, <span class="refDoi"> DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&issue=18&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+Identification+of+2-%281+H+-Indazol-4-Yl%29-6-%284-Methanesulfonyl-Piperazin-1-Ylmethyl%29-4-Morpholin-4-Yl-Thieno%5B3%2C2-+d+%5DPyrimidine+%28GDC-0941%29+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Inhibitor+of+Class+I+PI3+Kinase+for+the+Treatment+of+Cancer+%E2%80%A0&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0ljoOiywk8dAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Identification%2520of%25202-%25281%2520H%2520-Indazol-4-Yl%2529-6-%25284-Methanesulfonyl-Piperazin-1-Ylmethyl%2529-4-Morpholin-4-Yl-Thieno%255B3%252C2-%2520d%2520%255DPyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitor%2520of%2520Class%2520I%2520PI3%2520Kinase%2520for%2520the%2520Treatment%2520of%2520Cancer%2520%25E2%2580%25A0%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D18%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of 4-Morpholino-2-Phenylquinazolines and Related Derivatives as Novel PI3 Kinase P110α Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6847</span>– <span class="NLM_lpage">6858</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2006.06.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=6847-6858&issue=20&author=M.+Hayakawaauthor=H.+Kaizawaauthor=H.+Moritomoauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+Tsukamotoauthor=P.+Parkerauthor=P.+Workmanauthor=M.+Waterfield&title=Synthesis+and+Biological+Evaluation+of+4-Morpholino-2-Phenylquinazolines+and+Related+Derivatives+as+Novel+PI3+Kinase+P110%CE%B1+Inhibitors&doi=10.1016%2Fj.bmc.2006.06.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DMoritomo%26aufirst%3DH.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWaterfield%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%25204-Morpholino-2-Phenylquinazolines%2520and%2520Related%2520Derivatives%2520as%2520Novel%2520PI3%2520Kinase%2520P110%25CE%25B1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26issue%3D20%26spage%3D6847%26epage%3D6858%26doi%3D10.1016%2Fj.bmc.2006.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodny, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3 - Kinase (PI3K) and Phosphatidylinositol 3 - Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3+-+Kinase+%28PI3K%29+and+Phosphatidylinositol+3+-+Kinase-Related+Kinase+%28PIKK%29+Inhibitors%3A+Importance+of+the+Morpholine+Ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203%2520-%2520Kinase%2520%2528PI3K%2529%2520and%2520Phosphatidylinositol%25203%2520-%2520Kinase-Related%2520Kinase%2520%2528PIKK%2529%2520Inhibitors%253A%2520Importance%2520of%2520the%2520Morpholine%2520Ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">7579</span>– <span class="NLM_lpage">7587</span>, <span class="refDoi"> DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&issue=21&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+Potent%2C+Selective%2C+and+Orally+Available+Class+I+Phosphatidylinositol+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28MTOR%29+Kinase+Inhibitor+%28GDC-0980%29+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528MTOR%2529%2520Kinase%2520Inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D21%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span> <span> </span><span class="NLM_article-title">Identification of GNE-477, a Potent and Efficacious Dual PI3K/MTOR Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2411</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2010.03.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2408-2411&issue=8&author=T.+P.+Heffronauthor=M.+Berryauthor=G.+Castanedoauthor=C.+Changauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folkesauthor=J.+Gunznerauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=A.+Oliveroauthor=J.+Pangauthor=D.+Petersonauthor=L.+Salphatiauthor=D.+Sampathauthor=S.+Siderisauthor=D.+P.+Sutherlinauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=S.+Wongauthor=B.+Zhu&title=Identification+of+GNE-477%2C+a+Potent+and+Efficacious+Dual+PI3K%2FMTOR+Inhibitor&doi=10.1016%2Fj.bmcl.2010.03.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DD.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520GNE-477%252C%2520a%2520Potent%2520and%2520Efficacious%2520Dual%2520PI3K%252FMTOR%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D8%26spage%3D2408%26epage%3D2411%26doi%3D10.1016%2Fj.bmcl.2010.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartwright, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheguillaume, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krintel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukadam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tivitmahaisoon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5887</span>– <span class="NLM_lpage">5900</span>, <span class="refDoi"> DOI: 10.1021/jm3003747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5887-5900&issue=12&author=B.+S.+Safinaauthor=S.+Bakerauthor=M.+Baumgardnerauthor=P.+M.+Blaneyauthor=B.+K.+Chanauthor=Y.-H.+Chenauthor=M.+W.+Cartwrightauthor=G.+Castanedoauthor=C.+Chabotauthor=A.+J.+Cheguillaumeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=B.+Goyalauthor=T.+Hancoxauthor=R.+K.+Handaauthor=P.+S.+Iyerauthor=J.+Kaurauthor=R.+Kondruauthor=J.+R.+Kennyauthor=S.+L.+Krintelauthor=J.+Liauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=S.+Mukadamauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=F.+Padillaauthor=W.+S.+Palmerauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=L.+Salphatiauthor=P.+A.+Savyauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=S.+Tayauthor=P.+Tivitmahaisoonauthor=B.+Waszkowyczauthor=B.+Weiauthor=Q.+Yueauthor=C.+Zhangauthor=D.+P.+Sutherlin&title=Discovery+of+Novel+PI3-Kinase+%CE%B4+Specific+Inhibitors+for+the+Treatment+of+Rheumatoid+Arthritis%3A+Taming+CYP3A4+Time-Dependent+Inhibition&doi=10.1021%2Fjm3003747"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm3003747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003747%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.-H.%26aulast%3DCartwright%26aufirst%3DM.%2BW.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DCheguillaume%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DGoyal%26aufirst%3DB.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DHanda%26aufirst%3DR.%2BK.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKrintel%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPadilla%26aufirst%3DF.%26aulast%3DPalmer%26aufirst%3DW.%2BS.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSavy%26aufirst%3DP.%2BA.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DTivitmahaisoon%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520of%2520Novel%2520PI3-Kinase%2520%25CE%25B4%2520Specific%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520Taming%2520CYP3A4%2520Time-Dependent%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D12%26spage%3D5887%26epage%3D5900%26doi%3D10.1021%2Fjm3003747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8007</span>– <span class="NLM_lpage">8020</span>, <span class="refDoi"> DOI: 10.1021/jm300867c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300867c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8007-8020&issue=18&author=T.+P.+Heffronauthor=L.+Salphatiauthor=B.+Alickeauthor=J.+Cheongauthor=J.+Dotsonauthor=K.+Edgarauthor=R.+Goldsmithauthor=S.+E.+Gouldauthor=L.+B.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=C.+Ndubakuauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=J.+Pangauthor=E.+G.+Pliseauthor=S.+Siderisauthor=S.+Trappauthor=J.+Wallinauthor=L.+Wangauthor=X.+Zhang&title=The+Design+and+Identification+of+Brain+Penetrant+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B1&doi=10.1021%2Fjm300867c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300867c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300867c%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DJ.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPlise%26aufirst%3DE.%2BG.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTrapp%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DThe%2520Design%2520and%2520Identification%2520of%2520Brain%2520Penetrant%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D18%26spage%3D8007%26epage%3D8020%26doi%3D10.1021%2Fjm300867c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Inhibitors of PI3Kδ: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4296</span>– <span class="NLM_lpage">4302</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.05.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4296-4302&issue=13&author=D.+P.+Sutherlinauthor=S.+Bakerauthor=A.+Bisconteauthor=P.+M.+Blaneyauthor=A.+Brownauthor=B.+K.+Chanauthor=D.+Chantryauthor=G.+Castanedoauthor=P.+DePledgeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=T.+Hancoxauthor=J.+Kaurauthor=D.+Knowlesauthor=R.+Kondruauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=B.+S.+Safinaauthor=L.+Salphatiauthor=S.+Stabenauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=M.+Ultschauthor=B.+Waszkowyczauthor=B.+Wei&title=Potent+and+Selective+Inhibitors+of+PI3K%CE%B4%3A+Obtaining+Isoform+Selectivity+from+the+Affinity+Pocket+and+Tryptophan+Shelf&doi=10.1016%2Fj.bmcl.2012.05.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DDePledge%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKnowles%26aufirst%3DD.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26atitle%3DPotent%2520and%2520Selective%2520Inhibitors%2520of%2520PI3K%25CE%25B4%253A%2520Obtaining%2520Isoform%2520Selectivity%2520from%2520the%2520Affinity%2520Pocket%2520and%2520Tryptophan%2520Shelf%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D13%26spage%3D4296%26epage%3D4302%26doi%3D10.1016%2Fj.bmcl.2012.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savy, P. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7686</span>– <span class="NLM_lpage">7695</span>, <span class="refDoi"> DOI: 10.1021/jm300717c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300717c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7686-7695&issue=17&author=J.+M.+Murrayauthor=Z.+K.+Sweeneyauthor=B.+K.+Chanauthor=M.+Balazsauthor=E.+Bradleyauthor=G.+Castanedoauthor=C.+Chabotauthor=D.+Chantryauthor=M.+Flagellaauthor=D.+M.+Goldsteinauthor=R.+Kondruauthor=J.+Lesnickauthor=J.+Liauthor=M.+C.+Lucasauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=L.+Salphatiauthor=B.+Safinaauthor=P.+P.+A.+Savyauthor=E.+M.+Sewardauthor=M.+Ultschauthor=D.+P.+Sutherlin&title=Potent+and+Highly+Selective+Benzimidazole+Inhibitors+of+PI3-Kinase+Delta&doi=10.1021%2Fjm300717c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm300717c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300717c%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSafina%26aufirst%3DB.%26aulast%3DSavy%26aufirst%3DP.%2BP.%2BA.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DPotent%2520and%2520Highly%2520Selective%2520Benzimidazole%2520Inhibitors%2520of%2520PI3-Kinase%2520Delta%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7686%26epage%3D7695%26doi%3D10.1021%2Fjm300717c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Identification of GNE-293, a Potent and Selective PI3Kδ Inhibitor: Navigating in Vitro Genotoxicity While Improving Potency and Selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4953</span>– <span class="NLM_lpage">4959</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2013.06.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4953-4959&issue=17&author=B.%0AS.+Safinaauthor=Z.+K.+Sweeneyauthor=J.+Liauthor=B.+K.+Chanauthor=A.+Bisconteauthor=D.+Carreraauthor=G.+Castanedoauthor=M.+Flagellaauthor=R.+Healdauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=K.+Reifauthor=L.+Salphatiauthor=E.+M.+Sewardauthor=B.+Weiauthor=D.+P.+Sutherlin&title=Identification+of+GNE-293%2C+a+Potent+and+Selective+PI3K%CE%B4+Inhibitor%3A+Navigating+in+Vitro+Genotoxicity+While+Improving+Potency+and+Selectivity&doi=10.1016%2Fj.bmcl.2013.06.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DCarrera%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DIdentification%2520of%2520GNE-293%252C%2520a%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitor%253A%2520Navigating%2520in%2520Vitro%2520Genotoxicity%2520While%2520Improving%2520Potency%2520and%2520Selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D17%26spage%3D4953%26epage%3D4959%26doi%3D10.1016%2Fj.bmcl.2013.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yaguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshimizu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamori, T.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor</span>. <i>JNCI J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1093/jnci/djj133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1093%2Fjnci%2Fdjj133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=16622124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=545-556&issue=8&author=S.+Yaguchiauthor=Y.+Fukuiauthor=I.+Koshimizuauthor=H.+Yoshimiauthor=T.+Matsunoauthor=H.+Goudaauthor=S.+Hironoauthor=K.+Yamazakiauthor=T.+Yamori&title=Antitumor+Activity+of+ZSTK474%2C+a+New+Phosphatidylinositol+3-Kinase+Inhibitor&doi=10.1093%2Fjnci%2Fdjj133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor</span></div><div class="casAuthors">Yaguchi, Shin-ichi; Fukui, Yasuhisa; Koshimizu, Ichiro; Yoshimi, Hisashi; Matsuno, Toshiyuki; Gouda, Hiroaki; Hirono, Shuichi; Yamazaki, Kanami; Yamori, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously synthesized a novel s-triazine deriv., ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells.  We identified its mol. target, investigated its effects on cellular signaling pathways, and examd. its antitumor efficacy and toxicity in vivo.  Methods: We used COMPARE anal. of chemosensitivity measurements from 39 human cancer cell lines and identified phosphatidylinositol 3-kinase (PI3K) as a mol. target for ZSTK474.  PI3K was immunopptd. from A549 cell lysates, and its activity was measured by assessing the incorporation of 32P into phosphatidylinositol.  We used the crystal structure of the PI3K-LY294002 complex to model the binding of ZSTK474 to PI3K (where LY294002 is a known PI3K inhibitor).  PI3K downstream activity was analyzed by immunoblotting.  Antitumor activity of ZSTK474 was examd. against A549, PC-3, and WiDr xenografts in nude mice.  Phosphorylation of Akt, a serine/threonine protein kinase and a major signaling component downstream of PI3K, was assessed in vivo by immunohistochem.  Results: PI3K was identified as a mol. target for ZSTK474 by COMPARE anal.  We confirmed that ZSTK474 directly inhibited PI3K activity more efficiently than the PI3K inhibitor LY294002.  At concns. of 1 μM, ZSTK474 and LY2194002 reduced PI3K activity to 4.7% (95% confidence interval [CI] = 3.2% to 6.1%) and 44.6% (95% CI = 38.9% to 50.3%), resp., of the untreated control level.  Mol. modeling of the PI3K-ZSTK474 complex indicated that ZSTK474 could bind to the ATP-binding pocket of PI3K.  ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3β, and mediated a decrease in cyclin D1 levels.  ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  Akt phosphorylation was reduced in xenograft tumors after oral administration of ZSTK474.  Conclusion: ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in crit. organs.  ZSTK474 merits further investigation as an anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0v8LFKdruLVg90H21EOLACvtfcHk0lhG7SGaCK4HyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslOjsLw%253D&md5=a2593024975536089ab2ee7e53234ebc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj133%26sid%3Dliteratum%253Aachs%26aulast%3DYaguchi%26aufirst%3DS.%26aulast%3DFukui%26aufirst%3DY.%26aulast%3DKoshimizu%26aufirst%3DI.%26aulast%3DYoshimi%26aufirst%3DH.%26aulast%3DMatsuno%26aufirst%3DT.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DYamori%26aufirst%3DT.%26atitle%3DAntitumor%2520Activity%2520of%2520ZSTK474%252C%2520a%2520New%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%26jtitle%3DJNCI%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26issue%3D8%26spage%3D545%26epage%3D556%26doi%3D10.1093%2Fjnci%2Fdjj133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&issue=10&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Class+I+PI3+Kinase+Inhibitor+for+Treating+Cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lhG7SGaCK4HyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Class%2520I%2520PI3%2520Kinase%2520Inhibitor%2520for%2520Treating%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D10%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renhowe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification and Structure–activity Relationship of 2-Morpholino 6-(3-Hydroxyphenyl) Pyrimidines, a Class of Potent and Selective PI3 Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6895</span>– <span class="NLM_lpage">6898</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2010.10.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6895-6898&issue=23&author=S.+Pecchiauthor=P.+A.+Renhoweauthor=C.+Taylorauthor=S.+Kaufmanauthor=H.+Merrittauthor=M.+Wiesmannauthor=K.+R.+Shoemakerauthor=M.+S.+Knappauthor=E.+Ornelasauthor=T.+F.+Hendricksonauthor=W.+Fantlauthor=C.+F.+Voliva&title=Identification+and+Structure%E2%80%93activity+Relationship+of+2-Morpholino+6-%283-Hydroxyphenyl%29+Pyrimidines%2C+a+Class+of+Potent+and+Selective+PI3+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2010.10.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DShoemaker%26aufirst%3DK.%2BR.%26aulast%3DKnapp%26aufirst%3DM.%2BS.%26aulast%3DOrnelas%26aufirst%3DE.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DFantl%26aufirst%3DW.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520and%2520Structure%25E2%2580%2593activity%2520Relationship%2520of%25202-Morpholino%25206-%25283-Hydroxyphenyl%2529%2520Pyrimidines%252C%2520a%2520Class%2520of%2520Potent%2520and%2520Selective%2520PI3%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D23%26spage%3D6895%26epage%3D6898%26doi%3D10.1016%2Fj.bmcl.2010.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleylein-Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blommers, M. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazic-Legueux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laborde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaxelaire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummendorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1747</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1158%2F1535-7163.MCT-11-1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22653967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1747-1757&issue=8&author=S.+M.+Brachmannauthor=J.+Kleylein-Sohnauthor=S.+Gaulisauthor=A.+Kauffmannauthor=M.+J.+J.+Blommersauthor=M.+Kazic-Legueuxauthor=L.+Labordeauthor=M.+Hattenbergerauthor=F.+Staufferauthor=J.+Vaxelaireauthor=V.+Romanetauthor=C.+Henryauthor=M.+Murakamiauthor=D.+A.+Guthyauthor=D.+Sterkerauthor=S.+Berglingauthor=C.+Wilsonauthor=T.+Brummendorfauthor=C.+Fritschauthor=C.+Garcia-Echeverriaauthor=W.+R.+Sellersauthor=F.+Hofmannauthor=S.-M.+Maira&title=Characterization+of+the+Mechanism+of+Action+of+the+Pan+Class+I+PI3K+Inhibitor+NVP-BKM120+across+a+Broad+Range+of+Concentrations&doi=10.1158%2F1535-7163.MCT-11-1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations</span></div><div class="casAuthors">Brachmann, Saskia M.; Kleylein-Sohn, Julia; Gaulis, Swann; Kauffmann, Audrey; Blommers, Marcel J. J.; Kazic-Legueux, Malika; Laborde, Laurent; Hattenberger, Marc; Stauffer, Fabian; Vaxelaire, Juliane; Romanet, Vincent; Henry, Chrystele; Murakami, Masato; Guthy, Daniel Alexander; Sterker, Dario; Bergling, Sebastian; Wilson, Christopher; Bruemmendorf, Thomas; Fritsch, Christine; Garcia-Echeverria, Carlos; Sellers, William R.; Hofmann, Francesco; Maira, Sauveur-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1747-1757</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The pan-phosphoinositide 3-kinase (PI3K) inhibitor BKM120 was found, at high concns., to cause cell death in various cellular systems, irresp. of their level of PI3K addiction.  Transcriptional and biochem. profiling studies were used to identify the origin of these unexpected and apparently PI3K-independent effects.  At 5- to 10-fold, the concn. needed to half-maximally inhibit PI3K signaling.  BKM120 treatment caused changes in expression of mitotic genes and the induction of a robust G2-M arrest.  Tubulin polymn. assays and NMR-binding studies revealed that BKM120 inhibited microtubule dynamics upon direct binding to tubulin.  To assess the contribution of this off-target activity vis-a-vis the antitumor activity of BKM120 in PI3K-dependent tumors, we used a mechanistic PI3K-α-dependent model.  We obsd. that, in vivo, daily treatment of mice with doses of BKM120 up to 40 mg/kg led to tumor regressions with no increase in the mitotic index.  Thus, strong antitumor activity can be achieved in PI3K-dependent models at exposures that are below those necessary to engage the off-target activity.  In comparison, the clin. data indicate that it is unlikely that BKM120 will achieve exposures sufficient to significantly engage the off-target activity at tolerated doses and schedules.  However, in preclin. settings, the consequences of the off-target activity start to manifest themselves at concns. above 1 μmol/L in vitro and doses above 50 mg/kg in efficacy studies using s.c. tumor-bearing mice.  Hence, careful concn. and dose range selection is required to ensure that any observation can be correctly attributed to BKM120 inhibition of PI3K.  Mol Cancer Ther; 11(8); 1747-57. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKHhs5m02qfrVg90H21EOLACvtfcHk0liArNSu3bHyCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrM&md5=26f5cd3377b49f9e61a092191d86194b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1021%26sid%3Dliteratum%253Aachs%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DKleylein-Sohn%26aufirst%3DJ.%26aulast%3DGaulis%26aufirst%3DS.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DBlommers%26aufirst%3DM.%2BJ.%2BJ.%26aulast%3DKazic-Legueux%26aufirst%3DM.%26aulast%3DLaborde%26aufirst%3DL.%26aulast%3DHattenberger%26aufirst%3DM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DVaxelaire%26aufirst%3DJ.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DGuthy%26aufirst%3DD.%2BA.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DBergling%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBrummendorf%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMaira%26aufirst%3DS.-M.%26atitle%3DCharacterization%2520of%2520the%2520Mechanism%2520of%2520Action%2520of%2520the%2520Pan%2520Class%2520I%2520PI3K%2520Inhibitor%2520NVP-BKM120%2520across%2520a%2520Broad%2520Range%2520of%2520Concentrations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D8%26spage%3D1747%26epage%3D1757%26doi%3D10.1158%2F1535-7163.MCT-11-1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s Mechanism of Action Defines Specific PI3K and Tubulin Inhibitors for Therapeutic Intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+Mechanism+of+Action+Defines+Specific+PI3K+and+Tubulin+Inhibitors+for+Therapeutic+Intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2ea8ZRGMp0C5G7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520Mechanism%2520of%2520Action%2520Defines%2520Specific%2520PI3K%2520and%2520Tubulin%2520Inhibitors%2520for%2520Therapeutic%2520Intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7268</span>– <span class="NLM_lpage">7274</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00235</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00235" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7268-7274&issue=15&author=J.-Q.+Zhangauthor=Y.-J.+Luoauthor=Y.-S.+Xiongauthor=Y.+Yuauthor=Z.-C.+Tuauthor=Z.-J.+Longauthor=X.-J.+Laiauthor=H.-X.+Chenauthor=Y.+Luoauthor=J.+Wengauthor=G.+Lu&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Substituted+Pyrimidines+as+Potential+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00235"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00235%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-Q.%26aulast%3DLuo%26aufirst%3DY.-J.%26aulast%3DXiong%26aufirst%3DY.-S.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLong%26aufirst%3DZ.-J.%26aulast%3DLai%26aufirst%3DX.-J.%26aulast%3DChen%26aufirst%3DH.-X.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWeng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Substituted%2520Pyrimidines%2520as%2520Potential%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D15%26spage%3D7268%26epage%3D7274%26doi%3D10.1021%2Facs.jmedchem.6b00235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delos Santos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khafizova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1021/jm901830p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901830p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2636-2645&issue=6&author=A.+M.+Venkatesanauthor=C.+M.+Dehnhardtauthor=E.+Delos+Santosauthor=Z.+Chenauthor=O.+Dos+Santosauthor=S.+Ayral-Kaloustianauthor=G.+Khafizovaauthor=N.+Brooijmansauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=K.+Yuauthor=J.+Gibbonsauthor=R.+T.+Abrahamauthor=I.+Chaudharyauthor=T.+S.+Mansour&title=Bis%28Morpholino-1%2C3%2C5-Triazine%29+Derivatives%3A+Potent+Adenosine+5%E2%80%B2-Triphosphate+Competitive+Phosphatidylinositol-3-Kinase%2FMammalian+Target+of+Rapamycin+Inhibitors%3A+Discovery+of+Compound+26+%28PKI-587%29%2C+a+Highly+Efficacious+Dual+Inhibitor&doi=10.1021%2Fjm901830p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm901830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901830p%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDos%2BSantos%26aufirst%3DO.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DKhafizova%26aufirst%3DG.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DBis%2528Morpholino-1%252C3%252C5-Triazine%2529%2520Derivatives%253A%2520Potent%2520Adenosine%25205%25E2%2580%25B2-Triphosphate%2520Competitive%2520Phosphatidylinositol-3-Kinase%252FMammalian%2520Target%2520of%2520Rapamycin%2520Inhibitors%253A%2520Discovery%2520of%2520Compound%252026%2520%2528PKI-587%2529%252C%2520a%2520Highly%2520Efficacious%2520Dual%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D6%26spage%3D2636%26epage%3D2645%26doi%3D10.1021%2Fjm901830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delos Santos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1021/jm9014982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9014982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=798-810&issue=2&author=C.+M.+Dehnhardtauthor=A.+M.+Venkatesanauthor=E.+Delos+Santosauthor=Z.+Chenauthor=O.+Santosauthor=S.+Ayral-Kaloustianauthor=N.+Brooijmansauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=I.+Chaudharyauthor=K.+Yuauthor=J.+Gibbonsauthor=R.+Abrahamauthor=T.+S.+Mansour&title=Lead+Optimization+of+N-3-Substituted+7-Morpholinotriazolopyrimidines+as+Dual+Phosphoinositide+3-Kinase%2FMammalian+Target+of+Rapamycin+Inhibitors%3A+Discovery+of+PKI-402&doi=10.1021%2Fjm9014982"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm9014982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9014982%26sid%3Dliteratum%253Aachs%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSantos%26aufirst%3DO.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DR.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DLead%2520Optimization%2520of%2520N-3-Substituted%25207-Morpholinotriazolopyrimidines%2520as%2520Dual%2520Phosphoinositide%25203-Kinase%252FMammalian%2520Target%2520of%2520Rapamycin%2520Inhibitors%253A%2520Discovery%2520of%2520PKI-402%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D2%26spage%3D798%26epage%3D810%26doi%3D10.1021%2Fjm9014982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span> <span> </span><span class="NLM_article-title">Regioselective Synthesis of 5- and 6-Methoxybenzimidazole-1,3,5-Triazines as Inhibitors of Phosphoinositide 3-Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">802</span>– <span class="NLM_lpage">805</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.11.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=802-805&issue=3&author=M.+S.+Millerauthor=J.-A.+Pinsonauthor=Z.+Zhengauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=Regioselective+Synthesis+of+5-+and+6-Methoxybenzimidazole-1%2C3%2C5-Triazines+as+Inhibitors+of+Phosphoinositide+3-Kinase&doi=10.1016%2Fj.bmcl.2012.11.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DRegioselective%2520Synthesis%2520of%25205-%2520and%25206-Methoxybenzimidazole-1%252C3%252C5-Triazines%2520as%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D802%26epage%3D805%26doi%3D10.1016%2Fj.bmcl.2012.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountford, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Künzli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span> <span> </span><span class="NLM_article-title">Development of Single and Mixed Isoform Selectivity PI3Kδ Inhibitors by Targeting Asn836 of PI3Kδ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4794</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.08.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4790-4794&issue=19&author=M.+S.+Millerauthor=S.+J.+Mountfordauthor=J.-A.+Pinsonauthor=Z.+Zhengauthor=M.+K%C3%BCnzliauthor=V.+Patelauthor=S.+J.+Hoggauthor=J.+Shorttauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=Development+of+Single+and+Mixed+Isoform+Selectivity+PI3K%CE%B4+Inhibitors+by+Targeting+Asn836+of+PI3K%CE%B4&doi=10.1016%2Fj.bmcl.2016.08.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DMountford%26aufirst%3DS.%2BJ.%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DK%25C3%25BCnzli%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DHogg%26aufirst%3DS.%2BJ.%26aulast%3DShortt%26aufirst%3DJ.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DDevelopment%2520of%2520Single%2520and%2520Mixed%2520Isoform%2520Selectivity%2520PI3K%25CE%25B4%2520Inhibitors%2520by%2520Targeting%2520Asn836%2520of%2520PI3K%25CE%25B4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D19%26spage%3D4790%26epage%3D4794%26doi%3D10.1016%2Fj.bmcl.2016.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span> <span> </span><span class="NLM_article-title">L-Aminoacyl-Triazine Derivatives Are Isoform-Selective PI3Kβ Inhibitors That Target Nonconserved Asp862 of PI3Kβ</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1021/ml300336j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300336j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=206-210&issue=2&author=J.-A.+Pinsonauthor=Z.+Zhengauthor=M.+S.+Millerauthor=D.+K.+Chalmersauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=L-Aminoacyl-Triazine+Derivatives+Are+Isoform-Selective+PI3K%CE%B2+Inhibitors+That+Target+Nonconserved+Asp862+of+PI3K%CE%B2&doi=10.1021%2Fml300336j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fml300336j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300336j%26sid%3Dliteratum%253Aachs%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DL-Aminoacyl-Triazine%2520Derivatives%2520Are%2520Isoform-Selective%2520PI3K%25CE%25B2%2520Inhibitors%2520That%2520Target%2520Nonconserved%2520Asp862%2520of%2520PI3K%25CE%25B2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D2%26spage%3D206%26epage%3D210%26doi%3D10.1021%2Fml300336j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollinger, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuila, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahinj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhumkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00322</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00322" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1190-1194&issue=12&author=S.+Dugarauthor=F.+P.+Hollingerauthor=D.+Mahajanauthor=S.+Senauthor=B.+Kuilaauthor=R.+Aroraauthor=Y.+Pawarauthor=V.+Shindeauthor=M.+Rahinjauthor=K.+K.+Kapoorauthor=R.+Bhumkarauthor=S.+Raiauthor=R.+Kulkarni&title=Discovery+of+Novel+and+Orally+Bioavailable+Inhibitors+of+PI3+Kinase+Based+on+Indazole+Substituted+Morpholino-Triazines&doi=10.1021%2Facsmedchemlett.5b00322"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00322%26sid%3Dliteratum%253Aachs%26aulast%3DDugar%26aufirst%3DS.%26aulast%3DHollinger%26aufirst%3DF.%2BP.%26aulast%3DMahajan%26aufirst%3DD.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DKuila%26aufirst%3DB.%26aulast%3DArora%26aufirst%3DR.%26aulast%3DPawar%26aufirst%3DY.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DRahinj%26aufirst%3DM.%26aulast%3DKapoor%26aufirst%3DK.%2BK.%26aulast%3DBhumkar%26aufirst%3DR.%26aulast%3DRai%26aufirst%3DS.%26aulast%3DKulkarni%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520Novel%2520and%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520PI3%2520Kinase%2520Based%2520on%2520Indazole%2520Substituted%2520Morpholino-Triazines%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D12%26spage%3D1190%26epage%3D1194%26doi%3D10.1021%2Facsmedchemlett.5b00322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamage, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giddens, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, S. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Sulfonamide Analogues of the Phosphatidylinositol 3-Kinase Inhibitor ZSTK474</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5859</span>– <span class="NLM_lpage">5874</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2017.09.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5859-5874&issue=20&author=S.+A.+Gamageauthor=A.+C.+Giddensauthor=K.+Y.+Tsangauthor=J.+U.+Flanaganauthor=J.+D.+Kendallauthor=W.-J.+Leeauthor=B.+C.+Baguleyauthor=C.+M.+Buchananauthor=S.+M.+F.+Jamiesonauthor=P.+R.+Shepherdauthor=W.+A.+Dennyauthor=G.+W.+Rewcastle&title=Synthesis+and+Biological+Evaluation+of+Sulfonamide+Analogues+of+the+Phosphatidylinositol+3-Kinase+Inhibitor+ZSTK474&doi=10.1016%2Fj.bmc.2017.09.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DGamage%26aufirst%3DS.%2BA.%26aulast%3DGiddens%26aufirst%3DA.%2BC.%26aulast%3DTsang%26aufirst%3DK.%2BY.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DBuchanan%26aufirst%3DC.%2BM.%26aulast%3DJamieson%26aufirst%3DS.%2BM.%2BF.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Sulfonamide%2520Analogues%2520of%2520the%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%2520ZSTK474%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5859%26epage%3D5874%26doi%3D10.1016%2Fj.bmc.2017.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and Biological Activity of a Novel Class I PI3K Inhibitor, CH5132799</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1772</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.01.065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1767-1772&issue=6&author=J.+Ohwadaauthor=H.+Ebiikeauthor=H.+Kawadaauthor=M.+Tsukazakiauthor=M.+Nakamuraauthor=T.+Miyazakiauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=O.+Kondohauthor=S.+Kuramotoauthor=K.+Ogawaauthor=Y.+Aokiauthor=N.+Shimma&title=Discovery+and+Biological+Activity+of+a+Novel+Class+I+PI3K+Inhibitor%2C+CH5132799&doi=10.1016%2Fj.bmcl.2011.01.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DKuramoto%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DShimma%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520Biological%2520Activity%2520of%2520a%2520Novel%2520Class%2520I%2520PI3K%2520Inhibitor%252C%2520CH5132799%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D6%26spage%3D1767%26epage%3D1772%26doi%3D10.1016%2Fj.bmcl.2011.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of a Dihydropyrrolopyrimidine Inhibitor against Phosphoinositide 3-Kinase (PI3K) to Improve the Phenol Glucuronic Acid Conjugation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.11.112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=673-678&issue=3&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shimmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Lead+Optimization+of+a+Dihydropyrrolopyrimidine+Inhibitor+against+Phosphoinositide+3-Kinase+%28PI3K%29+to+Improve+the+Phenol+Glucuronic+Acid+Conjugation&doi=10.1016%2Fj.bmcl.2012.11.112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.112%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DLead%2520Optimization%2520of%2520a%2520Dihydropyrrolopyrimidine%2520Inhibitor%2520against%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520to%2520Improve%2520the%2520Phenol%2520Glucuronic%2520Acid%2520Conjugation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D673%26epage%3D678%26doi%3D10.1016%2Fj.bmcl.2012.11.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Modification of a Dihydropyrrolopyrimidine Phosphoinositide 3-Kinase (PI3K) Inhibitor to Improve Oral Bioavailability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7650</span>– <span class="NLM_lpage">7660</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2015.11.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=7650-7660&issue=24&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=S.+Yamamotoauthor=K.+Koyamaauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shinmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Modification+of+a+Dihydropyrrolopyrimidine+Phosphoinositide+3-Kinase+%28PI3K%29+Inhibitor+to+Improve+Oral+Bioavailability&doi=10.1016%2Fj.bmc.2015.11.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShinma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DModification%2520of%2520a%2520Dihydropyrrolopyrimidine%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520Inhibitor%2520to%2520Improve%2520Oral%2520Bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D24%26spage%3D7650%26epage%3D7660%26doi%3D10.1016%2Fj.bmc.2015.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Optimization of the Phenylurea Moiety in a Phosphoinositide 3-Kinase (PI3K) Inhibitor to Improve Water Solubility and the PK Profile by Introducing a Solubilizing Group and Ortho Substituents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2016.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2897-2906&issue=13&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=S.+Yamamotoauthor=K.+Koyamaauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shimmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Optimization+of+the+Phenylurea+Moiety+in+a+Phosphoinositide+3-Kinase+%28PI3K%29+Inhibitor+to+Improve+Water+Solubility+and+the+PK+Profile+by+Introducing+a+Solubilizing+Group+and+Ortho+Substituents&doi=10.1016%2Fj.bmc.2016.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520the%2520Phenylurea%2520Moiety%2520in%2520a%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520Inhibitor%2520to%2520Improve%2520Water%2520Solubility%2520and%2520the%2520PK%2520Profile%2520by%2520Introducing%2520a%2520Solubilizing%2520Group%2520and%2520Ortho%2520Substituents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D13%26spage%3D2897%26epage%3D2906%26doi%3D10.1016%2Fj.bmc.2016.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Bioactivity of 4-(2-Arylpyrido[3′,2′:3,4]Pyrrolo[1,2-f][1,2,4]Triazin-4-Yl) Morpholine Derivatives as Novel PI3K Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.11.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=339-342&issue=1&author=J.+Wangauthor=X.+Wangauthor=Y.+Chenauthor=S.+Chenauthor=G.+Chenauthor=L.+Tongauthor=L.+Mengauthor=Y.+Xieauthor=J.+Dingauthor=C.+Yang&title=Discovery+and+Bioactivity+of+4-%282-Arylpyrido%5B3%E2%80%B2%2C2%E2%80%B2%3A3%2C4%5DPyrrolo%5B1%2C2-f%5D%5B1%2C2%2C4%5DTriazin-4-Yl%29+Morpholine+Derivatives+as+Novel+PI3K+Inhibitors&doi=10.1016%2Fj.bmcl.2011.11.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520Bioactivity%2520of%25204-%25282-Arylpyrido%255B3%25E2%2580%25B2%252C2%25E2%2580%25B2%253A3%252C4%255DPyrrolo%255B1%252C2-f%255D%255B1%252C2%252C4%255DTriazin-4-Yl%2529%2520Morpholine%2520Derivatives%2520as%2520Novel%2520PI3K%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D1%26spage%3D339%26epage%3D342%26doi%3D10.1016%2Fj.bmcl.2011.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez
González, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Arístegui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González Cantalapiedra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez Hergueta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarrán, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebriá, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendón, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrián, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span> <span> </span><span class="NLM_article-title">Generation of Tricyclic Imidazo[1,2- a ]Pyrazines as Novel PI3K Inhibitors by Application of a Conformational Restriction Strategy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2536</span>– <span class="NLM_lpage">2543</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.03.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2536-2543&issue=11&author=S.+Mart%C3%ADnez%0AGonz%C3%A1lezauthor=S.+Rodr%C3%ADguez-Ar%C3%ADsteguiauthor=A.+I.+Hern%C3%A1ndezauthor=C.+Varelaauthor=E.+Gonz%C3%A1lez+Cantalapiedraauthor=R.+M.+%C3%81lvarezauthor=A.+Rodr%C3%ADguez+Herguetaauthor=J.+R.+Bischoffauthor=M.+I.+Albarr%C3%A1nauthor=A.+Cebri%C3%A1author=E.+Cend%C3%B3nauthor=D.+Cebri%C3%A1nauthor=P.+Alfonsoauthor=J.+Pastor&title=Generation+of+Tricyclic+Imidazo%5B1%2C2-+a+%5DPyrazines+as+Novel+PI3K+Inhibitors+by+Application+of+a+Conformational+Restriction+Strategy&doi=10.1016%2Fj.bmcl.2017.03.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.090%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez%2BGonz%25C3%25A1lez%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-Ar%25C3%25ADstegui%26aufirst%3DS.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DA.%2BI.%26aulast%3DVarela%26aufirst%3DC.%26aulast%3DGonz%25C3%25A1lez%2BCantalapiedra%26aufirst%3DE.%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%2BM.%26aulast%3DRodr%25C3%25ADguez%2BHergueta%26aufirst%3DA.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26aulast%3DAlbarr%25C3%25A1n%26aufirst%3DM.%2BI.%26aulast%3DCebri%25C3%25A1%26aufirst%3DA.%26aulast%3DCend%25C3%25B3n%26aufirst%3DE.%26aulast%3DCebri%25C3%25A1n%26aufirst%3DD.%26aulast%3DAlfonso%26aufirst%3DP.%26aulast%3DPastor%26aufirst%3DJ.%26atitle%3DGeneration%2520of%2520Tricyclic%2520Imidazo%255B1%252C2-%2520a%2520%255DPyrazines%2520as%2520Novel%2520PI3K%2520Inhibitors%2520by%2520Application%2520of%2520a%2520Conformational%2520Restriction%2520Strategy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2536%26epage%3D2543%26doi%3D10.1016%2Fj.bmcl.2017.03.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez
González, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Lima, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarrán, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebriá, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Encinas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Arocha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrián, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Aparicio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel PI3K Inhibitors through a Scaffold Hopping Strategy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4794</span>– <span class="NLM_lpage">4799</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.09.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.09.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4794-4799&issue=21&author=S.+Mart%C3%ADnez%0AGonz%C3%A1lezauthor=A.+I.+Hern%C3%A1ndezauthor=R.+M.+%C3%81lvarezauthor=A.+Rodr%C3%ADguezauthor=F.+Ramos-Limaauthor=J.+R.+Bischoffauthor=M.+I.+Albarr%C3%A1nauthor=A.+Cebri%C3%A1author=E.+Hern%C3%A1ndez-Encinasauthor=J.+Garc%C3%ADa-Arochaauthor=D.+Cebri%C3%A1nauthor=C.+Blanco-Aparicioauthor=J.+Pastor&title=Identification+of+Novel+PI3K+Inhibitors+through+a+Scaffold+Hopping+Strategy&doi=10.1016%2Fj.bmcl.2017.09.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.09.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.09.059%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez%2BGonz%25C3%25A1lez%26aufirst%3DS.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DA.%2BI.%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%2BM.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DA.%26aulast%3DRamos-Lima%26aufirst%3DF.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26aulast%3DAlbarr%25C3%25A1n%26aufirst%3DM.%2BI.%26aulast%3DCebri%25C3%25A1%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez-Encinas%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa-Arocha%26aufirst%3DJ.%26aulast%3DCebri%25C3%25A1n%26aufirst%3DD.%26aulast%3DBlanco-Aparicio%26aufirst%3DC.%26aulast%3DPastor%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520Novel%2520PI3K%2520Inhibitors%2520through%2520a%2520Scaffold%2520Hopping%2520Strategy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D21%26spage%3D4794%26epage%3D4799%26doi%3D10.1016%2Fj.bmcl.2017.09.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhavsar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medikonda, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1021/jm3008745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=712-721&issue=3&author=M.+Nachtauthor=L.+Qiaoauthor=M.+P.+Sheetsauthor=T.+St.+Martinauthor=M.+Labenskiauthor=H.+Mazdiyasniauthor=R.+Karpauthor=Z.+Zhuauthor=P.+Chaturvediauthor=D.+Bhavsarauthor=D.+Niuauthor=W.+Westlinauthor=R.+C.+Petterauthor=A.+P.+Medikondaauthor=J.+Singh&title=Discovery+of+a+Potent+and+Isoform-Selective+Targeted+Covalent+Inhibitor+of+the+Lipid+Kinase+PI3K%CE%B1&doi=10.1021%2Fjm3008745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm3008745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008745%26sid%3Dliteratum%253Aachs%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DSheets%26aufirst%3DM.%2BP.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DBhavsar%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DMedikonda%26aufirst%3DA.%2BP.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Isoform-Selective%2520Targeted%2520Covalent%2520Inhibitor%2520of%2520the%2520Lipid%2520Kinase%2520PI3K%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D3%26spage%3D712%26epage%3D721%26doi%3D10.1021%2Fjm3008745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saurat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Tauzia, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colliandre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akssira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corlu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bénédetti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/MTOR Dual Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1021/jm401138v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401138v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=613-631&issue=3&author=T.+Sauratauthor=F.+Buronauthor=N.+Rodriguesauthor=M.-L.+de+Tauziaauthor=L.+Colliandreauthor=S.+Bourgauthor=P.+Bonnetauthor=G.+Guillaumetauthor=M.+Akssiraauthor=A.+Corluauthor=C.+Guillouzoauthor=P.+Berthierauthor=P.+Rioauthor=M.-L.+Jourdanauthor=H.+B%C3%A9n%C3%A9dettiauthor=S.+Routier&title=Design%2C+Synthesis%2C+and+Biological+Activity+of+Pyridopyrimidine+Scaffolds+as+Novel+PI3K%2FMTOR+Dual+Inhibitors&doi=10.1021%2Fjm401138v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors</span></div><div class="casAuthors">Saurat, Thibault; Buron, Frederic; Rodrigues, Nuno; de Tauzia, Marie-Ludivine; Colliandre, Lionel; Bourg, Stephane; Bonnet, Pascal; Guillaumet, Gerald; Akssira, Mohamed; Corlu, Anne; Guillouzo, Christiane; Berthier, Pauline; Rio, Pascale; Jourdan, Marie-Lise; Benedetti, Helene; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">613-631</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and screening of dual PI3K/mTOR inhibitors that gave nanomolar enzymic and cellular activities on both targets with an acceptable kinase selectivity profile are described.  A docking study was performed to understand the binding mode of the compds. and to explain the differences in biol. activity.  In addn., cellular effects of the best dual inhibitors were detd. on six cancer cell lines and compared to those on a healthy diploid cell line for cellular cytotoxicity.  Two compds. are highly potent on cancer cells in the submicromolar range without any toxicity on healthy cells.  A more detailed anal. of the cellular effect of these PI3K/mTOR dual inhibitors demonstrated that they induce G1-phase cell cycle arrest in breast cancer cells and trigger apoptosis.  These compds. show an interesting kinase profile as dual PI3K/mTOR tool compds. or as a chem. series for further optimization to progress into in vivo expts.  Compd. I was found to display the most interesting pharmacol. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZi2SpToKDBrVg90H21EOLACvtfcHk0ljotLa4TvqTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtrrE&md5=4ca2c231e2fd5289704aa7eb4ef79cce</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm401138v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401138v%26sid%3Dliteratum%253Aachs%26aulast%3DSaurat%26aufirst%3DT.%26aulast%3DBuron%26aufirst%3DF.%26aulast%3DRodrigues%26aufirst%3DN.%26aulast%3Dde%2BTauzia%26aufirst%3DM.-L.%26aulast%3DColliandre%26aufirst%3DL.%26aulast%3DBourg%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DCorlu%26aufirst%3DA.%26aulast%3DGuillouzo%26aufirst%3DC.%26aulast%3DBerthier%26aufirst%3DP.%26aulast%3DRio%26aufirst%3DP.%26aulast%3DJourdan%26aufirst%3DM.-L.%26aulast%3DB%25C3%25A9n%25C3%25A9detti%26aufirst%3DH.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Activity%2520of%2520Pyridopyrimidine%2520Scaffolds%2520as%2520Novel%2520PI3K%252FMTOR%2520Dual%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D613%26epage%3D631%26doi%3D10.1021%2Fjm401138v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollinger, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuila, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Pyrrolotriazine Based Molecules as PI3 Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3142</span>– <span class="NLM_lpage">3146</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2015.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3142-3146&issue=16&author=S.+Dugarauthor=F.+P.+Hollingerauthor=B.+Kuilaauthor=R.+Aroraauthor=S.+Senauthor=D.+Mahajan&title=Synthesis+and+Evaluation+of+Pyrrolotriazine+Based+Molecules+as+PI3+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2015.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DDugar%26aufirst%3DS.%26aulast%3DHollinger%26aufirst%3DF.%2BP.%26aulast%3DKuila%26aufirst%3DB.%26aulast%3DArora%26aufirst%3DR.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Pyrrolotriazine%2520Based%2520Molecules%2520as%2520PI3%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D16%26spage%3D3142%26epage%3D3146%26doi%3D10.1016%2Fj.bmcl.2015.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antitumor Activities Evaluation of M-(4-Morpholinoquinazolin-2-Yl)Benzamides in Vitro and in Vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.04.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2015.04.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=25911625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslels7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=382-395&author=X.-M.+Wangauthor=M.-H.+Xinauthor=J.+Xuauthor=B.-R.+Kangauthor=Y.+Liauthor=S.-M.+Luauthor=S.-Q.+Zhang&title=Synthesis+and+Antitumor+Activities+Evaluation+of+M-%284-Morpholinoquinazolin-2-Yl%29Benzamides+in+Vitro+and+in+Vivo&doi=10.1016%2Fj.ejmech.2015.04.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo</span></div><div class="casAuthors">Wang, Xiao-Meng; Xin, Min-Hang; Xu, Jing; Kang, Bo-Rui; Li, Yan; Lu, She-Min; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">382-395</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the present study, a series of m-(4-morpholinoquinazolin-2-yl)benzamides were designed, synthesized, and characterized.  The antiproliferative activities of the synthesized compds. were evaluated against two human cell lines (HCT-116 and MCF-7).  Compds. with IC50 values below 4 μM were further evaluated against U-87 MG and A549 cell lines.  Among these evaluated compds., compd. I displayed a remarkable antiproliferative effect in vitro.  The hoechst staining assay showed that compd. I caused morphol. changes.  The cell cycle and apoptosis assay further indicated that compd. I can arrest HCT-116 cells in G2/M and G0/G1 phase and induce apoptosis.  PI3K enzyme assays indicated that compds. I and II selectively inhibit PI3Kα.  A Western bolt assay further suggested that compd. I can block the PI3K/Akt/mTOR pathway.  Moreover, compd. I inhibited tumor growth on a mice S180 homograft model.  These findings directly identify m-(4-morpholinoquinazolin-2-yl)benzamide derivs. as novel anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBXC2Y2RqANbVg90H21EOLACvtfcHk0lghU9-VR0e9Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslels7o%253D&md5=45220465aa034e09de8288d3f94dded7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.037%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-M.%26aulast%3DXin%26aufirst%3DM.-H.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DB.-R.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DS.-M.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activities%2520Evaluation%2520of%2520M-%25284-Morpholinoquinazolin-2-Yl%2529Benzamides%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D96%26spage%3D382%26epage%3D395%26doi%3D10.1016%2Fj.ejmech.2015.04.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]Pyrimidine Derivatives Bearing Pyrazoline Scaffold</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1870</span>, <span class="refDoi"> DOI: 10.3390/molecules22111870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3390%2Fmolecules22111870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1870&issue=11&author=Q.+Wangauthor=X.+Liauthor=C.+Sunauthor=B.+Zhangauthor=P.+Zhengauthor=W.+Zhuauthor=S.+Xu&title=Synthesis+and+Structure%E2%80%93Activity+Relationships+of+4-Morpholino-7%2C8-Dihydro-5H-Thiopyrano%5B4%2C3-d%5DPyrimidine+Derivatives+Bearing+Pyrazoline+Scaffold&doi=10.3390%2Fmolecules22111870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22111870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22111870%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%25204-Morpholino-7%252C8-Dihydro-5H-Thiopyrano%255B4%252C3-d%255DPyrimidine%2520Derivatives%2520Bearing%2520Pyrazoline%2520Scaffold%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D11%26spage%3D1870%26doi%3D10.3390%2Fmolecules22111870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]Pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">310</span>, <span class="refDoi"> DOI: 10.3390/molecules22020310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3390%2Fmolecules22020310" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=310&issue=2&author=S.+Xuauthor=C.+Sunauthor=C.+Chenauthor=P.+Zhengauthor=Y.+Zhouauthor=H.+Zhouauthor=W.+Zhu&title=Synthesis+and+Biological+Evaluation+of+Novel+8-Morpholinoimidazo%5B1%2C2-a%5DPyrazine+Derivatives+Bearing+Phenylpyridine%2FPhenylpyrimidine-Carboxamides&doi=10.3390%2Fmolecules22020310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22020310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22020310%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25208-Morpholinoimidazo%255B1%252C2-a%255DPyrazine%2520Derivatives%2520Bearing%2520Phenylpyridine%252FPhenylpyrimidine-Carboxamides%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D310%26doi%3D10.3390%2Fmolecules22020310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwehm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garces, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowedder, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C–C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1534</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01801</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01801" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1534-1554&issue=4&author=C.+Schwehmauthor=B.+Kellamauthor=A.+E.+Garcesauthor=S.+J.+Hillauthor=N.+D.+Kindonauthor=T.+D.+Bradshawauthor=J.+Liauthor=S.+J.+F.+Macdonaldauthor=J.+E.+Rowedderauthor=L.+A.+Stoddartauthor=M.+J.+Stocks&title=Design+and+Elaboration+of+a+Tractable+Tricyclic+Scaffold+To+Synthesize+Druglike+Inhibitors+of+Dipeptidyl+Peptidase-4+%28DPP-4%29%2C+Antagonists+of+the+C%E2%80%93C+Chemokine+Receptor+Type+5+%28CCR5%29%2C+and+Highly+Potent+and+Selective+Phosphoinositol-3+Kinase+%CE%B4+%28PI3K%CE%B4%29+Inhib&doi=10.1021%2Facs.jmedchem.6b01801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01801%26sid%3Dliteratum%253Aachs%26aulast%3DSchwehm%26aufirst%3DC.%26aulast%3DKellam%26aufirst%3DB.%26aulast%3DGarces%26aufirst%3DA.%2BE.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26aulast%3DKindon%26aufirst%3DN.%2BD.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DRowedder%26aufirst%3DJ.%2BE.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DDesign%2520and%2520Elaboration%2520of%2520a%2520Tractable%2520Tricyclic%2520Scaffold%2520To%2520Synthesize%2520Druglike%2520Inhibitors%2520of%2520Dipeptidyl%2520Peptidase-4%2520%2528DPP-4%2529%252C%2520Antagonists%2520of%2520the%2520C%25E2%2580%2593C%2520Chemokine%2520Receptor%2520Type%25205%2520%2528CCR5%2529%252C%2520and%2520Highly%2520Potent%2520and%2520Selective%2520Phosphoinositol-3%2520Kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520Inhib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1534%26epage%3D1554%26doi%3D10.1021%2Facs.jmedchem.6b01801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1021/ci800429e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800429e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVShs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1025-1032&issue=4&author=T.+J.+Ritchieauthor=C.+N.+Luscombeauthor=S.+J.+F.+Macdonald&title=Analysis+of+the+Calculated+Physicochemical+Properties+of+Respiratory+Drugs%3A+Can+We+Design+for+Inhaled+Drugs+Yet%3F&doi=10.1021%2Fci800429e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?</span></div><div class="casAuthors">Ritchie, Timothy J.; Luscombe, Christopher N.; Macdonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1025-1032</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From an anal. of calcd. physicochem. properties for 81 currently marketed respiratory drugs, compds. administered via the inhaled/intranasal routes have a higher polar surface area, a higher mol. wt., and a trend toward lower lipophilicity, when compared with their orally administered counterparts.  Ranges of physicochem. space are described for the 29 drugs administered by the inhaled or intranasal routes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvP2GM6OuLlrVg90H21EOLACvtfcHk0ljWGpo5tushOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVShs7w%253D&md5=d85e39ce2ebea1d42be67103edac1b8d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fci800429e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800429e%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DAnalysis%2520of%2520the%2520Calculated%2520Physicochemical%2520Properties%2520of%2520Respiratory%2520Drugs%253A%2520Can%2520We%2520Design%2520for%2520Inhaled%2520Drugs%2520Yet%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D4%26spage%3D1025%26epage%3D1032%26doi%3D10.1021%2Fci800429e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of Pyrrolo[2,1-f][1,2,4]Triazin-4-Amines as Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4260</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.07.047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4256-4260&issue=17&author=R.+S.+Bhideauthor=J.+Neelsauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=S.+Stachuraauthor=C.+Weigeltauthor=J.+S.+Sackauthor=K.+Stefanskiauthor=X.+Guauthor=J.+H.+Xieauthor=C.+B.+Goldstineauthor=S.+Skalaauthor=D.+L.+Pedicordauthor=S.+Rueppauthor=T.+G.+M.+Dharauthor=P.+H.+Carterauthor=L.+M.+Salter-Cidauthor=M.+A.+Possauthor=P.+Davies&title=Discovery+and+SAR+of+Pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5DTriazin-4-Amines+as+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2016.07.047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DStachura%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DGoldstine%26aufirst%3DC.%2BB.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DPedicord%26aufirst%3DD.%2BL.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520Pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255DTriazin-4-Amines%2520as%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4256%26epage%3D4260%26doi%3D10.1016%2Fj.bmcl.2016.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susulic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde-Chinn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosnius, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(3-(Piperazin-1-Yl)Phenyl)Pyrrolo[2,1-f][1,2,4]Triazin-4-Amine Derivatives as Highly Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.01.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=855-861&issue=4&author=L.-Y.+Qinauthor=Z.+Ruanauthor=R.+J.+Cherneyauthor=T.+G.+M.+Dharauthor=J.+Neelsauthor=C.+A.+Weigeltauthor=J.+S.+Sackauthor=A.+S.+Srivastavaauthor=L.+A.+M.+Corneliusauthor=J.+A.+Tinoauthor=K.+Stefanskiauthor=X.+Guauthor=J.+Xieauthor=V.+Susulicauthor=X.+Yangauthor=M.+Yarde-Chinnauthor=S.+Skalaauthor=R.+Bosniusauthor=C.+Goldsteinauthor=P.+Daviesauthor=S.+Rueppauthor=L.+Salter-Cidauthor=R.+S.+Bhideauthor=M.+A.+Poss&title=Discovery+of+7-%283-%28Piperazin-1-Yl%29Phenyl%29Pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5DTriazin-4-Amine+Derivatives+as+Highly+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DWeigelt%26aufirst%3DC.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DSusulic%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYarde-Chinn%26aufirst%3DM.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DBosnius%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26atitle%3DDiscovery%2520of%25207-%25283-%2528Piperazin-1-Yl%2529Phenyl%2529Pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255DTriazin-4-Amine%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D855%26epage%3D861%26doi%3D10.1016%2Fj.bmcl.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J.</span></span> <span> </span><span class="NLM_article-title">Identification of Highly Potent and Selective PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2853</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.01.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2849-2853&issue=13&author=D.+Marcouxauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=Q.+Shiauthor=Q.+Ruanauthor=C.+Weigeltauthor=H.+Qiuauthor=G.+Schievenauthor=J.+Hynesauthor=R.+Bhideauthor=M.+Possauthor=J.+Tino&title=Identification+of+Highly+Potent+and+Selective+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.01.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.077%26sid%3Dliteratum%253Aachs%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DSchieven%26aufirst%3DG.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%26aulast%3DPoss%26aufirst%3DM.%26aulast%3DTino%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520Highly%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D13%26spage%3D2849%26epage%3D2853%26doi%3D10.1016%2Fj.bmcl.2017.01.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin-Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleczka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fancher, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RP, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajareddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruepp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5193</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5193-5208&issue=12&author=Q.+Liuauthor=Q.+Shiauthor=D.+Marcouxauthor=D.+G.+Battauthor=L.+Corneliusauthor=L.-Y.+Qinauthor=Z.+Ruanauthor=J.+Neelsauthor=M.+Beaudoin-Bertrandauthor=A.+S.+Srivastavaauthor=L.+Liauthor=R.+J.+Cherneyauthor=H.+Gongauthor=S.+H.+Wattersonauthor=C.+Weigeltauthor=K.+M.+Gilloolyauthor=K.+W.+McIntyreauthor=J.+H.+Xieauthor=M.+T.+Obermeierauthor=A.+Furaauthor=B.+Sleczkaauthor=K.+Stefanskiauthor=R.+M.+Fancherauthor=S.+Padmanabhanauthor=T.+RPauthor=I.+Kunduauthor=K.+Rajareddyauthor=R.+Smithauthor=J.+K.+Hennanauthor=D.+Xingauthor=J.+Fanauthor=P.+C.+Levesqueauthor=Q.+Ruanauthor=S.+Pittauthor=R.+Zhangauthor=D.+Pedicordauthor=J.+Panauthor=M.+Yardeauthor=H.+Luauthor=J.+Lippyauthor=C.+Goldstineauthor=S.+Skalaauthor=R.+A.+Rampullaauthor=A.+Mathurauthor=A.+Guptaauthor=P.+N.+Arunachalamauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=M.+E.+Cvijicauthor=L.+M.+Salter-Cidauthor=R.+S.+Bhideauthor=M.+A.+Possauthor=J.+Hynesauthor=P.+H.+Carterauthor=J.+E.+Macorauthor=S.+Rueppauthor=G.+L.+Schievenauthor=J.+A.+Tino&title=Identification+of+a+Potent%2C+Selective%2C+and+Efficacious+Phosphatidylinositol+3-Kinase+%CE%B4+%28PI3K%CE%B4%29+Inhibitor+for+the+Treatment+of+Immunological+Disorders&doi=10.1021%2Facs.jmedchem.7b00618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00618%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DCornelius%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DL.-Y.%26aulast%3DRuan%26aufirst%3DZ.%26aulast%3DNeels%26aufirst%3DJ.%26aulast%3DBeaudoin-Bertrand%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DA.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DSleczka%26aufirst%3DB.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DFancher%26aufirst%3DR.%2BM.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DRP%26aufirst%3DT.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DRajareddy%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DHennan%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DGoldstine%26aufirst%3DC.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DRampulla%26aufirst%3DR.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DArunachalam%26aufirst%3DP.%2BN.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DRuepp%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Phosphatidylinositol%25203-Kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Immunological%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D5193%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.7b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Be, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boezio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPont, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubinska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkel, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Triazine-Benzimidazoles as Selective Inhibitors of MTOR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2070</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2064-2070&issue=7&author=E.+A.+Petersonauthor=P.+S.+Andrewsauthor=X.+Beauthor=A.+A.+Boezioauthor=T.+L.+Bushauthor=A.+C.+Chengauthor=J.+R.+Coatsauthor=A.+E.+Collettiauthor=K.+W.+Copelandauthor=M.+DuPontauthor=R.+Graceffaauthor=B.+Grubinskaauthor=J.-C.+Harmangeauthor=J.+L.+Kimauthor=E.+L.+Mulladyauthor=P.+Olivieriauthor=L.+B.+Schenkelauthor=M.+K.+Stantonauthor=Y.+Tefferaauthor=D.+A.+Whittingtonauthor=T.+Caiauthor=D.+S.+La&title=Discovery+of+Triazine-Benzimidazoles+as+Selective+Inhibitors+of+MTOR&doi=10.1016%2Fj.bmcl.2011.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BA.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DBe%26aufirst%3DX.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCoats%26aufirst%3DJ.%2BR.%26aulast%3DColletti%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DK.%2BW.%26aulast%3DDuPont%26aufirst%3DM.%26aulast%3DGraceffa%26aufirst%3DR.%26aulast%3DGrubinska%26aufirst%3DB.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DOlivieri%26aufirst%3DP.%26aulast%3DSchenkel%26aufirst%3DL.%2BB.%26aulast%3DStanton%26aufirst%3DM.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DLa%26aufirst%3DD.%2BS.%26atitle%3DDiscovery%2520of%2520Triazine-Benzimidazoles%2520as%2520Selective%2520Inhibitors%2520of%2520MTOR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D2064%26epage%3D2070%26doi%3D10.1016%2Fj.bmcl.2011.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5188</span>– <span class="NLM_lpage">5219</span>, <span class="refDoi"> DOI: 10.1021/jm300184s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300184s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5188-5219&issue=11&author=A.+L.+Smithauthor=N.+D.+D%E2%80%99Angeloauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=V.+J.+Ceeauthor=B.+Herberichauthor=F.-T.+Hongauthor=C.+L.+M.+Jacksonauthor=B.+A.+Lanmanauthor=L.+Liuauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=S.+Tadesseauthor=N.+A.+Tamayoauthor=R.+P.+Wurzauthor=K.+Yangauthor=K.+L.+Andrewsauthor=D.+A.+Whittingtonauthor=J.+D.+McCarterauthor=T.+S.+Miguelauthor=L.+Zalamedaauthor=J.+Jiangauthor=R.+Subramanianauthor=E.+L.+Mulladyauthor=S.+Caenepeelauthor=D.+J.+Freemanauthor=L.+Wangauthor=N.+Zhangauthor=T.+Wuauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Structure-Based+Design+of+a+Novel+Series+of+Potent%2C+Selective+Inhibitors+of+the+Class+I+Phosphatidylinositol+3-Kinases&doi=10.1021%2Fjm300184s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm300184s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300184s%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHong%26aufirst%3DF.-T.%26aulast%3DJackson%26aufirst%3DC.%2BL.%2BM.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMiguel%26aufirst%3DT.%2BS.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DStructure-Based%2520Design%2520of%2520a%2520Novel%2520Series%2520of%2520Potent%252C%2520Selective%2520Inhibitors%2520of%2520the%2520Class%2520I%2520Phosphatidylinositol%25203-Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D11%26spage%3D5188%26epage%3D5219%26doi%3D10.1021%2Fjm300184s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amico, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakowec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Dual Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1811</span>, <span class="refDoi"> DOI: 10.1021/jm1014605</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1014605" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1789-1811&issue=6&author=N.+D.+D%E2%80%99Angeloauthor=T.-S.+Kimauthor=K.+Andrewsauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=K.+Chenauthor=D.+D%E2%80%99Amicoauthor=D.+Freemanauthor=J.+Jiangauthor=L.+Liuauthor=J.+D.+McCarterauthor=T.+San+Miguelauthor=E.+L.+Mulladyauthor=M.+Schragauthor=R.+Subramanianauthor=J.+Tangauthor=R.+C.+Wahlauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=T.+Wuauthor=N.+Xiauthor=Y.+Xuauthor=P.+Yakowecauthor=K.+Yangauthor=L.+P.+Zalamedaauthor=N.+Zhangauthor=P.+Hughesauthor=M.+H.+Norman&title=Discovery+and+Optimization+of+a+Series+of+Benzothiazole+Phosphoinositide+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28MTOR%29+Dual+Inhibitors&doi=10.1021%2Fjm1014605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm1014605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014605%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DD.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYakowec%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%2BP.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Series%2520of%2520Benzothiazole%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528MTOR%2529%2520Dual%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D6%26spage%3D1789%26epage%3D1811%26doi%3D10.1021%2Fjm1014605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationships of Dual PI3K/MTOR Inhibitors Based on a 4-Amino-6-Methyl-1,3,5-Triazine Sulfonamide Scaffold</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5714</span>– <span class="NLM_lpage">5720</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.06.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5714-5720&issue=17&author=R.+P.+Wurzauthor=L.+Liuauthor=K.+Yangauthor=N.+Nishimuraauthor=Y.+Boauthor=L.+H.+Pettusauthor=S.+Caenepeelauthor=D.+J.+Freemanauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=T.+San+Miguelauthor=L.+Wangauthor=N.+Zhangauthor=K.+L.+Andrewsauthor=D.+A.+Whittingtonauthor=J.+Jiangauthor=R.+Subramanianauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Synthesis+and+Structure-Activity+Relationships+of+Dual+PI3K%2FMTOR+Inhibitors+Based+on+a+4-Amino-6-Methyl-1%2C3%2C5-Triazine+Sulfonamide+Scaffold&doi=10.1016%2Fj.bmcl.2012.06.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.078%26sid%3Dliteratum%253Aachs%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationships%2520of%2520Dual%2520PI3K%252FMTOR%2520Inhibitors%2520Based%2520on%2520a%25204-Amino-6-Methyl-1%252C3%252C5-Triazine%2520Sulfonamide%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D17%26spage%3D5714%26epage%3D5720%26doi%3D10.1016%2Fj.bmcl.2012.06.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Angelo, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidasani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 [Erratum to Document Cited in CA157:426662]</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7796</span>– <span class="NLM_lpage">7816</span>, <span class="refDoi"> DOI: 10.1021/jm300846z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300846z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7796-7816&issue=17&author=M.+H.+Normanauthor=K.+L.+Andrewsauthor=Y.+Y.+Boauthor=S.+K.+Bookerauthor=S.+Caenepeelauthor=V.+J.+Ceeauthor=N.+D.+D%E2%80%99Angeloauthor=D.+J.+Freemanauthor=B.+J.+Herberichauthor=F.-T.+Hongauthor=C.+L.+M.+Jacksonauthor=J.+Jiangauthor=B.+A.+Lanmanauthor=L.+Liuauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=N.+Nishimuraauthor=L.+H.+Pettusauthor=A.+B.+Reedauthor=T.+San+Miguelauthor=A.+L.+Smithauthor=M.+M.+Stecauthor=S.+Tadesseauthor=A.+Taskerauthor=D.+Aidasaniauthor=X.+Zhuauthor=R.+Subramanianauthor=N.+A.+Tamayoauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=B.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=K.+Yangauthor=L.+Zalamedaauthor=N.+Zhangauthor=P.+E.+Hughes&title=Selective+Class+I+Phosphoinositide+3-Kinase+Inhibitors%3A+Optimization+of+a+Series+of+Pyridyltriazines+Leading+to+the+Identification+of+a+Clinical+Candidate%2C+AMG+511+%5BErratum+to+Document+Cited+in+CA157%3A426662%5D&doi=10.1021%2Fjm300846z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm300846z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300846z%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBo%26aufirst%3DY.%2BY.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DHerberich%26aufirst%3DB.%2BJ.%26aulast%3DHong%26aufirst%3DF.-T.%26aulast%3DJackson%26aufirst%3DC.%2BL.%2BM.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DAidasani%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DSelective%2520Class%2520I%2520Phosphoinositide%25203-Kinase%2520Inhibitors%253A%2520Optimization%2520of%2520a%2520Series%2520of%2520Pyridyltriazines%2520Leading%2520to%2520the%2520Identification%2520of%2520a%2520Clinical%2520Candidate%252C%2520AMG%2520511%2520%255BErratum%2520to%2520Document%2520Cited%2520in%2520CA157%253A426662%255D%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7796%26epage%3D7816%26doi%3D10.1021%2Fjm300846z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit94b"><span>Erratum cited in  <i>J. Med.
Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume">55</span>, (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8975</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Erratum+cited+in+J.+Med.%0AChem.+2012%2C+55%2C+%2820%29%2C+8975."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Med.%250AChem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3-Kinase Inhibitors: Evaluation of Substituted Alcohols as Replacements for the Piperazine Sulfonamide Portion of AMG 511</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5630</span>– <span class="NLM_lpage">5634</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2014.10.085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5630-5634&issue=24&author=B.%0AA.+Lanmanauthor=A.+B.+Reedauthor=V.+J.+Ceeauthor=F.-T.+Hongauthor=L.+H.+Pettusauthor=R.+P.+Wurzauthor=K.+L.+Andrewsauthor=J.+Jiangauthor=J.+D.+McCarterauthor=E.+L.+Mulladyauthor=T.+San+Miguelauthor=R.+Subramanianauthor=L.+Wangauthor=D.+A.+Whittingtonauthor=T.+Wuauthor=L.+Zalamedaauthor=N.+Zhangauthor=A.+S.+Taskerauthor=P.+E.+Hughesauthor=M.+H.+Norman&title=Phosphoinositide-3-Kinase+Inhibitors%3A+Evaluation+of+Substituted+Alcohols+as+Replacements+for+the+Piperazine+Sulfonamide+Portion+of+AMG+511&doi=10.1016%2Fj.bmcl.2014.10.085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.085%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DHong%26aufirst%3DF.-T.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DPhosphoinositide-3-Kinase%2520Inhibitors%253A%2520Evaluation%2520of%2520Substituted%2520Alcohols%2520as%2520Replacements%2520for%2520the%2520Piperazine%2520Sulfonamide%2520Portion%2520of%2520AMG%2520511%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D24%26spage%3D5630%26epage%3D5634%26doi%3D10.1016%2Fj.bmcl.2014.10.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullady, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span> <span> </span><span class="NLM_article-title">The Imidazo[1,2-a]Pyridine Ring System as a Scaffold for Potent Dual Phosphoinositide-3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4136</span>– <span class="NLM_lpage">4142</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2015.08.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4136-4142&issue=19&author=M.+M.+Stecauthor=K.+L.+Andrewsauthor=Y.+Boauthor=H.+Liaoauthor=N.+Tamayoauthor=M.+H.+Normanauthor=S.+Caenepeelauthor=L.+Wangauthor=N.+Zhangauthor=P.+E.+Hughesauthor=J.+McCarterauthor=T.+San+Miguelauthor=L.+P.+Zalamedaauthor=E.+L.+Mulladyauthor=R.+Subramanianauthor=D.+A.+Whittingtonauthor=T.+Wu&title=The+Imidazo%5B1%2C2-a%5DPyridine+Ring+System+as+a+Scaffold+for+Potent+Dual+Phosphoinositide-3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28MTOR%29+Inhibitors&doi=10.1016%2Fj.bmcl.2015.08.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DMcCarter%26aufirst%3DJ.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DZalameda%26aufirst%3DL.%2BP.%26aulast%3DMullady%26aufirst%3DE.%2BL.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DT.%26atitle%3DThe%2520Imidazo%255B1%252C2-a%255DPyridine%2520Ring%2520System%2520as%2520a%2520Scaffold%2520for%2520Potent%2520Dual%2520Phosphoinositide-3-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528MTOR%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4136%26epage%3D4142%26doi%3D10.1016%2Fj.bmcl.2015.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullion, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fracasso, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]Quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1530</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1002%2Fcmdc.201600148" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1517-1530&author=W.+J.+Scottauthor=M.+F.+Hentemannauthor=R.+B.+Rowleyauthor=C.+O.+Bullauthor=S.+Jenkinsauthor=A.+M.+Bullionauthor=J.+Johnsonauthor=A.+Redmanauthor=A.+H.+Robbinsauthor=W.+Eslerauthor=R.+P.+Fracassoauthor=T.+Garrisonauthor=M.+Hamiltonauthor=M.+Michelsauthor=J.+E.+Woodauthor=D.+P.+Wilkieauthor=H.+Xiaoauthor=J.+Levyauthor=E.+Stasikauthor=N.+Liuauthor=M.+Schaeferauthor=M.+Brandsauthor=J.+Lefranc&title=Discovery+and+SAR+of+Novel+2%2C3-Dihydroimidazo%5B1%2C2-c%5DQuinazoline+PI3K+Inhibitors%3A+Identification+of+Copanlisib+%28BAY+80-6946%29&doi=10.1002%2Fcmdc.201600148"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600148%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DW.%2BJ.%26aulast%3DHentemann%26aufirst%3DM.%2BF.%26aulast%3DRowley%26aufirst%3DR.%2BB.%26aulast%3DBull%26aufirst%3DC.%2BO.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DBullion%26aufirst%3DA.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DRedman%26aufirst%3DA.%26aulast%3DRobbins%26aufirst%3DA.%2BH.%26aulast%3DEsler%26aufirst%3DW.%26aulast%3DFracasso%26aufirst%3DR.%2BP.%26aulast%3DGarrison%26aufirst%3DT.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%2BE.%26aulast%3DWilkie%26aufirst%3DD.%2BP.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLevy%26aufirst%3DJ.%26aulast%3DStasik%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DLefranc%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520Novel%25202%252C3-Dihydroimidazo%255B1%252C2-c%255DQuinazoline%2520PI3K%2520Inhibitors%253A%2520Identification%2520of%2520Copanlisib%2520%2528BAY%252080-6946%2529%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1517%26epage%3D1530%26doi%3D10.1002%2Fcmdc.201600148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Copanlisib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2057</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0838-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1007%2Fs40265-017-0838-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2057-2062&issue=18&author=A.+Markham&title=Copanlisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0838-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0838-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0838-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DCopanlisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26issue%3D18%26spage%3D2057%26epage%3D2062%26doi%3D10.1007%2Fs40265-017-0838-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, F. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peña, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genvresse, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Phase I Study of Copanlisib (BAY 80-6946), an Intravenous Pan-Class I Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphomas</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1928</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1093%2Fannonc%2Fmdw282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27672108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1928-1940&issue=10&author=A.+Patnaikauthor=L.+J.+Applemanauthor=A.+W.+Tolcherauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=G.+J.+Weissauthor=J.+C.+Sachdevauthor=M.+Chadhaauthor=M.+Fulkauthor=S.+Ejadiauthor=J.+M.+Mountzauthor=M.+T.+Lotzeauthor=F.+G.+S.+Toledoauthor=E.+Chuauthor=M.+Jeffersauthor=C.+Pe%C3%B1aauthor=C.+Xiaauthor=S.+Reifauthor=I.+Genvresseauthor=R.+K.+Ramanathan&title=First-in-Human+Phase+I+Study+of+Copanlisib+%28BAY+80-6946%29%2C+an+Intravenous+Pan-Class+I+Phosphatidylinositol+3-Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+and+Non-Hodgkin%E2%80%99s+Lymphomas&doi=10.1093%2Fannonc%2Fmdw282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas</span></div><div class="casAuthors">Patnaik A; Tolcher A W; Papadopoulos K P; Beeram M; Rasco D W; Appleman L J; Mountz J M; Lotze M T; Toledo F G S; Chu E; Weiss G J; Sachdev J C; Chadha M; Fulk M; Ejadi S; Ramanathan R K; Jeffers M; Pena C; Xia C; Reif S; Genvresse I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1928-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).  PATIENTS AND METHODS:  Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus.  Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the dose range 0.1-1.2 mg/kg.  Plasma copanlisib levels were analyzed for pharmacokinetics.  Biomarker analysis included PIK3CA, KRAS, BRAF, and PTEN mutational status and PTEN immunohistochemistry.  Whole-body [(18)F]-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) was carried out at baseline and following the first dose to assess early pharmacodynamic effects.  Plasma glucose and insulin levels were evaluated serially.  RESULTS:  Fifty-seven patients received treatment.  The MTD was 0.8 mg/kg copanlisib.  The most frequent treatment-related adverse events were nausea and transient hyperglycemia.  Copanlisib exposure was dose-proportional with no accumulation; peak exposure positively correlated with transient hyperglycemia post-infusion.  Sixteen of 20 patients treated at the MTD had reduced (18)FDG-PET uptake; 7 (33%) had a reduction >25%.  One patient achieved a complete response (CR; endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss) and two had a partial response (PR; both metastatic breast cancer).  Among the nine NHL patients, all six with follicular lymphoma (FL) responded (one CR and five PRs) and one patient with diffuse large B-cell lymphoma had a PR by investigator assessment; two patients with FL who achieved CR (per post hoc independent radiologic review) were on treatment >3 years.  CONCLUSION:  Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg.  Copanlisib exhibited dose-proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with NHL.  CLINICALTRIALSGOV:  NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5iDaGefdSJNFxYDaSSP8XfW6udTcc2eagLSx21SiYRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D&md5=219db9cc72ca2493834406a977141667</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw282%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DFulk%26aufirst%3DM.%26aulast%3DEjadi%26aufirst%3DS.%26aulast%3DMountz%26aufirst%3DJ.%2BM.%26aulast%3DLotze%26aufirst%3DM.%2BT.%26aulast%3DToledo%26aufirst%3DF.%2BG.%2BS.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DPe%25C3%25B1a%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DReif%26aufirst%3DS.%26aulast%3DGenvresse%26aufirst%3DI.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DFirst-in-Human%2520Phase%2520I%2520Study%2520of%2520Copanlisib%2520%2528BAY%252080-6946%2529%252C%2520an%2520Intravenous%2520Pan-Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520and%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphomas%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3D10%26spage%3D1928%26epage%3D1940%26doi%3D10.1093%2Fannonc%2Fmdw282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&issue=18&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+J.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+Novel+Indazoles+as+Highly+Potent+and+Selective+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B4+for+the+Treatment+of+Respiratory+Disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0ljLvd4j4CO5cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520Novel%2520Indazoles%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520Respiratory%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D18%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunsire, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montembault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leemereise, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinanes-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span> <span> </span><span class="NLM_article-title">Safety, Pharmacokinetics and Dose-Response Characteristics of GSK2269557, an Inhaled PI3Kδ Inhibitor under Development for the Treatment of COPD</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.pupt.2017.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=28823947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=69-77&author=A.+Cahnauthor=J.+N.+Hamblinauthor=M.+Beggauthor=R.+Wilsonauthor=L.+Dunsireauthor=S.+Sriskantharajahauthor=M.+Montembaultauthor=C.+N.+Leemereiseauthor=L.+Galinanes-Garciaauthor=H.+Watzauthor=A.+M.+Kirstenauthor=R.+Fuhrauthor=E.+M.+Hessel&title=Safety%2C+Pharmacokinetics+and+Dose-Response+Characteristics+of+GSK2269557%2C+an+Inhaled+PI3K%CE%B4+Inhibitor+under+Development+for+the+Treatment+of+COPD&doi=10.1016%2Fj.pupt.2017.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD</span></div><div class="casAuthors">Cahn, A.; Hamblin, J. N.; Begg, M.; Wilson, R.; Dunsire, L.; Sriskantharajah, S.; Montembault, M.; Leemereise, C. N.; Galinanes-Garcia, L.; Watz, H.; Kirsten, A. M.; Fuhr, R.; Hessel, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">While current therapies reduce symptoms in chronic obstructive pulmonary disease (COPD) patients, substantial unmet need remains and novel treatments are highly desired.  Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase specifically expressed in leukocytes and involved in their recruitment and activation.  This study evaluated the safety, pharmacokinetics (PK) and dose-response characteristics of inhaled GSK2269557, a PI3Kδ inhibitor, in moderate-to-severe COPD patients with stable disease.  In this randomised, double-blind, placebo controlled, parallel group study, patients received once daily inhaled treatment with GSK2269557 1000 μg or placebo for 14 days (Part A, primary aim safety, N = 28 patients).  In part B of the study (primary aim pharmacodynamic dose-response, N = 36 patients), GSK2269557 100, 200, 500, 700, 1000, 2000 μg or placebo was given for 14 days.  In both Part A and B, GSK2269557 was added to the usual maintenance therapy.  Safety, PK assessments and induced sputum collection for cytokine anal. were conducted at baseline and after 7 and 14 days of treatment.  Adverse events (AEs) were monitored throughout.In Part A, mean age was 61.7 years (SD 6.7), 29% were females, and mean FEV1% predicted was 59.7% (SD 11.4)2.  In Part B, mean age was 63.3 years (SD 6.3), 44% were females, and mean FEV1% predicted was 56.5% (SD 11.5)2.  GSK2269557 was well tolerated in both parts of the study; the most commonly reported AEs were cough and headache, with cough being reported with a greater incidence in the GSK2269557 groups vs. placebo (Part A: 19% vs. 14% and Part B: range of 0-80% for different doses vs. 0% on placebo).  No drug-related serious AEs or clin. significant changes in any other safety parameters were reported.  GSK2269557 was rapidly absorbed into plasma following all doses with a max. peak at approx. 2 h.  Following repeat administration, accumulation in plasma was approx. 2-3 fold from Day 1 to Day 7.  At Day 14, relative to placebo, sputum interleukin (IL)-8 and IL-6 levels were reduced on av. by 32% and 29% resp. after inhalation of GSK2269557 1000 μg in Part A.  In Part B, although inhibition of both IL-8 and IL-6 levels was obsd., the levels were variable and there was insufficient evidence to support a monotonic dose-response.  In this study, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients.  Moreover, inhalation of GSK2269557 resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor.  Inhibition of inflammatory cytokines in the airway compartment may contribute to the potential therapeutic benefit of a PI3Kδ inhibitor in chronically inflamed COPD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLev2M055yDLVg90H21EOLACvtfcHk0liFoXENk39nyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M&md5=bf5733fdf1e02f3804724f1a523c758b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DDunsire%26aufirst%3DL.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DMontembault%26aufirst%3DM.%26aulast%3DLeemereise%26aufirst%3DC.%2BN.%26aulast%3DGalinanes-Garcia%26aufirst%3DL.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DKirsten%26aufirst%3DA.%2BM.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26atitle%3DSafety%252C%2520Pharmacokinetics%2520and%2520Dose-Response%2520Characteristics%2520of%2520GSK2269557%252C%2520an%2520Inhaled%2520PI3K%25CE%25B4%2520Inhibitor%2520under%2520Development%2520for%2520the%2520Treatment%2520of%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.pupt.2017.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Highly Potent PI3K/MTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1021/ml300309h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300309h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=91-97&issue=1&author=H.+Chengauthor=C.+Liauthor=S.+Baileyauthor=S.+M.+Baxiauthor=L.+Gouletauthor=L.+Guoauthor=J.+Hoffmanauthor=Y.+Jiangauthor=T.+O.+Johnsonauthor=T.+W.+Johnsonauthor=D.+R.+Knightonauthor=J.+Liauthor=K.+K.-C.+Liuauthor=Z.+Liuauthor=M.+A.+Marxauthor=M.+Wallsauthor=P.+A.+Wellsauthor=M.-J.+Yinauthor=J.+Zhuauthor=M.+Zientek&title=Discovery+of+the+Highly+Potent+PI3K%2FMTOR+Dual+Inhibitor+PF-04979064+through+Structure-Based+Drug+Design&doi=10.1021%2Fml300309h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design</span></div><div class="casAuthors">Cheng, Hengmiao; Li, Chunze; Bailey, Simon; Baxi, Sangita M.; Goulet, Lance; Guo, Lisa; Hoffman, Jacqui; Jiang, Ying; Johnson, Theodore Otto; Johnson, Ted W.; Knighton, Daniel R.; Li, John; Liu, Kevin K.-C.; Liu, Zhengyu; Marx, Matthew A.; Walls, Marlena; Wells, Peter A.; Yin, Min-Jean; Zhu, Jinjiang; Zientek, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-97</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncol.  To search for a structurally differentiated back-up candidate to PF-04691502, which is currently in phase I/II clin. trials for treating solid tumors, a lead optimization effort was carried out with a tricyclic imidazo[1,5]naphthyridine series.  Integration of structure-based drug design and phys. properties-based optimization yielded a potent and selective PI3K/mTOR dual kinase inhibitor PF-04979064 (I).  This manuscript discusses the lead optimization for the tricyclic series, which both improved the in vitro potency and addressed a no. of ADMET issues including high metabolic clearance mediated by both P 450 and aldehyde oxidase (AO), poor permeability, and poor soly.  An empirical scaling tool was developed to predict human clearance from in vitro human liver S9 assay data for tricyclic derivs. that were AO substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsQSJqL-ssP7Vg90H21EOLACvtfcHk0libaoCQ9NiSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr7I&md5=0059c9c220419aad748b4fcde92c28bb</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fml300309h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300309h%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%2BM.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DKnighton%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZientek%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520Highly%2520Potent%2520PI3K%252FMTOR%2520Dual%2520Inhibitor%2520PF-04979064%2520through%2520Structure-Based%2520Drug%2520Design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D91%26epage%3D97%26doi%3D10.1021%2Fml300309h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoegenauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveleau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingworth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=975-980&issue=9&author=K.+Hoegenauerauthor=N.+Soldermannauthor=F.+Zecriauthor=R.+S.+Strangauthor=N.+Graveleauauthor=R.+M.+Wolfauthor=N.+G.+Cookeauthor=A.+B.+Smithauthor=G.+J.+Hollingworthauthor=J.+Blanzauthor=S.+Gutmannauthor=G.+Rummelauthor=A.+Littlewood-Evansauthor=C.+Burkhart&title=Discovery+of+CDZ173+%28Leniolisib%29%2C+Representing+a+Structurally+Novel+Class+of+PI3K+Delta-Selective+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DHoegenauer%26aufirst%3DK.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DZecri%26aufirst%3DF.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DGraveleau%26aufirst%3DN.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DHollingworth%26aufirst%3DG.%2BJ.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DBurkhart%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520CDZ173%2520%2528Leniolisib%2529%252C%2520Representing%2520a%2520Structurally%2520Novel%2520Class%2520of%2520PI3K%2520Delta-Selective%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D975%26epage%3D980%26doi%3D10.1021%2Facsmedchemlett.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoegenauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveleau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingworth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feifel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecri, F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=762-767&issue=8&author=K.+Hoegenauerauthor=N.+Soldermannauthor=F.+Staufferauthor=P.+Furetauthor=N.+Graveleauauthor=A.+B.+Smithauthor=C.+Hebachauthor=G.+J.+Hollingworthauthor=I.+Lewisauthor=S.+Gutmannauthor=G.+Rummelauthor=M.+Knappauthor=R.+M.+Wolfauthor=J.+Blanzauthor=R.+Feifelauthor=C.+Burkhartauthor=F.+Zecri&title=Discovery+and+Pharmacological+Characterization+of+Novel+Quinazoline-Based+PI3K+Delta-Selective+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00119%26sid%3Dliteratum%253Aachs%26aulast%3DHoegenauer%26aufirst%3DK.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGraveleau%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DHebach%26aufirst%3DC.%26aulast%3DHollingworth%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DFeifel%26aufirst%3DR.%26aulast%3DBurkhart%26aufirst%3DC.%26aulast%3DZecri%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Characterization%2520of%2520Novel%2520Quinazoline-Based%2520PI3K%2520Delta-Selective%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D8%26spage%3D762%26epage%3D767%26doi%3D10.1021%2Facsmedchemlett.6b00119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoegenauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingworth, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Matt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haasen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Pyrrolidineoxy-Substituted Heteroaromatics as Potent and Selective PI3K Delta Inhibitors with Improved Physicochemical Properties</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5657</span>– <span class="NLM_lpage">5662</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.10.069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5657-5662&issue=23&author=K.+Hoegenauerauthor=N.+Soldermannauthor=C.+Hebachauthor=G.+J.+Hollingworthauthor=I.+Lewisauthor=A.+von+Mattauthor=A.+B.+Smithauthor=R.+M.+Wolfauthor=R.+Wilckenauthor=F.+Zecriauthor=D.+Haasenauthor=C.+Burkhart&title=Discovery+of+Novel+Pyrrolidineoxy-Substituted+Heteroaromatics+as+Potent+and+Selective+PI3K+Delta+Inhibitors+with+Improved+Physicochemical+Properties&doi=10.1016%2Fj.bmcl.2016.10.069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.069%26sid%3Dliteratum%253Aachs%26aulast%3DHoegenauer%26aufirst%3DK.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DHebach%26aufirst%3DC.%26aulast%3DHollingworth%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3Dvon%2BMatt%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZecri%26aufirst%3DF.%26aulast%3DHaasen%26aufirst%3DD.%26aulast%3DBurkhart%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Novel%2520Pyrrolidineoxy-Substituted%2520Heteroaromatics%2520as%2520Potent%2520and%2520Selective%2520PI3K%2520Delta%2520Inhibitors%2520with%2520Improved%2520Physicochemical%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D23%26spage%3D5657%26epage%3D5662%26doi%3D10.1016%2Fj.bmcl.2016.10.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalm, V. A. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šedivá, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hagen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Buck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pylvaenaeinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soldermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span> <span> </span><span class="NLM_article-title">Effective “Activated PI3Kδ Syndrome”-targeted Therapy with the PI3Kδ Inhibitor Leniolisib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2316</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-08-801191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1182%2Fblood-2017-08-801191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=2307-2316&issue=21&author=V.+K.+Raoauthor=S.+Websterauthor=V.+A.+S.+H.+Dalmauthor=A.+%C5%A0ediv%C3%A1author=P.+M.+van+Hagenauthor=S.+Hollandauthor=S.+D.+Rosenzweigauthor=A.+D.+Christauthor=B.+Slothauthor=M.+Cabanskiauthor=A.+D.+Joshiauthor=S.+de+Buckauthor=J.+Doucetauthor=D.+Gueriniauthor=C.+Kalisauthor=I.+Pylvaenaeinenauthor=N.+Soldermannauthor=A.+Kashyapauthor=G.+Uzelauthor=M.+J.+Lenardoauthor=D.+D.+Patelauthor=C.+L.+Lucasauthor=C.+Burkhart&title=Effective+%E2%80%9CActivated+PI3K%CE%B4+Syndrome%E2%80%9D-targeted+Therapy+with+the+PI3K%CE%B4+Inhibitor+Leniolisib&doi=10.1182%2Fblood-2017-08-801191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-08-801191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-08-801191%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DV.%2BK.%26aulast%3DWebster%26aufirst%3DS.%26aulast%3DDalm%26aufirst%3DV.%2BA.%2BS.%2BH.%26aulast%3D%25C5%25A0ediv%25C3%25A1%26aufirst%3DA.%26aulast%3Dvan%2BHagen%26aufirst%3DP.%2BM.%26aulast%3DHolland%26aufirst%3DS.%26aulast%3DRosenzweig%26aufirst%3DS.%2BD.%26aulast%3DChrist%26aufirst%3DA.%2BD.%26aulast%3DSloth%26aufirst%3DB.%26aulast%3DCabanski%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DA.%2BD.%26aulast%3Dde%2BBuck%26aufirst%3DS.%26aulast%3DDoucet%26aufirst%3DJ.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DKalis%26aufirst%3DC.%26aulast%3DPylvaenaeinen%26aufirst%3DI.%26aulast%3DSoldermann%26aufirst%3DN.%26aulast%3DKashyap%26aufirst%3DA.%26aulast%3DUzel%26aufirst%3DG.%26aulast%3DLenardo%26aufirst%3DM.%2BJ.%26aulast%3DPatel%26aufirst%3DD.%2BD.%26aulast%3DLucas%26aufirst%3DC.%2BL.%26aulast%3DBurkhart%26aufirst%3DC.%26atitle%3DEffective%2520%25E2%2580%259CActivated%2520PI3K%25CE%25B4%2520Syndrome%25E2%2580%259D-targeted%2520Therapy%2520with%2520the%2520PI3K%25CE%25B4%2520Inhibitor%2520Leniolisib%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26issue%3D21%26spage%3D2307%26epage%3D2316%26doi%3D10.1182%2Fblood-2017-08-801191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel 6-Aryl Substituted 4-Anilinequinazoline Derivatives as Potential PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1972</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.03.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1972-1977&issue=9&author=M.+Xinauthor=Y.-Y.+Heiauthor=H.+Zhangauthor=Y.+Shenauthor=S.-Q.+Zhang&title=Design+and+Synthesis+of+Novel+6-Aryl+Substituted+4-Anilinequinazoline+Derivatives+as+Potential+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.03.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DM.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25206-Aryl%2520Substituted%25204-Anilinequinazoline%2520Derivatives%2520as%2520Potential%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D9%26spage%3D1972%26epage%3D1977%26doi%3D10.1016%2Fj.bmcl.2017.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Novel 6-Aryl Substituted 4-Pyrrolidineaminoquinazoline Derivatives as Potent Phosphoinositide 3-Kinase Delta (PI3Kδ) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2040</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2018.03.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2028-2040&issue=8&author=M.+Xinauthor=W.+Duanauthor=Y.+Fengauthor=Y.-Y.+Heiauthor=H.+Zhangauthor=Y.+Shenauthor=H.-Y.+Zhaoauthor=S.+Maoauthor=S.-Q.+Zhang&title=Novel+6-Aryl+Substituted+4-Pyrrolidineaminoquinazoline+Derivatives+as+Potent+Phosphoinositide+3-Kinase+Delta+%28PI3K%CE%B4%29+Inhibitors&doi=10.1016%2Fj.bmc.2018.03.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.-Y.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DNovel%25206-Aryl%2520Substituted%25204-Pyrrolidineaminoquinazoline%2520Derivatives%2520as%2520Potent%2520Phosphoinositide%25203-Kinase%2520Delta%2520%2528PI3K%25CE%25B4%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2028%26epage%3D2040%26doi%3D10.1016%2Fj.bmc.2018.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antitumor Activity Evaluation of 4,6-Disubstituted Quinazoline Derivatives as Novel PI3K Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4413</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2016.08.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4408-4413&issue=18&author=Y.-Y.+Heiauthor=M.+Xinauthor=H.+Zhangauthor=X.-X.+Xieauthor=S.+Maoauthor=S.-Q.+Zhang&title=Synthesis+and+Antitumor+Activity+Evaluation+of+4%2C6-Disubstituted+Quinazoline+Derivatives+as+Novel+PI3K+Inhibitors&doi=10.1016%2Fj.bmcl.2016.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DX.-X.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activity%2520Evaluation%2520of%25204%252C6-Disubstituted%2520Quinazoline%2520Derivatives%2520as%2520Novel%2520PI3K%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D18%26spage%3D4408%26epage%3D4413%26doi%3D10.1016%2Fj.bmcl.2016.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel 6-Aryl Substituted 4-Anilinequinazoline Derivatives as Potential PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1972</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2017.03.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1972-1977&issue=9&author=M.+Xinauthor=Y.-Y.+Heiauthor=H.+Zhangauthor=Y.+Shenauthor=S.-Q.+Zhang&title=Design+and+Synthesis+of+Novel+6-Aryl+Substituted+4-Anilinequinazoline+Derivatives+as+Potential+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2017.03.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DM.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%25206-Aryl%2520Substituted%25204-Anilinequinazoline%2520Derivatives%2520as%2520Potential%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D9%26spage%3D1972%26epage%3D1977%26doi%3D10.1016%2Fj.bmcl.2017.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Series of N-(5-(Quinolin-6-Yl)Pyridin-3-Yl)Benzenesulfonamides as PI3K/MTOR Dual Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2017.01.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=509-520&author=J.+Zhangauthor=X.+Lvauthor=X.+Maauthor=Y.+Hu&title=Discovery+of+a+Series+of+N-%285-%28Quinolin-6-Yl%29Pyridin-3-Yl%29Benzenesulfonamides+as+PI3K%2FMTOR+Dual+Inhibitors&doi=10.1016%2Fj.ejmech.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Series%2520of%2520N-%25285-%2528Quinolin-6-Yl%2529Pyridin-3-Yl%2529Benzenesulfonamides%2520as%2520PI3K%252FMTOR%2520Dual%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D509%26epage%3D520%26doi%3D10.1016%2Fj.ejmech.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9205</span>– <span class="NLM_lpage">9221</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9205-9221&issue=22&author=S.+Mahauthor=J.+H.+Parkauthor=H.-Y.+Jungauthor=K.+Ahnauthor=S.+Choiauthor=H.+S.+Taeauthor=K.+H.+Jungauthor=J.+K.+Rhoauthor=J.+C.+Leeauthor=S.-S.+Hongauthor=S.+Hong&title=Identification+of+4-Phenoxyquinoline+Based+Inhibitors+for+L1196M+Mutant+of+Anaplastic+Lymphoma+Kinase+by+Structure-Based+Design&doi=10.1021%2Facs.jmedchem.7b01039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DIdentification%2520of%25204-Phenoxyquinoline%2520Based%2520Inhibitors%2520for%2520L1196M%2520Mutant%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520by%2520Structure-Based%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221%26doi%3D10.1021%2Facs.jmedchem.7b01039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Novel 4-Aminoquinazoline Derivatives Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis via PI3Kα Inhibition</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1675</span>– <span class="NLM_lpage">1685</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2018.02.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1675-1685&issue=8&author=Y.-H.+Fanauthor=H.-W.+Dingauthor=D.-D.+Liuauthor=H.-R.+Songauthor=Y.-N.+Xuauthor=J.+Wang&title=Novel+4-Aminoquinazoline+Derivatives+Induce+Growth+Inhibition%2C+Cell+Cycle+Arrest+and+Apoptosis+via+PI3K%CE%B1+Inhibition&doi=10.1016%2Fj.bmc.2018.02.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.-H.%26aulast%3DDing%26aufirst%3DH.-W.%26aulast%3DLiu%26aufirst%3DD.-D.%26aulast%3DSong%26aufirst%3DH.-R.%26aulast%3DXu%26aufirst%3DY.-N.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DNovel%25204-Aminoquinazoline%2520Derivatives%2520Induce%2520Growth%2520Inhibition%252C%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%2520via%2520PI3K%25CE%25B1%2520Inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1675%26epage%3D1685%26doi%3D10.1016%2Fj.bmc.2018.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwicke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSurdy-Freed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–activity Relationships of Imidazo[1,2-a]Pyrimidin-5(1H)-Ones as a Novel Series of Beta Isoform Selective Phosphatidylinositol 3-Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.01.092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2230-2234&issue=6&author=H.+Linauthor=K.+Erhardauthor=M.+A.+Hardwickeauthor=J.+I.+Luengoauthor=J.+F.+Mackauthor=J.+McSurdy-Freedauthor=R.+Plantauthor=K.+Rahaauthor=C.+M.+Romingerauthor=R.+M.+Sanchezauthor=M.+D.+Schaberauthor=M.+J.+Schulzauthor=M.+D.+Spenglerauthor=R.+Tedescoauthor=R.+Xieauthor=J.+J.+Zengauthor=R.+A.+Rivero&title=Synthesis+and+Structure%E2%80%93activity+Relationships+of+Imidazo%5B1%2C2-a%5DPyrimidin-5%281H%29-Ones+as+a+Novel+Series+of+Beta+Isoform+Selective+Phosphatidylinositol+3-Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2012.01.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.092%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DMack%26aufirst%3DJ.%2BF.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSanchez%26aufirst%3DR.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DSchulz%26aufirst%3DM.%2BJ.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%2BJ.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593activity%2520Relationships%2520of%2520Imidazo%255B1%252C2-a%255DPyrimidin-5%25281H%2529-Ones%2520as%2520a%2520Novel%2520Series%2520of%2520Beta%2520Isoform%2520Selective%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D6%26spage%3D2230%26epage%3D2234%26doi%3D10.1016%2Fj.bmcl.2012.01.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwicke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSurdy-Freed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–activity Relationships of 1,2,4-Triazolo[1,5-a]Pyrimidin-7(3H)-Ones as Novel Series of Potent β Isoform Selective Phosphatidylinositol 3-Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3198</span>– <span class="NLM_lpage">3202</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.03.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3198-3202&issue=9&author=R.+M.+Sanchezauthor=K.+Erhardauthor=M.+A.+Hardwickeauthor=H.+Linauthor=J.+McSurdy-Freedauthor=R.+Plantauthor=K.+Rahaauthor=C.+M.+Romingerauthor=M.+D.+Schaberauthor=M.+D.+Spenglerauthor=M.+L.+Mooreauthor=H.+Yuauthor=J.+I.+Luengoauthor=R.+Tedescoauthor=R.+A.+Rivero&title=Synthesis+and+Structure%E2%80%93activity+Relationships+of+1%2C2%2C4-Triazolo%5B1%2C5-a%5DPyrimidin-7%283H%29-Ones+as+Novel+Series+of+Potent+%CE%B2+Isoform+Selective+Phosphatidylinositol+3-Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2012.03.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DR.%2BM.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DMoore%26aufirst%3DM.%2BL.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593activity%2520Relationships%2520of%25201%252C2%252C4-Triazolo%255B1%252C5-a%255DPyrimidin-7%25283H%2529-Ones%2520as%2520Novel%2520Series%2520of%2520Potent%2520%25CE%25B2%2520Isoform%2520Selective%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D9%26spage%3D3198%26epage%3D3202%26doi%3D10.1016%2Fj.bmcl.2012.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 9-(1-Anilinoethyl)-2-Morpholino-4-Oxo-Pyrido[1,2-a]Pyrimidine-7-Carboxamides as PI3Kβ/δ Inhibitors for the Treatment of PTEN-Deficient Tumours</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3928</span>– <span class="NLM_lpage">3935</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2014.06.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3928-3935&issue=16&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=F.+Giordanettoauthor=S.+Greenauthor=T.+Inghardtauthor=L.+Hennequinauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=S.+Passauthor=P.+Pleauthor=T.+Salehauthor=L.+Ward&title=Discovery+of+9-%281-Anilinoethyl%29-2-Morpholino-4-Oxo-Pyrido%5B1%2C2-a%5DPyrimidine-7-Carboxamides+as+PI3K%CE%B2%2F%CE%B4+Inhibitors+for+the+Treatment+of+PTEN-Deficient+Tumours&doi=10.1016%2Fj.bmcl.2014.06.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPass%26aufirst%3DS.%26aulast%3DPle%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25209-%25281-Anilinoethyl%2529-2-Morpholino-4-Oxo-Pyrido%255B1%252C2-a%255DPyrimidine-7-Carboxamides%2520as%2520PI3K%25CE%25B2%252F%25CE%25B4%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520PTEN-Deficient%2520Tumours%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3928%26epage%3D3935%26doi%3D10.1016%2Fj.bmcl.2014.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquet, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Péru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vautier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warin, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-8-(1-(3,5-Difluorophenylamino)Ethyl)-N,N-Dimethyl-2-Morpholino-4-Oxo-4 H-Chromene-6-Carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&issue=2&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=J.-J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.-J.+Pasquetauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-Difluorophenylamino%29Ethyl%29-N%2CN-Dimethyl-2-Morpholino-4-Oxo-4+H-Chromene-6-Carboxamide+%28AZD8186%29%3A+A+Potent+and+Selective+Inhibitor+of+PI3K%CE%B2+and+PI3K%CE%B4+for+the+Treatment+of+PTEN-Deficient+Cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.-J.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.-J.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-Difluorophenylamino%2529Ethyl%2529-N%252CN-Dimethyl-2-Morpholino-4-Oxo-4%2520H-Chromene-6-Carboxamide%2520%2528AZD8186%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520PI3K%25CE%25B2%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520PTEN-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D2%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolekar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span> <span> </span><span class="NLM_article-title">Exploring the Isoform Selectivity of TGX-221 Related Pyrido[1,2- a ]Pyrimidinone-Based Class IA PI 3-Kinase Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3808</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2015.03.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3796-3808&issue=13&author=A.+J.+Marshallauthor=C.+L.+Lillauthor=M.+Chaoauthor=S.+V.+Kolekarauthor=W.-J.+Leeauthor=E.+S.+Marshallauthor=B.+C.+Baguleyauthor=P.+R.+Shepherdauthor=W.+A.+Dennyauthor=J.+U.+Flanaganauthor=G.+W.+Rewcastle&title=Exploring+the+Isoform+Selectivity+of+TGX-221+Related+Pyrido%5B1%2C2-+a+%5DPyrimidinone-Based+Class+IA+PI+3-Kinase+Inhibitors%3A+Synthesis%2C+Biological+Evaluation+and+Molecular+Modelling&doi=10.1016%2Fj.bmc.2015.03.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.073%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DA.%2BJ.%26aulast%3DLill%26aufirst%3DC.%2BL.%26aulast%3DChao%26aufirst%3DM.%26aulast%3DKolekar%26aufirst%3DS.%2BV.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26atitle%3DExploring%2520the%2520Isoform%2520Selectivity%2520of%2520TGX-221%2520Related%2520Pyrido%255B1%252C2-%2520a%2520%255DPyrimidinone-Based%2520Class%2520IA%2520PI%25203-Kinase%2520Inhibitors%253A%2520Synthesis%252C%2520Biological%2520Evaluation%2520and%2520Molecular%2520Modelling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3796%26epage%3D3808%26doi%3D10.1016%2Fj.bmc.2015.03.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wållberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenjans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Morpholino-Pyrimidin-6-One and 4-Morpholino-Pyrimidin-2-One-Containing Phosphoinositide 3-Kinase (PI3K) P110β Isoform Inhibitors through Structure-Based Fragment Optimisation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6665</span>– <span class="NLM_lpage">6670</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.08.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6665-6670&issue=21&author=F.+Giordanettoauthor=A.+W%C3%A5llbergauthor=J.+Casselauthor=S.+Ghosalauthor=M.+Kossenjansauthor=Z.-Q.+Yuanauthor=X.+Wangauthor=L.+Liang&title=Discovery+of+4-Morpholino-Pyrimidin-6-One+and+4-Morpholino-Pyrimidin-2-One-Containing+Phosphoinositide+3-Kinase+%28PI3K%29+P110%CE%B2+Isoform+Inhibitors+through+Structure-Based+Fragment+Optimisation&doi=10.1016%2Fj.bmcl.2012.08.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.101%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DA.%26aulast%3DCassel%26aufirst%3DJ.%26aulast%3DGhosal%26aufirst%3DS.%26aulast%3DKossenjans%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DZ.-Q.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204-Morpholino-Pyrimidin-6-One%2520and%25204-Morpholino-Pyrimidin-2-One-Containing%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520P110%25CE%25B2%2520Isoform%2520Inhibitors%2520through%2520Structure-Based%2520Fragment%2520Optimisation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D21%26spage%3D6665%26epage%3D6670%26doi%3D10.1016%2Fj.bmcl.2012.08.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wållberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliefski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Wachenfeldt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Phosphoinositide 3-Kinases (PI3K) P110β Isoform Inhibitor 4-[2-Hydroxyethyl(1-Naphthylmethyl)Amino]-6-[(2S)-2-Methylmorpholin-4-Yl]-1H-Pyrimidin-2-One, an Effective Antithrombotic Agent without Associated Bleeding and Insulin Resistance</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6671</span>– <span class="NLM_lpage">6676</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.08.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6671-6676&issue=21&author=F.+Giordanettoauthor=A.+W%C3%A5llbergauthor=S.+Ghosalauthor=T.+Iliefskiauthor=J.+Casselauthor=Z.-Q.+Yuanauthor=H.+von+Wachenfeldtauthor=S.+M.+Andersenauthor=T.+Inghardtauthor=A.+Tunekauthor=S.+Nylander&title=Discovery+of+Phosphoinositide+3-Kinases+%28PI3K%29+P110%CE%B2+Isoform+Inhibitor+4-%5B2-Hydroxyethyl%281-Naphthylmethyl%29Amino%5D-6-%5B%282S%29-2-Methylmorpholin-4-Yl%5D-1H-Pyrimidin-2-One%2C+an+Effective+Antithrombotic+Agent+without+Associated+Bleeding+and+Insulin+Resistance&doi=10.1016%2Fj.bmcl.2012.08.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.102%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DW%25C3%25A5llberg%26aufirst%3DA.%26aulast%3DGhosal%26aufirst%3DS.%26aulast%3DIliefski%26aufirst%3DT.%26aulast%3DCassel%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DZ.-Q.%26aulast%3Dvon%2BWachenfeldt%26aufirst%3DH.%26aulast%3DAndersen%26aufirst%3DS.%2BM.%26aulast%3DInghardt%26aufirst%3DT.%26aulast%3DTunek%26aufirst%3DA.%26aulast%3DNylander%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Phosphoinositide%25203-Kinases%2520%2528PI3K%2529%2520P110%25CE%25B2%2520Isoform%2520Inhibitor%25204-%255B2-Hydroxyethyl%25281-Naphthylmethyl%2529Amino%255D-6-%255B%25282S%2529-2-Methylmorpholin-4-Yl%255D-1H-Pyrimidin-2-One%252C%2520an%2520Effective%2520Antithrombotic%2520Agent%2520without%2520Associated%2520Bleeding%2520and%2520Insulin%2520Resistance%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D21%26spage%3D6671%26epage%3D6676%26doi%3D10.1016%2Fj.bmcl.2012.08.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghardt, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 9-(1-Phenoxyethyl)-2-Morpholino-4-Oxo-Pyrido[1,2-a]Pyrimidine-7-Carboxamides as Oral PI3Kβ Inhibitors, Useful as Antiplatelet Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3936</span>– <span class="NLM_lpage">3943</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2014.07.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3936-3943&issue=16&author=F.+Giordanettoauthor=B.+Barlaamauthor=S.+Berglundauthor=K.+Edmanauthor=O.+Karlssonauthor=J.+Lindbergauthor=S.+Nylanderauthor=T.+Inghardt&title=Discovery+of+9-%281-Phenoxyethyl%29-2-Morpholino-4-Oxo-Pyrido%5B1%2C2-a%5DPyrimidine-7-Carboxamides+as+Oral+PI3K%CE%B2+Inhibitors%2C+Useful+as+Antiplatelet+Agents&doi=10.1016%2Fj.bmcl.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DBerglund%26aufirst%3DS.%26aulast%3DEdman%26aufirst%3DK.%26aulast%3DKarlsson%26aufirst%3DO.%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DInghardt%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25209-%25281-Phenoxyethyl%2529-2-Morpholino-4-Oxo-Pyrido%255B1%252C2-a%255DPyrimidine-7-Carboxamides%2520as%2520Oral%2520PI3K%25CE%25B2%2520Inhibitors%252C%2520Useful%2520as%2520Antiplatelet%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3936%26epage%3D3943%26doi%3D10.1016%2Fj.bmcl.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virone-Oddos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Romme, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carry, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnevaux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquette, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Below, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vade, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatreaux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angouillant-Boniface, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kβ Inhibitors for the Treatment of Phosphatase and TENsin Homologue (PTEN)-Deficient Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4788</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1021/jm300241b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300241b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4788-4805&issue=10&author=V.+Certalauthor=F.+Halleyauthor=A.+Virone-Oddosauthor=C.+Delormeauthor=A.+Karlssonauthor=A.+Rakauthor=F.+Thompsonauthor=B.+Filoche-Rommeauthor=Y.+El-Ahmadauthor=J.-C.+Carryauthor=P.-Y.+Abecassisauthor=P.+Lejeuneauthor=L.+Vincentauthor=H.+Bonnevauxauthor=J.-P.+Nicolasauthor=T.+Bertrandauthor=J.-P.+Marquetteauthor=N.+Michotauthor=T.+Benardauthor=P.+Belowauthor=I.+Vadeauthor=F.+Chatreauxauthor=G.+Lebourgauthor=F.+Pilorgeauthor=O.+Angouillant-Bonifaceauthor=A.+Louboutinauthor=C.+Lengauerauthor=L.+Schio&title=Discovery+and+Optimization+of+New+Benzimidazole-+and+Benzoxazole-Pyrimidone+Selective+PI3K%CE%B2+Inhibitors+for+the+Treatment+of+Phosphatase+and+TENsin+Homologue+%28PTEN%29-Deficient+Cancers&doi=10.1021%2Fjm300241b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm300241b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300241b%26sid%3Dliteratum%253Aachs%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DVirone-Oddos%26aufirst%3DA.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romme%26aufirst%3DB.%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DCarry%26aufirst%3DJ.-C.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DLejeune%26aufirst%3DP.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DBonnevaux%26aufirst%3DH.%26aulast%3DNicolas%26aufirst%3DJ.-P.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DMarquette%26aufirst%3DJ.-P.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBelow%26aufirst%3DP.%26aulast%3DVade%26aufirst%3DI.%26aulast%3DChatreaux%26aufirst%3DF.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DAngouillant-Boniface%26aufirst%3DO.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520New%2520Benzimidazole-%2520and%2520Benzoxazole-Pyrimidone%2520Selective%2520PI3K%25CE%25B2%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Phosphatase%2520and%2520TENsin%2520Homologue%2520%2528PTEN%2529-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4788%26epage%3D4805%26doi%3D10.1021%2Fjm300241b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carry, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virone-Oddos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnevaux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquette, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaitre, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerflinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guizani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1021/jm401642q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401642q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=903-920&issue=3&author=V.+Certalauthor=J.-C.+Carryauthor=F.+Halleyauthor=A.+Virone-Oddosauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=Y.+El-Ahmadauthor=A.+Karlssonauthor=V.+Charrierauthor=C.+Delormeauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=C.+Amaraauthor=L.+Vincentauthor=H.+Bonnevauxauthor=J.-P.+Nicolasauthor=M.+Mathieuauthor=T.+Bertrandauthor=J.-P.+Marquetteauthor=N.+Michotauthor=T.+Benardauthor=M.-A.+Perrinauthor=O.+Lemaitreauthor=S.+Guerifauthor=S.+Perronauthor=S.+Mongetauthor=F.+Gruss-Leleuauthor=G.+Doerflingerauthor=H.+Guizaniauthor=M.+Brolloauthor=L.+Delbarreauthor=L.+Bertinauthor=P.+Richepinauthor=V.+Loyauauthor=C.+Garcia-Echeverriaauthor=C.+Lengauerauthor=L.+Schio&title=Discovery+and+Optimization+of+Pyrimidone+Indoline+Amide+PI3K%CE%B2+Inhibitors+for+the+Treatment+of+Phosphatase+and+Tensin+Homologue+%28PTEN%29-Deficient+Cancers&doi=10.1021%2Fjm401642q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers</span></div><div class="casAuthors">Certal, Victor; Carry, Jean-Christophe; Halley, Frank; Virone-Oddos, Angela; Thompson, Fabienne; Filoche-Romme, Bruno; El-Ahmad, Youssef; Karlsson, Andreas; Charrier, Veronique; Delorme, Cecile; Rak, Alexey; Abecassis, Pierre-Yves; Amara, Celine; Vincent, Loic; Bonnevaux, Helene; Nicolas, Jean-Paul; Mathieu, Magali; Bertrand, Thomas; Marquette, Jean-Pierre; Michot, Nadine; Benard, Tsiala; Perrin, Marc-Antoine; Lemaitre, Olivier; Guerif, Stephane; Perron, Sebastien; Monget, Sylvie; Gruss-Leleu, Florence; Doerflinger, Gilles; Guizani, Houlfa; Brollo, Maurice; Delbarre, Laurence; Bertin, Luc; Richepin, Patrick; Loyau, Veronique; Garcia-Echeverria, Carlos; Lengauer, Christoph; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">903-920</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compelling mol. biol. publications have reported the implication of phosphoinositide kinase PI3Kβ in PTEN-deficient cell line growth and proliferation.  These findings supported a scientific rationale for the development of PI3Kβ-specific inhibitors for the treatment of PTEN-deficient cancers.  This paper describes the discovery of 2-[2-(2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one and the optimization of this new series of active and selective pyrimidone indoline amide PI3Kβ inhibitors. 2-[2-(2-Methyl-2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (I), identified following a carefully designed Me scan, displayed improved physicochem. and in vitro pharmacokinetic properties.  Structural biol. efforts enabled the acquisition of the first x-ray cocrystal structure of p110β with the selective inhibitor compd. I bound to the ATP site.  The nonplanar binding mode described herein is consistent with obsd. structure-activity relationship for the series.  Compd. I demonstrated significant in vivo activity in a UACC-62 xenograft model in mice, warranting further preclin. investigation.  Following successful development, compd. 28 entered phase I/Ib clin. trial in patients with advanced cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5QsHhXYO6d7Vg90H21EOLACvtfcHk0ljhf-jH7Zc2UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFOjsw%253D%253D&md5=8141ae91a81b06ad129afd2263e2a007</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjm401642q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401642q%26sid%3Dliteratum%253Aachs%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DCarry%26aufirst%3DJ.-C.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DVirone-Oddos%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DCharrier%26aufirst%3DV.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DAmara%26aufirst%3DC.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DBonnevaux%26aufirst%3DH.%26aulast%3DNicolas%26aufirst%3DJ.-P.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DMarquette%26aufirst%3DJ.-P.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DM.-A.%26aulast%3DLemaitre%26aufirst%3DO.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DPerron%26aufirst%3DS.%26aulast%3DMonget%26aufirst%3DS.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DDoerflinger%26aufirst%3DG.%26aulast%3DGuizani%26aufirst%3DH.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DDelbarre%26aufirst%3DL.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Pyrimidone%2520Indoline%2520Amide%2520PI3K%25CE%25B2%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Phosphatase%2520and%2520Tensin%2520Homologue%2520%2528PTEN%2529-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D903%26epage%3D920%26doi%3D10.1021%2Fjm401642q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bédard, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreafico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartot-Cotton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazuir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micallef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients with Advanced Solid Tumors</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1002/cncr.31044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1002%2Fcncr.31044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=315-324&issue=2&author=P.+L.+B%C3%A9dardauthor=M.+A.+Daviesauthor=S.+Kopetzauthor=D.+Juricauthor=G.+I.+Shapiroauthor=J.+J.+Lukeauthor=A.+Spreaficoauthor=B.+Wuauthor=C.+Castellauthor=C.+Gomezauthor=S.+Cartot-Cottonauthor=F.+Mazuirauthor=M.+Dubarauthor=S.+Micallefauthor=B.+Demersauthor=K.+T.+Flaherty&title=First-in-Human+Trial+of+the+PI3K%CE%B2-Selective+Inhibitor+SAR260301+in+Patients+with+Advanced+Solid+Tumors&doi=10.1002%2Fcncr.31044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31044%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9dard%26aufirst%3DP.%2BL.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DSpreafico%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DCastell%26aufirst%3DC.%26aulast%3DGomez%26aufirst%3DC.%26aulast%3DCartot-Cotton%26aufirst%3DS.%26aulast%3DMazuir%26aufirst%3DF.%26aulast%3DDubar%26aufirst%3DM.%26aulast%3DMicallef%26aufirst%3DS.%26aulast%3DDemers%26aufirst%3DB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DFirst-in-Human%2520Trial%2520of%2520the%2520PI3K%25CE%25B2-Selective%2520Inhibitor%2520SAR260301%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26issue%3D2%26spage%3D315%26epage%3D324%26doi%3D10.1002%2Fcncr.31044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Thienobenzoxepin Inhibitors of PI3-Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4054</span>– <span class="NLM_lpage">4058</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&issue=13&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.-Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-Based+Design+of+Thienobenzoxepin+Inhibitors+of+PI3-Kinase&doi=10.1016%2Fj.bmcl.2011.04.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-Based%2520Design%2520of%2520Thienobenzoxepin%2520Inhibitors%2520of%2520PI3-Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D13%26spage%3D4054%26epage%3D4058%26doi%3D10.1016%2Fj.bmcl.2011.04.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span> <span> </span><span class="NLM_article-title">Cis-Amide Isosteric Replacement in Thienobenzoxepin Inhibitors of PI3-Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.10.121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=897-901&issue=3&author=S.+T.+Stabenauthor=N.+Blaquiereauthor=V.+Tsuiauthor=A.+Kolesnikovauthor=S.+Doauthor=E.+K.+Bradleyauthor=J.+Dotsonauthor=R.+Goldsmithauthor=T.+P.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=J.+Pangauthor=L.+Rougeauthor=L.+Salphatiauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wu&title=Cis-Amide+Isosteric+Replacement+in+Thienobenzoxepin+Inhibitors+of+PI3-Kinase&doi=10.1016%2Fj.bmcl.2012.10.121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.121%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DCis-Amide%2520Isosteric%2520Replacement%2520in%2520Thienobenzoxepin%2520Inhibitors%2520of%2520PI3-Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D897%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2012.10.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ord, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weismann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Thiazolobenzoxepin PI3-Kinase Inhibitors That Spare the PI3-Kinase β Isoform</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2606</span>– <span class="NLM_lpage">2613</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2013.02.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2606-2613&issue=9&author=S.+T.+Stabenauthor=C.+Ndubakuauthor=N.+Blaquiereauthor=M.+Belvinauthor=R.+J.+Bullauthor=D.+Dudleyauthor=K.+Edgarauthor=D.+Grayauthor=R.+Healdauthor=T.+P.+Heffronauthor=G.+E.+Jonesauthor=M.+Jonesauthor=A.+Kolesnikovauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=N.+J.+McLeanauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=R.+Ordauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=C.+Weismannauthor=P.+Wu&title=Discovery+of+Thiazolobenzoxepin+PI3-Kinase+Inhibitors+That+Spare+the+PI3-Kinase+%CE%B2+Isoform&doi=10.1016%2Fj.bmcl.2013.02.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.102%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DN.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DOrd%26aufirst%3DR.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWeismann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Thiazolobenzoxepin%2520PI3-Kinase%2520Inhibitors%2520That%2520Spare%2520the%2520PI3-Kinase%2520%25CE%25B2%2520Isoform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D9%26spage%3D2606%26epage%3D2613%26doi%3D10.1016%2Fj.bmcl.2013.02.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-Methyl-1H -1,2-4-Triazol-5-Yl)-5,6-Dihydrobenzo[f]Imidazo[1,2-d][1,4]Oxazepin-9-Yl]-1H -Pyrazol-1-Yl}-2-Methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Ro</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4597</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&issue=11&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-Methyl-1H+-1%2C2-4-Triazol-5-Yl%29-5%2C6-Dihydrobenzo%5Bf%5DImidazo%5B1%2C2-d%5D%5B1%2C4%5DOxazepin-9-Yl%5D-1H+-Pyrazol-1-Yl%7D-2-Methylpropanamide+%28GDC-0032%29%3A+A+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Ro&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-Methyl-1H%2520-1%252C2-4-Triazol-5-Yl%2529-5%252C6-Dihydrobenzo%255Bf%255DImidazo%255B1%252C2-d%255D%255B1%252C4%255DOxazepin-9-Yl%255D-1H%2520-Pyrazol-1-Yl%257D-2-Methylpropanamide%2520%2528GDC-0032%2529%253A%2520A%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Ro%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D11%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augistin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gancia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mörtl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[f]Imidazo[1,2-d][1,4]Oxazepin-9-Yl)Oxy)Propa</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01483</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01483" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=985-1002&issue=3&author=T.+P.+Heffronauthor=R.+A.+Healdauthor=C.+Ndubakuauthor=B.+Weiauthor=M.+Augistinauthor=S.+Doauthor=K.+Edgarauthor=C.+Eigenbrotauthor=L.+Friedmanauthor=E.+Ganciaauthor=P.+S.+Jacksonauthor=G.+Jonesauthor=A.+Kolesnikovauthor=L.+B.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=N.+McLeanauthor=M.+M%C3%B6rtlauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=S.+T.+Stabenauthor=S.+Steinbacherauthor=V.+Tsuiauthor=J.+Wallinauthor=D.+Sampathauthor=A.+G.+Olivero&title=The+Rational+Design+of+Selective+Benzoxazepin+Inhibitors+of+the+%CE%B1-Isoform+of+Phosphoinositide+3-Kinase+Culminating+in+the+Identification+of+%28S%29-2-%28%282-%281-Isopropyl-1H-1%2C2%2C4-Triazol-5-Yl%29-5%2C6-Dihydrobenzo%5Bf%5DImidazo%5B1%2C2-d%5D%5B1%2C4%5DOxazepin-9-Yl%29Oxy%29Propa&doi=10.1021%2Facs.jmedchem.5b01483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01483%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DAugistin%26aufirst%3DM.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGancia%26aufirst%3DE.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMcLean%26aufirst%3DN.%26aulast%3DM%25C3%25B6rtl%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DThe%2520Rational%2520Design%2520of%2520Selective%2520Benzoxazepin%2520Inhibitors%2520of%2520the%2520%25CE%25B1-Isoform%2520of%2520Phosphoinositide%25203-Kinase%2520Culminating%2520in%2520the%2520Identification%2520of%2520%2528S%2529-2-%2528%25282-%25281-Isopropyl-1H-1%252C2%252C4-Triazol-5-Yl%2529-5%252C6-Dihydrobenzo%255Bf%255DImidazo%255B1%252C2-d%255D%255B1%252C4%255DOxazepin-9-Yl%2529Oxy%2529Propa%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D3%26spage%3D985%26epage%3D1002%26doi%3D10.1021%2Facs.jmedchem.5b01483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">936</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00170</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00170" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=936-940&issue=9&author=B.+S.+Safinaauthor=R.+L.+Elliottauthor=A.+K.+Forrestauthor=R.+A.+Healdauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=E.+M.+Sewardauthor=S.+T.+Stabenauthor=M.+Ultschauthor=B.+Weiauthor=W.+Yangauthor=D.+P.+Sutherlin&title=Design+of+Selective+Benzoxazepin+PI3K%CE%B4+Inhibitors+Through+Control+of+Dihedral+Angles&doi=10.1021%2Facsmedchemlett.7b00170"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00170%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DElliott%26aufirst%3DR.%2BL.%26aulast%3DForrest%26aufirst%3DA.%2BK.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DDesign%2520of%2520Selective%2520Benzoxazepin%2520PI3K%25CE%25B4%2520Inhibitors%2520Through%2520Control%2520of%2520Dihedral%2520Angles%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D936%26epage%3D940%26doi%3D10.1021%2Facsmedchemlett.7b00170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggate, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plavec, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rharbaoui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor Reveals PI3Kγ Dependence of TH17 Cell Differentiation</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1038/nchembio.957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1038%2Fnchembio.957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22544264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Gqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=576-582&issue=6&author=G.+Bergaminiauthor=K.+Bellauthor=S.+Shimamuraauthor=T.+Wernerauthor=A.+Cansfieldauthor=K.+M%C3%BCllerauthor=J.+Perrinauthor=C.+Rauauthor=K.+Ellardauthor=C.+Hopfauthor=C.+Doceauthor=D.+Leggateauthor=R.+Manganoauthor=T.+Mathiesonauthor=A.+O%E2%80%99Mahonyauthor=I.+Plavecauthor=F.+Rharbaouiauthor=F.+Reinhardauthor=M.+M.+Savitskiauthor=N.+Ramsdenauthor=E.+Hirschauthor=G.+Drewesauthor=O.+Rauschauthor=M.+Bantscheffauthor=G.+Neubauer&title=A+Selective+Inhibitor+Reveals+PI3K%CE%B3+Dependence+of+TH17+Cell+Differentiation&doi=10.1038%2Fnchembio.957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation</span></div><div class="casAuthors">Bergamini, Giovanna; Bell, Kathryn; Shimamura, Satoko; Werner, Thilo; Cansfield, Andrew; Mueller, Katrin; Perrin, Jessica; Rau, Christina; Ellard, Katie; Hopf, Carsten; Doce, Carola; Leggate, Daniel; Mangano, Raffaella; Mathieson, Toby; O'Mahony, Alison; Plavec, Ivan; Rharbaoui, Faiza; Reinhard, Friedrich; Savitski, Mikhail M.; Ramsden, Nigel; Hirsch, Emilio; Drewes, Gerard; Rausch, Oliver; Bantscheff, Marcus; Neubauer, Gitte</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576-582</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We devised a high-throughput chemoproteomics method that enabled multiplexed screening of 16,000 compds. against native protein and lipid kinases in cell exts.  Optimization of one chem. series resulted in CZC24832, which is to our knowledge the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation.  Extensive target- and cell-based profiling of CZC24832 revealed regulation of interleukin-17-producing T helper cell (TH17) differentiation by PI3Kγ, thus reinforcing selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqinUn8kLqw_LVg90H21EOLACvtfcHk0li05zXQywKD8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Gqt7c%253D&md5=0141d8596ee10d4d796de57fb87a2c19</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.957%26sid%3Dliteratum%253Aachs%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DShimamura%26aufirst%3DS.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DCansfield%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DDoce%26aufirst%3DC.%26aulast%3DLeggate%26aufirst%3DD.%26aulast%3DMangano%26aufirst%3DR.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DPlavec%26aufirst%3DI.%26aulast%3DRharbaoui%26aufirst%3DF.%26aulast%3DReinhard%26aufirst%3DF.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DRausch%26aufirst%3DO.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DG.%26atitle%3DA%2520Selective%2520Inhibitor%2520Reveals%2520PI3K%25CE%25B3%2520Dependence%2520of%2520TH17%2520Cell%2520Differentiation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D6%26spage%3D576%26epage%3D582%26doi%3D10.1038%2Fnchembio.957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(2-Amino-[1,2,4]Triazolo[1,5-a]Pyridin-7-Yl)-N-(Tert-Butyl)Pyridine-3-Sulfonamide (CZC24758), as a Potent, Orally Bioavailable and Selective Inhibitor of PI3K for the Treatment of Inflammatory Disease</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4613</span>– <span class="NLM_lpage">4618</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.05.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4613-4618&issue=14&author=M.+Sunoseauthor=K.+Bellauthor=K.+Ellardauthor=G.+Bergaminiauthor=G.+Neubauerauthor=T.+Wernerauthor=N.+Ramsden&title=Discovery+of+5-%282-Amino-%5B1%2C2%2C4%5DTriazolo%5B1%2C5-a%5DPyridin-7-Yl%29-N-%28Tert-Butyl%29Pyridine-3-Sulfonamide+%28CZC24758%29%2C+as+a+Potent%2C+Orally+Bioavailable+and+Selective+Inhibitor+of+PI3K+for+the+Treatment+of+Inflammatory+Disease&doi=10.1016%2Fj.bmcl.2012.05.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DSunose%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DRamsden%26aufirst%3DN.%26atitle%3DDiscovery%2520of%25205-%25282-Amino-%255B1%252C2%252C4%255DTriazolo%255B1%252C5-a%255DPyridin-7-Yl%2529-N-%2528Tert-Butyl%2529Pyridine-3-Sulfonamide%2520%2528CZC24758%2529%252C%2520as%2520a%2520Potent%252C%2520Orally%2520Bioavailable%2520and%2520Selective%2520Inhibitor%2520of%2520PI3K%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D14%26spage%3D4613%26epage%3D4618%26doi%3D10.1016%2Fj.bmcl.2012.05.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span> <span> </span><span class="NLM_article-title">SAR Studies around a Series of Triazolopyridines as Potent and Selective PI3Kγ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">5257</span>– <span class="NLM_lpage">5263</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.06.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5257-5263&issue=16&author=K.+Bellauthor=M.+Sunoseauthor=K.+Ellardauthor=A.+Cansfieldauthor=J.+Taylorauthor=W.+Millerauthor=N.+Ramsdenauthor=G.+Bergaminiauthor=G.+Neubauer&title=SAR+Studies+around+a+Series+of+Triazolopyridines+as+Potent+and+Selective+PI3K%CE%B3+Inhibitors&doi=10.1016%2Fj.bmcl.2012.06.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DK.%26aulast%3DSunose%26aufirst%3DM.%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DW.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DNeubauer%26aufirst%3DG.%26atitle%3DSAR%2520Studies%2520around%2520a%2520Series%2520of%2520Triazolopyridines%2520as%2520Potent%2520and%2520Selective%2520PI3K%25CE%25B3%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D16%26spage%3D5257%26epage%3D5263%26doi%3D10.1016%2Fj.bmcl.2012.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel PI3Kγ/δ Inhibitors as Potential Agents for Inflammation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4546</span>– <span class="NLM_lpage">4549</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.05.121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4546-4549&issue=14&author=K.+Ellardauthor=M.+Sunoseauthor=K.+Bellauthor=N.+Ramsdenauthor=G.+Bergaminiauthor=G.+Neubauer&title=Discovery+of+Novel+PI3K%CE%B3%2F%CE%B4+Inhibitors+as+Potential+Agents+for+Inflammation&doi=10.1016%2Fj.bmcl.2012.05.121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.121%26sid%3Dliteratum%253Aachs%26aulast%3DEllard%26aufirst%3DK.%26aulast%3DSunose%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DNeubauer%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Novel%2520PI3K%25CE%25B3%252F%25CE%25B4%2520Inhibitors%2520as%2520Potential%2520Agents%2520for%2520Inflammation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D14%26spage%3D4546%26epage%3D4549%26doi%3D10.1016%2Fj.bmcl.2012.05.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of a Series of 2-Aminothiazole-Oxazoles as Potent Phosphoinositide 3-Kinase γ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7534</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.10.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7534-7538&issue=24&author=Y.+Okaauthor=T.+Yabuuchiauthor=Y.+Fujiiauthor=H.+Ohtakeauthor=S.+Wakaharaauthor=K.+Matsumotoauthor=M.+Endoauthor=Y.+Tamuraauthor=Y.+Sekiguchi&title=Discovery+and+Optimization+of+a+Series+of+2-Aminothiazole-Oxazoles+as+Potent+Phosphoinositide+3-Kinase+%CE%B3+Inhibitors&doi=10.1016%2Fj.bmcl.2012.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DY.%26aulast%3DYabuuchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DWakahara%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Series%2520of%25202-Aminothiazole-Oxazoles%2520as%2520Potent%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D24%26spage%3D7534%26epage%3D7538%26doi%3D10.1016%2Fj.bmcl.2012.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-{5-[3-(3-Hydroxypiperidin-1-Yl)-1,2,4-Oxadiazol-5-Yl]-4-Methyl-1,3-Thiazol-2-Yl}acetamide (TASP0415914) as an Orally Potent Phosphoinositide 3-Kinase γ Inhibitor for the Treatment of Inflammatory Diseases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7578</span>– <span class="NLM_lpage">7583</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmc.2013.10.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7578-7583&issue=24&author=Y.+Okaauthor=T.+Yabuuchiauthor=T.+Oiauthor=S.+Kurodaauthor=Y.+Fujiiauthor=H.+Ohtakeauthor=T.+Inoueauthor=S.+Wakaharaauthor=K.+Kimuraauthor=K.+Fujitaauthor=M.+Endoauthor=K.+Taguchiauthor=Y.+Sekiguchi&title=Discovery+of+N-%7B5-%5B3-%283-Hydroxypiperidin-1-Yl%29-1%2C2%2C4-Oxadiazol-5-Yl%5D-4-Methyl-1%2C3-Thiazol-2-Yl%7Dacetamide+%28TASP0415914%29+as+an+Orally+Potent+Phosphoinositide+3-Kinase+%CE%B3+Inhibitor+for+the+Treatment+of+Inflammatory+Diseases&doi=10.1016%2Fj.bmc.2013.10.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DY.%26aulast%3DYabuuchi%26aufirst%3DT.%26aulast%3DOi%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DS.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DWakahara%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DK.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520N-%257B5-%255B3-%25283-Hydroxypiperidin-1-Yl%2529-1%252C2%252C4-Oxadiazol-5-Yl%255D-4-Methyl-1%252C3-Thiazol-2-Yl%257Dacetamide%2520%2528TASP0415914%2529%2520as%2520an%2520Orally%2520Potent%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26issue%3D24%26spage%3D7578%26epage%3D7583%26doi%3D10.1016%2Fj.bmc.2013.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaq, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuenoud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand, D. Le</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilgrim, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sviridenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, L.</span></span> <span> </span><span class="NLM_article-title">Development of Isoform Selective PI3-Kinase Inhibitors as Pharmacological Tools for Elucidating the PI3K Pathway</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5445</span>– <span class="NLM_lpage">5450</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2012.07.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5445-5450&issue=17&author=I.+Bruceauthor=M.+Akhlaqauthor=G.+C.+Bloomfieldauthor=E.+Buddauthor=B.+Coxauthor=B.+Cuenoudauthor=P.+Finanauthor=P.+Gedeckauthor=J.+Hattoauthor=J.+F.+Haylerauthor=D.+Headauthor=T.+Kellerauthor=L.+Kirmanauthor=C.+Leblancauthor=D.+Le+Grandauthor=C.+McCarthyauthor=D.+O%E2%80%99Connorauthor=C.+Owenauthor=M.+S.+Ozaauthor=G.+Pilgrimauthor=N.+E.+Pressauthor=L.+Sviridenkoauthor=L.+Whitehead&title=Development+of+Isoform+Selective+PI3-Kinase+Inhibitors+as+Pharmacological+Tools+for+Elucidating+the+PI3K+Pathway&doi=10.1016%2Fj.bmcl.2012.07.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.042%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DAkhlaq%26aufirst%3DM.%26aulast%3DBloomfield%26aufirst%3DG.%2BC.%26aulast%3DBudd%26aufirst%3DE.%26aulast%3DCox%26aufirst%3DB.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayler%26aufirst%3DJ.%2BF.%26aulast%3DHead%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DKirman%26aufirst%3DL.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DGrand%26aufirst%3DD.%2BLe%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DOza%26aufirst%3DM.%2BS.%26aulast%3DPilgrim%26aufirst%3DG.%26aulast%3DPress%26aufirst%3DN.%2BE.%26aulast%3DSviridenko%26aufirst%3DL.%26aulast%3DWhitehead%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520Isoform%2520Selective%2520PI3-Kinase%2520Inhibitors%2520as%2520Pharmacological%2520Tools%2520for%2520Elucidating%2520the%2520PI3K%2520Pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D17%26spage%3D5445%26epage%3D5450%26doi%3D10.1016%2Fj.bmcl.2012.07.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&issue=13&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornebise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1021/jm500362j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500362j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=517-521&issue=1&author=P.+N.+Collierauthor=G.+Martinez-Botellaauthor=M.+Cornebiseauthor=K.+M.+Cottrellauthor=J.+D.+Doranauthor=J.+P.+Griffithauthor=S.+Mahajanauthor=F.+Maltaisauthor=C.+S.+Moodyauthor=E.+P.+Huckauthor=T.+Wangauthor=A.+M.+Aronov&title=Structural+Basis+for+Isoform+Selectivity+in+a+Class+of+Benzothiazole+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B3&doi=10.1021%2Fjm500362j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm500362j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500362j%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DCornebise%26aufirst%3DM.%26aulast%3DCottrell%26aufirst%3DK.%2BM.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DHuck%26aufirst%3DE.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DStructural%2520Basis%2520for%2520Isoform%2520Selectivity%2520in%2520a%2520Class%2520of%2520Benzothiazole%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D517%26epage%3D521%26doi%3D10.1021%2Fjm500362j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tiran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandarage, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damagnez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare-Pandit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledeboer, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roday, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5684</span>– <span class="NLM_lpage">5688</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5684-5688&issue=14&author=P.+N.+Collierauthor=D.+Messersmithauthor=A.+Le+Tiranauthor=U.+K.+Bandarageauthor=C.+Boucherauthor=J.+Comeauthor=K.+M.+Cottrellauthor=V.+Damagnezauthor=J.+D.+Doranauthor=J.+P.+Griffithauthor=S.+Khare-Panditauthor=E.+B.+Kruegerauthor=M.+W.+Ledeboerauthor=B.+Ledfordauthor=Y.+Liaoauthor=S.+Mahajanauthor=C.+S.+Moodyauthor=S.+Rodayauthor=T.+Wangauthor=J.+Xuauthor=A.+M.+Aronov&title=Discovery+of+Highly+Isoform+Selective+Thiazolopiperidine+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B3&doi=10.1021%2Facs.jmedchem.5b00498"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00498%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DLe%2BTiran%26aufirst%3DA.%26aulast%3DBandarage%26aufirst%3DU.%2BK.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DCome%26aufirst%3DJ.%26aulast%3DCottrell%26aufirst%3DK.%2BM.%26aulast%3DDamagnez%26aufirst%3DV.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DKhare-Pandit%26aufirst%3DS.%26aulast%3DKrueger%26aufirst%3DE.%2BB.%26aulast%3DLedeboer%26aufirst%3DM.%2BW.%26aulast%3DLedford%26aufirst%3DB.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DRoday%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DDiscovery%2520of%2520Highly%2520Isoform%2520Selective%2520Thiazolopiperidine%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D14%26spage%3D5684%26epage%3D5688%26doi%3D10.1021%2Facs.jmedchem.5b00498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Come, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Tiran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandarage, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizensky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damagnez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworakowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare-Pandit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5245</span>– <span class="NLM_lpage">5256</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5245-5256&issue=12&author=J.+H.+Comeauthor=P.+N.+Collierauthor=J.+A.+Hendersonauthor=A.+C.+Pierceauthor=R.+J.+Daviesauthor=A.+Le+Tiranauthor=H.+O%E2%80%99Dowdauthor=U.+K.+Bandarageauthor=J.+Caoauthor=D.+Deiningerauthor=R.+Greyauthor=E.+B.+Kruegerauthor=D.+B.+Loweauthor=J.+Liangauthor=Y.+Liaoauthor=D.+Messersmithauthor=S.+Nanthakumarauthor=E.+Sizenskyauthor=J.+Wangauthor=J.+Xuauthor=E.+Y.+Chinauthor=V.+Damagnezauthor=J.+D.+Doranauthor=W.+Dworakowskiauthor=J.+P.+Griffithauthor=M.+D.+Jacobsauthor=S.+Khare-Panditauthor=S.+Mahajanauthor=C.+S.+Moodyauthor=A.+M.+Aronov&title=Design+and+Synthesis+of+a+Novel+Series+of+Orally+Bioavailable%2C+CNS-Penetrant%2C+Isoform+Selective+Phosphoinositide+3-Kinase+%CE%B3+%28PI3K%CE%B3%29+Inhibitors+with+Potential+for+the+Treatment+of+Multiple+Sclerosis+%28MS%29&doi=10.1021%2Facs.jmedchem.8b00085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00085%26sid%3Dliteratum%253Aachs%26aulast%3DCome%26aufirst%3DJ.%2BH.%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DHenderson%26aufirst%3DJ.%2BA.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DDavies%26aufirst%3DR.%2BJ.%26aulast%3DLe%2BTiran%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DH.%26aulast%3DBandarage%26aufirst%3DU.%2BK.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DDeininger%26aufirst%3DD.%26aulast%3DGrey%26aufirst%3DR.%26aulast%3DKrueger%26aufirst%3DE.%2BB.%26aulast%3DLowe%26aufirst%3DD.%2BB.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DMessersmith%26aufirst%3DD.%26aulast%3DNanthakumar%26aufirst%3DS.%26aulast%3DSizensky%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DChin%26aufirst%3DE.%2BY.%26aulast%3DDamagnez%26aufirst%3DV.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DDworakowski%26aufirst%3DW.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DJacobs%26aufirst%3DM.%2BD.%26aulast%3DKhare-Pandit%26aufirst%3DS.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Novel%2520Series%2520of%2520Orally%2520Bioavailable%252C%2520CNS-Penetrant%252C%2520Isoform%2520Selective%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520%2528PI3K%25CE%25B3%2529%2520Inhibitors%2520with%2520Potential%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Sclerosis%2520%2528MS%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5245%26epage%3D5256%26doi%3D10.1021%2Facs.jmedchem.8b00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlbrandt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatoidsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5435</span>– <span class="NLM_lpage">5441</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00447</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00447" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5435-5441&issue=12&author=N.+Pembertonauthor=M.+Mogemarkauthor=S.+Arlbrandtauthor=P.+Boldauthor=R.+J.+Coxauthor=C.+Gardelliauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=J.+Karlssonauthor=S.+Leverauthor=X.+Liauthor=H.+Lindmarkauthor=M.+Norbergauthor=M.+W.+D.+Perryauthor=J.+Petersenauthor=S.+Rodrigo+Blomqvistauthor=M.+Thomasauthor=C.+Tyrchanauthor=A.+Westin+Erikssonauthor=P.+Zlatoidskyauthor=L.+%C3%96ster&title=Discovery+of+Highly+Isoform+Selective+Orally+Bioavailable+Phosphoinositide+3-Kinase+%28PI3K%29-%CE%B3+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span></div><div class="casAuthors">Pemberton, Nils; Mogemark, Mickael; Arlbrandt, Susanne; Bold, Peter; Cox, Rhona J.; Gardelli, Cristina; Holden, Neil S.; Karabelas, Kostas; Karlsson, Johan; Lever, Sarah; Li, Xueshan; Lindmark, Helena; Norberg, Monica; Perry, Matthew W. D.; Petersen, Jens; Rodrigo Blomqvist, Sandra; Thomas, Matthew; Tyrchan, Christian; Westin Eriksson, Annika; Zlatoidsky, Pavol; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5435-5441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a new chemotype of isoform selective PI3Kγ inhibitors.  Starting from an HTS hit, potency and physicochem. properties could be improved to give compds. such as 15, which is a potent and remarkably selective PI3Kγ inhibitor with ADME properties suitable for oral administration.  Compd. 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo3fbsxDWowrVg90H21EOLACvtfcHk0ljDRrmkaRZ6Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO&md5=da8067ecb7fff28145f1c2bf82f0a7e7</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00447%26sid%3Dliteratum%253Aachs%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DArlbrandt%26aufirst%3DS.%26aulast%3DBold%26aufirst%3DP.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DGardelli%26aufirst%3DC.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DKarlsson%26aufirst%3DJ.%26aulast%3DLever%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DNorberg%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26aulast%3DZlatoidsky%26aufirst%3DP.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Highly%2520Isoform%2520Selective%2520Orally%2520Bioavailable%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529-%25CE%25B3%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5435%26epage%3D5441%26doi%3D10.1021%2Facs.jmedchem.8b00447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4104</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&issue=15&author=C.+Qianauthor=C.-J.+Laiauthor=R.+Baoauthor=D.-G.+Wangauthor=J.+Wangauthor=G.-X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+S.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.-X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+Network+Disruption+by+a+Single+Molecule+Inhibitor+Targeting+Both+Histone+Deacetylase+Activity+and+Phosphatidylinositol+3-Kinase+Signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0ljDRrmkaRZ6Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%2BS.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520Network%2520Disruption%2520by%2520a%2520Single%2520Molecule%2520Inhibitor%2520Targeting%2520Both%2520Histone%2520Deacetylase%2520Activity%2520and%2520Phosphatidylinositol%25203-Kinase%2520Signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D15%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, Tolerability, and Preliminary Activity of CUDC-907, a First-in-Class, Oral, Dual Inhibitor of HDAC and PI3K, in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma: An Open-Label, Dose-Escalation, Phase 1 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&issue=5&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+Tolerability%2C+and+Preliminary+Activity+of+CUDC-907%2C+a+First-in-Class%2C+Oral%2C+Dual+Inhibitor+of+HDAC+and+PI3K%2C+in+Patients+with+Relapsed+or+Refractory+Lymphoma+or+Multiple+Myeloma%3A+An+Open-Label%2C+Dose-Escalation%2C+Phase+1+Trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0liNd7pR3jwFJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520Tolerability%252C%2520and%2520Preliminary%2520Activity%2520of%2520CUDC-907%252C%2520a%2520First-in-Class%252C%2520Oral%252C%2520Dual%2520Inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Lymphoma%2520or%2520Multiple%2520Myeloma%253A%2520An%2520Open-Label%252C%2520Dose-Escalation%252C%2520Phase%25201%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-Dependent Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&issue=2&author=K.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+S.+Samsonauthor=A.+W.+Maauthor=G.-X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+HDAC+and+PI3K+Inhibitor+CUDC-907+Downregulates+MYC+and+Suppresses+Growth+of+MYC-Dependent+Cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0liNd7pR3jwFJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%2BS.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520HDAC%2520and%2520PI3K%2520Inhibitor%2520CUDC-907%2520Downregulates%2520MYC%2520and%2520Suppresses%2520Growth%2520of%2520MYC-Dependent%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1552-1575&issue=4&author=D.+Chenauthor=C.+K.+Sohauthor=W.+H.+Gohauthor=H.+Wang&title=Design%2C+Synthesis%2C+and+Preclinical+Evaluation+of+Fused+Pyrimidine-Based+Hydroxamates+for+the+Treatment+of+Hepatocellular+Carcinoma&doi=10.1021%2Facs.jmedchem.7b01465"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01465%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSoh%26aufirst%3DC.%2BK.%26aulast%3DGoh%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Preclinical%2520Evaluation%2520of%2520Fused%2520Pyrimidine-Based%2520Hydroxamates%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1552%26epage%3D1575%26doi%3D10.1021%2Facs.jmedchem.7b01465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-R.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Novel 4-Aminoquinazolines as Dual Target Inhibitors of EGFR-PI3Kα</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1016%2Fj.ejmech.2018.01.081" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=460-470&author=H.-W.+Dingauthor=C.-L.+Dengauthor=D.-D.+Liauthor=D.-D.+Liuauthor=S.-M.+Chaiauthor=W.+Wangauthor=Y.+Zhangauthor=K.+Chenauthor=X.+Liauthor=J.+Wangauthor=S.-J.+Songauthor=H.-R.+Song&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+4-Aminoquinazolines+as+Dual+Target+Inhibitors+of+EGFR-PI3K%CE%B1&doi=10.1016%2Fj.ejmech.2018.01.081"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.081%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.-W.%26aulast%3DDeng%26aufirst%3DC.-L.%26aulast%3DLi%26aufirst%3DD.-D.%26aulast%3DLiu%26aufirst%3DD.-D.%26aulast%3DChai%26aufirst%3DS.-M.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DS.-J.%26aulast%3DSong%26aufirst%3DH.-R.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25204-Aminoquinazolines%2520as%2520Dual%2520Target%2520Inhibitors%2520of%2520EGFR-PI3K%25CE%25B1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D460%26epage%3D470%26doi%3D10.1016%2Fj.ejmech.2018.01.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pujala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguloth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randive, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez de Arce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirez, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCullagh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00356</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00356" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1161-1166&issue=12&author=B.+Pujalaauthor=A.+K.+Agarwalauthor=S.+Middyaauthor=M.+Banerjeeauthor=A.+Suryaauthor=A.+K.+Nayakauthor=A.+Guptaauthor=S.+Khareauthor=R.+Gugulothauthor=N.+A.+Randiveauthor=B.+U.+Shindeauthor=A.+Thakurauthor=D.+I.+Patelauthor=M.+Rajaauthor=M.+J.+Greenauthor=J.+Alfaroauthor=P.+Avilaauthor=F.+Perez+de+Arceauthor=R.+G.+Almirezauthor=S.+Kannoauthor=S.+Bernalesauthor=D.+T.+Hungauthor=S.+Chakravartyauthor=E.+McCullaghauthor=K.+P.+Quinnauthor=R.+Raiauthor=S.+M.+Pham&title=Discovery+of+Pyrazolopyrimidine+Derivatives+as+Novel+Dual+Inhibitors+of+BTK+and+PI3K%CE%B4&doi=10.1021%2Facsmedchemlett.6b00356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ</span></div><div class="casAuthors">Pujala, Brahmam; Agarwal, Anil K.; Middya, Sandip; Banerjee, Monali; Surya, Arjun; Nayak, Anjan K.; Gupta, Ashu; Khare, Sweta; Guguloth, Rambabu; Randive, Nitin A.; Shinde, Bharat U.; Thakur, Anamika; Patel, Dhananjay I.; Raja, Mohd.; Green, Michael J.; Alfaro, Jennifer; Avila, Patricio; Perez de Arce, Felipe; Almirez, Ramona G.; Kanno, Stacy; Bernales, Sebastian; Hung, David T.; Chakravarty, Sarvajit; McCullagh, Emma; Quinn, Kevin P.; Rai, Roopa; Pham, Son M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1161-1166</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aberrant activation of B-cells has been implicated in several types of cancers and hematol. disorders.  BTK and PI3Kδ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clin. benefit in certain types of lymphoma.  Simultaneous inhibition of these pathways could result in more robust responses or overcome resistance as obsd. in single agent use.  The authors report a series of novel compds. that have low nanomolar potency against both BTK and PI3Kδ as well as acceptable PK properties that could be useful in the development of treatments against B-cell related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WMataMc2hbVg90H21EOLACvtfcHk0lgtxW0a4fJVBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL&md5=2a977a59c1bd1ccc5682405628990617</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00356%26sid%3Dliteratum%253Aachs%26aulast%3DPujala%26aufirst%3DB.%26aulast%3DAgarwal%26aufirst%3DA.%2BK.%26aulast%3DMiddya%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DSurya%26aufirst%3DA.%26aulast%3DNayak%26aufirst%3DA.%2BK.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DGuguloth%26aufirst%3DR.%26aulast%3DRandive%26aufirst%3DN.%2BA.%26aulast%3DShinde%26aufirst%3DB.%2BU.%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DD.%2BI.%26aulast%3DRaja%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DAlfaro%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DP.%26aulast%3DPerez%2Bde%2BArce%26aufirst%3DF.%26aulast%3DAlmirez%26aufirst%3DR.%2BG.%26aulast%3DKanno%26aufirst%3DS.%26aulast%3DBernales%26aufirst%3DS.%26aulast%3DHung%26aufirst%3DD.%2BT.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DMcCullagh%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DK.%2BP.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520Pyrazolopyrimidine%2520Derivatives%2520as%2520Novel%2520Dual%2520Inhibitors%2520of%2520BTK%2520and%2520PI3K%25CE%25B4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D1161%26epage%3D1166%26doi%3D10.1021%2Facsmedchemlett.6b00356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eradat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ervin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coiffier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettitt, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahn, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span> <span> </span><span class="NLM_article-title">Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1315226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1056%2FNEJMoa1315226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=24450857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVyqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=997-1007&issue=11&author=R.+R.+Furmanauthor=J.+P.+Sharmanauthor=S.+E.+Coutreauthor=B.+D.+Chesonauthor=J.+M.+Pagelauthor=P.+Hillmenauthor=J.+C.+Barrientosauthor=A.+D.+Zelenetzauthor=T.+J.+Kippsauthor=I.+Flinnauthor=P.+Ghiaauthor=H.+Eradatauthor=T.+Ervinauthor=N.+Lamannaauthor=B.+Coiffierauthor=A.+R.+Pettittauthor=S.+Maauthor=S.+Stilgenbauerauthor=P.+Cramerauthor=M.+Aielloauthor=D.+M.+Johnsonauthor=L.+L.+Millerauthor=D.+Liauthor=T.+M.+Jahnauthor=R.+D.+Danseyauthor=M.+Hallekauthor=S.+M.+O%E2%80%99Brien&title=Idelalisib+and+Rituximab+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1315226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib and rituximab in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Furman, Richard R.; Sharman, Jeff P.; Coutre, Steven E.; Cheson, Bruce D.; Pagel, John M.; Hillmen, Peter; Barrientos, Jacqueline C.; Zelenetz, Andrew D.; Kipps, Thomas J.; Flinn, Ian; Ghia, Paolo; Eradat, Herbert; Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; Pettitt, Andrew R.; Ma, Shuo; Stilgenbauer, Stephan; Cramer, Paula; Aiello, Maria; Johnson, Dave M.; Miller, Langdon L.; Li, Daniel; Jahn, Thomas M.; Dansey, Roger D.; Hallek, Michael; O'Brien, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">997-1007</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with relapsed chronic lymphocytic leukemia (CLL) who have clin. significant coexisting medical conditions are less able to undergo std. chemotherapy.  Effective therapies with acceptable side-effect profiles are needed for this patient population.  In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, the authors assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab vs. rituximab plus placebo.  The authors randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily.  The primary end point was progression-free survival.  At the first prespecified interim anal., the study was stopped early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy.  The median progression-free survival was 5.5 mo in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001).  Patients receiving idelalisib vs. those receiving placebo had improved rates of overall response (81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 mo (92% vs. 80%; hazard ratio for death, 0.28; P = 0.02).  Serious adverse events occurred in 40% of the patients receiving idelalisib and rituximab and in 35% of those receiving placebo and rituximab.  The combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOhnTsUaIOybVg90H21EOLACvtfcHk0lgtxW0a4fJVBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVyqtLs%253D&md5=4bce9ab0dae94360abfcd4f312691503</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315226%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DCheson%26aufirst%3DB.%2BD.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DEradat%26aufirst%3DH.%26aulast%3DErvin%26aufirst%3DT.%26aulast%3DLamanna%26aufirst%3DN.%26aulast%3DCoiffier%26aufirst%3DB.%26aulast%3DPettitt%26aufirst%3DA.%2BR.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DCramer%26aufirst%3DP.%26aulast%3DAiello%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DJahn%26aufirst%3DT.%2BM.%26aulast%3DDansey%26aufirst%3DR.%2BD.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26atitle%3DIdelalisib%2520and%2520Rituximab%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D11%26spage%3D997%26epage%3D1007%26doi%3D10.1056%2FNEJMoa1315226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Weerdt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koopmans, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kater, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gelder, M.</span></span> <span> </span><span class="NLM_article-title">Incidence and Management of Toxicity Associated with Ibrutinib and Idelalisib: A Practical Approach</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1629</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.164103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3324%2Fhaematol.2017.164103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1629-1639&issue=10&author=I.+de+Weerdtauthor=S.+M.+Koopmansauthor=A.+P.+Katerauthor=M.+van+Gelder&title=Incidence+and+Management+of+Toxicity+Associated+with+Ibrutinib+and+Idelalisib%3A+A+Practical+Approach&doi=10.3324%2Fhaematol.2017.164103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.164103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.164103%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeerdt%26aufirst%3DI.%26aulast%3DKoopmans%26aufirst%3DS.%2BM.%26aulast%3DKater%26aufirst%3DA.%2BP.%26aulast%3Dvan%2BGelder%26aufirst%3DM.%26atitle%3DIncidence%2520and%2520Management%2520of%2520Toxicity%2520Associated%2520with%2520Ibrutinib%2520and%2520Idelalisib%253A%2520A%2520Practical%2520Approach%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26issue%3D10%26spage%3D1629%26epage%3D1639%26doi%3D10.3324%2Fhaematol.2017.164103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutré, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poleski, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A. D.</span></span> <span> </span><span class="NLM_article-title">Management of Adverse Events Associated with Idelalisib Treatment: Expert Panel Opinion</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2779</span>– <span class="NLM_lpage">2786</span>, <span class="refDoi"> DOI: 10.3109/10428194.2015.1022770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.3109%2F10428194.2015.1022770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=25726955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=2779-2786&issue=10&author=S.+E.+Coutr%C3%A9author=J.+C.+Barrientosauthor=J.+R.+Brownauthor=S.+de+Vosauthor=R.+R.+Furmanauthor=M.+J.+Keatingauthor=D.+Liauthor=S.+M.+O%E2%80%99Brienauthor=J.+M.+Pagelauthor=M.+H.+Poleskiauthor=J.+P.+Sharmanauthor=N.-S.+Yaoauthor=A.+D.+Zelenetz&title=Management+of+Adverse+Events+Associated+with+Idelalisib+Treatment%3A+Expert+Panel+Opinion&doi=10.3109%2F10428194.2015.1022770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse events associated with idelalisib treatment: expert panel opinion</span></div><div class="casAuthors">Coutre, Steven E.; Barrientos, Jacqueline C.; Brown, Jennifer R.; de Vos, Sven; Furman, Richard R.; Keating, Michael J.; Li, Daniel; O'Brien, Susan M.; Pagel, John M.; Poleski, Martin H.; Sharman, Jeff P.; Yao, Nai-Shun; Zelenetz, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2779-2786</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer.  Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clin. trials.  However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.  An expert panel was convened to review the pathol. of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy.  This article provides an overview of idelalisib TEAEs reported in clin. trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis.  For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or i.v. steroid therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGi1H-woJu7Vg90H21EOLACvtfcHk0lin36x1tUq6ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O&md5=649cb8c3d6fe0a60f74b3f9413e4706a</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1022770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1022770%26sid%3Dliteratum%253Aachs%26aulast%3DCoutr%25C3%25A9%26aufirst%3DS.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DPoleski%26aufirst%3DM.%2BH.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DN.-S.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26atitle%3DManagement%2520of%2520Adverse%2520Events%2520Associated%2520with%2520Idelalisib%2520Treatment%253A%2520Expert%2520Panel%2520Opinion%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2015%26volume%3D56%26issue%3D10%26spage%3D2779%26epage%3D2786%26doi%3D10.3109%2F10428194.2015.1022770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, F. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peña, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genvresse, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Phase I Study of Copanlisib (BAY 80-6946), an Intravenous Pan-Class I Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphomas</span>. <i>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1928</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=10.1093%2Fannonc%2Fmdw282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=27672108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1928-1940&issue=10&author=A.+Patnaikauthor=L.+J.+Applemanauthor=A.+W.+Tolcherauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=G.+J.+Weissauthor=J.+C.+Sachdevauthor=M.+Chadhaauthor=M.+Fulkauthor=S.+Ejadiauthor=J.+M.+Mountzauthor=M.+T.+Lotzeauthor=F.+G.+S.+Toledoauthor=E.+Chuauthor=M.+Jeffersauthor=C.+Pe%C3%B1aauthor=C.+Xiaauthor=S.+Reifauthor=I.+Genvresseauthor=R.+K.+Ramanathan&title=First-in-Human+Phase+I+Study+of+Copanlisib+%28BAY+80-6946%29%2C+an+Intravenous+Pan-Class+I+Phosphatidylinositol+3-Kinase+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors+and+Non-Hodgkin%E2%80%99s+Lymphomas&doi=10.1093%2Fannonc%2Fmdw282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas</span></div><div class="casAuthors">Patnaik A; Tolcher A W; Papadopoulos K P; Beeram M; Rasco D W; Appleman L J; Mountz J M; Lotze M T; Toledo F G S; Chu E; Weiss G J; Sachdev J C; Chadha M; Fulk M; Ejadi S; Ramanathan R K; Jeffers M; Pena C; Xia C; Reif S; Genvresse I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1928-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).  PATIENTS AND METHODS:  Phase I dose-escalation study including patients with advanced solid tumors or NHL, and a cohort of patients with type 2 diabetes mellitus.  Patients received three weekly intravenous infusions of copanlisib per 28-day cycle over the dose range 0.1-1.2 mg/kg.  Plasma copanlisib levels were analyzed for pharmacokinetics.  Biomarker analysis included PIK3CA, KRAS, BRAF, and PTEN mutational status and PTEN immunohistochemistry.  Whole-body [(18)F]-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) was carried out at baseline and following the first dose to assess early pharmacodynamic effects.  Plasma glucose and insulin levels were evaluated serially.  RESULTS:  Fifty-seven patients received treatment.  The MTD was 0.8 mg/kg copanlisib.  The most frequent treatment-related adverse events were nausea and transient hyperglycemia.  Copanlisib exposure was dose-proportional with no accumulation; peak exposure positively correlated with transient hyperglycemia post-infusion.  Sixteen of 20 patients treated at the MTD had reduced (18)FDG-PET uptake; 7 (33%) had a reduction >25%.  One patient achieved a complete response (CR; endometrial carcinoma exhibiting both PIK3CA and PTEN mutations and complete PTEN loss) and two had a partial response (PR; both metastatic breast cancer).  Among the nine NHL patients, all six with follicular lymphoma (FL) responded (one CR and five PRs) and one patient with diffuse large B-cell lymphoma had a PR by investigator assessment; two patients with FL who achieved CR (per post hoc independent radiologic review) were on treatment >3 years.  CONCLUSION:  Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg.  Copanlisib exhibited dose-proportional pharmacokinetics and promising anti-tumor activity, particularly in patients with NHL.  CLINICALTRIALSGOV:  NCT00962611; https://clinicaltrials.gov/ct2/show/NCT00962611.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5iDaGefdSJNFxYDaSSP8XfW6udTcc2eb88_k1SFVAubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Whtg%253D%253D&md5=219db9cc72ca2493834406a977141667</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw282%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DFulk%26aufirst%3DM.%26aulast%3DEjadi%26aufirst%3DS.%26aulast%3DMountz%26aufirst%3DJ.%2BM.%26aulast%3DLotze%26aufirst%3DM.%2BT.%26aulast%3DToledo%26aufirst%3DF.%2BG.%2BS.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DPe%25C3%25B1a%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DReif%26aufirst%3DS.%26aulast%3DGenvresse%26aufirst%3DI.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DFirst-in-Human%2520Phase%2520I%2520Study%2520of%2520Copanlisib%2520%2528BAY%252080-6946%2529%252C%2520an%2520Intravenous%2520Pan-Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%2520and%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphomas%26jtitle%3DAnn.%2520Oncol.%2520Off.%2520J.%2520Eur.%2520Soc.%2520Med.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3D10%26spage%3D1928%26epage%3D1940%26doi%3D10.1093%2Fannonc%2Fmdw282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&issue=17&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+Descriptors+of+Aromatic+Character+and+Their+Use+in+Drug+Discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520Descriptors%2520of%2520Aromatic%2520Character%2520and%2520Their%2520Use%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D17%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljGp7RdRwe8Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X38" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X38','PDB','2X38'); return false;">PDB: 2X38</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXF','PDB','2WXF'); return false;">PDB: 2WXF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XEO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XEO','PDB','4XEO'); return false;">PDB: 4XEO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DBS','PDB','3DBS'); return false;">PDB: 3DBS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E','PDB','5M7E'); return false;">PDB: 5M7E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VLR','PDB','5VLR'); return false;">PDB: 5VLR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G2N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G2N','PDB','5G2N'); return false;">PDB: 5G2N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR','PDB','4BFR'); return false;">PDB: 4BFR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R','PDB','3R7R'); return false;">PDB: 3R7R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT','PDB','5DXT'); return false;">PDB: 5DXT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PS3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PS3','PDB','4PS3'); return false;">PDB: 4PS3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i30"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01492">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74613"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01492">10.1021/acs.jmedchem.8b01492</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical structures of PI3K inhibitors in clinical development (Table ST1) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01492/suppl_file/jm8b01492_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01492/suppl_file/jm8b01492_si_001.pdf">jm8b01492_si_001.pdf (461.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01492&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01492%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-10%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01492" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994902e8dc2374","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
